methylprednisolone profile

Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	6741
CHEMBL ID	650
CHEBI ID	6888
SCHEMBL ID	5084
MeSH ID	M0013662

Synonym
MLS002207191
MLS001148159 ,
BRD-K35240538-001-03-1
(6a,11b)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6s,8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one
MLS000028541 ,
smr000058330
NCI60_001657
(6alpha,11beta)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
PRESTWICK3_000279
nsc19987
medrol
medesone
metrisone
medrate
pregna-1,20-dione, 11,17,21-trihydroxy-6-methyl-, (6.alpha.,11.beta.)-
6.alpha.-methylprednisolone
metilbetasone
moderin
medrone
wyacort
83-43-2
promacortine
mesopren
nsc-19987
metastab
pregna-1,20-dione, 6.alpha.-methyl-11.beta.-17,21-trihydroxy-
pregna-1,20-dione, 11.beta.,17,21-trihydroxy-6.alpha.-methyl-
urbason
dopomedrol
urbasone
noretona
methylprednisolone
besonia
methylprednisolone, 6-alpha
PRESTWICK_622
NCGC00016330-01
metilprednisolona
solomet
methylprednisolon
CHEBI:6888 ,
methylprednisolonum
6alpha-methylprednisolone
11beta,17,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
PRESTWICK2_000279
BSPBIO_000158
metysolon
predni n tablinen
delta(sup 1)-6-alpha-methylhydrocortisone
prednol- l
prednisolone, 6alpha-methyl-
pregna-1,4-diene-3,20-dione, 6-alpha-methyl-11-beta-17,21-trihydroxy-
medlone 21
metilprednisolone [dcit]
reactenol
prednisolone, methyl-
methylprednisolonum [inn-latin]
pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6alpha,11beta)-
medrol adt pak
medrol dosepak
pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl-
metipred
metrocort
methyleneprednisolone
artisone-wyeth
hsdb 3127
sieropresol
lemod
summicort;
6-alpha-methylprednisolone
11-beta,17,21-trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
medixon
suprametil
11beta,17alpha,21-trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
einecs 201-476-4
esametone
depo-medrol (acetate)
brn 2340300
nirypan
metilprednisolona [inn-spanish]
firmacort
6alpha-methylprednisolone, >=98%
1-dehydro-6alpha-methylhydrocortisone
delta(1)-6alpha-methylhydrocortisone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
DB00959
D00407
methylprednisolone (jp17/usp/inn)
medrol (tn)
PRESTWICK1_000279
SPBIO_002377
PRESTWICK0_000279
BPBIO1_000174
NCGC00022735-03
6 methylprednisolone
HMS2090B13
M1665
11beta,17alpha,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
CHEMBL650
j3.872e ,
HMS1568H20
LMST02030178
HMS2095H20
HMS3259J04
NCGC00255269-01
tox21_302018
dtxsid7023300 ,
cas-83-43-2
dtxcid903300
tox21_110376
HMS2230D16
AKOS015969744
6alpha-methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
x4w7zr7023 ,
metilprednisolone
ec 201-476-4
4-08-00-03498 (beilstein handbook reference)
summicort
methylprednisolone [usp:inn:ban:jan]
unii-x4w7zr7023
methylprednisolone [usp-rs]
methylprednisolone [green book]
methylprednisolone [mi]
methylprednisolone acetate impurity b [ep impurity]
methylprednisolone component of neo-medrol
methylprednisolone [inn]
neo-medrol component methylprednisolone
methylprednisolone [mart.]
methylprednisolone [ep monograph]
methylprednisolone [jan]
methylprednisolone [hsdb]
6-methyl-prednisolone
methylprednisolone [usp monograph]
methylprednisolone hydrogen succinate impurity a [ep impurity]
methylprednisolone [who-dd]
methylprednisolone [orange book]
methylprednisolone [vandf]
S1733
gtpl7088
CCG-220279
HY-B0260
NC00691
SCHEMBL5084
NCGC00022735-06
tox21_110376_1
KS-1273
11beta,17,21-trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
VHRSUDSXCMQTMA-PJHHCJLFSA-N
(6s,8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-3-one
Q-201395
6alpha-methylprednisolone base
11?,17?,21-trihydroxy-6?-methyl-1,4-pregnadiene-3,20-dione
pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6a,11b)-
(6?,11?)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
OPERA_ID_1576
SR-01000003089-2
C16437
sr-01000003089
6alpha-methylprednisolone, vetranal(tm), analytical standard
methylprednisolone, united states pharmacopeia (usp) reference standard
bdbm50103616
methylprednisolone, european pharmacopoeia (ep) reference standard
methylprednisolone for system suitability, european pharmacopoeia (ep) reference standard
methylprednisolone, pharmaceutical secondary standard; certified reference material
methylprednisolone for system suitability a, europepharmacopoeia (ep) reference standard
6-alpha-methylprednisolone 100 microg/ml in acetonitrile
HMS3712H20
methylprednisolone, british pharmacopoeia (bp) reference standard
Q417222
BRD-K35240538-001-11-4
BRD-K35240538-001-26-2
pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6i+/-,11i(2))-
1,4-pregnadien-6alpha-methyl-11beta, 17, 21-triol-3, 20-dione
A855290
methylprednisolone (standard)
CS-0694768
HY-B0260R
EN300-7414014
(1r,3as,3bs,5s,9ar,9bs,10s,11as)-1,10-dihydroxy-1-(2-hydroxyacetyl)-5,9a,11a-trimethyl-1h,2h,3h,3ah,3bh,4h,5h,7h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-7-one
metilprednisolona (inn-spanish)
methylpred dp
methylprednisolone (usp-rs)
radilem
methylprednisolone (ep monograph)
solpredone
prednol-l
methylprednisolene tablets
depmedalone
metilbetasone solubile
duralone
veriderm medrol
medrol tablets
methylprednisolonum (inn-latin)
methylprednisolone (usp:inn:ban:jan)
methylprednisolone (mart.)
meprolone
prednilen
caberdelta m
depo moderin
methylprednisolone (usp monograph)
mega-star
predni-m-tablinen
depo-nisolone
methylprednisole

Excerpt	Reference	Relevance
" Tests of adrenal function suggest that beclomethasone dipropionate at dosages of 400 to 800 mug daily has little or no adverse effect."	( Beclomethasone dipropionate inhaler: a review of its pharmacology, therapeutic value and adverse effects. I: Asthma. Avery, GS; Brogden, RN; Pinder, RM; Sawyer, PR; Speight, TM, 1975)	0.25
" This suggests that occult vascular lesions may have been present in the allograft which were exacerbated when exposed to the irritant vascular effects of contrast media, producing a mild, reversible toxic nephritis."	( Adverse effects of meglumine diatrizoate on renal function in the early post-transplant period. Etheredge, EE; Hill, G; Light, JA; Perloff, LJ; Spees, EK, 1975)	0.25
"To determine the frequency of significant adverse effects associated with high-dose intravenous methylprednisolone therapy (HIVMP) given as methylprednisolone 1 g/d for three consecutive days."	( A study of adverse effects of high-dose intravenous (pulse) methylprednisolone therapy in patients with rheumatic disease. Baethge, BA; Goldberg, JW; Lidsky, MD, 1992)	0.28
"Subjective complaints were elicited via a standardized questionnaire that identified adverse effects through organ system review."	( A study of adverse effects of high-dose intravenous (pulse) methylprednisolone therapy in patients with rheumatic disease. Baethge, BA; Goldberg, JW; Lidsky, MD, 1992)	0.28
"HIVMP has an acceptably low risk of significant adverse effects."	( A study of adverse effects of high-dose intravenous (pulse) methylprednisolone therapy in patients with rheumatic disease. Baethge, BA; Goldberg, JW; Lidsky, MD, 1992)	0.28
" The ability to induce "shock protein" synthesis obviously seems to be restricted to toxic drugs."	( A cell culture assay for the detection of cardiotoxicity. Löw-Friedrich, I; Schoeppe, W; von Bredow, F, 1991)	0.28
" Other features of this adverse drug reaction were unremitting fever, leukocytosis with eosinophilia and atypical lymphocytosis, and proteinuria."	( Phenobarbital hepatotoxicity in an 8-month-old infant. Goldbach, M; Phillips, MJ; Roberts, EA; Spielberg, SP, 1990)	0.28
" In this study we examined whether steroids could reduce the adverse cardiopulmonary effects of rIL-2."	( Steroid pretreatment reduces interleukin-2 toxicity in sheep. Gunther, RA; Hughes, KS; Jesmok, GJ; Morse, ED, 1990)	0.28
"A less frequently reported adverse side effect of local steroid injections has been described."	( Perilymphatic atrophy of skin. An adverse side effect of intralesional steroid injections. Kravette, MA, 1986)	0.27
"5 X 10(-3) M was toxic to all cell lines."	( Lymphotoxic activity of methyl prednisolone in vitro--I. Comparative toxicity of methyl prednisolone in human cell lines of B and T origin. Bell, JB; Hall, JG; Hobbs, SM; Jackson, E; Millar, BC, 1987)	0.27
"A retrospective analysis of 350 treatment courses using high dose pulsed intravenous methylprednisolone for relapses of multiple sclerosis revealed a low number of adverse effects."	( Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects. Lyons, PR; Newman, PK; Saunders, M, 1988)	0.27
" The findings suggest that this policy is safe and avoids the potential hazards of long-term CyA."	( Conversion from cyclosporin to azathioprine 3 months after renal transplantation--is it safe? Cassidy, MJ; Irving, E; Jacobson, JE; Pascoe, MD; Swanepoel, CR; van Zyl-Smit, R, 1986)	0.27
" Thus, toxic effects can be caused by preservatives or inadequate osmolarity of the vehicles alone."	( Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Arena, JE; Chandler, D; Hida, T; Machemer, R, 1986)	0.27
" The LD50 values of THS-201 both in mice and rats were estimated more than 5000 mg/kg at each route, and these are for above larger than those of TA or MPA."	( [Study on toxicity of halopredone acetate. (I) Acute toxicity study in mice and rats]. Ichinohe, M; Kaga, M; Okazaki, S; Shinpo, K; Sudo, J; Takeuchi, M; Tanabe, T; Tsuga, T, 1985)	0.27
"Because previous studies have suggested that some of the toxic effects of oxygen may result from impaired surfactant phospholipid metabolism, we examined the effects of methylprednisolone on the surfactant system in adult mice exposed to greater than 98% O2."	( Methylprednisolone increases the toxicity of oxygen in adult mice. Mechanical and biochemical effects on the surfactant system. Gross, NJ; Smith, DM, 1984)	0.27
" CPH-only treated rats had severe toxic nephrosis characterised by acute tubular necrosis, and elevated blood urea and creatinine."	( Glucocorticoid amelioration of nephrotoxicity: a study of cephaloridine-methylprednisolone interaction in the rat. Cockburn, A; Everett, DJ; Garcia Conesa, MT; Harvey, PW; Healing, G; Major, IR; McFarlane, M; Olatunde, O; Purdy, KA, 1995)	0.29
" We conclude that two times 250 mg MPNS administered six hours and one hour before the first administration of OKT3 effectively attenuates adverse reactions following administration of OKT3."	( Pretreatment with divided doses of steroids strongly decreases side effects of OKT3. Bemelman, FJ; Buysmann, S; Schellekens, PT; Surachno, J; ten Berge, IJ; Wilmink, JM, 1994)	0.29
"Cis-diamminedichloroplatinum (II) (cisplatin) is an effective antitumor drug, but it has an adverse effect of nephrotoxicity."	( [Prophylactic effect of methylprednisolone on cisplatin-induced nephrotoxicity]. Koikawa, Y, 1995)	0.29
" To examine this theory and to investigate the relationship of glucocorticoid metabolism to steroid-induced adverse effects among specific ethnic groups of renal transplant recipients, 9 black and 9 white male patients chronically receiving methylprednisolone were enrolled."	( Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. Biocevich, DM; Reed, K; Singh, JP; Tornatore, KM; Tousley, K; Venuto, RC, 1995)	0.29
" The outcome variables were: duration of hospitalization, percent of predicted peak expiratory flow rates recorded at 12-hour intervals, number of albuterol treatments required, and adverse effects."	( Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations. Bonagura, VR; Strauss, RE; Valacer, DJ; Wertheim, DL, 1994)	0.29
" In the Am group, 6 of the 14 patients who entered the study experienced significant adverse effects consisting of nausea, emesis, headache, abdominal pain, and palpitations."	( Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations. Bonagura, VR; Strauss, RE; Valacer, DJ; Wertheim, DL, 1994)	0.29
"There is no benefit and considerable risk of adverse effects associated with the use of Am in hospitalized asthmatic children."	( Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations. Bonagura, VR; Strauss, RE; Valacer, DJ; Wertheim, DL, 1994)	0.29
"Cis-diamminedichloroplatinum (II) (cisplatin) is a very effective antitumor drug, but It has an adverse effect of nephrotoxicity."	( [Prophylactic effect of methylprednisolone on cisplatin-induced nephrotoxicity in rats]. Koikawa, Y; Kumazawa, J; Ueda, T; Uozumi, J; Yasumasu, T, 1993)	0.29
"Acute encephalopathy is a recognized toxic effect of Cyclosporin A (CsA) in organ transplantation recipients."	( Case report: cyclosporin A-induced neurotoxicity. Almeida-Pinto, J; Lopes, G; Monteiro, L; Rocha, J; Rocha, N, 1993)	0.29
"TAO is safe and may be a reasonable treatment alternative in a limited trial for patients who are unable to tolerate tapering of their glucocorticoid dosage."	( Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Brenner, AM; Hill, MR; Iklé, DN; Kamada, AK; Szefler, SJ, 1993)	0.29
"The main side effect of alpha-CD3-IT, vascular leak syndrome, was entirely prevented by adjunctive immunosuppressive therapy."	( Tolerability and side effects of anti-CD3-immunotoxin in preclinical testing in kidney and pancreatic islet transplant recipients. Cartner, S; Contreras, JL; Eckhoff, DE; Frenette, L; Neville, DM; Robbin, ML; Thomas, FT; Thomas, JM, 1999)	0.3
"8%), adverse effects persisted."	( Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. Emre, S; Fishbein, TM; Genyk, Y; Guy, SR; Miller, CM; Schluger, LK; Schwartz, ME; Sheiner, PA, 2000)	0.31
"Systemic toxic effects may develop as a result of topical and local use of ophthalmic corticosteroid preparations in susceptible patients."	( Systemic toxicity of topical and periocular corticosteroid therapy in an 11-year-old male with posterior uveitis. Cheng, L; Freeman, WR; Levi, L; Ozerdem, U; Scher, C; Song, MK, 2000)	0.31
" The long-term effectiveness and side-effect profiles of pulse immunosuppressive regimens warrant further study."	( Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Austin, HA; Balow, JE; Boumpas, DT; Collins, L; Crane, M; Danning, CL; Gourley, MF; Illei, GG; Klippel, JH; Kuroiwa, T; Steinberg, AD; Vaughan, EM; Yarboro, CH, 2001)	0.31
"Rates of treatment failure (defined as need for supplemental immunosuppressive therapy or doubling of serum creatinine concentration, or death) and adverse events."	( Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Austin, HA; Balow, JE; Boumpas, DT; Collins, L; Crane, M; Danning, CL; Gourley, MF; Illei, GG; Klippel, JH; Kuroiwa, T; Steinberg, AD; Vaughan, EM; Yarboro, CH, 2001)	0.31
" Combination therapy and cyclophosphamide therapy alone did not differ statistically in terms of effectiveness or adverse events."	( Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Austin, HA; Balow, JE; Boumpas, DT; Collins, L; Crane, M; Danning, CL; Gourley, MF; Illei, GG; Klippel, JH; Kuroiwa, T; Steinberg, AD; Vaughan, EM; Yarboro, CH, 2001)	0.31
" The combination of pulse cyclophosphamide and methylprednisolone appears to provide additional benefit over pulse cyclophosphamide alone and does not confer additional risk for adverse events."	( Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Austin, HA; Balow, JE; Boumpas, DT; Collins, L; Crane, M; Danning, CL; Gourley, MF; Illei, GG; Klippel, JH; Kuroiwa, T; Steinberg, AD; Vaughan, EM; Yarboro, CH, 2001)	0.31
" LFM-A13 was not toxic to mice when administered systemically at dose levels ranging from 10 to 80 mg/kg."	( In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. Carpenter, R; Cetkovic-Cvrlje, M; Chen, CL; Chen, H; Lisowski, E; Uckun, FM; Vassilev, A; Waurzyniak, B; Zheng, Y, 2002)	0.31
"A major thrust of transplantation research is to find more effective and less broadly toxic immunosuppressive agents."	( Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients. Koch, M; Kuse, ER; Light, S; Nashan, B; Niemeyer, G, 2002)	0.31
" None of the three adverse events reported were considered to be related to treatment."	( A randomized, controlled study of the safety and efficacy of topical corticosteroid treatments of sunburn in healthy volunteers. Duteil, L; Lorenz, B; Ortonne, JP; Queille-Roussel, C; Thieroff-Ekerdt, R, 2002)	0.31
" Adverse events were more frequently observed in infliximab-treated patients, but only gold-treated patients discontinued treatment because adverse events (2 patients due to proteinuria, 2 patients due to mucocutaneous changes and one patient due to leucopenia)."	( [Analysis of efficacy and safety of multiple intravenous infusion of anti-tumor necrosis factor-alpha monoclonal antibody (Remicade) combined with methotrexate compared with sodium aurothiomalate and intramuscular depot methylprednisolone in rheumatoid ar Chlebicki, A; Głowska, A; Szechiński, J; Wiland, P, 2002)	0.31
" In this series, intralesional steroid proved to be a safe effective treatment."	( Capillary haemangioma of the eyelids and orbit: a clinical review of the safety and efficacy of intralesional steroid. Byrne, SA; Lanigan, B; O'Keefe, M, 2003)	0.32
" Adverse events were also evaluated."	( Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy. Bloch, J; Delgado, A; Khayat, D; Meric, JB; Rixe, O, 2005)	0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" An objective causality assessment revealed that the adverse reaction was possibly related to ibuprofen."	( Optic neuritis with visual field defect--possible Ibuprofen-related toxicity. Gabel, VP; Gamulescu, MA; Schalke, B; Schuierer, G, 2006)	0.33
" Although idiopathic optic neuritis cannot be completely ruled out, the absence of other risk factors and additional findings plus the improvement after discontinuation of the drug speak for isolated toxic optic neuritis of the right eye."	( Optic neuritis with visual field defect--possible Ibuprofen-related toxicity. Gabel, VP; Gamulescu, MA; Schalke, B; Schuierer, G, 2006)	0.33
"The aim of this study was to evaluate the long-term adverse effect (AE) profile of azathioprine (AZA) plus methylprednisolone combined immunosuppressive treatment in myasthenia gravis (MG) in a larger patient cohort."	( Safety of long-term combined immunosuppressive treatment in myasthenia gravis--analysis of adverse effects of 163 patients. Fornadi, L; Komoly, S; Lovas, G; Rozsa, C; Szabo, G, 2006)	0.33
" Drug-related adverse events were only observed in the tacrolimus group."	( Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Arcangeli, F; Belloni-Fortina, A; Bieber, T; Fölster-Holst, R; Städtler, G; Vick, K; Worm, M, 2007)	0.34
" All adverse effects were self-limiting."	( Side effects of postoperative administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space. Mercieca, F; Mercieca, K, 2007)	0.34
"Celiac plexus neurolysis and block are considered safe but provide limited pain relief."	( Initial evaluation of the efficacy and safety of endoscopic ultrasound-guided direct Ganglia neurolysis and block. Chari, ST; Clain, JE; de la Mora, JG; Gleeson, FC; Levy, MJ; Pearson, RK; Pelaez, MC; Petersen, BT; Rajan, E; Topazian, MD; Vege, SS; Wang, KK; Wiersema, MJ, 2008)	0.35
" There were no differences in the number and type of adverse events."	( A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Belzunegui, J; Bonilla, G; Carreño, L; Figueroa, M; López-Longo, J; Martínez-Taboada, VM; Mola, EM; Rodríguez-Valverde, V, 2008)	0.35
"IFN-alpha2a is efficient and safe for the long-term management of severe uveitis associated with Behçet disease."	( Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Bodaghi, B; Cassoux, N; Fardeau, C; Gendron, G; Gueudry, J; Lehoang, P; Piette, JC; Terrada, C; Wechsler, B, 2008)	0.35
"No meaningful difference occurred between siplizumab and placebo groups in the incidence or severity of adverse events or laboratory test results."	( Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease. Adkins, D; Ratanatharathorn, V; White, B; Yang, H, 2009)	0.35
"Liver toxicity, although not mentioned among the possible adverse effects of corticosteroids, has been occasionally reported in literature."	( Hepatotoxicity after high-dose methylprednisolone for demyelinating disease. Banfi, P; Bono, G; Cosentino, M; Loraschi, A; Mauri, M; Sessa, F, )	0.13
" We did not find any difference in treatment-emergent adverse events between the ITM and placebo group."	( Efficacy and safety of a single intrathecal methylprednisolone bolus in chronic complex regional pain syndrome. Ferrari, MD; Marinus, J; Munts, AG; Teepe-Twiss, IM; van der Plas, AA; van Hilten, JJ, 2010)	0.36
"Combining intra-articular corticosteroid and anti-TNF agent has proved to be safe in our cohort of patients."	( Efficacy and safety of combining intra-articular methylprednisolone and anti-TNF agent to achieve prolonged remission in patients with recurrent inflammatory monoarthritis. Haroon, M; O'Gradaigh, D, 2010)	0.36
"The adverse effects and risks associated with intracarotid propofol injection during Wada testing were retrospectively compared in two groups of patients with (n = 75) and without (n = 58) intravenous methylprednisolone administered before intracarotid propofol injection."	( Intravenous methylprednisolone reduces the risk of propofol-induced adverse effects during Wada testing. Hashimoto, N; Kikuchi, T; Matsumoto, A; Mikuni, N; Miyamoto, S; Yamada, S; Yokoyama, Y, 2010)	0.36
" MPA has an optimized efficacy/safety profile with minimal local or systemic adverse effects."	( Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. Luger, TA, 2011)	0.37
" On follow-up for the second epidural at 1 to 2 months, VAS scores and any reports of adverse side effects were obtained by pain clinic nursing staff who were blinded to the type of corticosteroid used."	( Efficacy and safety of lumbar epidural dexamethasone versus methylprednisolone in the treatment of lumbar radiculopathy: a comparison of soluble versus particulate steroids. Brown, J; Kim, D, )	0.13
" They are mostly presented in the group of mood stabilizers and antiepileptic drugs, particularly the carbamazepine and lamotrigine, and can be manifested through the Stevens Johnson syndrome, Toxic Epidermal Necrolysis (TEN)/Lyell's syndrome with about 30% lethality."	( Exanthema medicamentosum as a side effect of promazine. Cvitanović, MZ; Hlevnjak, I; Lasić, D; Uglešić, B; Višić, V, 2011)	0.37
" Its safety has been debated after reports of adverse events."	( Safety assessment and pharmacokinetics of intrathecal methylprednisolone acetate in dogs. Grafe, MR; Kalkman, CJ; Meulenhoff, PC; Rijsdijk, M; Steinauer, J; van Wijck, AJ; Yaksh, TL, 2012)	0.38
"Other than a brief motor block, no adverse clinical event occurred in any animal."	( Safety assessment and pharmacokinetics of intrathecal methylprednisolone acetate in dogs. Grafe, MR; Kalkman, CJ; Meulenhoff, PC; Rijsdijk, M; Steinauer, J; van Wijck, AJ; Yaksh, TL, 2012)	0.38
" The WOMAC scale was applied at 4 weeks and adverse events were recorded."	( Safety and efficacy of methylprednisolone infiltration in anserine syndrome treatment. Esquivel-Valerio, JA; Galarza-Delgado, DÁ; Garza-Elizondo, MA; Negrete-López, R; Vega-Morales, D, )	0.13
" The incidence of adverse events did not show any differences either."	( Safety and efficacy of methylprednisolone infiltration in anserine syndrome treatment. Esquivel-Valerio, JA; Galarza-Delgado, DÁ; Garza-Elizondo, MA; Negrete-López, R; Vega-Morales, D, )	0.13
" Adverse events were recorded at each visit."	( Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. Azzolini, C; Baldeschi, L; Bartalena, L; Bernard, M; Boboridis, KG; Boschi, A; Bournaud, C; Currò, N; Daumerie, C; Krassas, GE; Marcocci, C; Mourits, MP; Nardi, M; Salvi, M; Sassi, L; Soeters, MR; Stahl, M; Veronesi, G; von Arx, G; Wiersinga, W, 2012)	0.38
" Major adverse events were slightly more frequent using the highest dose but occurred also using the lowest dose."	( Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. Azzolini, C; Baldeschi, L; Bartalena, L; Bernard, M; Boboridis, KG; Boschi, A; Bournaud, C; Currò, N; Daumerie, C; Krassas, GE; Marcocci, C; Mourits, MP; Nardi, M; Salvi, M; Sassi, L; Soeters, MR; Stahl, M; Veronesi, G; von Arx, G; Wiersinga, W, 2012)	0.38
" By repeated physical and laboratory examinations and history taking, patients were assessed for adverse effects that would be related to pulse therapy before, within, and 3 months after the treatment."	( Short-term safety of pulse steroid therapy in multiple sclerosis relapses. Alinaghian, M; Ashtari, F; Fatehi, F; Norouzi, R; Salari, M; Shaygannejad, V, )	0.13
"6%) developed minor adverse effects of which the most common were palpitation, flashing, dyspepsia, insomnia, and virulent taste."	( Short-term safety of pulse steroid therapy in multiple sclerosis relapses. Alinaghian, M; Ashtari, F; Fatehi, F; Norouzi, R; Salari, M; Shaygannejad, V, )	0.13
"This study approved that high-dose intravenous methylprednisolone is a safe treatment in MS attacks and the short-term adverse effects were mostly minor and transient."	( Short-term safety of pulse steroid therapy in multiple sclerosis relapses. Alinaghian, M; Ashtari, F; Fatehi, F; Norouzi, R; Salari, M; Shaygannejad, V, )	0.13
"MP infusion therapy in combination with CsA-based immunosuppression could be safe and effective in treating recurrent FSGS after kidney transplantation."	( Combination of pulse methylprednisolone infusions with cyclosporine-based immunosuppression is safe and effective to treat recurrent focal segmental glomerulosclerosis after pediatric kidney transplantation. Aikawa, A; Asanuma, H; Hamasaki, Y; Hataya, H; Honda, M; Ishikura, K; Muramatsu, M; Satou, H; Shishido, S, )	0.13
" GCS treatment is significantly higher than oral glucocorticoid (oral GCS) therapy and is associated with fewer adverse events."	( Is high dose intravenous methylprednisolone pulse therapy in patients with Graves' orbitopathy safe? Ambroziak, U; Bednarczuk, T; Główczyńska, R; Kahaly, G; Kryczka, A; Miśkiewicz, P; Opolski, G; Rutkowska, B, 2014)	0.4
" Frequency, severity and characterization of adverse events (AE) were prospectively analyzed."	( Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves' orbitopathy. Kahaly, GJ; Kampmann, E; Kolbe, E; Krämer, I; Riedl, M, 2015)	0.42
" AEs judged as at least possibly related to drug treatment were graded as side effect (SE)."	( Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves' orbitopathy. Kahaly, GJ; Kampmann, E; Kolbe, E; Krämer, I; Riedl, M, 2015)	0.42
" Adverse effects were more frequent among HD recipients (MD=43%, HD=66%, p=0."	( Effectiveness and safety of medium-dose prednisone in giant cell arteritis: a retrospective cohort study of 103 patients. Les, I; Martínez-Berriotxoa, A; Pijoán, JI; Rodríguez-Álvarez, R; Ruiz-Irastorza, G, )	0.13
"MD prednisone regimen may be an effective and safe alternative to HD prednisone regimen in GCA."	( Effectiveness and safety of medium-dose prednisone in giant cell arteritis: a retrospective cohort study of 103 patients. Les, I; Martínez-Berriotxoa, A; Pijoán, JI; Rodríguez-Álvarez, R; Ruiz-Irastorza, G, )	0.13
" Safety was monitored estimating the frequency of adverse events (AEs) and controlling vital functions and laboratory indicators."	( [Efficacy and safety of intravenous methylprednisolone in the treatment of patients with active ankylosing spondylitis: results of a 12-week, prospective, open-label, pilot (METALL) study]. Gaydukova, IZ; Poddubnyi, DA; Rebrov, AP, 2015)	0.42
"Pulse therapy with MP 500 mg is safe and effective in the short-term treatment of patients with active AS who have achieved no benefits of NSAIDs."	( [Efficacy and safety of intravenous methylprednisolone in the treatment of patients with active ankylosing spondylitis: results of a 12-week, prospective, open-label, pilot (METALL) study]. Gaydukova, IZ; Poddubnyi, DA; Rebrov, AP, 2015)	0.42
"We describe a case of a patient from Far North Queensland, Australia, with life-threatening hepatotoxicity caused by ipilimumab induced immune-related adverse events (irAEs)."	( Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. Ahmed, T; Black, J; Pandey, R; Shah, B, 2015)	0.42
" Although human islets are prone to direct toxic effect of tacrolimus and sirolimus, we found no additive effects of the drug combination."	( Treatment with Tacrolimus and Sirolimus Reveals No Additional Adverse Effects on Human Islets In Vitro Compared to Each Drug Alone but They Are Reduced by Adding Glucocorticoids. Bergan, S; Foss, A; Kloster-Jensen, K; Korsgren, O; Sahraoui, A; Scholz, H; Vethe, NT, 2016)	0.43
" Overall, our data indicate that high-dose CS treatment for neurological diseases is relatively safe with respect to psychiatric complications."	( Psychiatric side effects of acute high-dose corticosteroid therapy in neurological conditions. Benninger, F; Fireman, L; Lotan, I; Steiner, I; Weizman, A, 2016)	0.43
"After LT, an immunosuppressive regimen without steroids could be a safe and feasible treatment for HBVrelated HCC patients, thus resulting in the reduction of HBV recurrence."	( Efficacy and Safety of a Steroid-Free Immunosuppressive Regimen after Liver Transplantation for Hepatocellular Carcinoma. Shen, Y; Wang, C; Wang, W; Wei, Q; Wu, J; Xie, H; Xu, X; Zhang, M; Zheng, S; Zhou, L; Zhuang, L; Zhuang, R, 2016)	0.43
"Safety was evaluated based on occurrence of adverse events."	( A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host Disease. Abud, TB; Amparo, F; Ciolino, JB; Dana, R; Di Zazzo, A; Dohlman, TH; Hamrah, P; Saboo, US, 2016)	0.43
" Changes in ophthalmic parameters after treatment and frequencies of adverse effects due to GCs of the 2 groups were compared."	( Overall safety and efficacy of high-dose and low-dose intravenous glucocorticoid therapy in patients with moderate-to-severe active Graves' ophthalmopathy. Fushimi, Y; Inagaki, N; Kanamoto, N; Miura, M; Nakao, K; Okada, T; Sone, M; Tanaka-Mizuno, S; Togashi, K; Ueda-Sakane, Y; Yasoda, A; Yasuno, S, 2016)	0.43
"In a prospective multi-center observational study, we evaluated the frequency, severity, and impact on activities of daily living (ADL) of adverse effects (AEs) of high-dose intravenous methylprednisolone (IVMP) in relapsing remitting multiple sclerosis (MS) patients with a relapse."	( Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse. Boringa, J; Gaillard, P; Gladdines, W; Heerings, M; Hoogervorst, E; Jongen, PJ; Linssen, WH; Lönnqvist, F; Sinnige, LG; Stavrakaki, I; van der Kruijk, R; van Munster, E; Verhagen, WI; Verheul, F; Visser, LH; Voet, B, 2016)	0.43
" Response to therapy, duration of clinical remission, serology of the response, and adverse effects of rituximab were evaluated."	( Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey. Akman Karakaş, A; Alpsoy, E; Bilgiç Temel, A; Bozkurt, S; Dicle, Ö; Erat, A; Ergün, E; Eskiocak, AH; Koç, S; Nazlım, B; Özkesici, B; Uğurlu, N; Uzun, S; Yılmaz, E, 2016)	0.43
"Rituximab is a beneficial and relatively safe adjuvant treatment for PV that facilitates prolonged clinical remission and has a significant steroid-sparing effect."	( Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey. Akman Karakaş, A; Alpsoy, E; Bilgiç Temel, A; Bozkurt, S; Dicle, Ö; Erat, A; Ergün, E; Eskiocak, AH; Koç, S; Nazlım, B; Özkesici, B; Uğurlu, N; Uzun, S; Yılmaz, E, 2016)	0.43
"Short episodes of corticosteroids seem to be safe in HBV carriers, even in the presence of DMARDs, but lamivudine prophylaxis should be considered for patients exposed to biologicals or cyclophosphamide."	( Safety of Corticosteroid Treatment in Rheumatologic Patients With Markers of Hepatitis B Viral Infection: Pilot Evaluation Study. Balbir-Gurman, A; Braun, M; Braun-Moscovici, Y; Markovits, D; Nahir, MA; Saadi, T, 2016)	0.43
" An effective and safe alternative induction regimen is needed."	( Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Babu, BG; Basu, B; Roy, B, 2017)	0.46
" In comparison with few minor adverse events in the other two cohorts, several serious adverse events occurred in the CYC group."	( Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Babu, BG; Basu, B; Roy, B, 2017)	0.46
" In this retrospective, observational cohort study, we compared time to any adverse event (primary outcome); serious or nonserious events; partial and complete remission of the nephrotic syndrome; and a composite of doubling of serum creatinine, ESRD, or death between 100 Rtx-treated patients and 103 patients who received daily St-Cp We monitored patients with standardized protocols and adjusted for baseline characteristics by Cox regression."	( Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. Chianca, A; Hofstra, JM; Perna, A; Remuzzi, G; Ruggenenti, P; Ruggiero, B; van den Brand, JAJG; Wetzels, JFM, 2017)	0.46
"Nephrotoxicity is a well-known side effect of platinum-based chemotherapy."	( Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma. Batlle, M; Feliu, E; Ferra, C; Garcia, O; Ibarra, G; Lopez, D; Moreno, M; Pineda, A; Ribera, JM; Sancho, JM; Sorigue, M; Tapia, G; Vives, S, 2017)	0.46
" Very few diseases are known to produce such high levels of GFAP, indicating a toxic effect on astrocytes."	( Heroin-induced acute myelopathy with extreme high levels of CSF glial fibrillar acidic protein indicating a toxic effect on astrocytes. Herrman, L; Hietala, MA; Sveinsson, O, 2017)	0.46
"To assess the efficacy of viscosupplementation (hyaluronic acid [HA]) on the pain and disability caused by hip osteoarthritis, and to determine the occurrence of adverse events."	( Viscosupplementation for Hip Osteoarthritis: A Systematic Review and Meta-Analysis of the Efficacy on Pain and Disability, and the Occurrence of Adverse Events. Buehler, AM; Daud Amadera, JE; Leite, VF, 2018)	0.48
"69), and high evidence that it is not superior in adverse events (risk ratio [RR]=1."	( Viscosupplementation for Hip Osteoarthritis: A Systematic Review and Meta-Analysis of the Efficacy on Pain and Disability, and the Occurrence of Adverse Events. Buehler, AM; Daud Amadera, JE; Leite, VF, 2018)	0.48
" Knee pain (Numeric Rating Scale [NRS]), Oxford Knee Score, overall treatment effect (Global Perceived Effect), analgesic drug use, and adverse events were compared between CRFA and IAS cohorts at 1, 3, and 6 months after intervention."	( Prospective, Multicenter, Randomized, Crossover Clinical Trial Comparing the Safety and Effectiveness of Cooled Radiofrequency Ablation With Corticosteroid Injection in the Management of Knee Pain From Osteoarthritis. Buvanendran, A; Choi, D; Davis, T; DePalma, M; Desai, M; Gupta, A; Hunter, C; Kapural, L; Lindley, D; Loudermilk, E; Patel, N; Soloman, M, 2018)	0.48
" There were no procedure-related serious adverse events."	( Prospective, Multicenter, Randomized, Crossover Clinical Trial Comparing the Safety and Effectiveness of Cooled Radiofrequency Ablation With Corticosteroid Injection in the Management of Knee Pain From Osteoarthritis. Buvanendran, A; Choi, D; Davis, T; DePalma, M; Desai, M; Gupta, A; Hunter, C; Kapural, L; Lindley, D; Loudermilk, E; Patel, N; Soloman, M, 2018)	0.48
"Our strategy for refractory Kawasaki disease was safe and effective in preventing CAA."	( The Clinical Utility and Safety of a New Strategy for the Treatment of Refractory Kawasaki Disease. Ebato, T; Fujimoto, M; Ishii, M; Kitagawa, A; Ogata, S; Ogihara, Y; Takanashi, M, 2017)	0.46
"Corticosteroids (CSs), used to treat rheumatoid arthritis (RA), confer a risk of adverse events (AEs)."	( Safety and efficacy of alternate-day corticosteroid treatment as adjunctive therapy for rheumatoid arthritis: a comparative study. Kishimoto, M; Ohde, S; Okada, M; Suda, M; Tsuda, T, 2018)	0.48
" Variables studied: age, sex, MTP cumulative doses, duration of treatment, therapeutic response and adverse effects."	( [Methylprednisolone for the treatment of Immune-mediates Diseases flares. Relationship between doses, effectiveness and safety. A pilot study]. Danza Galdo, Á, 2017)	0.46
" The mean dose in patients with adverse effects was 4,4 (SD 1,8) grams, and in cases without adverse effects was 3,2 (SD 1,6) grams (p<0,05)."	( [Methylprednisolone for the treatment of Immune-mediates Diseases flares. Relationship between doses, effectiveness and safety. A pilot study]. Danza Galdo, Á, 2017)	0.46
" However, an association between higher doses of MTP and adverse effects was observed."	( [Methylprednisolone for the treatment of Immune-mediates Diseases flares. Relationship between doses, effectiveness and safety. A pilot study]. Danza Galdo, Á, 2017)	0.46
" Outcomes were number of responders to treatment, remission rate of treatment responders, overall probability of 5-year remission, and the occurrence of adverse events."	( Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. Basta, I; Doneddu, PE; Eftimov, F; Gallia, F; Nikolic, A; Nobile-Orazio, E; Peric, S; van Lieverloo, GGA; van Schaik, IN; Verhamme, C; Wieske, L, 2018)	0.48
" Adverse events leading to a change in treatment occurred in ten patients (8%)."	( Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. Basta, I; Doneddu, PE; Eftimov, F; Gallia, F; Nikolic, A; Nobile-Orazio, E; Peric, S; van Lieverloo, GGA; van Schaik, IN; Verhamme, C; Wieske, L, 2018)	0.48
" The recently published European Group on Graves Orbitopathy guidelines re-evaluated the recommended doses of intravenous methylprednisolone (ivMP) in response to the potential for adverse effects."	( RETROSPECTIVE ANALYSIS OF PATIENTS WITH GRAVES ORBITOPATHY TREATED BY PULSES OF METHYLPREDNISOLONE, WITH A FOCUS ON ADVERSE EVENTS. Cibickova, L; Frysak, Z; Karasek, D; Karhanova, M; Kovarova, D; Schovanek, J, 2018)	0.48
" Adverse events were reported using Version 4 of Common Terminology Criteria for Adverse Events."	( RETROSPECTIVE ANALYSIS OF PATIENTS WITH GRAVES ORBITOPATHY TREATED BY PULSES OF METHYLPREDNISOLONE, WITH A FOCUS ON ADVERSE EVENTS. Cibickova, L; Frysak, Z; Karasek, D; Karhanova, M; Kovarova, D; Schovanek, J, 2018)	0.48
"Ninety-two percent of patients who started the treatment were able to finish it; 5% did not finish the study due to adverse events, and 3% did not finish the treatment protocol because of noncompliance."	( RETROSPECTIVE ANALYSIS OF PATIENTS WITH GRAVES ORBITOPATHY TREATED BY PULSES OF METHYLPREDNISOLONE, WITH A FOCUS ON ADVERSE EVENTS. Cibickova, L; Frysak, Z; Karasek, D; Karhanova, M; Kovarova, D; Schovanek, J, 2018)	0.48
"High-dose ivMP for active, moderate to severe, and sight-threatening GO, when applied cautiously in carefully selected and monitored patients, is generally safe during the treatment period."	( RETROSPECTIVE ANALYSIS OF PATIENTS WITH GRAVES ORBITOPATHY TREATED BY PULSES OF METHYLPREDNISOLONE, WITH A FOCUS ON ADVERSE EVENTS. Cibickova, L; Frysak, Z; Karasek, D; Karhanova, M; Kovarova, D; Schovanek, J, 2018)	0.48
"AE = adverse effect; CAS = clinical activity score; CTCAE = Common Terminology Criteria for Adverse Events; DM = diabetes mellitus; EUGOGO = European Group on Graves Orbitopathy; GC = glucocorticoid; GO = Graves orbitopathy; ivMP = intravenous methylprednisolone."	( RETROSPECTIVE ANALYSIS OF PATIENTS WITH GRAVES ORBITOPATHY TREATED BY PULSES OF METHYLPREDNISOLONE, WITH A FOCUS ON ADVERSE EVENTS. Cibickova, L; Frysak, Z; Karasek, D; Karhanova, M; Kovarova, D; Schovanek, J, 2018)	0.48
" Eight patients complained of adverse effects from steroid therapy such as heartburn, insomnia, weight gain, and myalgia."	( Efficacy and Safety of Low-to-Moderate Dose Oral Corticosteroid Treatment in Ocular Myasthenia Gravis. Kim, US; Lee, YG, 2018)	0.48
" The secondary outcomes include adverse effects (gastrointestinal events and pruritus) and postoperative complications (deep venous thrombosis, pulmonary embolism and infection); (5) Study design: RCTs."	( The efficacy and safety of methylprednisolone for pain control after total knee arthroplasty: A meta-analysis of randomized controlled trials. Gao, Z; Liu, J; Shen, S, 2018)	0.48
"Methylprednisolone could significantly decrease postoperative pain score, narcotic consumption and opioid-related adverse effects after TKA."	( The efficacy and safety of methylprednisolone for pain control after total knee arthroplasty: A meta-analysis of randomized controlled trials. Gao, Z; Liu, J; Shen, S, 2018)	0.48
" A dysregulated activation of T-cells directed to normal tissues stands as the main mechanism of immune-related adverse events (irAE)."	( Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma. Aubin, F; Beaudoin, MA; Borg, C; Borot, S; Cattin, F; Gauthier, AS; Nardin, C; Puzenat, E; Schillo, F, 2019)	0.51
" Although their conventional adverse effects including hyperglycemia, hypertension, hyperlipidemia, and osteoporosis are well-recognized and managed, steroid-induced cardiac arrhythmias are known to a lesser extent."	( Dose-dependent bradycardia as a rare side effect of corticosteroids: a case report and review of the literature. Bodakçi, E; Korkmaz, C; Üsküdar Cansu, D, 2018)	0.48
"Overall, adjunctive systemic corticosteroids therapy was effective and safe for patients with severe CAP."	( Efficacy and safety of adjunctive corticosteroids therapy for patients with severe community-acquired pneumonia: A systematic review and meta-analysis. Guo, J; Huang, J; Huang, W; Li, H; Zhang, T, 2019)	0.51
" Ublituximab proved to be safe in all 5 NMOSD subjects, with no serious adverse events recorded."	( A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. Levy, M; Mealy, MA, 2019)	0.51
"Ublituximab is a safe add-on therapy for NMOSD patients presenting with acute transverse myelitis and optic neuritis."	( A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. Levy, M; Mealy, MA, 2019)	0.51
"This study provides Class IV evidence that for patients with NMOSD with acute transverse myelitis or optic neuritis, ublituximab is safe and may improve neurological outcome."	( A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. Levy, M; Mealy, MA, 2019)	0.51
" Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare yet severe adverse drug-induced reaction characterized by exfoliative dermatitis and maculopapular rash, lymphadenopathy, fever, eosinophilia, leukocytosis, and myriad internal organ involvement."	( A rare and severe cutaneous adverse effect of telaprevir: drug rash with eosinophilia and systemic symptoms. Bahali, AG; Biyik Ozkaya, D; Cengiz, FP; Emiroglu, N; Onsun, N; Su, O, 2019)	0.51
" We evaluated adverse events of an acute treatment in NMOSD patients in a university-based hospital during January 2009 and December 2017."	( Retrospective study of the adverse events of the treatment for an acute attack of neuromyelitis optica spectrum disorder. Prayoonwiwat, N; Siritho, S; Veerachit-O-Larn, T, 2020)	0.56
"We conclude that high-dose methylprednisolone is effective in the treatment of SMPP without increasing the incidence of adverse reactions."	( Meta-analysis of the Clinical Efficacy and Safety of High- and Low-dose Methylprednisolone in the Treatment of Children With Severe Mycoplasma Pneumoniae Pneumonia. Deng, ZZ; Sun, LL; Wang, CJ; Ye, C; Zhou, YL; Zuo, SR, 2020)	0.56
"The most effective and safe treatment protocol for Graves' orbitopathy (GO) needs to be further assessed."	( Comparison of efficacy and safety of parenteral versus parenteral and oral glucocorticoid therapy in Graves' orbitopathy. Ciric, J; Knezevic, M; Lalic, T; Miletic, M; Nedeljkovic Beleslin, B; Savic, S; Stankovic, B; Stojanovic, M; Stojkovic, M; Zarkovic, M, 2020)	0.56
" The efficacy outcomes included a cessation of epileptic spasms (as per caregiver reporting) and resolution of hypsarrhythmia on electroencephalogram; safety outcome was the frequency of various adverse effects."	( Safety, Feasibility and Effectiveness of Pulse Methylprednisolone Therapy in Comparison with Intramuscular Adrenocorticotropic Hormone in Children with West Syndrome. Gupta, A; Madaan, P; Rajpurohit, M; Sahu, JK; Singhi, P, 2021)	0.62
" The survival time, cause of death, adverse events, liver function, and HBV DNA replication were analyzed."	( The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: a prospective multi-center clinical trial. Duan, ZH; He, WP; Jia, L; Li, J; Liu, HX; Meng, QH; Ren, MX; Wang, XM; Xing, HC; Xue, R; Zhao, J; Zhu, Y, 2020)	0.56
"MP therapy is an effective and safe clinical strategy in HBV-ACLF, increasing the 6-month survival rate."	( The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: a prospective multi-center clinical trial. Duan, ZH; He, WP; Jia, L; Li, J; Liu, HX; Meng, QH; Ren, MX; Wang, XM; Xing, HC; Xue, R; Zhao, J; Zhu, Y, 2020)	0.56
" The incidence of adverse events was assessed using the same questionnaire."	( Efficacy and safety of oral prednisolone tapering following intravenous methyl prednisolone in patients with multiple sclerosis relapses: A randomized, double-blind, placebo-controlled trial. Baghbanian, SM; Bazi, A; Ghazaeian, M; Hendoiee, N; Saeedi, M, 2021)	0.62
"MP group than the TG group experienced adverse events."	( Efficacy and safety of tripterygium glycosides for active moderate to severe Graves' ophthalmopathy: a randomised, observer-masked, single-centre trial. Liu, J; Lu, B; Shao, J; Wang, J; Ye, X; Zhao, H, 2021)	0.62
" The primary adverse reaction was infection."	( Efficacy and Safety of Long-Term Corticosteroid Monotherapy in 26 Cases of Nephrotic Syndrome with Biopsy-Proven Membranous Nephropathy Induced by Seronegative Hepatitis B Virus-Associated Glomerulonephritis. Chen, S; Han, H; Liu, J; Yang, D; Yang, X; Zhang, X; Zhang, Y, 2021)	0.62
"The long-term middle-dose corticosteroid therapy without antiviral drugs is effective and safe for membranous sn HBV-GN patients."	( Efficacy and Safety of Long-Term Corticosteroid Monotherapy in 26 Cases of Nephrotic Syndrome with Biopsy-Proven Membranous Nephropathy Induced by Seronegative Hepatitis B Virus-Associated Glomerulonephritis. Chen, S; Han, H; Liu, J; Yang, D; Yang, X; Zhang, X; Zhang, Y, 2021)	0.62
" We did not observe any severe adverse events relating to the IVMP procedures."	( Efficacy and safety of i.v. methylprednisolone pulse therapy for vitiligo: A retrospective study of 58 therapy experiences for 33 vitiligo patients. Aiba, S; Hatchome, N; Kimura, Y; Sasaki, R; Tsuchiyama, K; Wada-Irimada, M; Watabe, A; Yamasaki, K, 2021)	0.62
" However, the benefits and adverse effects of methylprednisolone have not been well assessed in patients with ARDS."	( Efficacy and safety of methylprednisolone against acute respiratory distress syndrome: A systematic review and meta-analysis. Chen, M; Chen, Q; Cheng, L; Dai, L; Geng, Y; Lu, J; Lv, H; Wang, X, 2021)	0.62
"10; I2 = 0%) in patients with ARDS, but it was not associated with increased rates of adverse events (OR = 0."	( Efficacy and safety of methylprednisolone against acute respiratory distress syndrome: A systematic review and meta-analysis. Chen, M; Chen, Q; Cheng, L; Dai, L; Geng, Y; Lu, J; Lv, H; Wang, X, 2021)	0.62
"This systematic review and meta-analysis demonstrated that Methylprednisolone is safe against ARDS."	( Efficacy and safety of methylprednisolone against acute respiratory distress syndrome: A systematic review and meta-analysis. Chen, M; Chen, Q; Cheng, L; Dai, L; Geng, Y; Lu, J; Lv, H; Wang, X, 2021)	0.62
"TCZ combined with mPSL pulse therapy improved the survival rate without significant adverse events in critical HD and non-HD patients with COVID-19 by strongly suppressing systemic hyperinflammation."	( Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients. Fujii, K; Itoh, K; Kikuchi, T; Kondo, Y; Ryuzaki, M; Sekine, K; Toda, M; Yoshifuji, A, 2022)	0.72
" Mpz and Hc seem safe as a rescue therapy in terms of adverse outcomes for established BPD in which lung and brain tissue is already impaired."	( Glucocorticoids in a Neonatal Hyperoxic Lung Injury Model: Pulmonary and Neurotoxic effects. Büyüktiryaki, M; Çakır, E; Çakır, U; Koyuncu, İ; Özer Bekmez, B; Tayman, C; Türkmenoğlu, TT, 2022)	0.72
" During study, adverse events of the treatments were recorded."	( Comparing efficacy and safety of tocilizumab and methylprednisolone in the treatment of patients with severe COVID-19. Abbasian, L; Alizade, F; Azadbakhsh Kanaf Gorabi, M; Ghaderkhani, S; Ghiasvand, F; Hasannezhad, M; Jafari, S; Khalili, H; Nakhostin, M; Rahmani, H; Salahshour, F; Salehi, M; Toroghi, N, 2022)	0.72
" Other adverse events were comparable among patients in the groups."	( Comparing efficacy and safety of tocilizumab and methylprednisolone in the treatment of patients with severe COVID-19. Abbasian, L; Alizade, F; Azadbakhsh Kanaf Gorabi, M; Ghaderkhani, S; Ghiasvand, F; Hasannezhad, M; Jafari, S; Khalili, H; Nakhostin, M; Rahmani, H; Salahshour, F; Salehi, M; Toroghi, N, 2022)	0.72
"Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases SUMMARY Programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) have been widely used in lung cancer treatment, but their immune-related adverse events (irAEs) require intensive attention."	( [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases]. Cao, BS; Gu, YC; Liu, Y; Xie, C, 2022)	0.72
"Routine systemic therapy for bullous pemphigoid (BP) has been challenged due to the inevitably adverse effects."	( Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid. Chen, S; Chen, Z; Gao, H; He, S; Hu, Y; Liu, S; Luo, X; Ma, L; Tang, C; Tang, L; Wang, L; Xu, Y; Yang, F; Yang, J; Zhang, Z; Zhao, Y, 2022)	0.72
" Overall, corticosteroids reduced inflammatory complications after 3MS and did not show any serious adverse effects."	( Comparative efficacy and safety of different corticosteroids to reduce inflammatory complications after mandibular third molar surgery: a systematic review and network meta-analysis. Canellas, JVDS; Ritto, FG; Tiwana, P, 2022)	0.72
" The two groups did not differ in severe adverse events."	( Efficacy and safety of methylprednisolone pulse followed by oral prednisone vs. oral prednisone alone in sarcoidosis tubulointerstitial nephritis: a randomized, open-label, controlled clinical trial. Audard, V; Boffa, JJ; Cez, A; Daugas, E; Delahousse, M; Guerrot, D; Hanrotel, C; Krastinova, E; Mahevas, M; Pillebout, E; Rousseau, A; Valeyre, D; Verhelst, D, 2023)	0.91
" We extracted data on trials and patient characteristics, and the following primary outcomes: all-cause mortality (ACM), and treatment-emergent adverse events (TEAEs)."	( Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials. Chen, J; Cheng, Q; Fang, Z; Jia, Q; Zhao, G, 2022)	0.72
" We found that most medications were safe in treating severe COVID-19."	( Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials. Chen, J; Cheng, Q; Fang, Z; Jia, Q; Zhao, G, 2022)	0.72
" Moreover, no significant adverse events were observed, compared to placebo or standard support therapy."	( Safety and efficacy of corticosteroids in ARDS patients: a systematic review and meta-analysis of RCT data. Chang, X; Dang, H; Fu, Y; Li, S; Liu, C, 2022)	0.72
"Budesonide-MMX is a topically active corticosteroid degraded by cytochrome-P450 enzymes, resulting in favorable side-effect profile."	( Possible genetical predictors of efficacy and safety of budesonide-MMX in patients with mild-to-moderate ulcerative colitis, and safety comparison with methylprednisolone. Bacsur, P; Bálint, A; Bor, R; Fábián, A; Farkas, K; Keresztes, C; Mangó, K; Milassin, Á; Molnár, T; Monostory, K; Pigniczki, D; Resál, T; Rutka, M; Szántó, K; Szepes, Z, )	0.13
" Glucocorticoid-related adverse events were more common following methylprednisolone treatment (47."	( Possible genetical predictors of efficacy and safety of budesonide-MMX in patients with mild-to-moderate ulcerative colitis, and safety comparison with methylprednisolone. Bacsur, P; Bálint, A; Bor, R; Fábián, A; Farkas, K; Keresztes, C; Mangó, K; Milassin, Á; Molnár, T; Monostory, K; Pigniczki, D; Resál, T; Rutka, M; Szántó, K; Szepes, Z, )	0.13
" No adverse event associated with dupilumab was recorded."	( The efficacy and safety of dupilumab combined with methylprednisolone in the treatment of bullous pemphigoid in China. Qi, W; Rushan, X, 2023)	0.91
" Clinicoserological features, initial response, relapse during follow-ups, cumulative doses of glucocorticoids, and adverse effects of glucocorticoids were compared for the IV and oral steroid groups."	( Efficacy and safety of intravenous glucocorticoid therapy for IgG4-related ophthalmic disease. Choi, YA; Kim, GJ; Sa, HS; Yang, MK, 2023)	0.91
"Recent advances in immune-checkpoint inhibitors (ICIs) have highlighted the need for effective management of immune-related adverse events (irAEs)."	( Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes. Egashira, N; Hata, K; Hirota, T; Ieiri, I; Matsuda, K; Matsukane, R; Minami, H; Nakao, S; Suetsugu, K; Watanabe, H, 2023)	0.91
" In terms of safety endpoints, the total adverse event rates (AEs), leucopenia, gastrointestinal (GI) AEs, skin diseases, and liver dysfunction of the "IGU+MP" group and the "HCQ+MP" group were comparable."	( Efficacy and safety of iguratimod combined with methylprednisolone for primary Sjögren's syndrome: a meta-analysis and trial sequential analysis. Hu, G; Xu, Q; Yang, XY; Yin, S; You, H; Yu, YF, 2023)	0.91
" IGU combined with MP does not increase the risk of adverse events, which means that IGU combined with MP may be a safe and effective strategy for the treatment of pSS and has value for further research exploration."	( Efficacy and safety of iguratimod combined with methylprednisolone for primary Sjögren's syndrome: a meta-analysis and trial sequential analysis. Hu, G; Xu, Q; Yang, XY; Yin, S; You, H; Yu, YF, 2023)	0.91
" In this case series the authors describe three pediatric patients with this side effect in the setting of severe macrophage activation syndrome (MAS) in KD and sJIA."	( Anakinra and hepatotoxicity in pediatric rheumatology: a case series. Aguiar, F; Azevedo, AC; Brito, I; Ganhão, S; Martins, FR; Rodrigues, M, 2023)	0.91
" Exclusion of sepsis / toxic shock syndrome warranted introduction of IV methylprednisolone and immunoglobulin (IG IV), with partial response."	( Anakinra and hepatotoxicity in pediatric rheumatology: a case series. Aguiar, F; Azevedo, AC; Brito, I; Ganhão, S; Martins, FR; Rodrigues, M, 2023)	0.91
" Notably, no serious adverse effects were observed in the study."	( Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study. Ding, Y; Gao, Y; Huang, D; Jiang, Y; Kong, L; Shi, Y; Yu, Y; Zhang, Y, 2023)	0.91
" The statistical analysis revealed no significant differences in adverse events."	( Efficacy and safety of corticosteroid therapy in patients with cardiac arrest: A meta-analysis of randomized controlled trials. Li, DZ; Liu, C; Zhang, Y; Zhou, FC; Zhou, FW, 2024)	1.44

Excerpt	Reference	Relevance
" After intravenous infusion, methylprednisolone hemisuccinate was rapidly converted to methylprednisolone with a half-life of about 20 min."	( Pharmacokinetics of high-dose methylprednisolone in children. Ito, S; Ito, Y; Kusunoki, Y; Oka, T; Okuno, A; Yoshioka, H, 1992)	0.28
" Indeed, test doses of cyclosporin followed by series of blood samples and the calculation of individual pharmacokinetic parameters are needed to assure successful immunosuppression right from the start."	( Optimisation of immunosuppressive therapy using pharmacokinetic principles. Grevel, J, 1992)	0.28
" The 50% inhibitory concentration values for methylprednisolone derived from pharmacodynamic models were also similar, indicating no difference in intrinsic responsiveness."	( Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 am versus 4 pm. Fisher, LE; Jusko, WJ; Ludwig, EA; Middleton, E; Sloan, RR; Wald, JA, 1992)	0.28
" Blood samples were collected and assayed for MP by HPLC for pharmacokinetic analysis."	( Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics. Chen, HY; Jusko, WJ; Salazar, DE; Wald, JA, 1991)	0.28
" Pharmacodynamic models were applied for these immediate effects of methylprednisolone based on the premise that receptor interactions of steroids are followed by rapid suppression of the circadian rhythm of cortisol and recirculation of basophils and helper T cells, which persist until inhibitory concentrations (IC50) of methylprednisolone disappear."	( Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Camara, DS; Dunn, TE; Jusko, WJ; Ludwig, EA; Slaughter, RL, 1991)	0.28
" To ascertain which pharmacokinetic properties of these drugs explain this difference, we gave methylprednisolone and prednisolone, 5 mg/kg intravenous bolus, to 23 adult rabbits."	( Methylprednisolone achieves greater concentrations in the lung than prednisolone. A pharmacokinetic analysis. Bloedow, DC; Greos, LS; Hill, MR; Irvin, CG; Larsen, GL; Szefler, SJ; Vichyanond, P, 1991)	0.28
" Forty different pharmacodynamic parameters were followed for 1 week."	( Pharmacodynamics of methylprednisolone phosphate after single intravenous administration to healthy volunteers. Barth, J; Derendorf, H; Krieg, M; Möllmann, C; Möllmann, H; Röthig, HJ; Tunn, S, 1991)	0.28
" The pharmacokinetic values of the two drugs in patients having cardiopulmonary bypass were compared to those in younger, healthy subjects."	( Pharmacokinetics of methylprednisolone sodium succinate and methylprednisolone in patients undergoing cardiopulmonary bypass. Beam, TR; Jungbluth, GL; Jusko, WJ; Kong, AN; Pasko, MT, 1990)	0.28
" A pharmacodynamic model for basophil cell distribution to and from an extravascular compartment describes the effects of MP after both regimens."	( Steroid dose sparing: pharmacodynamic responses to single versus divided doses of methylprednisolone in man. Jusko, WJ; Ludwig, EA; Middleton, E; Reiss, WG; Slaughter, RL, 1990)	0.28
" After the development of a data base of pharmacokinetic parameters, we examined glucocorticoid pharmacokinetics in 54 patients between 2 and 70 years of age using 70 pharmacokinetic studies after administration of intravenous methylprednisolone (n = 25), oral methylprednisolone (n = 15), intravenous prednisolone (n = 18), and oral prednisone (n = 12)."	( Monitoring glucocorticoid therapy: a pharmacokinetic approach. Ball, BD; Bartoszek, M; Brenner, AM; Hill, MR; Szefler, SJ, 1990)	0.28
" The same parasitic burden provoked only a slight decrease in the elimination half-life of methylprednisolone alcohol when its hemisuccinate ester was administered."	( Comparative incidence of experimental fascioliasis on corticosteroid pharmacokinetics in sheep. Alvinerie, M; Galtier, P; Houin, G; Toutain, PL; Tufenkji, AE, 1989)	0.28
" The presented methods are simple, rapid, specific, sensitive, reproducible, and economical for the pharmacokinetic study of these steroids."	( Two chromatographic methods for the determination of corticosteroids in human biological fluids: pharmacokinetic applications. al-Habet, SM; Rogers, HJ, 1989)	0.28
"A pharmacokinetic investigation of administered corticosteroids was conducted in a 16-year-old girl with cystic fibrosis (CF)."	( Rapid methylprednisolone clearance in a patient with cystic fibrosis. Farrell, PM; Green, CG; Jusko, WJ; Kraus, CK; Lemanske, RF, 1988)	0.27
"499 L/h/kg and its half-life was 15."	( Pharmacokinetics of methylprednisolone succinate, methylprednisolone, and lidocaine in the normal dog and during hemorrhagic shock. Alvinerie, M; Autefage, A; Oukessou, M; Toutain, PL, 1987)	0.27
" To compare clinical and pharmacokinetic variables of methylprednisolone and oral prednisolone in patients with RA, a controlled crossover study was carried out."	( Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study. Boutagy, J; Brooks, PM; Cosh, D; Donovan, S; McCredie, M; Needs, CJ; Smith, M, 1988)	0.27
"The absolute bioavailability and pharmacokinetic parameters of two methylprednisolone formulations (methylprednisolone sodium succinate and methylprednisolone acetate) were determined in five dogs."	( Pharmacokinetics of methylprednisolone, methylprednisolone sodium succinate, and methylprednisolone acetate in dogs. Alvinerie, M; Fayolle, PM; Koritz, GD; Toutain, PL, 1986)	0.27
"The pharmacokinetic properties of cyclosporine and mainly its absorption and hepatic elimination can vary in each patient in relation to the subject's individual characteristics (inter-subject variability), as well as in an individual patient during his treatment because of clinical episodes or drug interactions (intra-subject variabilities)."	( [Pharmacokinetics and metabolism of cyclosporin; drug interactions]. Kiechel, JR; Lavene, D; Le Bigot, JF, 1987)	0.27
" A physiologic pharmacodynamic model was developed to describe changes in circulating lymphocytes as a function of both endogenous cortisol and methylprednisolone concentrations."	( Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking. Anné, S; Jusko, WJ; Ludwig, EA; Middleton, E; Milad, MA, 1994)	0.29
"Due to the short pharmacokinetic half-life of its active metabolite, pharmacodynamic effects of deflazacort are of shorter duration than those of methylprednisolone and prednisolone."	( Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Barth, J; Derendorf, H; Hochhaus, G; Möllmann, H; Rohatagi, S, 1995)	0.29
" Rabbits are a good animal model for pharmacokinetic studies of these drugs."	( Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. Chow, FS; Jusko, WJ; Piekoszewski, W, 1994)	0.29
" A 24-hour pharmacokinetic evaluation was conducted in a sub-group of African-American and Caucasian patients after intravenous administration of methylprednisolone."	( Post-transplant diabetes mellitus and methylprednisolone pharmacokinetics in African-American and Caucasian renal transplant recipients. Biocevich, DM; Gray, V; Murray, BM; Reed, KA; Singh, JP; Tornatore, KM; Tousley, K; Venuto, RC, 1995)	0.29
" The serum samples were analyzed for methylprednisolone with high-performance liquid chromatography (HPLC) and pharmacokinetic parametes were generated."	( Pharmacokinetics of methylprednisolone during acute renal allograft rejection. Reed, K; Tornatore, KM; Venuto, RC; Walshe, JJ, 1995)	0.29
"Rejection crises after kidney transplantation could be associated with individual variability of pharmacokinetic parameters of steroids."	( Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients. Hemmen, T; Keller, F; Offermann, G; Schöneshöfer, M; Schwarz, A, 1995)	0.29
"Serum methylprednisolone concentrations were determined by HPLC and were used to generate the pharmacokinetic parameters of the drug."	( Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients. Reed, KA; Tornatore, KM; Venuto, RC, 1995)	0.29
" The net response (area under the curve) and inhibitory concentrations (IC50) of methylprednisolone for each pharmacodynamic parameter were similar in both groups."	( Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure. Jusko, WJ; Kohli, RK; Lew, KH; Ludwig, EA; Milad, MA, 1995)	0.29
" No dependence on time was apparent for any prodrug pharmacokinetic parameter."	( Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers. Della-Coletta, AA; Ferry, JJ; VanderLugt, JT; Weber, DJ, 1994)	0.29
" Standard pharmacokinetic parameters for methylprednisolone were determined and cortisol responses were characterized by total cortisol area under the concentration curve (AUC), return cortisol AUC, and cortisol suppression half-life."	( Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. Biocevich, DM; Reed, K; Singh, JP; Tornatore, KM; Tousley, K; Venuto, RC, 1995)	0.29
"A randomized, parallel pharmacokinetic trial."	( Pharmacokinetics of methylprednisolone in elderly and young healthy males. Davis, PJ; Logue, G; Tornatore, KM; Venuto, RC, 1994)	0.29
" Serum methylprednisolone concentrations were determined by high performance liquid chromatography and utilized to determine the pharmacokinetic parameters."	( Pharmacokinetics of methylprednisolone in elderly and young healthy males. Davis, PJ; Logue, G; Tornatore, KM; Venuto, RC, 1994)	0.29
" This pharmacokinetic alteration seen in healthy elderly subjects may contribute to the increased incidence of adverse effects from chronic glucocorticoid therapy that has been observed among elderly patients."	( Pharmacokinetics of methylprednisolone in elderly and young healthy males. Davis, PJ; Logue, G; Tornatore, KM; Venuto, RC, 1994)	0.29
"Four basic models for characterizing indirect pharmacodynamic responses after drug administration have been developed and compared."	( Comparison of four basic models of indirect pharmacodynamic responses. Dayneka, NL; Garg, V; Jusko, WJ, 1993)	0.29
"To examine the pharmacodynamic patterns of cortisol and pharmacokinetic values of long-term methylprednisolone in renal transplant recipients."	( Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. Reed, K; Tornatore, KM; Venuto, RC; Walshe, JJ, )	0.13
"Twenty-four-hour pharmacokinetic and pharmacodynamic evaluation of patients who participated in a glucocorticoid-monitoring program."	( Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. Reed, K; Tornatore, KM; Venuto, RC; Walshe, JJ, )	0.13
"The pharmacodynamic response of cortisol in renal transplant recipients may be associated in part with long-term steroid exposure."	( Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. Reed, K; Tornatore, KM; Venuto, RC; Walshe, JJ, )	0.13
"Comprehensive pharmacokinetic evaluations of patients who participated in our glucocorticoid-monitoring program."	( Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. Reed, KA; Tornatore, KM; Venuto, RC, )	0.13
"Serum methylprednisolone concentrations were determined by HPLC and were used to generate pharmacokinetic parameters for this drug."	( Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. Holdsworth, MT; Reed, KA; Tornatore, KM; Venuto, RC; Walshe, JJ, 1993)	0.29
" Therefore, the pharmacokinetic variability noted in this study may have important clinical implications regarding the development of chronic toxicity (e."	( Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. Holdsworth, MT; Reed, KA; Tornatore, KM; Venuto, RC; Walshe, JJ, 1993)	0.29
" Twenty-two different pharmacodynamic parameters were followed as a function of time for 48 hours."	( Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids. Barth, J; Derendorf, H; Hochhaus, G; Krieg, M; Möllmann, C; Möllmann, H; Tunn, S, 1993)	0.29
" Pharmacodynamic parameters measured were plasma cortisol, whole blood histamine (reflecting basophils), and blood helper T lymphocytes."	( Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Ferry, JJ; Jusko, WJ; Lew, KH; Ludwig, EA; Middleton, E; Slayter, KL, 1996)	0.29
"447 L/hr/kg), resulting in a longer elimination half-life (2."	( Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Ferry, JJ; Jusko, WJ; Lew, KH; Ludwig, EA; Middleton, E; Slayter, KL, 1996)	0.29
" This slower clearance rate contributed to a longer elimination half-life for methylprednisolone (2."	( Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Ferry, JJ; Jusko, WJ; Lew, KH; Ludwig, EA; Middleton, E; Slayter, KL, 1996)	0.29
" Dose-dependent changes in pharmacokinetic parameters were observed for both free and liposomal drug."	( Liposomal methylprednisolone in rats: dose-proportionality and chronic-dose pharmacokinetics/pharmacodynamics. Jusko, WJ; Mishina, EV, 1996)	0.29
" Pharmacodynamic parameters were obtained by fitting seven differential equations in a piecewise fashion."	( Third-generation model for corticosteroid pharmacodynamics: roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver. Almon, RR; DuBois, DC; Jusko, WJ; Sun, YN; Xu, ZX, 1995)	0.29
" The objectives of this study were to compare the effect of methylprednisolone on cortisol patterns in elderly and young healthy men, to define the relationship between pharmacokinetic parameters of methylprednisolone and pharmacodynamics of cortisol in the elderly and young men."	( Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. Davis, PJ; Logue, G; Tornatore, KM; Venuto, RC, 1997)	0.3
"Ninety volunteers were included in the pharmacokinetic analysis."	( A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. Daley-Yates, PT; Parker, TJ; Wood, SA, 1997)	0.3
" Based on individual Bayesian estimates, the exposure of patients to MP was marginally lower for MP suleptanate although the parameter estimates were not significantly different for half-life (2."	( A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. Daley-Yates, PT; Parker, TJ; Wood, SA, 1997)	0.3
"The aim of this study was to establish whether pharmacokinetic differences between two pro-drugs of methylprednisolone (MP) are likely to be of clinical significance."	( Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone. Brooks, CD; Daley-Yates, PT; Gregory, AJ, 1997)	0.3
" Bioequivalence was assessed by conventional pharmacokinetic analysis, by measuring pharmacodynamic responses plus a novel approach using pharmacokinetic/pharmacodynamic modeling."	( Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone. Brooks, CD; Daley-Yates, PT; Gregory, AJ, 1997)	0.3
"The MP Cmax was less for MP suleptanate due to a longer absorption halflife of the prodrug from the intramuscular injection site."	( Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone. Brooks, CD; Daley-Yates, PT; Gregory, AJ, 1997)	0.3
" The use of both pharmacokinetic and pharmacodynamic response data together gives greater confidence in the conclusions compared with those based only on conventional pharmacokinetic bioequivalence analysis."	( Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone. Brooks, CD; Daley-Yates, PT; Gregory, AJ, 1997)	0.3
" Due to the complicated pharmacokinetic properties of prednisolone, it is extremely difficult to determine the dose needed to obtain a desired target concentration."	( Pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral administration. Barth, J; Derendorf, H; Hochhaus, G; Möllmann, C; Möllmann, H; Rohatagi, S; Soldner, A, 1997)	0.3
" Pharmacodynamic monitoring has been investigated by us and other investigators on primarily five immunosuppressive drugs: cyclosporine (CsA), mycophenolate mofetil (MMF), rapamycin (RAPA), azathioprine (AZA), and methylprednisolone (MP)."	( The monitoring of immunosuppressive drugs: a pharmacodynamic approach. Aspeslet, LJ; Yatscoff, RW, 1998)	0.3
" Pharmacodynamic parameters were obtained by fitting seven differential equations piecewise using the maximum likelihood method in the ADAPT II program."	( Fourth-generation model for corticosteroid pharmacodynamics: a model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. Almon, RR; DuBois, DC; Jusko, WJ; Sun, YN, 1998)	0.3
"In the present study, we established cochlear fluid pharmacokinetic profiles of hydrocortisone, methylprednisolone, and dexamethasone in the guinea pig following oral, intravenous, and topical (intratympanic) administration."	( Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Freeman, DJ; Parnes, LS; Sun, AH, 1999)	0.3
" Indirect Pharmacodynamic Response Model I (Model A) where the complex in the nucleus decreases the transcription rate of GR mRNA better described GR mRNA/GR down-regulation."	( Dose-dependence and repeated-dose studies for receptor/gene-mediated pharmacodynamics of methylprednisolone on glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. Almon, RR; DuBois, DC; Jusko, WJ; Pyszczynski, NA; Sun, YN, 1998)	0.3
" Preliminary pharmacokinetic data were obtained from one patient who showed illustrative plasma concentration-time curves and renal excretion-time profiles after a short-lasting infusion (0."	( High-performance liquid chromatography analysis, preliminary pharmacokinetics, metabolism and renal excretion of methylprednisolone with its C6 and C20 hydroxy metabolites in multiple sclerosis patients receiving high-dose pulse therapy. Jongen, PJ; Lagerwerf, AJ; Verwey-van Wissen, CP; Vree, TB, 1999)	0.3
" infusion of 5FU in patients with advanced solid tumors to determine the maximum tolerated dose, the recommended dose for Phase II studies, and the safety and pharmacokinetic profiles of this combination."	( A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. Bartholomeus, S; Bleiberg, H; Brassinne, C; Cazenave, I; de Valeriola, D; Hennebert, P; Kerger, J; Kusenda, Z; Lefresne-Soulas, F; Piccart, M; Selleslags, J; Van Den Neste, E; Wythouck, H, 2000)	0.31
" This phase I study was performed to determine the maximum tolerated dose (MTD) and side-effects of the combination, and to establish whether there is any pharmacokinetic interaction between the two compounds."	( A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Gordon, RJ; Osterwalder, B; Planting, AS; Pronk, LC; Reigner, B; Sparreboom, A; Twelves, C; Vasey, P; Verweij, J, 2000)	0.31
" Both PKS and CAPCIL failed to predict theophylline serum levels based exclusively on population pharmacokinetic parameters."	( Theophylline pharmacokinetics with concomitant steroid and gold therapy. Almeida, AM; Caramona, MM; Falcão, AC; Rocha, MJ, 2000)	0.31
" Plasma cortisol concentrations were determined as a pharmacodynamic index."	( Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Archer, VC; Chosidow, O; Diquet, B; Lebrun-Vignes, B; Levron, JC; Puech, AJ; Warot, D, 2001)	0.31
" The pharmacokinetic interaction between methylprednisolone and itraconazole is probably related to inhibition of hepatic CYP3A4 activity by itraconazole."	( Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Archer, VC; Chosidow, O; Diquet, B; Lebrun-Vignes, B; Levron, JC; Puech, AJ; Warot, D, 2001)	0.31
"Although the elimination half-life of most glucocorticoids is short, they are usually administered once daily, or even on alternate days."	( Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. Boehm, BO; Czock, D; Keller, F; Mertz, A; Uhl, A; Zellner, D, 2002)	0.31
"There were no significant differences in methylprednisolone half-life (2."	( Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. Boehm, BO; Czock, D; Keller, F; Mertz, A; Uhl, A; Zellner, D, 2002)	0.31
" These patterns are consistent with and rationalized by pharmacodynamic expectations based on earlier models."	( Pharmacodynamics and pharmacogenomics of diverse receptor-mediated effects of methylprednisolone in rats using microarray analysis. Almon, RR; Brandenburg, EH; DuBois, DC; Jusko, WJ; Shi, W; Straubinger, RM; Zhang, S, 2002)	0.31
" Pharmacodynamic factors were assessed by plasma cortisol and T-helper and T-suppressor lymphocytes by means of extended indirect response models."	( Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. Blum, RA; Booker, BM; Jusko, WJ; Lates, CD; Magee, MH, 2002)	0.31
"8 L/h), resulting in a longer half-life (2."	( Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. Blum, RA; Booker, BM; Jusko, WJ; Lates, CD; Magee, MH, 2002)	0.31
"Controlled-delivery diltiazem, 180 mg, significantly increased methylprednisolone AUC and half-life and reduced clearance, lending to greater systemic exposure to the steroid."	( Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. Blum, RA; Booker, BM; Jusko, WJ; Lates, CD; Magee, MH, 2002)	0.31
"We demonstrated that pharmacokinetic interaction occurs between steroids and tacrolimus in renal transplant patients."	( Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Anglicheau, D; Beaune, P; Cassinat, B; Flamant, M; Legendre, C; Martinez, F; Schlageter, MH; Thervet, E, 2003)	0.32
" The coadministration of daclizumab did not result in a pharmacokinetic interaction with MPA, the active metabolite of MMF."	( Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. Bumgardner, G; Gaston, RS; Kirkman, RL; Light, S; Nieforth, K; Patel, IH; Pescovitz, MD; Vincenti, F, 2003)	0.32
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."	( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004)	0.32
" The study objectives were (a) to compare the pharmacokinetics of methylprednisolone in premenopausal renal transplant recipients with previously studied male counterparts and (b) to describe the pharmacodynamic response of the hypothalamic-pituitary-adrenal axis during chronic steroid therapy."	( Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. Farooqui, M; Gilliland-Johnson, KK; Reed, KA; Tornatore, KM; Venuto, RC, 2004)	0.32
" Concentration-time data of MPHS and MP were analyzed using population pharmacokinetic analysis with NONMEM software."	( Population pharmacokinetics of methylprednisolone in accident victims with spinal cord injury. Balbach, S; Barth, J; Derendorf, H; Madabushi, R; Möllenhoff, G; Möllmann, H; Nagaraja, NV; Schumann, R; Winkler, J, 2004)	0.32
" Pharmacokinetic and pharmacodynamic parameter values were similar on 2 occasions during the consumption of a low-carbohydrate diet and a Weight Watchers diet, indicating that the decreased clearance was unlikely attributable to a change in diet composition."	( Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition. Calis, KA; Goldstein, JA; Hon, YY; Jann, MW; Jusko, WJ; Lee, SJ; Salaita, CG; Spratlin, VE, 2006)	0.33
" To demonstrate the potential value of the model, methylprednisolone distribution in the cochlea was calculated for two clinically relevant application protocols using pharmacokinetic parameters derived from a prior one-dimensional (1D) model."	( Cochlear pharmacokinetics with local inner ear drug delivery using a three-dimensional finite-element computer model. Plontke, SK; Salt, AN; Siedow, N; Wegener, R; Zenner, HP, 2007)	0.34
" Finally, theoretical assumptions about the potential pharmacokinetic changes of glucocorticoids in pregnancy and their application to clinical settings are discussed."	( Pharmacokinetics of corticosteroids during pregnancy. Ghulmiyyah, LM; Hankins, GD; Pacheco, LD; Snodgrass, WR, 2007)	0.34
") dosing for use in pharmacodynamic studies."	( Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats. Almon, RR; DuBois, DC; Hazra, A; Jusko, WJ; Pyszczynski, N, 2007)	0.34
" An integrated pharmacodynamic (PD) model with inhibition of lymphocyte trafficking from tissue to blood by both MPL and CS and induction of cell apoptosis by MPL reasonably captured this lymphocytopenia."	( Pharmacokinetic/pharmacodynamic modeling of corticosterone suppression and lymphocytopenia by methylprednisolone in rats. Almon, RR; DuBois, DC; Jusko, WJ; Yao, Z, 2008)	0.35
" AUCs of OP and IVMP were determined by the trapezoid method; pharmacokinetic parameters were obtained using noncompartmental and compartmental analysis."	( Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Daru, JA; Gursahaney, A; Ngai, KL; Pachman, LM; Rouster-Stevens, KA, 2008)	0.35
" Mean peak concentration was higher for IVMP (34."	( Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Daru, JA; Gursahaney, A; Ngai, KL; Pachman, LM; Rouster-Stevens, KA, 2008)	0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"A physiologic pharmacodynamic model was developed to jointly describe the effects of methylprednisolone (MPL) on adrenal suppression and glycemic control in normal rats."	( Pharmacodynamics of glucose regulation by methylprednisolone. II. normal rats. Jin, JY; Jusko, WJ, 2009)	0.35
" The large pharmacokinetic (PK) and pharmacodynamic (PD) variability and narrow therapeutic range of MPA provide a potential for therapeutic drug monitoring."	( Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study. Bergan, S; Bremer, S; Holdaas, H; Jørgensen, PF; Midtvedt, K; Rootwelt, H; Stenstrøm, J; Vethe, NT, 2009)	0.35
" Prodrug and drug concentrations were quantitated using HPLC, and noncompartmental pharmacokinetic parameters were estimated."	( Plasma pharmacokinetics and tissue disposition of novel dextran-methylprednisolone conjugates with peptide linkers in rats. Agarwal, HK; Mehvar, R; Parang, K; Penugonda, S, 2010)	0.36
"5 hours (C1/2) and 2 hours (C2), providing a total of 114 pharmacokinetic profiles at various periods from 3 days to 6 months posttransplantation (D3, D7, D14, M1, M3, and M6)."	( Pharmacokinetics of mycophenolic acid in living donor liver transplantation. Choi, GS; Joh, JW; Jung, H; Kim, JM; Kim, SJ; Kwon, CH; Lee, SK; Lee, ST; Lee, SY; Moon, JI; Shin, M, 2010)	0.36
" Of 114 pharmacokinetic profiles, 40 (35%) AUC and 7 (6."	( Pharmacokinetics of mycophenolic acid in living donor liver transplantation. Choi, GS; Joh, JW; Jung, H; Kim, JM; Kim, SJ; Kwon, CH; Lee, SK; Lee, ST; Lee, SY; Moon, JI; Shin, M, 2010)	0.36
" This multiple-dose, randomized, crossover, open-label study evaluated and compared pharmacodynamic outcomes in subjects who received ACTH analog (80 U subcutaneously) or IVMP (1 g) daily for 5 days."	( Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: A comparison with intravenous methylprednisolone. Becker, PM; Bell, S; Challenger, R; Decker, D; Hammock, V; Lal, R; Nyberg, M; Young, D, 2016)	0.43
" This regimen was associated with durable donor engraftment and relatively low rates of regimen related toxicity (RRT); future alemtuzumab pharmacokinetic studies may improve outcomes, by allowing targeted alemtuzumab clearance to reduce graft rejection and promote more rapid immune reconstitution."	( Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. Abdel-Azim, H; Crooks, GM; Kapoor, N; Khazal, S; Kohn, DB; Mahadeo, KM; Shah, AJ; Zhao, Q, 2015)	0.42
" An in-depth functional analysis was performed using rich pharmacodynamic (temporal-based) proteomic data measured over 66h in rat liver following a single dose of methylprednisolone (MPL)."	( Functional proteomic analysis of corticosteroid pharmacodynamics in rat liver: Relationship to hepatic stress, signaling, energy regulation, and drug metabolism. Almon, RR; Ayyar, VS; DuBois, DC; Jusko, WJ; Qu, J; Sukumaran, S, 2017)	0.46
" These studies characterize GILZ as a pharmacodynamic marker of corticosteroid actions in several tissues."	( Mechanistic Multi-Tissue Modeling of Glucocorticoid-Induced Leucine Zipper Regulation: Integrating Circadian Gene Expression with Receptor-Mediated Corticosteroid Pharmacodynamics. Almon, RR; Ayyar, VS; DuBois, DC; Jusko, WJ, 2017)	0.46
"A multiscale pharmacodynamic model was developed to characterize the receptor-mediated, transcriptomic, and proteomic determinants of corticosteroid (CS) effects on clinically relevant hepatic processes following a single dose of methylprednisolone (MPL) given to adrenalectomized (ADX) rats."	( Receptor/gene/protein-mediated signaling connects methylprednisolone exposure to metabolic and immune-related pharmacodynamic actions in liver. Almon, RR; Ayyar, VS; DuBois, DC; Jusko, WJ; Qu, J; Sukumaran, S, 2018)	0.48
" SIGNIFICANCE STATEMENT: Mechanisms relating to sex-based pharmacodynamic variability in genomic responses to corticosteroids have been unclear."	( Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part III: Estrous Cycle and Estrogen Receptor-Dependent Antagonism of Glucocorticoid-Induced Leucine Zipper (GILZ) Enhancement by Corticosteroids. Almon, RR; Ayyar, VS; DuBois, DC; Jusko, WJ, 2019)	0.51
"The plasma and tissue binding properties of two corticosteroids, dexamethasone (DEX) and methylprednisolone (MPL), were assessed in the rat in anticipation of developing physiologically based pharmacokinetic and pharmacokinetic/pharmacodynamic models."	( Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part I: Determination and Prediction of Dexamethasone and Methylprednisolone Tissue Binding in the Rat. Almon, RR; Ayyar, VS; DuBois, DC; Jusko, WJ; Song, D, 2019)	0.51
"The aim of this study was to identify factors affecting blood concentrations of voriconazole following letermovir coadministration using population pharmacokinetic (PPK) analysis in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients."	( Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study. Akashi, K; Egashira, N; Fukumoto, J; Hirota, T; Ieiri, I; Matsukane, R; Miyamoto, T; Mori, Y; Muraki, S; Suetsugu, K, 2021)	0.62
"The aims of this study were to evaluate and compare the pharmacokinetic profiles and bioequivalence of two tablet formulations of methylprednisolone (test formulation: Zhejiang Xianju Pharmaceutical Co."	( Pharmacokinetics and bioequivalence of two methylprednisolone tablet formulations in healthy Chinese subjects under fasting and fed conditions. Fan, L; Gan, C; Huang, Q; Mai, G; Qiu, D; Shen, Z; Shentu, J; Xiao, X; Yang, Y; Zhang, P, 2023)	0.91

Excerpt	Reference	Relevance
" Also, large doses of cyclophosphamide and methylprednisolone as pretreatment did not cause any detrimental effect to the allograft kidney when used in combination with cryoprecipitated plasma and pulsatile perfusion."	( Immunological donor pretreatment in combination with pulsatile preservation in cadaveric renal transplantation. Holley, KE; Khan, AU; Leary, FJ; Woods, JE; Zincke, H, 1978)	0.26
"Peptichemio, a new oncolytic drug with alkylating and antimetabolic properties was employed in combination with vincristine and 6-methylprednisolone (PVP) for the treatment of diffuse non-Hodgkin's lymphomas (NHL), stages III and IV."	( Peptichemio: A new oncolytic drug in combination with vincristine and prednisolone in the treatment of non-Hodgkin lymphomas. Bacigalupo, A; Carella, AM; Damasio, EE; Fusco, FA; Giordano, D; Marmont, AM; Rossi, E; Santini, G, 1977)	0.26
"Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported."	( Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting corticosteroid suspensions in combination with other drugs: I. Clinical studies. Havener, WH; McGrew, RN; Wilson, RS, 1978)	0.26
"An experimental dog model was used to reproduce the clinical picture of bilateral arteriole and choriocapillaris occlusion from a unilateral intracarotid injection of long-acting corticosteroids combined with other drugs including lidocaine, epinephrine, and penicillin."	( Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting corticosteroid suspensions in combination with other drugs: II. Animal experimental studies. McGrew, RN; White, HJ; Wilson, RS, 1978)	0.26
"Inhibition of renal vasoconstriction during hyperacute rejection by phenoxybenzamine or methylprednisolone combined with either the antiplatelet agent pyridinolcarbamate or heparin was evaluted in primates."	( Successful short-term modification of hyperacute renal allograft rejection in the primate. Intrarenal effects of phenoxybenzamine and methylprednisolone combined with heparin. Busch, GJ; Colman, RW; Hollenberg, NK; Martins, AC; Moretz, RC; Wilson, RE, 1976)	0.26
" We have, therefore, carried out a multicenter, double-blind randomized trial comparing a combination of high-dose metoclopramide (MTC) (1 mg/kg x 4) and methylprednisolone (P) (treatment A) with a shorter but higher single-dose schedule of metoclopramide (3 mg/kg x 2) combined with dexamethasone (DEX) and diphenhydramine (DIP) to prevent extrapyramidal reactions (treatment B)."	( Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research Basurto, C; Bracarda, S; Di Costanzo, F; Donati, D; Malacarne, P; Monici, L; Patoia, L; Picciafuoco, M; Roila, F; Tonato, M, 1989)	0.28
"Nausea and vomiting are reported in approximately 60% of neoplastic patients treated with doxorubicin used alone at doses greater than or equal to 50 mg/m2 or in combination with other noncisplatin antiblastic agents."	( A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in combination with other antiblastic agents. Ballatori, E; Basurto, C; Bracarda, S; Del Favero, A; Roila, F; Tonato, M, 1988)	0.27
"The authors provided evidence of a positive effect of combined therapy (plasmapheresis in combination with pulse-therapy) on a course of cryoglobulinemic glomerulonephritis and ulcerative-necrotic vasculitis in patients with Sjögren's disease (SD)."	( [A positive effect of combined therapy (plasmapheresis in combination with pulse therapy) on the course of cryoglobulinemic glomerulonephritis and ulcerative-necrotic vasculitis in patients with Sjögren's disease]. Chiklikchi, AS; Kirtava, ZZ; Mach, ES; Solov'ev, SK; Vasil'ev, VI, 1987)	0.27
"We designed a multicenter, double-blind randomized study to determine the safety and antiemetic effectiveness of intravenous (IV) methylprednisolone (P) combined with high-dose IV metoclopramide (MTC) v MTC alone in 200 untreated cancer patients receiving cisplatin chemotherapy."	( Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. Ballatori, E; Basurto, C; Bella, M; DiCostanzo, F; Donati, D; Morsia, D; Passalacqua, R; Roila, F; Tognoni, G; Tonato, M, 1987)	0.27
" In conclusion, the present study indicates that both orbital cobalt irradiation combined with systemic methylprednisolone treatment and systemic methylprednisolone therapy alone are valuable methods of treatment for Graves' ophthalmopathy, but the combined therapy proved to be more effective."	( Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. Andreani, D; Bartalena, L; Baschieri, L; Cavallacci, G; Chiovato, L; Laddaga, M; Lepri, G; Marcocci, C; Pinchera, A, 1983)	0.27
" To further assess its effectiveness, we studied the effects of natural human interferon-alpha (nIFN alpha), alone and in combination with 6-methyl-prednisolone (PDN), in a prospective, randomized, controlled trial in patients with symptomatic MC."	( Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Cornacchiulo, V; Dammacco, F; Han, JH; Iacobelli, AR; Lauletta, G; Rizzi, R; Sansonno, D; Shyamala, V, 1994)	0.29
" Pharmacokinetic studies did not show any significant difference in clearance of FK506 when administered alone or in combination with methylprednisolone or MTX."	( Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Anasetti, C; Appelbaum, FR; Doney, K; Etzioni, R; Furlong, T; Gooley, T; Martin, P; Nash, RA; Slattery, J; Storb, R, 1995)	0.29
"In treatment of GO, 24 Gy of radiation is a more effective dose than 10 Gy when combined with systemic corticosteroids."	( Graves ophthalmopathy: MR evaluation of 10-Gy versus 24-Gy irradiation combined with systemic corticosteroids. Futami, S; Hoshi, H; Jinnouchi, S; Morita, M; Murakami, N; Nagamachi, S; Nakahara, H; Noguchi, S; Ohnishi, T; Tamaru, M, 1995)	0.29
"We enrolled 11 patients with secondary progressive MS in a randomized single-masked cross-over study of plasma exchange (PE) in combination with azathioprine 2 mg/kg."	( Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study. Christiansen, P; Jensen, CV; Nordenbo, A; Ravnborg, M; Schreiber, K; Szpirt, W; Sørensen, PS; Wanscher, B, 1996)	0.29
"In experiment A, craniectomy was performed in combination with durotomy, diuretic administration, methylprednisolone sodium succinate administration, and hyperventilation, and effect of these manipulations on ICP was determined."	( Effect of craniectomy/durotomy alone and in combination with hyperventilation, diuretics, and corticosteroids on intracranial pressure in clinically normal dogs. Bagley, RS; Gavin, PR; Greene, SA; Harrington, ML; Keegan, RD; Moore, MP; Pluhar, GE, 1996)	0.29
" Thirteen patients were treated with an intravenous pulse of methylprednisolone, and fifteen with methylprednisolone combined with cyclophosphamide."	( Intravenous cyclophosphamide combined with methylprednisolone in the treatment of severe refractory rheumatoid arthritis: the effect on lymphocytes. Lacki, JK; Leszczynski, P; Mackiewicz, SH, )	0.13
"In this selected group of patients with multiple sclerosis with very active disease, mitoxantrone combined with methylprednisolone was effective in improving both clinical and MRI indices of disease activity over a period of six months whereas methylprednisolone alone was not."	( Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. Berry, I; Brochet, B; Cabanis, E; Clanet, M; Confavreux, C; Edan, G; Froment, JC; Gandon, JM; Iba-Zizen, MT; Lai, HM; Lubetzki, C; Lyon-Caen, O; Miller, D; Moseley, I; Rolland, Y; Sabouraud, O, 1997)	0.3
" The preventive effect of azathioprine alone and its combination with methylprednisolone on chronic cerebral vasospasm was studied."	( [Azathioprine and its combination with methylprednisolone: preventive effect on chronic cerebral vasospasm]. Liu, B; Wang, Z; Wu, J, 1996)	0.29
" Pathological examination showed that azathioprine alone and its combination with methylprednisolone obviously reduced the damage to the BA wall."	( [Azathioprine and its combination with methylprednisolone: preventive effect on chronic cerebral vasospasm]. Liu, B; Wang, Z; Wu, J, 1996)	0.29
"The calcium channel blocker diltiazem is often included in post-transplant regimens in combination with other immunosuppressive drugs such as cyclosporin A (CyA)."	( The modulatory effect of diltiazem on human in vitro alloreactivity when used alone or in combination with cyclosporin A and/or methylprednisolone. D'Ambrosio, A; Quintieri, F; Segoloni, G, 1997)	0.3
"The prevention of nausea, vomiting and appetite loss induced by remission induction chemotherapy for acute myeloid leukemia was compared by randomization between granisetron alone and combination with granisetron plus methylprednisolone."	( [Efficacy of combination with granisetron and methylprednisolone for nausea, vomiting and appetite loss in remission induction chemotherapy of acute myeloid leukemia--a randomized comparative trial between granisetron alone and granisetron plus methylpred Hirota, K; Kikuchi, H; Nakayama, T; Nasu, M; Ohno, E; Ohtuka, E; Ono, K; Saburi, Y; Uchida, I; Uno, N, 1999)	0.3
" In the groups receiving GH and GH combined with IGF-I, urinary hydroxyproline excretion increased more when compared with methylprednisolone alone (P<0."	( Effects of IGF-I combined with GH on glucocorticoid-induced changes of bone and connective tissue turnover in man. Berneis, K; Keller, U; Kraenzlin, M; Oehri, M, 1999)	0.3
"The possible pharmacokinetic interaction between the new immunosuppressive mycophenolate mofetil (MMF) and tacrolimus (TAC), respectively, was assessed by comparing routinely estimated mycophenolic acid (MPA) plasma trough levels of 15 consecutive renal transplant patients receiving MMF in combination with methylprednisolone (MEP) and cyclosporin A (CSA, 10 patients) or in combination with MEP and tacrolimus (TAC, 5 patients)."	( Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Eismann, R; Hübner, GI; Sziegoleit, W, 1999)	0.3
" The pharmacokinetics of docetaxel are not influenced by combination with ifosfamide, regardless of the drug sequence, but ifosfamide pharmacokinetics are changed by docetaxel, depending on the sequence of administration."	( Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study. Bruno, R; De Bruijn, E; Highley, M; Locci-Tonelli, D; Pronk, L; Schrijvers, D; Van Oosterom, AT; Verweij, J, 2000)	0.31
" Eighty-six patients were treated in combination with high-dose or pulsed corticosteroids and irradiation."	( Clinical outcomes of orbital irradiation combined with or without systemic high-dose or pulsed corticosteroids for Graves' ophthalmopathy. Abe, M; Fukada, S; Hagiwara, M; Hirota, S; Hishikawa, Y; Kono, M; Takada, Y; Tsujino, K, 2000)	0.31
"Orbital irradiation combined with high-dose or pulsed corticosteroids is an effective treatment for moderate to severe GO, especially in cases with major manifestations of soft-tissue signs, extraocular muscle impairment, or sight loss."	( Clinical outcomes of orbital irradiation combined with or without systemic high-dose or pulsed corticosteroids for Graves' ophthalmopathy. Abe, M; Fukada, S; Hagiwara, M; Hirota, S; Hishikawa, Y; Kono, M; Takada, Y; Tsujino, K, 2000)	0.31
"1, 1, 5 and 10 mg/ml), phenylbutazone (1000 microgram/ml) and acetylsalicylic acid (25, 250, 2500 microgram/ml) alone, and combined with 10 mg/ml of ofloxacin on the respiratory burst."	( [Effect of anti-inflammatory drugs, alone and combined with ofloxacin, on the respiratory burst of human polymorphonuclear leukocytes]. Cabrera, E; Cantón, E; Martínez, P; Orero, A; Velert, MM, 2001)	0.31
" Both clinical symptoms and MRI findings of these cases significantly improved in response to cyclosporin A (CsA) combined with methylprednisolone (mPSL) pulse therapy."	( [Therapeutic effect of cyclosporin A combined with methylprednisolone pulse therapy on hemophagocytic syndrome with the central nervous system involvement]. Otake, M; Takayanagi, M; Yamamoto, K, 2002)	0.31
"Cyclosporine (INN: ciclosporin) A or tacrolimus have been used mostly in combination with azathioprine as primary immunosuppression after lung transplantation."	( Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. Birsan, T; Deviatko, E; Klepetko, W; Reichart, B; Reichenspurner, H; Treede, H; Zuckermann, A, 2003)	0.32
"This 2-center, prospective randomized study showed high immunosuppressive potency of both cyclosporine A and tacrolimus in combination with mycophenolate mofetil."	( Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. Birsan, T; Deviatko, E; Klepetko, W; Reichart, B; Reichenspurner, H; Treede, H; Zuckermann, A, 2003)	0.32
" We evaluated the efficacy of methylprednisolone and urokinase pulse therapy combined with cyclophosphamide for patients with HSPN of at least grade IVb."	( Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: a clinical and histopathological study. Kawasaki, Y; Suzuki, H; Suzuki, J, 2004)	0.32
" Of them, 20 (Group A) were treated with methylprednisolone and urokinase pulse therapy, and 17 (Group B) were treated with methylprednisolone and urokinase pulse therapy combined with cyclophophamide."	( Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: a clinical and histopathological study. Kawasaki, Y; Suzuki, H; Suzuki, J, 2004)	0.32
"Our study suggests that methylprednisolone and urokinase pulse therapy combined with cyclophosphamide is useful for patients with severe HSPN."	( Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: a clinical and histopathological study. Kawasaki, Y; Suzuki, H; Suzuki, J, 2004)	0.32
"To evaluate the efficacy of prednisolone, warfarin, and dipyridamole therapy combined with mizoribine (PWDM) in the treatment of diffuse immunoglobulin A (IgA) nephropathy in comparison with prednisolone, warfarin, and dipyridamole therapy without mizoribine (PWD) and with methylprednisolone pulse therapy (PWD pulse)."	( Efficacy of multidrug therapy combined with mizoribine in children with diffuse IgA nephropathy in comparison with multidrug therapy without mizoribine and with methylprednisolone pulse therapy. Hosoya, M; Isome, M; Kawasaki, Y; Nozawa, R; Onishi, N; Suzuki, H; Suzuki, J; Takahashi, A, )	0.13
" He was diagnosed as having acute respiratory distress syndrome due to severe pneumonia, and was treated with pulse methylprednisolone and sivelestat sodium in combination with intravenous erythromycin and ciprofloxacin."	( [A case of Legionella pneumonia complicated with acute respiratory distress syndrome treated with methylprednisolone and sivelestat sodium in combination with intravenous erythromycin and ciprofloxacin]. Arinobu, Y; Himeji, D; Kikuchi, I; Kojima, T; Oguma, A; Ueda, A, 2004)	0.32
"An assessment of complications during systemic corticosteroid therapy combined with orbital radiotherapy in patients with thyroid eye disease."	( [Complications during systemic corticosteroid therapy combined with orbital radiotherapy in patients with graves orbitopathy]. Kaźmierczyk-Puchalska, A; Krzyzanowska-Swiniarska, B; Kulig, G; Pilarska, K, 2004)	0.32
" In the present study, the authors conducted a randomized controlled trial to compare the success of treatment between surgery and aspiration combined with methylprednisolone acetate injection plus wrist immobilization."	( Randomized controlled trial between surgery and aspiration combined with methylprednisolone acetate injection plus wrist immobilization in the treatment of dorsal carpal ganglion. Limpaphayom, N; Wilairatana, V, 2004)	0.32
"To evaluate the efficacy of pulsed high-dose corticosteroids combined with orally administered low-dose methotrexate therapy in patients with severe localized scleroderma (LS)."	( Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Altmeyer, P; Breuckmann, F; Freitag, M; Gambichler, T; Hoffmann, K; Kreuter, A; Rotterdam, S; Stuecker, M, 2005)	0.33
" Interventions Oral methotrexate (15 mg/wk) combined with pulsed intravenous methylprednisolone (1000 mg for 3 days monthly) for at least 6 months."	( Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Altmeyer, P; Breuckmann, F; Freitag, M; Gambichler, T; Hoffmann, K; Kreuter, A; Rotterdam, S; Stuecker, M, 2005)	0.33
"These data suggest that pulsed high-dose corticosteroids combined with orally administered low-dose methotrexate therapy is beneficial and safe in the treatment of patients with LS."	( Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Altmeyer, P; Breuckmann, F; Freitag, M; Gambichler, T; Hoffmann, K; Kreuter, A; Rotterdam, S; Stuecker, M, 2005)	0.33
" We conducted a phase II trial of sirolimus combined with tacrolimus and methylprednisolone in patients with steroid-resistant cGVHD."	( Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Andersson, B; Champlin, R; Couriel, DR; de Lima, MJ; Donato, M; Escalón, MP; Ghosh, S; Giralt, S; Hicks, K; Hosing, C; Hsu, Y; Ippoliti, C; Khouri, IF; Neumann, J; Saliba, R, 2005)	0.33
"We report a case of IgA nephropathy with tuberculous pleurisy that was treated with steroid pulse therapy combined with tonsillectomy."	( [Steroid pulse therapy combined with tonsillectomy in a patient with IgA nephropathy complicated with tuberculous pleurisy]. Koike, K; Okuda, S; Sugawara, K; Takeda, K; Tamaki, K; Wakasugi, D, 2005)	0.33
"Tacrolimus (TAC) combined with mycophenolate mofetil (MMF) has been suggested to play a critical role in the reversal of C4d-positive acute humoral rejection (AHR) in renal transplantation, but the efficacy of using only TAC-MMF without immunoadsorption or plasmapheresis has not been investigated."	( Tacrolimus combined with mycophenolate mofetil can effectively reverse C4d-positive steroid-resistant acute rejection in Chinese renal allograft recipients. Chen, H; Chen, J; Ji, S; Li, LS; Liu, ZH; Sun, Q; Yin, G, 2006)	0.33
"To compare the effects of methotrexate (MTX), alone or in combination with intravenous (IV) methylprednisolone (MP) or infliximab, on magnetic resonance imaging (MRI)-detected synovitis, bone edema, and erosive changes in patients with early rheumatoid arthritis (RA)."	( Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Corluy, L; Depresseux, G; Durez, P; Houssiau, FA; Lauwerys, BR; Luyten, FP; Malghem, J; Nzeusseu Toukap, A; Verschueren, P; Westhovens, R, 2007)	0.34
" Conclusion Methylprednisolone combined with lipopolysaccharide can induce typical rabbit model for early avascular necrosis of femoral head."	( [Experimental study on avascular necrosis of femoral head induced by methylprednisolone combined with lipopolysaccharide in rabbits]. Chai, Y; Li, X; Ma, H; Zeng, B, 2008)	0.35
"We compared the short-term results of anti-inflammatory drugs alone or in combination with local injection of a corticosteroid and anesthetic mixture in the treatment of tennis elbow."	( [Short-term results of treatment of tennis elbow with anti-inflammatory drugs alone or in combination with local injection of a corticosteroid and anesthetic mixture]. Aksakalli, E; Gülcan, E; Kilinçoğlu, V; Ozkan, K; Toker, S, )	0.13
" The patients were randomized to oral and topical anti-inflammatory drugs alone (group 1, n=10) or combined with a single local injection of a corticosteroid and anesthetic mixture (group 2, n=11)."	( [Short-term results of treatment of tennis elbow with anti-inflammatory drugs alone or in combination with local injection of a corticosteroid and anesthetic mixture]. Aksakalli, E; Gülcan, E; Kilinçoğlu, V; Ozkan, K; Toker, S, )	0.13
" Fourteen patients were treated with three cycles of rituximab (375 mg/m(2) weekly for 4 weeks) in combination with HDMP (1 gm/m(2) daily for 5 days)."	( Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Bole, J; Castro, JE; Kipps, TJ; Rassenti, L; Sandoval-Sus, JD, 2008)	0.35
" 60 MM patients including 19 de novo patients, out of them 14 patients received the treatment using regimen of bortezomib in combination with thalidomide (BT), 5 patients received bortezomib-methylprednisolone regimen (BMP)."	( [Bortezomib combined with other drugs for treating 60 cases of multiple myeloma]. Chen, SL; Hu, Y; Li, X; Zhang, JJ; Zhong, YP, 2009)	0.35
"To investigate the efficiency and safety of two-dose steroid combined with two-dose daclizumab and tacrolimus (FK506) regimen in liver transplant recipients."	( [Two-dose steroid combined with two-dose daclizumab and tacrolimus regimen in liver transplant recipients]. He, XS; Hu, AB; Huang, JF; Ju, WQ; Ma, Y; Tai, Q; Tan, YL; Wang, DP; Wu, LW; Zhu, XF, 2009)	0.35
"Two-dose steroid combined with two-dose daclizumab and tacrolimus would be a safe and efficient immunosuppression strategy without increase the acute rejection rate hazard, that could reduce post-transplant infection and other complications from side-effect of long-term usage of steroid."	( [Two-dose steroid combined with two-dose daclizumab and tacrolimus regimen in liver transplant recipients]. He, XS; Hu, AB; Huang, JF; Ju, WQ; Ma, Y; Tai, Q; Tan, YL; Wang, DP; Wu, LW; Zhu, XF, 2009)	0.35
"In this prospective, randomized, open-label, single-center study, we compared the efficacy and safety of two anti-interleukin-2 receptor monoclonal antibodies combined with triple immunosuppression."	( Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study. Arnol, M; Bren, AF; Kandus, A; Kmetec, A; Oblak, M; Omahen, K; Vidan-Jeras, B, 2010)	0.36
"Basiliximab or daclizumab combined with triple therapy was an efficient and a safe immunosuppression strategy, demonstrated with low incidence of acute rejections, excellent graft function, high survival rates, and acceptable adverse event profile in adult recipients within the 1st year after deceased donor renal transplantation."	( Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study. Arnol, M; Bren, AF; Kandus, A; Kmetec, A; Oblak, M; Omahen, K; Vidan-Jeras, B, 2010)	0.36
"The effectiveness of steroid pulse therapy combined with tonsillectomy (ST) has been shown in immunoglobulin A nephropathy (IgAN) patients with moderate or severe urinary abnormalities."	( Clinical effectiveness of steroid pulse therapy combined with tonsillectomy in patients with immunoglobulin A nephropathy presenting glomerular haematuria and minimal proteinuria. Fukuhara, S; Gillespie, B; Hayashino, Y; Hotta, O; Ieiri, N; Kawaguchi, T; Miyazaki, M; Taguma, Y; Yamazaki, S, 2010)	0.36
"In 2001, we designed a multicentre, double-blind, randomised, parallel-group trial, termed the methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN) study."	( Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Andersson, M; Bartholomé, E; Beer, K; Celius, EG; Constantinescu, CS; Elovaara, I; Garde, E; Jongen, PJ; Ravnborg, M; Sperling, B; Sørensen, PS, 2010)	0.36
"Monthly pulses of methylprednisolone in combination with interferon beta-1a do not seem to affect disability progression any more than interferon beta-1a treatment alone."	( Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Andersson, M; Bartholomé, E; Beer, K; Celius, EG; Constantinescu, CS; Elovaara, I; Garde, E; Jongen, PJ; Ravnborg, M; Sperling, B; Sørensen, PS, 2010)	0.36
" We concluded that orbital MR imaging combined with CAS could improve the sensitivity of detection of active disease and the prediction of the response to ivGC."	( Orbital magnetic resonance imaging combined with clinical activity score can improve the sensitivity of detection of disease activity and prediction of response to immunosuppressive therapy for Graves' ophthalmopathy. Murakami, T; Nakashima, A; Noguchi, H; Noguchi, S; Noguchi, Y; Ohyabu, Y; Tachibana, S, 2010)	0.36
" To reduce the total dose of steroids, we have been using mizoribine (MZR) in combination with tonsillectomy-steroid pulse therapy since 2004."	( Methylprednisolone pulse therapy combined with mizoribine following tonsillectomy for immunoglobulin A nephropathy: clinical remission rate, steroid sparing effect, and maintenance of renal function. Fujino, T; Hirama, A; Iino, Y; Kaneko, T; Katayama, Y; Ueda, K; Utsumi, K, 2011)	0.37
"The aim of this study was to explore the clinical effect and toxicity of bortezomib combined with methylprednisolone in treatment of relapsed or refractory multiple myeloma (MM)."	( [Effects of bortezomib combined with methylprednisolone in treatment of 33 cases of relapsed or refractory multiple myeloma]. An, N; Chen, SL; Hu, Y; Li, X; Zhang, JJ; Zhong, YP, 2011)	0.37
" Some immunosuppressive drugs also interact with one another: cyclosporine raises the level of mTOR inhibitors and lowers the level of mycophenolate."	( [Drug interactions and immunosuppression in organ transplant recipients]. Amundsen, R; Asberg, A; Bergan, S; Midtvedt, K; Vethe, NT, 2011)	0.37
"We previously reported the efficacy of extensive eradication of infectious foci in oral and ENT lesions, combined with tonsillectomy plus methylprednisolone (MP) pulse therapy, for curing pediatric Henoch-Schönlein purpura (HSP) and HSP nephritis."	( Impact of periodontal treatment in combination with tonsillectomy plus methylprednisolone pulse therapy and angiotensin blockade for pediatric IgA nephropathy. Chiba, Y; Homma, R; Inoue, CN; Ishidoya, M; Matsutani, S; Nagasaka, T, 2012)	0.38
"To compare the efficacy and safety of a low dose (LD) methotrexate (MTX) in combination with a LD methylprednisolone(MP) or standard dose(SD) MP in the treatment of acute graft-versus-host disease (aGVHD)."	( [Comparison study on treatment of acute graft-versus-host disease with low-dose methotrexate in combination with low-dose methylprednisolone or standard-dose methylprednisolone]. Chen, H; Chen, YH; Han, W; Huang, XJ; Liu, DH; Liu, KY; Wang, J; Wang, Y; Xu, LP, 2011)	0.37
" The UGI combined with shoulder exercises in the treatment of subacromial adhesive bursitis is effective to ensure a more frequent complete pain relief in the medium term."	( Effectiveness of ultrasound-guided injections combined with shoulder exercises in the treatment of subacromial adhesive bursitis. Benedetti, MG; Fusaro, I; Galletti, S; Gasparre, G; Volini, S, 2012)	0.38
"Tonsillectomy combined with steroid pulse therapy achieved higher RR after 1 year of treatment, compared with steroid pulse monotherapy in patients with IgAN."	( Comparison between steroid pulse therapy alone and in combination with tonsillectomy for IgA nephropathy. Moriyama, T; Nitta, K; Ochi, A; Takei, T; Uchida, K, 2013)	0.39
"To study the effectiveness of mycophenolate mofetil (MMF) as first-line therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada (VKH) disease."	( The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease. Abu El-Asrar, AM; Al-Mezaine, HS; Al-Muammar, AM; Hemachandran, S; Kangave, D, 2012)	0.38
"To investigate the effect of prostaglandins E1 combined with Xuebijing injection on the expression of transforming growth factor-β₁ (TGF-β₁) and tumor necrosis factor-α (TNF-α) in rats with acute pulmonary interstitial fibrosis."	( [Effect of prostaglandin E1 combined with Xuebijing injection on transforming growth factor-β₁ in rats with pulmonary interstitial fibrosis]. Li, ZJ; Zhang, WX, 2012)	0.38
"Prostaglandin E1 combined with Xuebijing injection may significantly inhibit TGF-β₁ expression in the lung tissue of rats with acute pulmonary interstitial fibrosis, which reduces alveolar inflammatory response."	( [Effect of prostaglandin E1 combined with Xuebijing injection on transforming growth factor-β₁ in rats with pulmonary interstitial fibrosis]. Li, ZJ; Zhang, WX, 2012)	0.38
"The possibility to prevent acute spinal cord injury (ASCI) by selective infliximab combined with methylprednisolone (MP) was assessed in experimental ASCI."	( Effect of infliximab combined with methylprednisolone on expressions of NF-κB, TRADD, and FADD in rat acute spinal cord injury. Chengke, L; Hao, Z; Penghui, Z; Ping, W; Wei, P; Weiwei, L; Xiaoyang, P; Xiyang, W; Zhengquan, X, 2013)	0.39
"To investigate the effects of infliximab, MP, and the combination of these 2 agents on expressions of NF-κB (nuclear factor Kappa B), TRADD (tumor necrosis factor receptor associated death domain), and FADD (fas associated death domain) in a rat model of acute spinal cord injury (ASCI), and to confirm the therapeutic efficacy and possible mechanism of infliximab combined with MP in the treatment of ASCI."	( Effect of infliximab combined with methylprednisolone on expressions of NF-κB, TRADD, and FADD in rat acute spinal cord injury. Chengke, L; Hao, Z; Penghui, Z; Ping, W; Wei, P; Weiwei, L; Xiaoyang, P; Xiyang, W; Zhengquan, X, 2013)	0.39
" Moreover, infliximab combined with MP exhibited the more powerful ability to this amelioration."	( Effect of infliximab combined with methylprednisolone on expressions of NF-κB, TRADD, and FADD in rat acute spinal cord injury. Chengke, L; Hao, Z; Penghui, Z; Ping, W; Wei, P; Weiwei, L; Xiaoyang, P; Xiyang, W; Zhengquan, X, 2013)	0.39
"Infliximab combined with methylprednisolone may be an effective treatment for the recovery of ASCI."	( Effect of infliximab combined with methylprednisolone on expressions of NF-κB, TRADD, and FADD in rat acute spinal cord injury. Chengke, L; Hao, Z; Penghui, Z; Ping, W; Wei, P; Weiwei, L; Xiaoyang, P; Xiyang, W; Zhengquan, X, 2013)	0.39
"To study the anatomical outcome of rhegmatogenous retinal detachment combined with choroidal detachment after pars plana vitrectomy with periocular/intravitreal injection of steroids."	( Vitrectomy combined with periocular/intravitreal injection of steroids for rhegmatogenous retinal detachment associated with choroidal detachment. Bi, C; Chen, F; Wang, H; Wang, N; Wei, Y; Yang, X; Zu, Z, 2014)	0.4
"Seventy-seven eyes that have rhegmatogenous retinal detachment combined with choroidal detachment were treated by pars plana vitrectomy with oral prednisolone (Group A) or periocular/intravitreal injection of steroids (Group B) and then divided into 5 subgroups according to different intraocular tamponade agents; Group A1: oral steroids and silicone oil, Group A2: oral steroids and C(3)F(8), Group B1: periocular/intravitreal steroid injections and silicone oil, Group B2: periocular steroid injection and silicone oil, and Group B3: periocular steroid injection and C(3)F(8)."	( Vitrectomy combined with periocular/intravitreal injection of steroids for rhegmatogenous retinal detachment associated with choroidal detachment. Bi, C; Chen, F; Wang, H; Wang, N; Wei, Y; Yang, X; Zu, Z, 2014)	0.4
"For the treatment of rhegmatogenous retinal detachment combined with choroidal detachment, pars plana vitrectomy with periocular/intravitreal corticosteroids was comparable in reattachment rate to pars plana vitrectomy with systemic steroids, suggesting an acceptable alternative for patients with this condition who cannot tolerate systemic steroids."	( Vitrectomy combined with periocular/intravitreal injection of steroids for rhegmatogenous retinal detachment associated with choroidal detachment. Bi, C; Chen, F; Wang, H; Wang, N; Wei, Y; Yang, X; Zu, Z, 2014)	0.4
" This study evaluated the efficacy and safety of alefacept compared with placebo when combined with tacrolimus, mycophenolate mofetil and corticosteroids in de novo renal transplant recipients."	( Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. Charpentier, B; First, R; Franks, B; Glyda, M; Hettich, F; Holman, JM; Houbiers, JG; Rigotti, P; Rostaing, L, 2013)	0.39
" Elevated serum tumor necrosis factor-α, interferon-γ, and IL-12 levels returned to normal 10 days after initiating plasma exchange combined with leukocytapheresis, with a reduction in white blood cell count."	( Successful remission induced by plasma exchange combined with leukocytapheresis against refractory systemic juvenile idiopathic arthritis. Abe, J; Fujimaru, T; Ito, S; Kamei, K; Miyazono, A; Ogura, M; Sato, M, 2014)	0.4
" In our current treatment protocol, the total steroid dose has been significantly reduced through the use of the immunosuppressant mizoribine in combination with tonsillectomy-steroid pulse therapy for the treatment of active IgA nephropathy in patients with renal impairment."	( Efficacy of steroid pulse therapy in combination with mizoribine following tonsillectomy for immunoglobulin A nephropathy in renally impaired patients. Iino, Y; Kaneko, T; Katayama, Y; Shimizu, A; Tsuruoka, S, 2013)	0.39
" One week later, intravenous methylprednisolone pulse therapy (500 mg/day) was administered for 3 days, followed by oral prednisolone in combination with mizoribine (100 to 150 mg/day)."	( Efficacy of steroid pulse therapy in combination with mizoribine following tonsillectomy for immunoglobulin A nephropathy in renally impaired patients. Iino, Y; Kaneko, T; Katayama, Y; Shimizu, A; Tsuruoka, S, 2013)	0.39
"Steroid pulse therapy in combination with mizoribine following tonsillectomy is effective in improving urinary findings and preserving renal function in the treatment of IgA nephropathy, which remained active in patients with renal impairment (estimated glomerular filtration rate ≥20 and <60 mL/min/1."	( Efficacy of steroid pulse therapy in combination with mizoribine following tonsillectomy for immunoglobulin A nephropathy in renally impaired patients. Iino, Y; Kaneko, T; Katayama, Y; Shimizu, A; Tsuruoka, S, 2013)	0.39
" We treated SRNS patients resistant to CIs and MPT with additional rituximab combined with MPT and immunosuppressive agents."	( Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome. Fujimaru, T; Iijima, K; Ito, S; Kaito, H; Kamei, K; Nakayama, M; Ogura, M; Okada, M; Sato, M, 2014)	0.4
"Additional rituximab combined with conventional MPT and immunosuppressive agents is a promising option for overcoming refractory SRNS."	( Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome. Fujimaru, T; Iijima, K; Ito, S; Kaito, H; Kamei, K; Nakayama, M; Ogura, M; Okada, M; Sato, M, 2014)	0.4
"Patients with biopsy-proven IgAN, proteinuria and low serum creatinine were randomly allocated to receive tonsillectomy combined with steroid pulses (Group A; n = 33) or steroid pulses alone (Group B; n = 39)."	( A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Fujimoto, S; Furusu, A; Hamaguchi, A; Hirano, K; Horikoshi, S; Imai, H; Imasawa, T; Ishii, T; Kanozawa, K; Kasai, K; Kawamura, T; Kimura, K; Matsuo, S; Matsushima, M; Miura, N; Miyazaki, Y; Ogura, M; Okamoto, H; Okonogi, H; Shibata, T; Shirai, S; Soma, J; Suzuki, Y; Tomino, Y; Ueda, H; Utsunomiya, Y; Wada, A; Yamaji, I; Yasuda, T; Yokoo, T; Yoshimura, M, 2014)	0.4
"The results indicate tonsillectomy combined with steroid pulse therapy has no beneficial effect over steroid pulses alone to attenuate hematuria and to increase the incidence of clinical remission."	( A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Fujimoto, S; Furusu, A; Hamaguchi, A; Hirano, K; Horikoshi, S; Imai, H; Imasawa, T; Ishii, T; Kanozawa, K; Kasai, K; Kawamura, T; Kimura, K; Matsuo, S; Matsushima, M; Miura, N; Miyazaki, Y; Ogura, M; Okamoto, H; Okonogi, H; Shibata, T; Shirai, S; Soma, J; Suzuki, Y; Tomino, Y; Ueda, H; Utsunomiya, Y; Wada, A; Yamaji, I; Yasuda, T; Yokoo, T; Yoshimura, M, 2014)	0.4
"The aim of this study was to investigate the effects of two different treatment regimes in patients with IgA nephropathy (IgAN): steroids alone and in combination with a medium dose of cyclosporine A (CsA)."	( Comparison of glucocorticoids alone and combined with cyclosporine a in patients with IgA nephropathy: a prospective randomized controlled trial. Ding, X; Fang, Y; Ji, J; Liu, C; Liu, H; Xu, X; Yuan, M; Zhang, X, 2014)	0.4
"The objective is to explore the clinical curative effects of methylprednisolone combined with MTX and DXM intrathecal injection in treating neuropsychiatric systemic lupus erythematosus (NPSLE) and its effects on autoantibody level and anti-N-methyl-D-aspartate receptor subtype NR2a/2b antibody (anti-NR2 antibody) level."	( Impact analysis of autoantibody level and NR2 antibody level in neuropsychiatric SLE treated by methylprednisolone combined with MTX and DXM intrathecal injection. Fu, B; Lei, H; Wang, J; Zhang, J; Zhao, Y; Zhu, G, 2014)	0.4
" The aim of this study was to investigate the therapeutic efficacy of the usage of aminoguanidine (AG), in myocardial damage occurring after BCT, alone and in combination with methylprednisolone (MP)."	( Cardioprotective effect of aminoguanidine in combination with steroid therapy after blunt chest trauma. Akdemir, HU; Alacam, H; Demir, F; Duran, L; Gacar, A; Guvenc, T; Guzel, A; Karadeniz, C; Murat, N; Ozdemir, S, 2014)	0.4
"To study the effects of a Gold Belt (GB, a traditional Chinese herbal medicine) combined with methyl-prednisolone (MP) on the motor function and brain-derived neurotrophic factor (BDNF) expression in rats with contusive spinal cord injury (SCI)."	( [Effect of Gold Belt combined with methylprednisolone on motor function and brain-derived neurotrophic factor expression in rats following traumatic spinal cord injury]. Li, C; Wang, T; Xu, Z, 2015)	0.42
"GB combined with MP produces better therapeutic effects for treating SCI than GB or MP used alone, and such effects are probably related with enhanced BDNF expression in the spinal cord."	( [Effect of Gold Belt combined with methylprednisolone on motor function and brain-derived neurotrophic factor expression in rats following traumatic spinal cord injury]. Li, C; Wang, T; Xu, Z, 2015)	0.42
"This paper aims to make an analysis of the effects of ganglioside (GM) combined with methylprednisolone (MP) in early acute spinal injury."	( Clinical study of ganglioside (GM) combined with methylprednisolone (MP) for early acute spinal injury. Li, Y; Sun, Y; Xu, D; Yang, L, 2015)	0.42
"The efficacy of double-filtration plasmapheresis (DFPP), combined with methylprednisolone, to treat diffuse proliferative lupus nephritis (LN) was studied."	( Therapeutic effect of double-filtration plasmapheresis combined with methylprednisolone to treat diffuse proliferative lupus nephritis. Chen, X; Gao, Y; Li, M; Qiu, Q; Wang, Y; Wei, R; Zhang, L; Zhang, X, 2016)	0.43
" The patients in the treatment group were first treated with DFPP combined with methylprednisolone (0."	( Therapeutic effect of double-filtration plasmapheresis combined with methylprednisolone to treat diffuse proliferative lupus nephritis. Chen, X; Gao, Y; Li, M; Qiu, Q; Wang, Y; Wei, R; Zhang, L; Zhang, X, 2016)	0.43
"Appropriate application of DFPP combined with glucocorticoid therapy could accelerate the remission of diffuse proliferative LN, reduce overall glucocorticoid dosage, prevent recurrence, and maintain C3 level in a higher level."	( Therapeutic effect of double-filtration plasmapheresis combined with methylprednisolone to treat diffuse proliferative lupus nephritis. Chen, X; Gao, Y; Li, M; Qiu, Q; Wang, Y; Wei, R; Zhang, L; Zhang, X, 2016)	0.43
"We evaluated the clinical efficacy and side effect of oral methylprednisolone (MPD) mini-pulse therapy combined with narrow-band UVB (NBUVB) for adults with non-segmental vitiligo retrospectively."	( A Retrospective Study of Methylprednisolone Mini-Pulse Therapy Combined with Narrow-Band UVB in Non-Segmental Vitiligo. Chu, H; Kim, DS; Kim, M; Lee, H; Lee, J; Oh, SH, 2016)	0.43
"Oral MPD mini-pulse therapy combined with NBUVB appears effective in arresting vitiligo progression and rapidly inducing repigmentation with minimal side effects."	( A Retrospective Study of Methylprednisolone Mini-Pulse Therapy Combined with Narrow-Band UVB in Non-Segmental Vitiligo. Chu, H; Kim, DS; Kim, M; Lee, H; Lee, J; Oh, SH, 2016)	0.43
" Treatment protocols were a single-course steroid pulse combined with mizoribine during a period from August 2006 to June 2010 (Group A; n = 34) and a three-course steroid pulse during a period from July 2010 to March 2013 (Group B; n = 32)."	( Comparison of immunosuppressive therapies for IgA nephropathy after tonsillectomy: three-course versus one-course steroid pulse combined with mizoribine. Arai, M; Hirama, A; Ikeda, M; Kaneko, T; Morita, M; Shimizu, A; Tsuruoka, S; Watanabe, Y, 2015)	0.42
"Single-course steroid pulse therapy combined with mizoribine was considered to have a protective effect on the renal function in IgA nephropathy, especially accompanying renal dysfunction."	( Comparison of immunosuppressive therapies for IgA nephropathy after tonsillectomy: three-course versus one-course steroid pulse combined with mizoribine. Arai, M; Hirama, A; Ikeda, M; Kaneko, T; Morita, M; Shimizu, A; Tsuruoka, S; Watanabe, Y, 2015)	0.42
" This study was performed to compare two treatment regimens, steroid-pulse therapy or combined with mizoribine (MZR) in progressive IgAN."	( Comparison of steroid-pulse therapy and combined with mizoribine in IgA nephropathy: a randomized controlled trial. Hirakata, H; Hirakawa, M; Katafuchi, R; Kitazono, T; Masutani, K; Mitsuiki, K; Tsuchimoto, A; Tsuruya, K; Yamada, T, 2016)	0.43
"Study design was a prospective randomized controlled trial of 40 patients with moderate to severe glomerular injuries who were randomly administered either pulse methylprednisolone followed by a 25-month course of oral prednisolone (P group, n = 20) or in combination with MZR (150 mg/day for 24 months, M + P group, n = 20)."	( Comparison of steroid-pulse therapy and combined with mizoribine in IgA nephropathy: a randomized controlled trial. Hirakata, H; Hirakawa, M; Katafuchi, R; Kitazono, T; Masutani, K; Mitsuiki, K; Tsuchimoto, A; Tsuruya, K; Yamada, T, 2016)	0.43
" We could not find the additional effect of MZR in combination with steroid-pulses in this small-scale controlled trial."	( Comparison of steroid-pulse therapy and combined with mizoribine in IgA nephropathy: a randomized controlled trial. Hirakata, H; Hirakawa, M; Katafuchi, R; Kitazono, T; Masutani, K; Mitsuiki, K; Tsuchimoto, A; Tsuruya, K; Yamada, T, 2016)	0.43
"MSC combined with budesonide, almeterol and azithromycin has been confirmed to be generally safe and can reduce the dose of glucocorticoid in treatment of BOS after HSCT."	( [Mesenchymal Stem Cells Combined with Budesonide, Almeterol and Azithromycin for the Treatment of Bronchiolitis Obliterans Syndrome after Hematopoietic Stem Cell Transplantation]. Cao, XP; Ding, L; Guo, ZK; Han, DM; Liu, J; Wang, HX; Wang, ZD; Xue, M; Yan, HM; Zheng, XL; Zhu, L, 2016)	0.43
" The efficacy of tonsillectomy combined with steroid pulse (SP) administration (TSP) for clinical remission of IgAN has been reported."	( Comparison of methods of steroid administration combined with tonsillectomy for IgA nephropathy patients. Aoyagi, R; Goto, S; Hosojima, M; Kaneko, Y; Kondo, D; Narita, I; Takata, T; Watanabe, H; Yamamoto, S; Yamazaki, H, 2017)	0.46
"We retrospectively compared clinical remission in IgAN patients treated with tonsillectomy combined with two different steroid administration methods: (1) three courses of SP therapy and oral prednisolone administered on alternate days (group 3A; n = 25); and (2) one course of SP therapy and oral prednisolone administered on consecutive days (group 1C; n = 22)."	( Comparison of methods of steroid administration combined with tonsillectomy for IgA nephropathy patients. Aoyagi, R; Goto, S; Hosojima, M; Kaneko, Y; Kondo, D; Narita, I; Takata, T; Watanabe, H; Yamamoto, S; Yamazaki, H, 2017)	0.46
" Low-dose indomethacin combined with methylprednisolone may be a new choice for AFOP treatment."	( Methylprednisolone combined with low-dose indomethacin treating acute fibrinous and organizing pneumonia after a surgical resection of rectal adenocarcinoma: a case report and literature review. Bian, LJ; Chen, M; Chen, QK; Huang, LJ; Jiang, SP; Lin, XL; Tang, TT; Zhou, CX, 2016)	0.43
"To discuss the effects glucocorticoid combined with gamma globulins in the treatment of children with myasthenia gravis and its effects on immune globulin and complement of children."	( Effect of glucocorticoid combined with gamma globulin in treatment of children with myasthenia gravis and its effects on immune globulin and complement of children. An, Q; Deng, XQ; Huang, XX; Wang, MG; Yao, D, 2016)	0.43
"To evaluate the effectiveness and safety of mycophenolate mofetil (MMF) as first-line therapy combined with systemic corticosteroids in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada (VKH) disease."	( Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease. Abu El-Asrar, AM; Al-Muammar, A; Dosari, M; Gikandi, PW; Hemachandran, S, 2017)	0.46
"Use of MMF as first-line therapy combined with systemic corticosteroids in patients with initial-onset acute VKH disease prevents progression to chronic recurrent granulomatous inflammation and development of 'sunset glow fundus'."	( Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease. Abu El-Asrar, AM; Al-Muammar, A; Dosari, M; Gikandi, PW; Hemachandran, S, 2017)	0.46
"To investigate the clinical efficacy and safety of intravenous injection of low-dose versus high-dose gamma globulin combined with glucocorticoid pulse therapy in the treatment of children with moderate/severe acute Guillain-Barré syndrome (GBS)."	( [Clinical efficacy of different doses of gamma globulin combined with glucocorticoid in treatment of moderate/severe acute Guillain-Barré syndrome in children: a comparative analysis]. Li, Y; Li, Z; Ma, XY; Ma, YP; Wang, XJ; Ye, JJ, 2016)	0.43
"4 g/(kg · d) gamma globulin respectively combined with methylprednisolone."	( [Clinical efficacy of different doses of gamma globulin combined with glucocorticoid in treatment of moderate/severe acute Guillain-Barré syndrome in children: a comparative analysis]. Li, Y; Li, Z; Ma, XY; Ma, YP; Wang, XJ; Ye, JJ, 2016)	0.43
"Low-dose versus high-dose gamma globulin combined with methylprednisolone pulse therapy have comparable clinical efficacy and safety in the treatment of children with moderate/severe acute GBS."	( [Clinical efficacy of different doses of gamma globulin combined with glucocorticoid in treatment of moderate/severe acute Guillain-Barré syndrome in children: a comparative analysis]. Li, Y; Li, Z; Ma, XY; Ma, YP; Wang, XJ; Ye, JJ, 2016)	0.43
" The aim of this study was to investigate the efficacy and safety of bortezomib combined with glucocorticoids in refractory lupus patients."	( The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis. Hou, J; Hu, W; Huang, L; Huang, X; Liu, Z; Zhang, H; Zhou, M, 2017)	0.46
" The objective of this study was to characterize the potential drug-drug interactions (DDIs) between voriconazole and glucocorticoids using physiologically based pharmacokinetic (PBPK) models."	( Assessment of drug-drug interactions between voriconazole and glucocorticoids. Chen, L; Li, M; Li, N; Qi, F; Zhu, L, 2018)	0.48
"In this study we compared the anatomic and functional outcomes of two steroid treatments on rhegmatogenous retinal detachment (RRD) combined with choroidal detachment (CD), namely treatment with oral prednisolone (1 mg/kg daily) for 3-7 days before vitrectomy or a single periocular injection of methylprednisolone (40 mg) 1-3 days before vitrectomy."	( The effect of single periocular injection of methylprednisolone and drainage of suprachoroidal fluid in the treatment of rhegmatogenous retinal detachment combined with choroidal detachment. Chen, H; Chen, X; Wang, X; Wei, Y; Zhou, R, 2019)	0.51
" Seventy five eyes with RRD combined with CD were divided into 2 groups based on the two different treatment regimens as above."	( The effect of single periocular injection of methylprednisolone and drainage of suprachoroidal fluid in the treatment of rhegmatogenous retinal detachment combined with choroidal detachment. Chen, H; Chen, X; Wang, X; Wei, Y; Zhou, R, 2019)	0.51
"For RRD combined with CD, eyes treated with a single periocular injection of methylprednisolone (40 mg, 1-3 days before pars plana vitrectomy) combined with the drainage of suprachoroidal fluids during the surgery had similar anatomic and functional outcomes compared to the eyes treated with oral prednisolone for 3-7 days before vitrectomy."	( The effect of single periocular injection of methylprednisolone and drainage of suprachoroidal fluid in the treatment of rhegmatogenous retinal detachment combined with choroidal detachment. Chen, H; Chen, X; Wang, X; Wei, Y; Zhou, R, 2019)	0.51
"To study the effect of the leukotriene receptor agonist montelukast combined with methylprednisolone on inflammatory response and peripheral blood lymphocyte subset content in children with mycoplasma pneumonia."	( Effect of montelukast combined with methylprednisolone for the treatment of mycoplasma pneumonia. Ding, X; Ji, W; Liang, Y; Wu, H; Zhao, D, 2019)	0.51
"Montelukast combined with methylprednisolone for the treatment of mycoplasma pneumonia can inhibit inflammatory responses and regulate levels of Th1/Th2 and Th17/Treg cells."	( Effect of montelukast combined with methylprednisolone for the treatment of mycoplasma pneumonia. Ding, X; Ji, W; Liang, Y; Wu, H; Zhao, D, 2019)	0.51
" As a conservative therapy for SLE-associated AAC, corticosteroid therapy combined with azathioprine might be beneficial."	( Systemic Lupus Erythematosus-associated Acute Acalculous Cholecystitis Successfully Treated by a Corticosteroid Combined with Azathioprine. Fujiyama, S; Kudo, N; Shimomura, T; Suzushima, H; Takaoka, H, 2019)	0.51
" We analyzed the efficacy of tonsillectomy combined with steroid pulse therapy (TSP)."	( The impact of tonsillectomy combined with steroid pulse therapy in patients with advanced IgA nephropathy and impaired renal function. Kamiyama, T; Karasawa, K; Kumon, S; Moriyama, T; Nitta, K, 2020)	0.56
"To determine the curative effect of gamma globulin combined with methylprednisolone sodium succinate on paediatric patients with severe hand-foot-mouth disease and analyse its influence on cardio-pulmonary functions."	( Effectiveness of gamma globulin combined with methylprednisolone sodium succinate in severe hand foot mouth disease - Baoding Children's Hospital, China. Jie, C; Li-Po, H; Yu, Z; Yuan-da, Z, 2020)	0.56
" Those in the test group accepted gamma globulin combined with methylprednisolone sodium succinate."	( Effectiveness of gamma globulin combined with methylprednisolone sodium succinate in severe hand foot mouth disease - Baoding Children's Hospital, China. Jie, C; Li-Po, H; Yu, Z; Yuan-da, Z, 2020)	0.56
"Curative effect of gamma globulin combined with methylprednisolone sodium succinate on paediatric patients showed significance and this treatment could be effectively improve clinical symptoms and cardio-pulmonary functions of paediatric patients."	( Effectiveness of gamma globulin combined with methylprednisolone sodium succinate in severe hand foot mouth disease - Baoding Children's Hospital, China. Jie, C; Li-Po, H; Yu, Z; Yuan-da, Z, 2020)	0.56
" We analyzed the effects of roflumilast combined with ESHAP (etoposide, cisplatin, methylprednisolone, and cytarabine) chemotherapy in experimental and clinical settings."	( Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma. Chung, JS; Kim, DY; Kim, SW; Nam, J; Shin, HJ, 2022)	0.72
"We found that roflumilast is efficient when combined with other chemotherapy drugs, especially cytarabine."	( Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma. Chung, JS; Kim, DY; Kim, SW; Nam, J; Shin, HJ, 2022)	0.72
"We found that roflumilast, when combined with ESHAP chemotherapy, for relapsed/refractory DLBCL was clinically active and well tolerated."	( Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma. Chung, JS; Kim, DY; Kim, SW; Nam, J; Shin, HJ, 2022)	0.72
" IA combined with methylprednisolone to induce and alleviate the disease effectively, and cyclophosphamide (0."	( Diffuse alveolar hemorrhage in a patient with anti-neutrophil cytoplasm antibody-associated vasculitis successfully treated with immunoadsorption combined with methylprednisolone. Jin, S; Luo, J; Wang, D; Wu, M; Zhang, W, 2022)	0.72
" Recently, tonsillectomy combined with corticosteroid pulse (TSP) has been shown to be effective for achieving clinical remission and favorable renal outcome in patients with IgAN."	( Comparison of administration of single- and triple-course steroid pulse therapy combined with tonsillectomy for immunoglobulin A nephropathy. Atsumi, T; Fukasawa, Y; Iwasaki, S; Kaneshima, N; Maoka, T; Matsuoka, N; Nakagaki, T; Nakazawa, D; Nishimoto, N; Nishio, S; Tsuji, T; Watanabe-Kusunoki, K; Yamamoto, J; Yamamoto, R, 2021)	0.62
" According to the successful applications of dupilumab in BP cases reported, therefore, we investigate the real-life efficacy and safety of dupilumab combined with low-dose oral steroid for BP."	( Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid. Chen, S; Chen, Z; Gao, H; He, S; Hu, Y; Liu, S; Luo, X; Ma, L; Tang, C; Tang, L; Wang, L; Xu, Y; Yang, F; Yang, J; Zhang, Z; Zhao, Y, 2022)	0.72
" This case report indicated that remdesivir might interact with cytochrome P450 3A4 substrates, such as tacrolimus and everolimus, and elevate their blood concentrations under high inflammatory conditions."	( Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient. Hirai, T; Inoue, T; Iwamoto, T; Mizuta, A; Nishikawa, K; Sasaki, T, 2022)	0.72
"Diabetic kidney disease (DKD) combined with Membranous Nephropathy (MN) was observed in some patients with the increasing of Diabetic patients."	( Retrospective analysis of leflunomide and low-dose methylprednisolone for the treatment of diabetic nephropathy combined with membranous nephropathy. Cui, S; Li, P; Li, Q; Li, W; Shang, S; Wang, C; Wang, W, 2022)	0.72
"This study was aimed to evaluate the clinical efficacy of flap transplantation combined with vacuum sealing drainage and methylprednisolone and cyclosporine in the treatment of ulcer wound of patients with pyoderma gangrenosum (PG)."	( Clinical efficacy of flap transplantation combined with vacuum sealing drainage and methylprednisolone and cyclosporine in the treatment of pyoderma gangrenosum. Feng, Z; Hao, Y; He, J; Li, C; Zhao, Z, 2023)	0.91
" We aimed to evaluate the effect of methylprednisolone added to ultrasound-guided peripheral nerve blocks (PNBs) combined with multimodal analgesia including intravenous dexamethasone for prolonged analgesia after early discharge."	( Effect of Adding Perineural Methylprednisolone to Peripheral Nerve Blocks Combined With Intravenous Dexamethasone for Prolonged Postdischarge Analgesia After Fast-track Total Knee Arthroplasty: A Randomized Controlled Trial. Akaravinek, P; Kampitak, W; Limsakul, K; Ngarmukos, S; Tanavalee, A; Tanavalee, C, 2023)	0.91
" There are rare reports regarding the treatment of systemic lupus erythematosus (SLE) combined with CSC."	( A case report of systemic lupus erythematosus combined with central serous chorioretinopathy treated with glucocorticoids. Ku, M; Rao, Q; Wan, Q, 2023)	0.91
"We access the safety and efficacy of methylprednisolone combined with dupilumab in treating the bullous pemphigoid."	( The efficacy and safety of dupilumab combined with methylprednisolone in the treatment of bullous pemphigoid in China. Qi, W; Rushan, X, 2023)	0.91
"We studied the neuroprotective effect of local application of methylprednisolone in combination with a block copolymer after contusion spinal cord injury in rats."	( Morphofunctional Changes in the Spinal Cord of Rats after Contusion Injury with Local Delivery of Methylprednisolone in Combination with a Copolymer. Baltin, ME; Baltina, TV; Chernova, ON; Sabirova, DE; Sachenkov, OA, 2023)	0.91
"Clinical studies of IGU combined with MP for pSS were searched through eight databases."	( Efficacy and safety of iguratimod combined with methylprednisolone for primary Sjögren's syndrome: a meta-analysis and trial sequential analysis. Hu, G; Xu, Q; Yang, XY; Yin, S; You, H; Yu, YF, 2023)	0.91
"IGU combined with MP effectively attenuates autoimmune responses (IgG, IgM, IgA), reduces clinical symptoms and disease activity (ESR, PLT, ESSPRI, ESSDAI), and improves the exocrine gland functional status (SIT) in patients with pSS."	( Efficacy and safety of iguratimod combined with methylprednisolone for primary Sjögren's syndrome: a meta-analysis and trial sequential analysis. Hu, G; Xu, Q; Yang, XY; Yin, S; You, H; Yu, YF, 2023)	0.91
"In this study, the clinical effect of lamivudine combined with leflunomide and methylprednisolone in the treatment of hepatitis B virus-associated glomerulonephritis (HBV-GN) and their influence on renal function indexes was explored."	( Clinical Effect of Lamivudine Combined with Leflunomide and Methylprednisolone Tablets in the Treatment of Hepatitis B Virus-Associated Glomerulonephritis and Its Influence on Renal Function Indicators. Jiang, F; Liu, H; Xing, X; Zhang, M; Zheng, K; Zhou, C, 2023)	0.91
"Lamivudine combined with methylprednisolone and leflunomide treatment is conducive to clearing Hepatitis B virus (HBV) and improving renal function."	( Clinical Effect of Lamivudine Combined with Leflunomide and Methylprednisolone Tablets in the Treatment of Hepatitis B Virus-Associated Glomerulonephritis and Its Influence on Renal Function Indicators. Jiang, F; Liu, H; Xing, X; Zhang, M; Zheng, K; Zhou, C, 2023)	0.91

Excerpt	Reference	Relevance
" The median value of bioavailability (relative to oral dose) of methylprednisolone acetate based on unchanged methylprednisolone plasma levels was 14."	( Rectal and oral absorption of methylprednisolone acetate. Albert, KS; Garg, DC; Sakmar, E; Wagner, JG; Weidler, DJ, 1979)	0.26
"The variability and relative bioavailability of methylprednisolone tablets were evaluated utilizing a double Latin square crossover design in which each of 20 subjects was given four of five treatments."	( Double Latin square study to determine variability and relative bioavailability of methylprednisolone. Albert, KS; Brown, SW; Chen, TT; DeSante, KA; DiSanto, AR; Stewart, RD, 1979)	0.26
"This presentation has attempted to provide a brief view of the importance of bioavailability and bioequivalence to those physicians who use corticosteroids."	( Corticosteroids and bioavailability. Stubbs, SS, 1975)	0.25
" This method was successfully implemented for the analysis of specimens generated from a single-dose bioavailability and safety study for a new formulation of Depo-Medrol sterile aqueous suspension."	( Validation of the simultaneous determination of methylprednisolone and methylprednisolone acetate in human plasma by high-performance liquid chromatography. Addison, TE; Brisson, J; Hopkins, NK; Wagner, CM, 1992)	0.28
" The relative oral bioavailability of the sterol was 69."	( High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response. Ahern, MJ; Cosh, DG; Hayball, PJ; Roberts-Thomson, PJ; Schultz, DW, 1992)	0.28
" Although the effects of precipitate formation on drug bioavailability and toxicity have not been fully determined, until such information is available, the use of combinations of drugs that remain in solution during administration is recommended."	( The solubility of antibiotic and corticosteroid combinations. Lee, BL; Matoba, AY; Osato, MS; Robinson, NM, 1992)	0.28
" We studied the immunosuppressive properties of new, synthetic, prostaglandin E1 (PGE1) methyl ester analogs (misoprostol, enisoprost) with oral bioavailability using an allogeneic in vitro immunoassay."	( The immunosuppressive properties of new oral prostaglandin E1 analogs. Dumble, LJ; Maddux, MS; Moran, M; Pollak, R; Wiederkehr, JC, 1990)	0.28
" Oral bioavailability was essentially 100 percent, ruling out impaired absorption."	( Rapid methylprednisolone clearance in a patient with cystic fibrosis. Farrell, PM; Green, CG; Jusko, WJ; Kraus, CK; Lemanske, RF, 1988)	0.27
"The absolute bioavailability and pharmacokinetic parameters of two methylprednisolone formulations (methylprednisolone sodium succinate and methylprednisolone acetate) were determined in five dogs."	( Pharmacokinetics of methylprednisolone, methylprednisolone sodium succinate, and methylprednisolone acetate in dogs. Alvinerie, M; Fayolle, PM; Koritz, GD; Toutain, PL, 1986)	0.27
" Bioavailability of prednisolone after the oral administration of prednisone and methylprednisolone ranged from 86% to 104% during anticonvulsant therapy."	( Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. Bartoszek, M; Brenner, AM; Szefler, SJ, 1987)	0.27
" When methylprednisolone (80 mg) was also taken by mouth, the relative bioavailability of the tablets was 99%."	( Kinetics of methylprednisolone and its hemisuccinate ester. Derendorf, H; Möllmann, H; Rehder, J; Rohdewald, P; Schmidt, EW, 1985)	0.27
" In vivo pharmacokinetic studies in rhesus monkeys were also conducted to compare the bioconversion rates and overall bioavailability of several solution-stable prodrugs with the 21-succinate ester."	( Strategies in the design of solution-stable, water-soluble prodrugs III: influence of the pro-moiety on the bioconversion of 21-esters of corticosteroids. Anderson, BD; Conradi, RA; Forbes, AD; Spilman, CH, 1985)	0.27
" Assessment of methylprednisolone disposition following oral and intravenous doses revealed no effect of cimetidine on the bioavailability (74 to 81 percent absorption) or plasma clearance (22 to 24 liters per hour) of the steroid."	( Cimetidine-methylprednisolone-theophylline metabolic interaction. Ebling, WF; Gardner, MJ; Green, AW; Jusko, WJ, 1984)	0.27
"This study was conducted to evaluate the influence of route of administration upon the bioavailability and pharmacokinetics of methylprednisolone sodium succinate."	( Influence of route of administration on the pharmacokinetics of methylprednisolone. Albert, KS; Antal, EJ; Gillespie, WR; Wright, CE, 1983)	0.27
"This was a single-blind, single-dose, randomized crossover study to determine the absolute bioavailability of Medrol, a new high dose (100 mg) methylprednisolone tablet product, by comparing it with 100 mg methylprednisolone from an intravenous formulation, Solu-Medrol."	( Absolute bioavailability of a new high dose methylprednisolone tablet formulation. Groenewoud, G; Hundt, HK; Luus, HG; Müller, FO; Schall, R, 1994)	0.29
" The aim of the study was to determine the oral bioavailability of high dose methylprednisolone and to establish whether this is a feasible and more convenient route of administration."	( Pharmacokinetics of high dose methylprednisolone and use in hematological malignancies. Graham, MA; McElwain, TJ; Newell, DR; Patel, PM; Selby, PJ; Viner, C, )	0.13
" In addition the differences in the pharmacokinetics for the prodrugs resulted in only a small difference in the relative bioavailability of MP for MP suleptanate (0."	( A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. Daley-Yates, PT; Parker, TJ; Wood, SA, 1997)	0.3
" The bioavailability of MP was equivalent when based on AUC with a MP suleptanate median 108% of the MP succinate value (90% CI: 102-114%)."	( Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone. Brooks, CD; Daley-Yates, PT; Gregory, AJ, 1997)	0.3
" These complications could be reduced by techniques that increase the spinal bioavailability of intravenously administered methylprednisolone while simultaneously decreasing plasma bioavailability."	( Spinal cord bioavailability of methylprednisolone after intravenous and intrathecal administration: the role of P-glycoprotein. Bernards, CM; Koszdin, KL; Shen, DD, 2000)	0.31
" In addition, wild-type mice and P-glycoprotein knockout mice were used to determine the role of P-glycoprotein in limiting spinal bioavailability of methylprednisolone."	( Spinal cord bioavailability of methylprednisolone after intravenous and intrathecal administration: the role of P-glycoprotein. Bernards, CM; Koszdin, KL; Shen, DD, 2000)	0.31
"These pig studies demonstrate that the spinal cord bioavailability of methylprednisolone is poor after intravenous administration."	( Spinal cord bioavailability of methylprednisolone after intravenous and intrathecal administration: the role of P-glycoprotein. Bernards, CM; Koszdin, KL; Shen, DD, 2000)	0.31
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."	( QSAR model for drug human oral bioavailability. Topliss, JG; Yoshida, F, 2000)	0.31
"The significance of intestinal P-glycoprotein (P-gp) in determining the oral bioavailability of tacrolimus has been still controversial."	( Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine. Achiwa, K; Aungst, BJ; Kobayashi, M; Oda, M; Saikachi, Y; Saitoh, H; Tadano, K; Takahashi, Y; Yamaguchi, M; Yuhki, Y, 2006)	0.33
" The pharmacokinetics of MPL showed bi-exponential disposition with two first-order absorption components from the injection site and bioavailability was 21%."	( Modeling receptor/gene-mediated effects of corticosteroids on hepatic tyrosine aminotransferase dynamics in rats: dual regulation by endogenous and exogenous corticosteroids. Almon, RR; DuBois, DC; Hazra, A; Jusko, WJ; Pyszczynski, N, 2007)	0.34
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
"To investigate the effect of PEO-PPO-PEO polymeric micelles (PM) formulation on the bioavailability of methylprednisolone (MP), a treatment of spinal cord injury (SCI), to the blood and spinal cord (SC) of rabbits."	( Bioavailability effect of methylprednisolone by polymeric micelles. Chang, SF; Chen, CL; Hsu, CY; Lee, D; Lee, YH; Liaw, J; Lin, SJ; Yang, LY, 2008)	0.35
"Patients with juvenile DM and ERL loss may have decreased bioavailability of OP compared with IVMP."	( Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Daru, JA; Gursahaney, A; Ngai, KL; Pachman, LM; Rouster-Stevens, KA, 2008)	0.35
"We included 13 patients with MS with NAbs and a low IFN-beta bioavailability detected by the MxA-mRNA response in a descriptive, non-randomized trial."	( Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. Bendtzen, K; Christensen, O; Hesse, D; Jensen, PE; Ravnborg, M; Sørensen, PS; Tovey, MG, 2009)	0.35
"The intestinal absorption rate constant of methylprednisolone (MP) evaluated by the loop method increased significantly with increasingly higher concentrations of the drug up to 500 microM in a nonlinear fashion but did not increase further at higher concentrations."	( Nonlinear absorption of methylprednisolone by absorptive and secretory transporters. Fujinaga, I; Hayashi, M; Tomita, M; Watanabe, A; Yamakawa, T, 2010)	0.36
" Analysis of dose-adjusted exposure parameters showed significant increases in AUC and Cmin after SL administration confirming a better bioavailability of the SL route compared with oral route."	( Sublingual administration improves systemic exposure of tacrolimus in kidney transplant recipients: comparison with oral administration. Apicella, L; Balletta, MM; Capone, D; Carrano, R; Federico, S; Mosca, T; Nappi, R; Russo, L; Sabbatini, M; Santangelo, M; Tarantino, G, 2016)	0.43
"Risedronate sodium is a bisphosphonate derivative having very low bioavailability when administered through the oral route."	( Improvement of bone microarchitecture in methylprednisolone induced rat model of osteoporosis by using thiolated chitosan-based risedronate mucoadhesive film. Anbu, J; Azamthulla, M; Banala, VT; Mukherjee, D; Ramachandra, SG; Srinivasan, B, 2018)	0.48
"Olmesartan medoxomil (OLM) is an antihypertensive drug with low oral bioavailability due to extensive first-pass metabolism."	( Use of transethosomes for enhancing the transdermal delivery of olmesartan medoxomil: in vitro, ex vivo, and in vivo evaluation. Abdelbary, AA; Albash, R; El-Nabarawi, MA; Refai, H, 2019)	0.51
"We review prior and current literature on the use of MP treatment for ASCI patients with a discussion of novel drug delivery systems that have demonstrated the potential to improve MP's bioavailability at the site of injury while minimizing systemic side effects."	( Updated Review: The Steroid Controversy for Management of Spinal Cord Injury. Bowles, DR; Canseco, JA; DiMaria, SL; Karamian, BA; Leibensperger, MR; Markowitz, MP; Semenza, NC; Smith, ML; Vaccaro, AR, 2021)	0.62

Excerpt	Relevance	Reference
" As the results indicated 400 mug a day to have the most pronounced effect on nasal symptoms, this dosage is recommended for children as well as adults suffering from summer hay fever."	( Beclomethasone dipropionate aerosol treatment of hay fever. A dose-response investigation. Andersen, JB; Halberg, P; Mygind, N, 1975)	0.25
" In the first case rapidly progressive glomerulonephritis with 100% crescents was arrested and followed by improvement of renal function from a creatinine clearance of 5 ml/min to 30 ml/min; in the second case multiple lung granulomata of 8 months' standing, unresponsive to oral steroids, disappeared 8 days after treatment with high dosage intravenous methylprednisolone."	( Methylprednisolone pulse therapy in the treatment of polyarteritis nodosa. Lee, HA; Neild, GH, 1977)	0.26
"This study was designed to determine the effect of methylprednisolone on the profile of hepatic oxygen supply and selected blood parameters in fasted, male rats administered an LD85 dosage of E coli endotoxin intraperitoneally."	( The effect of methylprednisolone on hepatic oxygen supply and plasma lactate and glucose in endotoxemia. Casey, JP; Rink, RD; Short, BL, 1979)	0.26
"Long-term glucocorticoid dosing directly enhances a facilitatory function of cat soleus motor nerve terminals."	( Effects of a single methylprednisolone dose on a facilitatory response of mammalian motor nerve. Baker, T; Hall, ED; Riker, WF, 1977)	0.26
" Since increased cardiac output was associated with increased stroke volume and left ventricular stroke work index, but without an increase in preload (PWP) or a decrease in afterload (MABP), methylprednisolone(MP), in pharmacologic dosage appears to have a positive inotropic effect on the myocardium of trauma patients during resuscitation."	( Evaluation of glucocorticoids during resuscitation of injured patients. Dutton, RE; Newell, JC; Powers, SR; Rhodes, GR; Scovill, WA; Shah, DM, 1979)	0.26
" The failure to demonstrate any beneficial effect and the slight increased mortality and morbidity associated with the bolus methylprednisolone dosage makes this therapy unjustifiable."	( High dose (bolus) intravenous methylprednisolone at the time of kidney homotransplantation. Fox, PS; Kauffman, HM; Sampson, D; Stawicki, AT, 1977)	0.26
" Methylprednisolone in an early pharmacologic dosage is effective in fulminant instances of fat embolism that occur in spite of adequate respiratory care and the proper treatment of fractures."	( Corticosteroids in patients with a high risk of fat embolism syndrome. Alho, A; Eerola, P; Hämäläinen, M; Koskinen, M; Saikku, K, 1978)	0.26
" ALG in the dosage used did not show any beneficial effects and varying degrees of rejection occurred in the majority of these unmatched animal pairs."	( Segmental pancreatic transplantation in pigs. Kyriakides, GK; Miller, J; Nuttall, FQ, 1979)	0.26
" Endotoxin in a dosage of 3,000 microgram was not lethal for nonmedicated control animals."	( Endotoxin toxicity in rats with 6-sulfanilamidoindazole arthritis. Hiramoto, RN; Miller, ML; Samuelson, CO; Ward, JR, 1979)	0.26
" Our data suggest that for optimal graft and patient survival the dosage of steroids should be less than 150 mg/day of methylprednisolone on days 1-3, less than 50 mg/day of prednisone on days 4-21, less than 30 mg/day on days 22-30, and less than 20 mg/day between one mo and one yr."	( Steroid treatment for routine immunosuppression in cadaver renal transplantation. A survey of hospitals. Gonzalez, FM; Kodlin, D; Kumar, P; Leech, SH, )	0.13
" These results suggest a significant cumulative effect in reducing infarct size over that achieved with one agent alone; however, further studies are needed to determine the appropriate dosage and temporal factors."	( Reduction of experimental myocardial infarct size by combined treatment with methylprednisolone sodium succinate and betahistine hydrochloride. Joyce, LD; Lillehei, RC; Mauer, HG; Smith, JM, 1978)	0.26
"While corticosteroids in standard neurosurgical dosage do not appear to influence recovery from severe head injury or elevated intracranial pressure (ICP), some reports claim that a much higher dose is effective."	( Failure of high-dose steroid therapy to influence intracranial pressure in patients with severe head injury. Becker, DP; Gudeman, SK; Miller, JD, 1979)	0.26
" The most likely effect of high dosage steroids is reduction of cerebral oedema."	( Use of high dose corticosteroids in patients with inoperable brain tumours. Glass, P; Goodgold, A; LeBrun, Y; Lieberman, A; Lux, W; Ransohoff, J; Wise, A, 1977)	0.26
" Topical steroid in the dosage used does not potentiate infection in standard burn wound sepsis models."	( Prevention of dermal ischemia after thermal injury. Eriksson, E; Kucan, JO; Paik, KI; Robson, MC, 1978)	0.26
" The special feature of this treatment involved a high dosage (96 mg."	( New method of treatment of immune infertility. Davis, P; Harlin, B; Shulman, S, 1978)	0.26
" in the same dosage in combination with heparin 5000 U/day."	( Treatment of acute allograft rejection with high doses of corticosteroids. Alarcon-Zurita, A; Ladefoged, J, 1976)	0.26
" Allergic nasal symptoms were disabling in many patients when the oral dosage of corticosteroids was tapered."	( Beclomethasone dipropionate aerosol in the treatment of steroid-dependent asthma. A 12-week double-blind study comparing beclomethasone dipropionate and a vehicle aerosol. Harvey, LL; Kass, I; Nair, SV, 1976)	0.26
" The significant dialysance of methylprednisolone may require adjustment of dosage in certain clinical situations when hemodialysis is necessary for patients receiving the steroid."	( Effect of hemodialysis on methylprednisolone plasma levels. Letteri, JM; Sherlock, JE, 1977)	0.26
" Injections of hydrocortisone sodium succinate 10 mg twice daily (but not at the reduced dosage of 5 mg twice daily) or methyprenisolone acetate 5 mg twice daily beginning 30 min before the first challenge and continued to the time of killing reduced the extent and intensity of vasculitis in both the treated groups and showed less alveolar septal thickening in the hydrocortisone treated group and less alveolar consolidation in the methylprednisolone treated group compared to the pulmonary lesions in the rabbits which were sensitized and then subjected to OA aerosol challenges, but received no treatment."	( A study of the effects of systemic administration of adrenal glucocorticoids in an experimental model of hypersensitivity pneumonitis. Dill, J; Ghose, T; Landrigan, P, 1977)	0.26
" The method was applied to samples of one subject's plasma containing methylprednisolone and endogenous hydrocortisone after oral dosing with multiple doses of methylprednisolone."	( Determination of methylprednisolone and hydrocortisone in plasma using high pressure liquid chromatography. Ayres, JW; Garg, DC; Wagner, JG, 1977)	0.26
"On the basis of curves illustrating the effects of dosage on experimental animals, it was shown that glucocorticoids inhibit as well as stimulate lecithin synthesis in the fetal lung."	( [Experimental investigations in regard to the optimal stimulation of lecithin synthesis in the fetal lung via glucocorticoids (author's transl)]. Gerner, R; Halberstadt, E, 1976)	0.26
"In a controlled study, a 1-week course of a moderate dosage of corticosteroids given to ragweed-sensitive subjects was associated with a statistically significant decrease in blood eosinophi, levels and tissue esosinophil, but not mast cell, responses to ragweed antibody levels or gross whealing responses to antigen or compound 48/80."	( Histologic studies of human skin test responses to ragweed and compound 48/80. II. Effects of corticosteroid therapy. Slott, RI; Zeweiman, B, 1975)	0.25
" A persistent fall of the IgG globulins was noted in the first ten days after renal allograft with the immunosuppressive regimen of an initial gramme of methylprednisolon and high dosage of azothioprine."	( [Immunglobulin levels after kidney transplantation and during rejection crisis (author's transl)]. Leithner, C; Oppolzer, R; Pinggera, W; Schieler, K; Singer, F; Stummvoll, H; Wolf, A, 1975)	0.25
" To assess the role of glucocorticoids given in pharmacologic dosage in the early treatment of patients with acute myocardial infarction, serial serum creatine phosphokinase (CPK) were obtained every 1-2 hours in 39 consecutive patients admitted with acute myocardial infarction."	( Effect of methylprednisolone on predicted myocardial infarction size in man. Brandon, J; Gulotta, S; Maley, T; Morrison, J; Pyros, I; Reduto, L; Victa, C, )	0.13
" On the maximum dosage of desiccated thyroid, the patient developed mild weight loss associated with an increased appetite; there was no other sign or symptom of hyperthyroidism."	( Nerve regeneration and thyroid hormone treatment. McQuarrie, IG, 1975)	0.25
"Beclomethasone dipropionate, a new corticosteroid for inhalation in the form of a pressurised aerosol with a daily dosage of 300-400/mug, has been given to 130 adult asthmatics."	( [Beclomethasonedipropionate for corticoid inhalation therapy in bronchial asthma]. Debelić, M; Virchow, C, 1975)	0.25
" The increase in renal resistance is generally irreversible (three or four cases) under conditions of high MP dosage (2."	( Effect of high doses of methylprednisolone on the isolated, perfused canine kidney. Banowsky, LH; Braun, WE; Dvorak, KJ; Magnusson, MO; Stowe, NT, 1976)	0.26
" We conclude that IVGG plus methylprednisolone can be given safely at monthly intervals for a prolonged period but in the dosage administered did not prevent exacerbations in 80% of patients with progressive multiple sclerosis."	( Intravenous gamma globulin in progressive MS. Bansil, S; Bielory, L; Cook, SD; Dowling, PC; Jotkowitz, A; Mehta, PD; Oleske, J; Rohowsky-Kochan, C; Troiano, R, 1992)	0.28
" Three of five patients developed flare of aGVHD during reduction of the corticosteroid dosage and died with aGVHD and infection."	( High-dose methylprednisolone therapy for acute graft-versus-host disease associated with matched unrelated donor bone marrow transplantation. Coyle, K; Felker, D; Myers, L; Oblon, DJ, 1992)	0.28
" Psychiatric symptoms usually resolve with dosage reduction or controlled withdrawal of glucocorticoids, but antipsychotic medication may be indicated if symptoms are severe or prolonged."	( Adverse psychiatric effects of systemic glucocorticoid therapy. Klein, JF, 1992)	0.28
" In this study we examined the dose-response effect and the effect of delayed treatment with MP in an established rat model of retinal photic injury."	( Therapeutic parameters of methylprednisolone treatment for retinal photic injury in a rat model. Lam, TT; Rosner, M; Tso, MO, 1992)	0.28
" Among the many pharmacological agents presently in use, only prednisone (or methylprednisolone) and cyclosporin require dosage individualisation."	( Optimisation of immunosuppressive therapy using pharmacokinetic principles. Grevel, J, 1992)	0.28
" This pharmacodynamic model allows flexibility for characterizing any type of steroid dosing regimen and is relevant in describing complex response data for corticosteroid immunosuppressive effects in man."	( Pharmacoimmunodynamics of methylprednisolone: trafficking of helper T lymphocytes. Fisher, LE; Jusko, WJ; Ludwig, EA, 1992)	0.28
") dosage formulation of methylprednisolone, as the sodium hemisuccinate salt (Solu Medrol, Upjohn) was administered both parenterally and orally (pulse steroid therapy) on separate occasions, to eight elderly (mean 65 y) patients with active rheumatoid arthritis."	( High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response. Ahern, MJ; Cosh, DG; Hayball, PJ; Roberts-Thomson, PJ; Schultz, DW, 1992)	0.28
" Regimen B, employing a lower dosage of metoclopramide and steroids and using a more simple schedule of administration should be the preferred treatment."	( Antiemetic activity of two different high doses and schedules of metoclopramide in dacarbazine-treated cancer patients. Basurto, C; Boschetti, E; Bracarda, S; Del Favero, A; Lupattelli, M; Picciafuoco, M; Roila, F; Sassi, M; Tonato, M, 1992)	0.28
" Antirheumatic therapy therefore requires strict adherence to the prescribed indications and careful selection of the specific drug type and dosage regimen."	( [Glucocorticoids]. Hayashi, T, 1992)	0.28
" Prednisone was used in 17 cases, high dosage of methylprednisolone in 8 (in one case twice), azathioprine in 11 and cyclophosphamide in 10."	( Immunosuppressive treatment for juvenile myasthenia gravis. Badurska, B; Ryniewicz, B; Strugalska, H, 1992)	0.28
" These results suggest the usefulness of boluses of methylprednisolone in exacerbations of Still's disease, avoiding the disadvantages of high dosage daily corticosteroids."	( [Treatment of Still's disease with bolus methylprednisolone. Retrospective study of 7 patients]. Bisagni-Faure, A; Job-Deslandre, C; Menkès, CJ, 1992)	0.28
" There has been no recurrence of pain after stepwise reduction over one year of the steroid dosage until its discontinuation."	( [Giant-cell arteritis limited to the femoral arteries]. Baumann, G; Bogner, J; Haschka, C; Spengel, FA; Stautner-Brückmann, C, 1992)	0.28
" The patients were randomly assigned to receive either alternating one-month courses of methylprednisolone and then chlorambucil for a total of six months (group 1) or methylprednisolone alone for six months at the same cumulative dosage (group 2)."	( Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. Cesana, B; Passerini, P; Ponticelli, C; Zucchelli, P, 1992)	0.28
" In this regard a low dosage of methylprednisolone is equally effective as the most often recommended high dose."	( Methylprednisolone prophylaxis protects against endotoxin-induced death in rabbits. Hoiting, BH; Jansen, NJ; van Oeveren, W; Wildevuur, CR, 1991)	0.28
"A 24-hour intensive intravenous dosing regimen with the glucocorticoid steroid methylprednisolone has recently been shown to be effective in enhancing neurological recovery in spinal cord-injured patients when initiated within 8 hours after injury."	( The neuroprotective pharmacology of methylprednisolone. Hall, ED, 1992)	0.28
" We conducted a randomized, double-blinded, 7 arm clinical trial to: (1) identify the presence of a dose-response for complete protection from emesis, and (2) compare batanopride with a standard antiemetic, methylprednisolone if a dose-response was found not to exist."	( A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy. Findlay, B; Kaizer, L; Laberge, F; Latreille, J; Lofters, WS; Osoba, D; Pater, J; Rusthoven, J; Warr, D; Wilson, K, 1991)	0.28
" None of the previous studies with the usual dosage of steroids or ACTH has proven that this therapy is beneficial."	( [Effect of prednisolone on the course of optic neuritis. Results of a double-blind study]. Aulhorn, E; Diener, HC; Minder, C; Pfluger, D; Trauzettel-Klosinski, S, 1991)	0.28
" All had failed previous attempts to reduce their dosage of steroids."	( Use of troleandomycin as a steroid-sparing agent in both asthma and chronic obstructive pulmonary disease. Cash, M; Shivaram, U, 1991)	0.28
" However, methylprednisolone should be administered on the basis of ideal body weight, and the dosing interval should be potentially lengthened because of decreased methylprednisolone clearance in obesity."	( Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Camara, DS; Dunn, TE; Jusko, WJ; Ludwig, EA; Slaughter, RL, 1991)	0.28
" Baseline daily steroid dosage requirements decreased from 15."	( Benefits and complications of troleandomycin (TAO) in young children with steroid-dependent asthma. Flotte, TR; Loughlin, GM, 1991)	0.28
" Although the combination of CSA and MP in this dosing schedule was active in preventing acute GVHD, nephrotoxicity remained a problem, and outcome was limited by the inability to achieve the target CSA trough concentration in a substantial proportion of patients."	( Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease. Bloom, EJ; Przepiorka, D; Rosenfeld, CS; Schwinghammer, TL; Shadduck, RK; Shapiro, S; Venkataramanan, R, 1991)	0.28
" In vivo studies included iv and oral dosing of 10 or 50 mg/kg of MP in both forms, while liver perfusion involved initial perfusate concentrations of 5 and 25 micrograms/mL of either compound."	( Disposition of methylprednisolone and its sodium succinate prodrug in vivo and in perfused liver of rats: nonlinear and sequential first-pass elimination. Jusko, WJ; Kong, AN, 1991)	0.28
" bolus doses are required to achieve this effect, but the biphasic dose-response curve limits the dose size to approximately 30 mg/kg."	( Inhibition of lipid peroxidation in CNS trauma. Hall, ED, 1991)	0.28
" The corticosteroid dosage administered at the time CyA therapy was initiated was variable and was continued following CyA therapy."	( Long-term cyclosporine A treatment of steroid-resistant and steroid-dependent nephrotic syndrome. Cohen, AH; Fine, RN; Kamil, ES; Melocoton, TL, 1991)	0.28
" The method of a local step-by-step intrapulmonary administration of GCS made it possible to increase the treatment efficacy by bringing down the GCS dosage required to maintain++ remission and excluding complications caused during intrapulmonary injection of drugs to patients with corticoid dependent bronchial asthma."	( [Treatment of patients with corticoid-dependent bronchial asthma by step-by-step intra-pulmonary administration of glucocorticoids]. Nikitin, AV; Omeliusik, VV, 1990)	0.28
" Thus, time of initiation, dosage and duration of treatment may differentially affect the course of EAE."	( Development of experimental allergic encephalomyelitis during steroid administration. Outcome of neurological immune-mediated disorders under immunosuppressive therapy. Abramsky, O; Brenner, T; Mizrachi-Kol, R; Steiner, I, 1991)	0.28
"9 years (min 33, max 93) were given intranasal sCT at the dosage regimen of 200 IU/day/6 months."	( [Use of salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis in bullous diseases]. Cappio, F; Caputo, R; Colombo, MD, 1990)	0.28
"A study of the dose-response effects of naloxone and methylprednisolone after rat ventral spinal cord injury is presented."	( Dose-dependent effects of naloxone and methylprednisolone in the ventral compression model of spinal cord injury. Beal, JA; Benzel, EC; Hoffpauir, GM; Kesterson, L; Lancon, JA; Thomas, MM, 1990)	0.28
" Dose-response and time-course considerations make it unlikely that these effects are mediated via the glucocorticoid receptor, a concept further supported by the ability of sex steroids to work similar effects."	( Steroids decrease granulocyte membrane fluidity, while phorbol ester increases membrane fluidity. Studies using electron paramagnetic resonance. Hammerschmidt, DE; Jacob, HS; Knabe, AC; Lamche, HR; Silberstein, PT; Thomas, DD, 1990)	0.28
" One patient receiving methylprednisolone had a relapse of symptoms when the dosage was tapered, but symptoms again remitted when the dosage was increased to 32 mg/d."	( The beneficial effect of methylprednisolone in acute vestibular vertigo. Adour, KK; Ariyasu, L; Byl, FM; Sprague, MS, 1990)	0.28
" Height standard deviation scores positively improved in males but not in females, as prednisone dosage was decreased."	( Growth in children following kidney transplantation. Capen, RC; Carter, RL; Fennell, RS; Howard, RJ; Iravani, A; Moles, M; Pfaff, W; Richard, GA; Walker, RD, 1990)	0.28
" This technique can be used to individualize glucocorticoid dosing regimens."	( Monitoring glucocorticoid therapy: a pharmacokinetic approach. Ball, BD; Bartoszek, M; Brenner, AM; Hill, MR; Szefler, SJ, 1990)	0.28
" The mechanism of action and therapeutic usefulness of high dosage steroids in tumoral obstructive pathology is discussed."	( [The value of high dose steroid therapy in obstructive uropathy caused by a tumor]. Bello, I; Díaz-González, R; Gutierres-Millet, V; Hernández, E; Moreno, F; Rodicio, JL; Rodríguez, A, )	0.13
" The regimen consisted of dosing patients with two applications of the two drugs every day for 4 weeks."	( [Alclometasone dipropionate (Legederm) for the treatment of steroid-sensitive dermatoses in the elderly]. Criante, P; Giacchetti, A; Mambelli, V; Marchesi, E; Morresi, A; Mozzicafreddo, G; Simonacci, M; Sisti, S, 1990)	0.28
" We conclude that methylprednisolone, when administered at the dosage used in previous studies of adult humans and animals, does not affect the response of the pulmonary vascular bed to hypoxia in newborn lambs."	( The effect of methylprednisolone on hypoxic pulmonary vasoconstriction in the newborn late-gestation lamb. Alpan, G; Clyman, RI, 1990)	0.28
" Different from the regimen for immunosuppressive treatment after organ transplantation, the dosage of cyclosporine was set not according to whole-blood levels but individualized to variations in serum transaminases."	( [Successful treatment of primary biliary cirrhosis with cyclosporin]. Lie, TS; Preissinger, H, 1990)	0.28
" Our results show that MP at the dosage of 30 mg/kg does not affect complement-mediated granulocytopenia in any important way."	( Complement activated leucopenia during hemodialysis: effect of pulse methyl-prednisolone. Catalano, C; Enia, G; Maggiore, Q; Misefari, V; Mundo, N; Salnitro, F; Tetta, C, 1990)	0.28
" ALG dosage modifications were made in order to maintain peripheral CD3+ cells between 10 and 20%."	( Antilymphoblast globulin, cyclosporine, and steroids in cadaveric renal transplantation. Alsina, J; Andres, E; Castelao, AM; Diaz, C; Gil-Vernet, S; Griño, JM; Mestre, M; Sabate, I; Sabater, R; Seron, D, 1990)	0.28
" A new protocol avoids these adverse effects by a rapid reduction in the dose of MP to alternating administrations and low TAO dosage (250 mg)."	( [Experiences with a combination therapy of methylprednisolone and troleandomycin in severe bronchial asthma requiring high-dose corticoids]. Haack, D; Hauser, F; Menz, G; Rothe, T; Schmitt, M; Schmitz, M; Virchow, C, 1990)	0.28
" Anti-rejection therapy consisted of methylprednisolone 10 mg/kg/day iv for 5 days and an increase of oral cyclosporine dosage to 25 mg/kg/day."	( Percutaneous fine needle aspiration biopsy of canine pancreas allograft provides diagnosis of treatable rejection. Allen, RD; Allwright, SJ; Deane, SA; Earl, MJ; Ekberg, H; Greenberg, ML; Hawthorne, WJ; Little, JM; Stewart, GJ; Williamson, P, 1989)	0.28
" The toxicity of high dose IVIG was minimal, but the cost is high, search for an optimal dosage is warranted."	( Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Chiang, H; Hsu, HC; Lin, CY, 1989)	0.28
" Research work on high dosage cyclophosphamide and total lymphoid irradiation is still too limited."	( Multiple sclerosis. II. A critical assessment of immunotherapy. Bergamini, L; Durelli, L, )	0.13
" She went into hematological remission 6 weeks following 40 mg/day treatment with prednisolone, but the anemia relapsed frequently when the dosage was lessened."	( [Chronic T-cell lymphoproliferative disorder associated with pure red cell aplasia]. Akihama, T; Chubachi, A; Endo, Y; Kuwayama, A; Miura, A; Yoshida, K, 1989)	0.28
" Moreover, they seem to correlate with the dosage applied."	( Psychiatric disorders associated with corticosteroid therapy. Kostić, VS; Lević, Z, 1989)	0.28
" Reduced dosage of steroids is feasible and safe, and a decrease in steroid-related side effects can be achieved without jeopardizing the graft."	( Pulsed steroids for treatment of cardiac rejection after transplantation. What dosage is necessary? Haverich, A; Heublein, B; Wahlers, T, 1989)	0.28
" The steroid dosage given was significantly lower in the second group."	( Low-dose cyclosporin A therapy in cadaver renal transplantation in children. Bonzel, KE; Gretz, N; Mehls, O; Möhring, K; Müller-Wiefel, DE; Pomer, S; Ruder, H; Schaefer, F; Schärer, K; Strehlau, J, 1989)	0.28
" All patients had previously received the same chemotherapy with metoclopramide in conventional dosage and experienced severe emesis."	( Methylprednisolone and chlorpromazine in patients receiving cancer chemotherapy: a prospective non-randomized study. Ben-Baruch, N; Biran, S; Brufman, G; Gera, C; Gez, E; Kaufman, B; Sulkes, A; Yitzhaki, N, 1989)	0.28
" Therapeutic lessons learned from this experience involve (1) selection of monoclonal antibodies over methylprednisolone for rejection control, (2) return of drained bile to the gastrointestinal tract, and (3) careful cyclosporine level and dosage monitoring."	( Significance of asymptomatic biliary tract disease in heart transplant recipients. Attum, AA; Barbie, RN; DeWeese, BM; Girardet, RE; Lansing, AM; Lusk, RA; Masri, ZH; Rosenbloom, P; Yared, SF, )	0.13
" In a prospective randomized multicenter trial, 123 patients undergoing acute rejection of cadaveric renal transplants were treated either with OKT3 daily for a mean of 14 days, with concomitant lowering of the dosage of other immunosuppressive drugs (63 patients), or with conventional high-dose steroids (60 patients)."	( A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. , 1985)	0.27
" Dosing with the free alcohol or ester produces identical disposition curves for methylprednisolone."	( Methylprednisolone disposition in rabbits. Analysis, prodrug conversion, reversible metabolism, and comparison with man. Ebling, WF; Jusko, WJ; Szefler, SJ, )	0.13
" The response was characterized by dose-response and kinetics investigations."	( The proliferative T-lymphocyte response to streptokinase. Bruserud, O; Jørgensen, PF; Sollid, L, 1986)	0.27
" One may hope that this dosage of mechlorethamine will not be gonadotoxic."	( [Value of chlormethine in children with corticoid-dependent or partially corticoid-sensitive nephrosis, in steroid poisoning]. Loirat, C; Macher, MA; Maisin, A; Mathieu, H; Pillion, G, )	0.13
" This demonstrated that at the dosage levels used in this study, MPSS was an effective antioxidant."	( Iron-induced lipid peroxidation in spinal cord: protection with mannitol and methylprednisolone. Anderson, DK; Means, ED, 1985)	0.27
" The ability of intensive dosing with the glucocorticoid steroid methylprednisolone to beneficially affect post-traumatic ischemia and to promote chronic neurologic recovery in spinal cord injured animals has been correlated not with its glucocorticoid activity, but rather with the ability to inhibit post-traumatic spinal lipid peroxidation."	( New pharmacological treatment of acute spinal cord trauma. Braughler, JM; Hall, ED; McCall, JM, 1988)	0.27
" Contrary to the majority of similar reported cases, no decompression operation was performed, because the neurological signs had not progressed and the clinical findings in fact quickly regressed once the steroid dosage had been reduced and they showed a clear dependence on the amount of steroid administered."	( [Epidural lipomatosis as a complication of a long-term glucocorticoid therapy]. Bischoff, C, 1988)	0.27
" The corticosteroid dosage and the serum testosterone level were inversely related (r = -0."	( Reduction of serum testosterone levels during chronic glucocorticoid therapy. Chipps, BE; MacAdams, MR; White, RH, 1986)	0.27
" The same protective effect was obtained with lower cyclophosphamide dosage (15 mg/kg on day 0 and then 2 mg/kg per day)."	( Effect of methylprednisolone and cyclophosphamide in mercury-induced autoimmune glomerulonephritis. Bariety, J; Belair, MF; Druet, P; Mandet, C; Pasquier, R; Pelletier, L; Vial, MC, 1987)	0.27
" In its classic form the disease is monitored by adjusting the steroid dosage with the erythrocyte sed rate (ESR)."	( Giant cell arteritis. Ishak, AW; Mitchell, PC; Persak, GC; Warwick, S, 1988)	0.27
" No dose-response relationship was observed."	( Methylprednisolone for the control of CMF-induced emesis. Bruzzi, P; Campora, E; Chiara, S; Lionetto, R; Rosso, R, 1987)	0.27
" In group II, cyclosporine was started only after the procedure at a lower dosage and was complemented by azathioprine, which was used for the first postoperative week."	( Cardiac transplantation: improved quality of survival with a modified immunosuppressive protocol. Bahnson, HT; Griffith, BP; Hardesty, RL; Kormos, RL; Thompson, ME; Trento, A, 1987)	0.27
"8%) the oral prednisolone dosage was increased, from a mean of 10."	( [Management of rejection following heart transplantation using oral steroid medication]. Fieguth, HJ; Frimpong, K; Haverich, A; Herrmann, G; Jurmann, M; Kemnitz, J; Schäfers, HJ; Wahlers, T, 1987)	0.27
" dose, while initially supportive, lost its effect during the later stages of the experiment, indicating a sharp biphasic dose-response relationship for the effect of methylprednisolone on caudate blood flow after subarachnoid hemorrhage."	( Attenuation of progressive brain hypoperfusion following experimental subarachnoid hemorrhage by large intravenous doses of methylprednisolone. Hall, ED; Travis, MA, 1988)	0.27
" Careful tailoring of dosage is important to avoid adrenal atrophy and signs of adrenocortical hypofunction."	( Corticosteroids for rheumatic disease. 1. Physiology, pharmacology, and therapeutic strategies. Jamieson, T, 1986)	0.27
" Each patient improved considerably and in each case the dosage of conventional immunosuppression was reduced."	( PUVA therapy for drug-resistant graft-versus-host disease. Atkinson, K; Biggs, J; Ryman, W; Weller, P, 1986)	0.27
" Since its inception, cyclosporine loading dosage has been reduced between 20 to 50 percent."	( Therapeutic immunosuppression in cardiac transplantation. O'Connell, JB; Robinson, JA, )	0.13
"22 mg/kg by the fourth month being also administered at the same dosage during the fifth and the sixth month."	( Cyclosporin A in nephrotic syndrome of childhood--a 14 month experience. Capodicasa, G; De Santo, NG; Giordano, C; Nuzzi, F, )	0.13
" A further trial is necessary to determine the optimal dosage and scheduling of the available agents."	( [Randomized crossover trial of the antiemetic effects obtained with metoclopramide and droperidol versus those obtained with metoclopramide, droperidol and methylprednisolone in patients receiving cis-platinum chemotherapy]. Fujii, M; Kiura, K; Okabe, K; Tamai, M; Toki, H, 1986)	0.27
" These effects were mitigated at a lower dosage especially by the addition of cefoxitin and deoxycortone."	( An attempt to develop a model to study the effects of intrathecal steroids. Rosen, M; Swai, EA, 1986)	0.27
" In vitro, the dose-response curves to MP were examined in pretransplant PHA cultures."	( The impact of high lymphocyte sensitivity to glucocorticoids on kidney graft survival in patients treated with azathioprine and cyclosporine. Ladefoged, J; Langhoff, E, 1987)	0.27
"We report a young woman with systemic lupus erythematosus complicated by pseudotumor cerebri which resolved with high dosage corticosteroid therapy."	( Dural sinus thrombosis: a mechanism for pseudotumor cerebri in systemic lupus erythematosus. Goodwin, JA; Levinson, DJ; Parnass, SM; Patel, DV; Reinhard, JD, 1987)	0.27
" It may lead to erroneous conclusions concerning patient compliance, unwarranted increases in salicylate dosage and resultant toxicity, and delay of appropriate therapeutic maneuvers."	( Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis. Baer, PA; Ikeman, RL; Shore, A, 1987)	0.27
" The intensive 48-hour dosing regimen was designed to maintain therapeutic tissue levels of MP and consisted of an initial 30 mg/kg intravenous bolus of MP; 2 and 6 hours later additional 15 mg/kg MP doses were administered by intravenous bolus."	( Evaluation of an intensive methylprednisolone sodium succinate dosing regimen in experimental spinal cord injury. Anderson, DK; Braughler, JM; Hall, ED; Means, ED; Waters, TR, 1987)	0.27
" Serum methylprednisolone levels rose rapidly, giving a dose-response curve similar to that after an intramuscular injection in humans."	( The systemic and local effects of an intramedullary injection of methylprednisolone acetate in growing rabbits. Aronson, DD; Colville, MR; Crissman, JD; Prcevski, P, )	0.13
" The initial dosage was maintained for 1 or 2 weeks in each group, tailing off with a period of several weeks of oral prednisolone."	( High-dose intravenous corticosteroids in the treatment of multiple sclerosis. Hamaguchi, K; Ohno, R; Sowa, K; Tanaka, H; Watanabe, Y, 1987)	0.27
"9% NaCl, at the rate of 10 cc/min, for a dosage of 30 mg/kg."	( The morphological changes of the pancreas in hypovolemic shock and the effect of pretreatment with steroids. Barzilai, A; Dreiling, DA; Medina, JA; Ryback, BJ; Toth, L, 1987)	0.27
" It is effective in many disorders, and these are documented, together with the dosage ranges which can be used."	( Stosstherapy: a fresh look at some principles of therapy--especially chemotherapy. Keipert, JA, 1986)	0.27
" Applying the same dosage we now investigated whether there is a similar effect of a short-term application of prednisolone in mesenchymal and parenchymal organs of young adult and presenile rats of the same strain (Chbb: THOM/SPF) analyzing the physiological cell regeneration (DNA concentration) as well as functional parameters of the glycosaminoglycan metabolism (e."	( [Age-related changes in cell content (DNA) and glycosaminoglycan-degrading enzymes (beta-glucuronidase, beta-N-acetylglucosaminidase of connective tissue and parenchymal organs of the rat caused by 6-methylprednisolone (enzyme induction, adaptation, accel Lindner, J; Nüssgen, A; Schmiegelow, P; Schönrock, P, )	0.13
"The deleterious effects of corticosteroids (CS) on bone are well known, but probably differ depending on duration and dosage of CS therapy."	( Bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis. Bijlsma, JW; Duursma, SA; Huber-Bruning, O, 1986)	0.27
" Subsequently, patients received weekly injections of MP on a reducing dosage regime to a maintenance dose of 125 mg IV weekly."	( Methylprednisolone pulse therapy in severe anterior uveitis. Wakefield, D, 1985)	0.27
" Recipients were also given pulse doses of methylprednisolone (100 mg/kg) and azathioprine (3 mg/kg) once a week, the dosage schedule being gradually reduced and azathioprine discontinued as recipients became long-term survivors (greater than 60 days)."	( Orthotopic cardiac xenografting in the newborn goat. Bailey, LL; Jang, J; Johnson, W; Jolley, WB, 1985)	0.27
" Methylprednisolone seemed to be effective in the cases administrated in the dosage of 10, 15 mg/kg/day."	( [A study of the optimum dose of a glucocorticoid, methylprednisolone sodium succinate, before and after neurosurgical major operations--relationship between beta-glucuronidase level and post operative brain edema]. Niizuma, H; Shirane, R; Suzuki, J, 1985)	0.27
" In the face of increased levels, the dosage is reduced in order to prevent CsA-induced nephrotoxicity."	( Effect of renal allograft dysfunction upon cyclosporine trough levels in host blood. Anaise, D; Arnold, AN; Rapaport, FT; Waltzer, WC; Weinstein, SW, 1985)	0.27
" Ten animals received the same dosage of methylprednisolone beginning 2 h after the start of endotoxin infusion."	( Prophylactic and delayed treatment with high-dose methylprednisolone in a porcine model of early ARDS induced by endotoxaemia. Borg, T; Gerdin, B; Modig, J, 1985)	0.27
"Of nineteen patients with RPCGN who responded promptly to initial treatment with PMP or PX, and who were subsequently maintained on oral immunosuppression with prednisolone (reducing dosage from 30mg/day) and azathioprine/cyclophosphamide (1-3 mg/kg/day), five showed progressive loss of renal function within one year of responding to treatment."	( Follow-up prednisolone dosage in rapidly progressive crescentic glomerulonephritis successfully treated with pulse methylprednisolone or plasma exchange. Bone, JM; Stevens, ME, 1985)	0.27
" They contend that in view of their poor clinical record, it is unlikely that increasing the steroid dose or changing the dosing regimen will improve clinical efficacy, since steroids have already failed at what may be considered huge doses by glucocorticoid standards."	( Current application of "high-dose" steroid therapy for CNS injury. A pharmacological perspective. Braughler, JM; Hall, ED, 1985)	0.27
"The effect of methylprednisolone (MP) of high dosage on not only surfactant lipids but also other phospholipid components of adult rat lungs was studied."	( Alteration in phospholipid content of lung of adult rats treated with methylprednisolone of high doses. Ichikawa, I; Kikkawa, Y, 1985)	0.27
" The side effects of antihistamines are minor, and the dosage of corticosteroid used and length of time it is given are small enough to avoid major side effects."	( Chronic urticaria. Possible causes, suggested treatment alternatives. Kaplan, AP, 1983)	0.27
" Azathioprine or corticosteroid dosage intake on the day of the test did not influence the level of graft recipient NKCA."	( Decrease in natural killer cell activity in kidney allograft recipients. Fauconnier, B; Hegaret, A; Moreau, JF; Soulillou, JP; Ythier, A, )	0.13
" After pentobarbital anesthesia, intra-arterial pressure and dose-response curves to AII were determined, before and after SQ14225 (d-3-mercapto-2-methylpropranoyl-l-proline) (1 mg/kg iv)."	( Effect of converting enzyme inhibition on glucocorticoid hypertension in the rat. Elijovich, F; Krakoff, LR, 1980)	0.26
" The data suggest that, in order to be of therapeutic value in the treatment of acute spinal cord trauma, early intervention with high-dose intravenous methylprednisolone (30 to 40 mg/kg) is necessary, followed by intravenous maintenance dosing of 15 to 20 mg/kg every 2 to 3 hours."	( Correlation of methylprednisolone levels in cat spinal cord with its effects on (Na+ + K+)-ATPase, lipid peroxidation, and alpha motor neuron function. Braughler, JM; Hall, ED, 1982)	0.26
" We conclude from these results (1) that previously the dosage of CyA administered at this centre was probably too high, and (2) early adjustment of dose levels on the basis of blood concentrations and with low-dose prednisone cover appears to be safe and effective, but requires further verification."	( Cyclosporin A used alone or in combination with low-dose steroids in cadaveric renal transplantation. Brünisholz, M; Brunner, F; Follath, F; Harder, F; Landmann, J; Lörtscher, R; Mihatsch, M; Thiel, G; Wenk, M, 1983)	0.27
" This randomized double-blind study describes the effect of various dosing regimens of naloxone and MPSS upon hemodynamics and plasma catecholamines in patients with septic shock (n = 57)."	( Naloxone and methylprednisolone sodium succinate enhance sympathomedullary discharge in patients with septic shock. Hughes, GS, 1984)	0.27
" In fact, over a certain dosage range of MP an increased number of suppressor cells appeared to be generated."	( Opposing effects of methylprednisolone on in vitro alloantigen-induced cytotoxic and suppressor lymphocytes in man. Hirschberg, H; Hirschberg, T; Pfeffer, P; Randazzo, B, 1980)	0.26
" All patients were evaluated from the standpoint of clinical response to thymectomy, and the number and dosage of anti-myasthenic drugs required after operation."	( Cervical thymectomy in the treatment of myasthenia gravis. Donnelly, RJ; Fabri, B; Florence, AM; Hayward, M; Laquaglia, MP, 1984)	0.27
" Metoclopramide and methylprednisolone, at the dosage and schedule used, were well tolerated and moderately active in preventing nausea and vomiting induced by cis-platin; their use in combination could further improve these results."	( Comparison of methylprednisolone and metoclopramide in the prophylactic treatment of cis-platin-induced nausea and vomiting. Bertetto, O; Calciati, A; Ciuffreda, L; Clerico, M; Donadio, M; Ferrati, P; Giaccone, G; Musella, R, 1984)	0.27
" The optimal routes of administration, dosage, dosage interval, and other factors are unknown."	( Intermediate-dose intramuscular methylprednisolone acetate in the treatment of rheumatic disease. Kovarsky, J, 1983)	0.27
" CT measurements on the first day without medication, continued with an initial dosage of 1000 mg Urbason, followed by 3 X 40 mg daily during the second to the fifth day, and finally on the seventh day after the steroid was stopped."	( [Influence of alpha-methyl-prednisolone on perifocal brain edema--CT observations in ten patients with circumscribed supratentorial brain tumours]. Lerch, KD; von Wild, K, 1983)	0.27
" The other group received the same dosage of ADR but also MP 20 mg/kg subcutaneously 3 hr before, with ADR and 3 hr after ADR."	( Prevention of adriamycin (ADR)-induced cardiotoxicity in rats using methylprednisolone (MP). Dasmahapatra, KS; Karakousis, CP; Perez-Brett, R; Rao, U; Vezeridis, M, 1984)	0.27
"By measuring airway resistance (Raw) as an index of response, dose-response curves to aerosolized carbachol were constructed in 10 patients suffering from grass pollen allergy."	( Seasonal increase of carbachol airway responsiveness in patients allergic to grass pollen. Reversal by corticosteroids. Badier, M; Orehek, J; Sotomayor, H; Vervloet, D, 1984)	0.27
" Cutting down the dosage to half resulted in an improvement of the one-year patient survival by 16 per cent (from 63 to 79 per cent and the one-year graft survival by 10 percent (from 46 to 56 per cent)."	( Effect on patient and graft survival of reducing the methylprednisolone dose after renal transplantation. Kuhlbäck, B, 1981)	0.26
"Steroids are commonly used in the treatment of acute spinal cord injury patients although a review of the literature fails to define a consistent regimen for administration with regard to optimal preparation or dosage or schedule."	( A comparative study of steroid therapy in acute experimental spinal cord injury. Green, BA; Kahn, T; Klose, KJ, 1980)	0.26
" Oral prednisolone in the dosage described is as effective as about 10 times that dose of intravenous methylprednisolone; it is much cheaper and is viewed as less unpleasant by patients."	( Comparison of high-dose intravenous methylprednisolone with low-dose oral prednisolone in acute renal allograft rejection in children. Bewick, M; Chantler, C; Haycock, G; Orta-Sibu, N, 1982)	0.26
" The use of high glucocorticoid doses, early therapy initiation, and rigorous maintenance dosing is discussed."	( Lactate and pyruvate metabolism in injured cat spinal cord before and after a single large intravenous dose of methylprednisolone. Braughler, JM; Hall, ED, 1983)	0.27
" The administration of pharmacological doses of glucocorticoids increased the dosage of 1,25(OH)2D3 needed to maintain a normal serum calcium level 7- to 10-fold in 2 patients whose renal grafts failed to function, but there was no decrease in sensitivity to 1,25(OH)2D3 in 1 patient whose renal graft functioned normally."	( Interactions between treatment with 1,25(OH)2D3 and glucocorticoids in uremic patients after kidney transplantation. Coburn, JW; Siemsen, AW; Sugihara, JG; Wong, EG, 1980)	0.26
" The findings suggest that the development of steroid diabetes can serve as a warning signal for excessive dosage of corticosteroids, and help to identify patients that are particularly sensitive to immunosuppressive therapy with large doses of steroids."	( Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient? Groth, CG; Gunnarsson, R; Lundgren, G; Magnusson, G; Ost, L, 1980)	0.26
" It seems that a rather moderate dosage of methylprednisolone allows us to prolong and repeat the courses according to individual needs, and this may be the main reason for the significantly improved graft function at one year."	( Steroids and rejection treatment in the Gothenburg transplant programme. Brynger, H; Gelin, LE, 1980)	0.26
"On the basis of 15-years' experience with the allogeneic transplantation of the kidney, the authors present recommendations, concerning the dosage of azathioprine and prednisone (methylprednisolone) during the schematic immunosuppression."	( Schematic and controlled immunosupression after renal allotransplantation. Jirka, J; Kaslík, J; Kaslíková, J; Kocandrle, V, 1981)	0.26
" For all dosage strengths of methylprednisolone sodium succinate studied, these data indicate that solutions can be made stable for at least 12 hours by selecting the appropriate volume of diluent."	( Stability of methylprednisolone sodium succinate in small volumes of 5% dextrose and 0.9% sodium chloride injections. Nail, SL; Puchala, AH; Townsend, RJ, 1981)	0.26
" The dose-response curve for prednisolone plateaued at high doses."	( Influence of prednisolone on ethanol-induced gastric injury in the rat. Derelanko, MJ; Long, JF, 1982)	0.26
" The results reported in this paper have shown that glucocorticoid dosing produces numerous effects on motor neuron excitability and impulse generation and conduction."	( Glucocorticoid effects on the electrical properties of spinal motor neurons. Hall, ED, 1982)	0.26
" The limited variability of the pharmacokinetics of methylprednisolone suggests that tissue sensitivity may be a more important indicator of drug dosage needs in nephrotic syndrome."	( Disposition of pulse dose methylprednisolone in adult and paediatric patients with the nephrotic syndrome. Appiani, AC; Assael, BM; Banfi, G; Edefonti, A; Jusko, WJ, 1982)	0.26
" By 12 hours, plasma zinc concentrations had decreased below control levels and the extent and duration of the depression depended on the dosage of the steroid administered."	( Influence of synthetic corticosteroids on plasma zinc and copper levels in humans. Czerwinski, AW; Lindeman, RD; Yunice, AA, )	0.13
" The recommended dosage of Solu-Medrol would appear to be 20 mg and not less."	( A 3 1/2-year experience with double-lumen implants in breast surgery. Braun, H; Ellenberg, AH, 1980)	0.26
" Methylprednisolone exhibited a dose-response effect in reducing LDH leakage in cultures, which were subsequently deprived of oxygen and glucose for 4 hr."	( Reduction of cell injury in hypoxic cultures of rat myocardial cells by methylprednisolone. Acosta, D; Li, CP; Puckett, M, 1980)	0.26
" However, dosage of both methylprednisolone and dexamethasone could be increased to a level at which damage by oxygen was reduced to 50% of nuclei compared with 90% damaged in cells unprotected by steroids."	( Protective effect of steroids on cultured cells damaged by high concentrations of oxygen. Hulands, GH; Sturrock, JE, 1980)	0.26
" Using the cat spinal cord compression model (180g x 5 min at L3; Na pentobarbitol anesthesia), we examined whether 30 min postinjury dosing with MP (30 mg/kg IV) could attenuate spinal tissue eicosanoid levels measured by enzyme immunoassay at 1 h (Experiment 1)."	( Lack of effect of postinjury treatment with methylprednisolone or tirilazad mesylate on the increase in eicosanoid levels in the acutely injured cat spinal cord. Hall, ED; Sun, FF; Taylor, BM; Yonkers, PA, 1995)	0.29
" The initial heavy proteinuria promptly decreased after the prednisolone dosage was increased and disappeared 4 weeks later."	( Minimal-change nephrotic syndrome associated with systemic lupus erythematosus. Haramoto, T; Makino, H; Ogura, T; Ota, Z; Shikata, K, 1995)	0.29
" These results show: 1) possible synergism exists between methylprednisolone and bFGF, such that combinations of these drugs significantly enhance neurological recovery, 2) bFGF exhibits a dose-response effect in function but not in capillary density, and 3) heated, inactivated bFGF is not therapeutically effective."	( Synergistic effect of basic fibroblast growth factor and methylprednisolone on neurological function after experimental spinal cord injury. Achanta, K; Baffour, R; Berman, J; Friedmann, P; Garb, JL; Kaufman, J; Rhee, S, 1995)	0.29
" Cyclosporine in a dosage of 10 mg/kg per day can effectively suppress the immune response after transplantation of vascularized tracheal allografts."	( Experimental tracheal allograft revascularization and transplantation. Delaere, PR; Feenstra, L; Hermans, R; Liu, ZY; Sciot, R, 1995)	0.29
" Corticosteroid dosage was then reduced according to clinical improvement."	( Long-term corticosteroid and dipyridamole treatment of membranoproliferative glomerulonephritis type I in children. Matsutani, H; Niimura, F; Takeda, A, 1995)	0.29
"A dose of CBG to yield 95% binding with 1000 ng/ml of prednisolone in vitro in rat plasma or saline was administered before dosing 2 mg/kg of prednisolone hemisuccinate or methylprednisolone intravenously."	( Effect of corticosteroid binding globulin on the pharmacokinetics of prednisolone in rats. Almon, RR; Jusko, WJ; Ko, HC, 1995)	0.29
" The absolute bioavailability of the tablet product was 82%, which is in agreement with published data for other oral dosage forms of methylprednisolone."	( Absolute bioavailability of a new high dose methylprednisolone tablet formulation. Groenewoud, G; Hundt, HK; Luus, HG; Müller, FO; Schall, R, 1994)	0.29
"The effect of a liposomal formulation of methylprednisolone (MPL) on the inhibition of lymphocyte proliferation in spleen cells was investigated following IV dosing in rats."	( Inhibition of rat splenocyte proliferation with methylprednisolone: in vivo effect of liposomal formulation. Jusko, WJ; Mishina, EV, 1994)	0.29
"To investigate the efficacy of intravenous methylprednisolone pulse therapy on Graves' ophthalmopathy (GO), fifteen patients with severe GO were treated with large dose intravenous methylprednisolone (at a daily dosage of 1 g for 3 successive days)."	( Intravenous methylprednisolone pulse therapy for Graves' ophthalmopathy. Hiromatsu, Y; Kaise, N; Kojima, K; Kuroki, T; Nishida, H; Nishimura, H; Nonaka, K; Sato, M; Tanaka, K, 1993)	0.29
"Liposomal methylprednisolone (L-MPL) applied in monotherapy prolonged cardiac allograft survival in rats in comparison with the same dosage regimen of drug in solution (Solu-Medrol)."	( Effect of liposomal methylprednisolone on heart allograft survival and immune function in rats. Binder, J; Jusko, WJ; Kupiec-Weglinski, JW; Mishina, EV, 1994)	0.29
" Initial methylprednisolone (MP) treatment helps to implement task, optimal dosage is, however, a yet unresolved problem."	( [The importance of administration of a series of methylprednisolone minipulses in the treatment of active rheumatoid arthritis]. Hrncír, Z, 1994)	0.29
" Dose-response evaluation of MPSS determined more effective doses."	( Modeling of acute spinal cord injury in the rat: neuroprotection and enhanced recovery with methylprednisolone, U-74006F and YM-14673. Beattie, MS; Behrmann, DL; Bresnahan, JC, 1994)	0.29
" These findings suggest a more individualized dosing method may be necessary to optimize the immunosuppressive effect of glucocorticoids and minimize clinical toxicity."	( Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. Reed, K; Tornatore, KM; Venuto, RC; Walshe, JJ, )	0.13
"8) and less total dosage (34 +/- 16 mg compared with 70 +/- 34 mg; mean difference, -36 mg; CI, -60."	( Does aminophylline benefit adults admitted to the hospital for an acute exacerbation of asthma? Aull, L; Harman, E; Hendeles, L; Huang, D; O'Brien, RG; Reents, S; Shieh, G; Visser, J, 1993)	0.29
" Incorporating the differences may allow for more individualized dosing and more efficacious use of the agent in this patient population."	( Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. Reed, KA; Tornatore, KM; Venuto, RC, )	0.13
" Although the alpha phase kinetics of both dosage forms were similar, L-MPL showed a substantially slower elimination phase than did free drug."	( Enhancement of tissue delivery and receptor occupancy of methylprednisolone in rats by a liposomal formulation. Jusko, WJ; Mishina, EV; Pyszczynski, NA; Straubinger, RM, 1993)	0.29
" The delayed dosing was associated with improved graft survival and no increase in the frequency of rejection episodes."	( Is there an optimal time for the first cyclosporin dose in renal transplantation? Fenn, N; Griffin, PJ; Krishnan, H; Moore, RH; Salaman, JR, 1993)	0.29
"The mean daily methylprednisolone dosage was 19 +/- 19 mg in the double-drug group and 9 +/- 2 mg in the triple-drug group."	( Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. Holdsworth, MT; Reed, KA; Tornatore, KM; Venuto, RC; Walshe, JJ, 1993)	0.29
" Typically, methylprednisolone is prescribed according to a standardized dosing protocol that assumes minimal interpatient variation."	( Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. Holdsworth, MT; Reed, KA; Tornatore, KM; Venuto, RC; Walshe, JJ, 1993)	0.29
" The experimental group received a standard dosage of oral postoperative corticosteroids."	( Arthroscopy of the knee. Ten-day pain profiles and corticosteroids. Highgenboten, CL; Jackson, AW; Meske, NB, )	0.13
" We conclude that, in multidrug therapies, the continuation of corticosteroid at conventional dosage beyond the first course does not improve response rate or survival time in multiple myeloma."	( Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. Finnish Leukaemia Group. Ala-Harja, K; Almqvist, A; Elonen, E; Hallman, H; Hänninen, A; Ilvonen, M; Isomaa, B; Järvenpää, E; Jouppila, J; Palva, IP, 1993)	0.29
" ATG dosage was adjusted on a daily basis to keep the absolute T lymphocyte count under 50 cells/microliters."	( Administration of ATG according to the absolute T lymphocyte count during therapy for steroid-resistant rejection. Clark, KR; Forsythe, JL; Lennard, TW; Proud, G; Shenton, BK; Taylor, RM, 1993)	0.29
" The vast majority of patients in both groups achieved alternate-day dosing (29 of 30 on TAO and 23 of 27 on placebo in the first year)."	( A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. Bucher, BL; Buchmeier, AD; Corsello, PR; Hamilos, DL; Levesque, NV; Nelson, HS, 1993)	0.29
"The purpose of this study was to determine the effects of two dosage regimens of dexamethasone on the serum cortisol levels of a group of patients undergoing major maxillofacial surgical procedures."	( Dosage effects of pulsed steroid therapy on serum cortisol levels in oral and maxillofacial surgery patients. Butler, RC; Finstuen, K; Vorono, AA, 1993)	0.29
"This experiment was undertaken for three purposes: (1) to determine a dose-response curve of acute steroid inhibition of wound contraction in the rat; (2) to confirm the results of our preliminary study that platelet-derived growth factor (PDGF) enhanced wound contraction in acutely steroid impaired rats; and (3) to examine the histology of the PDGF-treated wounds."	( Platelet-derived growth factor and wound contraction in the rat. Bubak, PJ; Engrav, LH; Karr, BP; Pavlin, EG; Sprugel, KH, 1995)	0.29
" For initial evaluation and follow-up, MRI and US yielded reliable results in comparison to plain films and CT, thus helping to reduce the radiation dosage in children."	( Localized Langerhans cell histiocytosis of bone: treatment and follow- up in children. Libicher, M; Roeren, T; Tröger, J, 1995)	0.29
"The purpose of this study was to examine the relationship of cumulative steroid dosage and duration of therapy with osteoporosis."	( Osteoporosis in steroid-dependent asthma. Gordon, EH; Hahn, TJ; Klaustermeyer, WB; Villareal, MS, 1996)	0.29
" The clinical utilization of methylprednisolone during the early post-transplant period is based upon standardized dosing protocols that do not consider factors which may influence the pharmacokinetics of this drug during the post-transplant period."	( Methylprednisolone and cortisol metabolism during the early post-renal transplant period. Reed, KA; Tornatore, KM; Venuto, RC, 1995)	0.29
" Since there was no activity of the mixed connective tissue disease the methylprednisolone dosage was reduced and the administration of azathioprine was ceased."	( [Chronic recurrent subileus due to Strongyloides stercoralis infection under immunosuppressive therapy]. Back, W; Birck, R; Braun, C; Gottstein, T; Gretz, N; Manegold, BC; Rohmeiss, P; Strauch, M, 1996)	0.29
" The remaining patients (group A, n = 10) were given diclofenac in a dosage of 150 mg per day for three days then 75 mg per day for three days."	( Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs. Gabay, C; Vischer, TL; Werlen, D, 1996)	0.29
" GC mini pulses are effective on early clinical and biological parameters of inflammation and requires a lower cumulative daily dosage than conventional oral GC treatment."	( 6-methylprednisolone 'mini-pulses': a new modality of glucocorticoid treatment in systemic onset juvenile chronic arthritis. Borrone, C; Buoncompagni, A; Gattorno, M; Picco, P; Pistoia, V, 1996)	0.29
"0 mg x kg-1 of methylprednisolone (6 alpha methylprednisolone 21-acetate) by intramuscular injection 6 hours before and every 48 hours after irradiation; (3) an untreated control group (C); and (4) a methylprednisolone control group (S), which received the same dosage of methylprednisolone as the RS group."	( [Suppression by methylprednisolone of the expression of LFA-1 by alveolar macrophages in irradiated rat lungs]. Katoh, H; Kawana, A; Ohta, Y; Shioya, S; Tsuji, C, 1996)	0.29
" Methotrexate was given weekly for 8 weeks beginning at the conclusion of OKT3 therapy (postoperative days 8 to 16), and dosed according to white blood cell count."	( Methotrexate for rejection prophylaxis after heart transplantation. Ensley, RD; Olsen, SL; Renlund, DG; Taylor, DO, )	0.13
" MP dosage based on BMI may be a reasonable alternative to a fixed-dose regimen with the advantage of limiting steroid exposure and the consequent side-effects."	( Treatment of renal allograft acute rejection with methylprednisolone: effect of fixed dose versus dose per body mass index. Carson, RW; Douzdjian, V; Fisch, JC; Gugliuzza, KK; Rice, JC, 1996)	0.29
" 2) Eight week treatment with the selected dosing regimen (n = 6) of the steroid and histomorphometry including strut analysis measured the development of a characteristic osteopenia which can be described briefly as "uncut but thinning" of trabecular bone structure, and which was prevented by salmon calcitonin (0."	( Glucocorticoid-induced osteopenia in rats: histomorphometrical and microarchitectural characterization and calcitonin effect. Hoshino, T; Koida, M; Nakamuta, H; Nitta, T, 1996)	0.29
"Using standard lymphocyte culture techniques, the concentration of prednisolone (P) and methylprednisolone (MP) required to cause 50% inhibition (IC50) of the proliferative response to phytohemagglutinin (PHA) was determined from dose-response curves."	( Differential glucocorticoid responsiveness of dialysis patients' lymphocytes. Briggs, WA; Burdick, JF; Choi, MJ; Gao, ZH; Gimenez, LF; Scheel, PJ, )	0.13
" From the dose-response curves, the concentration of steroid required to cause 50% inhibition (IC50) of the PHA-induced proliferative response was determined."	( Lymphocyte responsiveness to glucocorticoids, cyclosporine, or both. Briggs, WA; Burdick, JF; Choi, MJ; Gao, ZH; Gimenez, LF; Scheel, PJ, 1996)	0.29
" Dosing according to area under the serum MP time vs."	( Methylprednisolone exposure, rather than dose, predicts adrenal suppression and growth inhibition in children with liver and renal transplants. Holmberg, C; Hoppu, K; Laine, J; Neuvonen, PJ; Sarna, S, 1997)	0.3
" Dosage was reduced gradually to 10 mg daily over 4 weeks."	( Therapeutic responses to corticosteroids in Graves' ophthalmopathy. Chang, TC; Hsiao, YL; Huang, KM; Kao, SC; Lu, CP; Tzeng, SS, 1996)	0.29
" However, the optimal dosage of HDMP and its role in maintenance therapy should be determined in future, randomized studies."	( High-dose methylprednisolone for children with acute lymphoblastic leukemia and unfavorable presenting features. Atahan, L; Gümrük, F; Gürgey, A; Hiçsönmez, G; Ozsoylu, S; Tuncer, MA; Yetgin, S; Zamani, PV, 1997)	0.3
"continuous intravenous infusion of cyclosporine at dosage of 2 mg/kg/day is a highly effective and safe therapy that may avoid or defer colectomy to eligible conditions."	( [Treatment of acute a steroid-resistant ulcerative colitis with continuous venous infusion of cyclosporine]. Casà, A; Cottone, M; Oliva, L; Orlando, A; Rosselli, M, 1996)	0.29
" The optimal dosage and route of corticosteroid treatment for GCA with visual loss remain elusive and warrant a treatment trial."	( Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone. Cornblath, WT; Eggenberger, ER, 1997)	0.3
"It was concluded that for the multiple dosage regimen used in patients with acute asthma the systemic exposure to MP following dosing with MP suleptanate is similar to that arising from MP succinate."	( A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. Daley-Yates, PT; Parker, TJ; Wood, SA, 1997)	0.3
" However, a dose-response effect was seen only in the DFZ group."	( In vitro improvement of chlorambucil-induced cytotoxicity by deflazacort and 6-methylprednisolone in B-cell chronic lymphocytic leukaemia. Brugiatelli, M; Callea, I; Cartisano, G; Dattola, A; Irrera, G; Morabito, F; Rodinò, A, 1997)	0.3
" The initial dose of 1 mg/kg body weight was reduced by 20 mg each every 2 weeks, until a maintenance dosage of 8-12 mg/day was achieved."	( [Immunosuppressive therapy for effective suppression of life threatening ventricular tachyarrhythmias in chronic myocarditis]. Ganschow, US; Hennersdorf, M; Klein, RM; Kühl, U; Perings, C; Schannwell, CM; Schultheiss, HP; Strauer, BE; Vester, EG, 1997)	0.3
" Combined azathioprine methylprednisolone has produces better effects when only lower dosage is used."	( [Azathioprine and its combination with methylprednisolone: preventive effect on chronic cerebral vasospasm]. Liu, B; Wang, Z; Wu, J, 1996)	0.29
" Three patients were treated with intravenous acyclovir with concomitant reduction of steroid dosage and recovered completely."	( Management of varicella infection during the course of inflammatory bowel disease. Balasubramanian, S; Giannadaki, E; Greenstein, AJ; Manousos, ON; Mouzas, IA; Sachar, DB, 1997)	0.3
" If varicella infection occurs, prompt diagnosis and treatment with acyclovir and concomitant reduction in immunosuppressive therapy (reduction in steroid dosage and discontinuation of azathioprine) should be initiated immediately to limit viremia and avoid fatal complications."	( Management of varicella infection during the course of inflammatory bowel disease. Balasubramanian, S; Giannadaki, E; Greenstein, AJ; Manousos, ON; Mouzas, IA; Sachar, DB, 1997)	0.3
" As the steroid dosage was reduced, bone mass improved."	( Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Corrigall, V; Dasgupta, B; Dolan, AL; Li, F; Mackintosh, C; Moniz, C; Panayi, GS; Todd, P, 1997)	0.3
" The slope and the shape of the dose-response curve of DEX were similar irrespective of either the input stimuli or the output cytokines; half-maximal inhibition was observed at 10(-8) mol/L, and nearly complete abolishment was observed at 10(-7) mol/L."	( Glucocorticoids inhibit chemokine generation by human eosinophils. Hirai, K; Izumi, S; Kasahara, T; Matsushima, K; Misaki, Y; Miyamasu, M; Morita, Y; Nakamura, H; Takaishi, T, 1998)	0.3
" The study design required dosing with less tacrolimus (mean mg/day +/- SEM), which was achieved at 1 week (23."	( Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Bynon, JS; Contreras, JL; Eckhoff, DE; Frenette, LR; Hudson, SL; McGuire, BM, 1998)	0.3
" Over 20 years, we have simply observed our patients clinically after diagnosis, and only used aggressive therapy with steroids in high dosage and azathioprine for 21 patients with progressive renal failure."	( 'Progressive' versus 'indolent' idiopathic membranous glomerulonephritis. Bone, JM; Rustom, R; Williams, PS, 1997)	0.3
"The higher dosage of IVMP has a more powerful and prolonged action in maintaining blood-brain barrier integrity after a clinical relapse."	( Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Aguglia, U; Bono, F; Fera, F; Gambardella, A; Oliveri, RL; Pardatscher, K; Quattrone, A; Russo, C; Sibilia, G; Valentino, P; Zappia, M, 1998)	0.3
"A postal questionnaire covering the use of corticosteroids for acute multiple sclerosis relapse and chronic progressive multiple sclerosis with regard to frequency of use, type of corticosteroid, and dosage regime was sent to all members of the Association of British Neurologists with a United Kingdom address."	( Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom. Luscombe, DK; Tremlett, HL; Wiles, CM, 1998)	0.3
" Throughout the dosing interval, enzyme activity parallels that of drug concentrations."	( The monitoring of immunosuppressive drugs: a pharmacodynamic approach. Aspeslet, LJ; Yatscoff, RW, 1998)	0.3
" The dosage of tacrolimus (D), the trough blood concentrations (C), and the evolution of the ratio (D/C) were followed up for 2 years after transplantation in 50 adult patients (38 men, 12 women) undergoing liver allograft transplantation."	( Therapeutic drug monitoring of tacrolimus in liver transplantation, phase III FK506 multicenter Spanish Study Group: a two-year follow-up. Andres, I; Andreu, H; Bilbao, I; Brunet, M; Corbella, J; Lopez, R; Margarit, C; Pou, L; Rimola, A, 1998)	0.3
"Mesalamine in microgranular formulation seems to be equally as effective as a standard dosage of steroids in the treatment of the mild to moderate form of Crohn's ileitis."	( Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Annese, V; Bianchi Porro, G; Cerutti, R; Cottone, M; Franzè, A; Pallone, F; Prantera, C, 1999)	0.3
" Down-regulation of GR mRNA and GR density were observed: GR mRNA level declined to 45-50% of the baseline in 8-10 hr, and slowly returned to predose level in about 3 days; GR density fell to 0 soon after dosing and returned to the baseline in two phases."	( Fourth-generation model for corticosteroid pharmacodynamics: a model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. Almon, RR; DuBois, DC; Jusko, WJ; Sun, YN, 1998)	0.3
" Standardized dosage tables for high-dose methylprednisolone were developed for prescribers, nurses, and pharmacists."	( Standardized dosing tables to reduce errors involving high-dose methylprednisolone for acute spinal cord injury. Lesar, TS, 1994)	0.29
" Corticosteroid dosing involves six phases: (1) initial high doses to control inflammation; (2) tapering to a maintenance dose that will continue to suppress the inflammation but lessen the risk of corticosteroid toxic reactions; (3) continuing to receive the maintenance dose until a decision to taper off corticosteroids is made; (4) tapering off corticosteroid therapy; (5) observation for relapse; and (6) treatment if relapse occurs."	( An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Judson, MA, 1999)	0.3
"The administration of one single weekly dose of methotrexate 10 mg in adults and 15 in one pediatric patient allowed for a decrease of approximately 50% in the glucocorticosteroid dosage in this group of patients with corticosteroid-dependent bronchial asthma with no relevant adverse reactions during therapy."	( [Efficiency of methotrexate in the treatment of cortico-dependent asthmatic patients]. Bosque García, M; Comet Monte, R; Domingo Ribas, C; Montón Soler, C; Morón Besolí, A, 1999)	0.3
" There was no dose-response to intraperitoneal MP (up to 12 mg/kg) for nociceptive thresholds to heat (Peltier) or mechanical (analgesy-meter and von Frey fibers) stimuli in normal rats."	( Methylprednisolone prevents the development of autotomy and neuropathic edema in rats, but has no effect on nociceptive thresholds. Castellote, JM; Kingery, WS; Maze, M, 1999)	0.3
" Except for the angiotensin-converting enzyme inhibitor, these medications were not effective in terms of allowing a reduction in the high dosage of steroid, which in turn threatened progressive osteoporosis and lumbar vertebrae fracture."	( Effect of pituitary microsurgery on acromegaly complicated nephrotic syndrome with focal segmental glomerulosclerosis: report of a rare clinical case. Akikusa, B; Hasegawa, S; Iesato, K; Murotani, N; Saeki, N; Shimada, T; Wakashin, M; Yamamoto, S; Yoshida, H, 1999)	0.3
" There was no indication that the dosage or timing of corticosteroid treatment or the timing of surgery was associated with an increased probability of visual improvement."	( The treatment of traumatic optic neuropathy: the International Optic Nerve Trauma Study. Beck, RW; Joseph, MP; Kraker, R; Levin, LA; Seiff, S, 1999)	0.3
" Steroid therapy can be considered in the treatment of children with refractory late ARDS but larger prospective studies are needed to define indications, timing, dosing and safety of this mode of treatment in children."	( Corticosteroid rescue in late paediatric acute respiratory distress syndrome. Goh, AY; Roziah, M; Sekaran, D, 1999)	0.3
"We investigated the bronchodilator dose-response to nebulized albuterol and the dose of albuterol which produces maximal bronchodilation in the acutely ill, hospitalized asthmatic."	( Dose-response characteristics of nebulized albuterol in the treatment of acutely ill, hospitalized asthmatics. Brennan, K; Ciccolella, DE; Criner, GJ; Kelsen, SG, 1999)	0.3
" In examined cases the antithyroid dosage was medium high (mean 40 mg/die)."	( [Methimazole-induced aplastic anemia]. Bolognesi, S; Castiglioni, MG; Mechelli, S; Siuti, E; Stefanelli, A, 1999)	0.3
" However, when the dosage was tapered, BOOP recurred."	( [Successful treatment of steroid-resistant bronchiolitis obliterans-organizing pneumonia with orally administered cyclosporin and pirfenidone]. Arai, Y; Isogane, N; Ito, K; Ogawa, C; Otomo, M; Sano, Y; Sekiya, T; Suzuki, N; To, Y, 2000)	0.31
" Depending on the intensity of allergen exposure, complaints now occur in February/March only, requiring updating of the therapy in respect of dosage and number of drugs used."	( [Two out-of-the-ordinary (?) case reports an asthmatic disease]. Hausen, T, 2000)	0.31
" The clinical responses of the patients to treatment, including alterations in muscle strength, muscle enzyme levels and corticosteroid dosage as well as the development of side-effects, were recorded."	( Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Al-Mayouf, S; Al-Mazyed, A; Bahabri, S, 2000)	0.31
" This consists of Plasmapheresis associated with pharmacological therapy so that dosage of immunosuppressors can be reduced and consequently also the side effects of the pharmacological therapy."	( [Plasmapheresis combined with pharmacology in the treatment of lupus nephritis: a new therapeutic protocol]. Bauco, B; Bisciglia, MF; Bonello, M; Bosco, M; De Paola, A; Maresca, L; Russo, GE; Tedaldi, M; Vitaliano, E, )	0.13
" The dosage of methylprednisolone recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2-day period for any clinical condition."	( High-dose methylprednisolone may do more harm for spinal cord injury. Campagnolo, D; Kirshblum, S; Qian, T, 2000)	0.31
" In severe ophthalmopathy steroids are effective in more than 60% of patients [1, 3], but to be effective high dosage is necessary [1, 4-6]."	( [Treatment of Grave's ophthalmopathy with high doses of corticosteroids]. Cirić, J; Drezgić, M; Gligorović, M; Nesović, M; Pepenezić, Z; Randjelović, G; Stojanović, M; Trbojević, B; Zarković, M, )	0.13
" Corticosteroid therapy with methylprednisolone at low dosage (0."	( A case of vesiculo-bullous Darier's disease associated with bipolar psychiatric disorder. Amato, L; Caproni, M; Fabbri, P; Gallerani, I; Mei, S; Palleschi, GM; Perrella, E, 2000)	0.31
" In the multiple regression test, a linear coincidence was observed between apo A1, apo B and prednisone cumulative dosage after the 1st month, TG and cyclosporine in the 6th month and LDL and cyclosporine in the 12th month after transplantation."	( Does immunosuppressive regimen influence the lipid disturbances in kidney recipients? Kisielnicka, E; Kortas, B; Lysiak-Szydłowska, W; Rutkowski, B; Wróblewska, M; Zdrojewski, Z, )	0.13
" However, it is important to monitor serum SRL levels to determine the optimal dosing regimen."	( A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Ascher, NL; Chang, GJ; Freise, CE; Hirose, R; Mahanty, HD; Roberts, JP; Stock, PG; Vincenti, F, 2000)	0.31
"A physiologic pharmacodynamic model was developed to jointly characterize the effects of corticosteroid treatment on adrenal suppression and T-helper cell trafficking during single and multiple dosing in asthmatic patients."	( Modeling interactions between adrenal suppression and T-helper lymphocyte trafficking during multiple dosing of methylprednisolone. Chow, FS; Jusko, WJ; Sharma, A, 1999)	0.3
" In conclusion, the systemic corticosteroids are effective in 36% of patients, independent of dosage and pharmacological agents and duration of the therapy."	( Management of cutaneous hemangiomas: a retrospective analysis of 1109 cases and comparison of conventional dose prednisolone with high-dose methylprednisolone therapy. Akyüz, C; Büyükpamukçu, M; Kutluk, MT; Yariş, N, )	0.13
"5 mg/kg q6h for 3 days, and group 2 was administered the same dosage of MP for the first 3 days, after which it was tapered and terminated on the tenth day."	( Systemic glucocorticoids in severe exacerbations of COPD. Aytemur, ZA; Cirit, M; Sayiner, A; Unsal, I, 2001)	0.31
" Despite this, the pharmacokinetics of prednisolone have never been fully characterized in these patients, and consequently dosing remains empirical."	( Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. Akhlaghi, F; Holt, DW; Lee, T; Majid, O; Trull, A, 2001)	0.31
" Five patients who treated with steroids at the onset of neurological symptoms showed clinical improvement, regardless of their age, sex, the pathology and stage of breast cancer, or the total dosage of chemotherapeutic agents."	( 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. Cho, KH; Choi, SM; Kim, BC; Kim, MK; Lee, SH; Yang, YS, 2001)	0.31
"Targeted topical steroid administration avoids the significant systemic side effects of oral steroids and may offer more effective dosing than simple transtympanic injection of medicine."	( Targeted topical steroid therapy in sudden sensorineural hearing loss. Hoffer, ME; Jackson, RL; Kopke, RD; O'Leary, MJ; Wester, D, 2001)	0.31
" In order to obtain a corticosteroid-sparing effect, new studies are necessary to evaluate a reduced initial dosage of corticosteroids."	( [Horton's disease in elderly patients aged over 75: clinical course, complications of corticotherapy. Comparative study of 164 patients. Towards a reduced initial dose]. Barrier, JH; Chevalet, P; de Wazières, B; Duhamel, E; el Kouri, D; Glémarec, J; Hamidou, M; Jégo, P; Maugars, Y; Planchon, B; Rodat, O, 2001)	0.31
"Eleven nondiabetic patients with worsening LSRPN were treated - ten with infusions of IV MP (1 gm/wk) for 8 to 16 weeks and one with an equivalent dosage of oral prednisone."	( Methylprednisolone may improve lumbosacral radiculoplexus neuropathy. Dyck, PJ; Norell, JE, 2001)	0.31
" Cyclosporin A dosage and trough levels were not significantly different before and after steroid withdrawal."	( Risk of steroid withdrawal in pediatric renal transplant patients with suspected steroid toxicity. Förster, B; Jeck, N; Klaus, G; Konrad, M; Soergel, M, 2001)	0.31
" Combined use of azathioprine with methylprednisolone allows lower dosage and less complication compared with a single agent, and results in a better outcome."	( Azathioprine and methylprednisolone: prevention of chronic cerebral vasospasm in dogs. Liu, B; Sun, Y; Wang, C; Wu, J; Wu, Z, 2000)	0.31
"8 months), total used dosage of steroids (G1= 20, G2= 28, G3= 16 grams) and time of drug use (G1= 20, G2= 26, G3= 14."	( [A comparative study of therapeutic complications in Systemic Lupus Erythematosus and in idiopathic glomerulopathy]. Almeida, DB; Balbi, AL; Barbosa, RA; Lima, MC, )	0.13
"Randomised trials comparing different routes of administration and dosage schemes of corticosteroid or adrenocorticotrophic hormone therapy versus a control group where no therapy considered effective for this condition was administered, unless it was also given in a similar way to the experimental group."	( Corticosteroids for Bell's palsy (idiopathic facial paralysis). Alvarez, G; Alvarez, MI; Ferreira, J; Salinas, RA, 2002)	0.31
" Complications due to treatment included: duodenal ulcer in one patient that responded to medical treatment, and transient elevation in serum creatinine levels in three patients, which returned to normal after decrease in dosage or cessation of oral CSA."	( Combined intravenous pulse methylprednisolone and oral cyclosporine A in the treatment of corneal graft rejection: 5-year experience. Cheng, LL; Lam, DS; Leung, AT; Rao, SK; Wong, AK; Young, AL, 2002)	0.31
" The dosage of steroids was tapered in 3 out of 4 CyA-responsive cases without re-exacerbation."	( Usefulness of cyclosporine A on rapidly progressive interstitial pneumonia in dermatomyositis. Inase, N; Miyake, S; Miyasaka, N; Miyazaki, Y; Ohtani, Y; Sawada, M; Takano, S; Yoshizawa, Y, 2002)	0.31
"008) with the divided dosage regimen than after the single dose (8422 +/- 2163 vs."	( Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. Boehm, BO; Czock, D; Keller, F; Mertz, A; Uhl, A; Zellner, D, 2002)	0.31
" High dose methylprednisolone (kg/30 mg) was administered by intravenous infusion in the 8th, 16th and 24th hours after injury followed by infusion of the same dosage every 6 hours for 24 hours."	( Efficacy of methylprednisolone in acute experimental cauda equina injury. Alptekin, M; Bakir, K; Erkutlu, I; Gök, A; Uk, C; Yilmaz, M, 2002)	0.31
" bolus dose of methylprednisolone (MPL) in male adrenalectomized rats, and confirmed using data from other acute dosage regimens."	( Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. Almon, RR; DuBois, DC; Jusko, WJ; Pyszczynski, NA; Ramakrishnan, R, 2002)	0.31
" The NASCIS III dosing regimen is the most commonly prescribed steroid protocol."	( Why do you prescribe methylprednisolone for acute spinal cord injury? A Canadian perspective and a position statement. Hurlbert, RJ; Moulton, R, 2002)	0.31
"Observational study on the timing and correct dosage of methylprednisolone."	( Failure to administer methylprednisolone for acute traumatic spinal cord injury-a prospective audit of 100 patients from a regional spinal injuries unit. Casey, AT; Middleton, F; Molloy, S, 2002)	0.31
"Intravenous methylprednisolone at the dosage and duration used in this retrospective study did not significantly improve the visual recovery of eyes with traumatic optic neuropathy compared to conservative treatment."	( Low-dose intravenous methylprednisolone or conservative treatment in the management of traumatic optic neuropathy. Au Eong, KG; Chng, NW; Heng, WJ; Lim, TH; Lim, WK; Yip, CC, )	0.13
" Every other week for 8 weeks, one shoulder in each rat was injected with methylprednisolone, betamethasone, or saline in a dosage equivalent to that used in humans."	( Effects of methylprednisolone and betamethasone injections on the rotator cuff: an experimental study in rats. Akpinar, S; Demirors, H; Hersekli, MA; Kayaselcuk, F; Tandogan, RN, )	0.13
" Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia."	( Steroid diabetes in children with Crohn disease. Banac, S; Cvijović, K; Persić, M, 2002)	0.31
" The dose-response (5-40 mg/kg) and time-course (6-72 h) curves of methylprednisolone on pancreatic HSP60 and HSP72 synthesis were evaluated following methylprednisolone treatment."	( The anti-inflammatory effect of methylprednisolone occurs down-stream of nuclear factor-kappaB DNA binding in acute pancreatitis. Boros, I; Duda, E; Iványi, B; Kaszaki, J; Lonovics, J; Rakonczay, Z; Takács, T, 2003)	0.32
" The dose-response (3 or 4 g/kg) and time-effect (0."	( NF-kappaB activation is detrimental in arginine-induced acute pancreatitis. Boros, I; Duda, E; Hegyi, P; Jármay, K; Kaszaki, J; Lonovics, J; Mándi, Y; Rakonczay, Z; Takács, T, 2003)	0.32
"The sirolimus/cyclosporine combination regimen reduced the incidence of acute renal allograft rejection, did not affect renal function, and reduced the dosage of cyclosporine and steroids compared with the cyclosporine regimen."	( Effect of sirolimus in combination with low-dose cyclosporine and steroids on acute renal allograft rejection. Chueh, SC; Hu, RH; Lee, PH; Tsai, MK, 2003)	0.32
" Dosing of these agents was concentration-controlled and open-labeled."	( Bicêtre hospital experience with sirolimus-based therapy in human renal transplantation: the Sirolimus European Renal Transplant Study. Bäckman, L; Brattström, C; Calne, R; Campistol, JM; Charpentier, B; Claesson, K; Durand, D; Groth, CG; Kreis, H; Lang, P; Morales, JM; Touraine, JL; Wramner, L, 2003)	0.32
" Psychosis was unpredictable by the routes and dosage of corticosteroid used."	( Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Chau, SY; Mok, CC, 2003)	0.32
" The highest dosage of MPA (10 mg/ml) reduced GAG synthesis less than lower dosages of MPA and all dosages of TA."	( Effects of dosage titration of methylprednisolone acetate and triamcinolone acetonide on interleukin-1-conditioned equine articular cartilage explants in vitro. Baxter, GM; Dechant, JE; Frisbie, DD; McIlwraith, CW; Trotter, GW, 2003)	0.32
" The course and dosage of glucocorticoid, counts of CD(4)(+), CD(8)(+) and CD(3)(+), electrolytes, blood routine, and sera albumin before and after the treatment were analysed."	( [Glucocorticoid in the treatment of severe acute respiratory syndrome patients: a preliminary report]. Guo, JZ; Jiang, RM; Li, XW, 2003)	0.32
" The dosage for 24 patients was 80 - 160 mg/d with the largest being 1,000 mg/d before admission to the hospital."	( [Glucocorticoid in the treatment of severe acute respiratory syndrome patients: a preliminary report]. Guo, JZ; Jiang, RM; Li, XW, 2003)	0.32
" Indications for use of glucocorticoid must strictly controlled and its large dosage is improper."	( [Glucocorticoid in the treatment of severe acute respiratory syndrome patients: a preliminary report]. Guo, JZ; Jiang, RM; Li, XW, 2003)	0.32
" Of 36 cases treated with steroids, 86% received middle or low dosage (80 - 240 mg/d)."	( [Clinical features of severe acute respiratory syndrome in forty-one confirmed health care workers]. Dong, PL; Hou, W; Hu, ZJ; Huang, C; Liang, LC; Meng, QH; Zhang, K; Zhao, CH, 2003)	0.32
" Middle or low dosage of steroid was reasonable to be used as early as possible."	( [Clinical features of severe acute respiratory syndrome in forty-one confirmed health care workers]. Dong, PL; Hou, W; Hu, ZJ; Huang, C; Liang, LC; Meng, QH; Zhang, K; Zhao, CH, 2003)	0.32
" Initial use of pulse methylprednisolone therapy appears to be a more efficacious and an equally safe steroid regimen when compared with regimens with lower dosage and should be considered as the preferred steroid regimen in the treatment of SARS, pending data from future randomized controlled trials."	( High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Chan, JW; Chan-Yeung, M; Ho, JC; Ho, PL; Hung, I; Ip, MS; Lai, KN; Lam, B; Lam, WK; Li, PC; Mok, TY; Ng, CK; Ooi, GC; Tsang, KW; Wong, PC, 2003)	0.32
"05) but only in the 2-g MMF dosing group."	( Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. Claes, K; Coosemans, W; Evenepoel, P; Kuypers, DR; Maes, B; Pirenne, J; Vanrenterghem, Y, 2003)	0.32
" In the dosage used, none of the compounds promoted discernible salt and water retention."	( 16a-Methyl corticosteroids; a new series of anti-inflammatory compounds; clinical appraisal of their antirheumatic potencies. BOLAND, EW, 1958)	0.24
" Steroid dosage, tacrolimus dosage, tacrolimus trough concentration (C0) and tacrolimus concentration/dose ratio [C0 divided by the 24 h dosage (mg/kg)] were assessed for each dosage group after 1 and 3 months of tacrolimus treatment."	( Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Anglicheau, D; Beaune, P; Cassinat, B; Flamant, M; Legendre, C; Martinez, F; Schlageter, MH; Thervet, E, 2003)	0.32
" At 1 and 3 months, the tacrolimus doses and concentration/dose ratios differed significantly in the three steroid dosage groups."	( Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Anglicheau, D; Beaune, P; Cassinat, B; Flamant, M; Legendre, C; Martinez, F; Schlageter, MH; Thervet, E, 2003)	0.32
" The higher the steroid dosage, the higher the dosage of tacrolimus needed to achieve target trough levels in these patients."	( Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Anglicheau, D; Beaune, P; Cassinat, B; Flamant, M; Legendre, C; Martinez, F; Schlageter, MH; Thervet, E, 2003)	0.32
"In treating SARS, ICWM was superior to the treatment with western medicine alone in aspects of improving clinical symptom, promoting recovery of immune function and absorption of lung inflammation, decreasing the dosage of hormone used and shortening the therapeutic course."	( [Controlled clinical study on 49 patients of SARS treated by integrative Chinese and Western medicine]. Jiao, Q; Wang, BG; Zhang, RL, 2003)	0.32
"Comparing OKT3 and antithymocyte globulin (ATG) in a prospective study, the dosage difference in regard to body weight (ATG: dependent on body weight/OKT3: independent) does not introduce any obvious source of mistake concerning clinical effectiveness or side effects."	( Dosage of OKT3 independent of body weight: a mistake? Bachofen, M; Bock, H; Gallati, H; Landmann, J; Pracht, I; Thiel, G, 1992)	0.28
" Initial dosage prednisolone was given for 1 month, and then tapered gradually in terms of dosage and interval."	( [Quadritherapy with cyclosporine for membranous lupus nephropathy]. Iwasawa, H; Matsumoto, H; Nagaoka, Y; Nakao, T; Okada, T; Tomaru, R; Wada, T, 2003)	0.32
" Levels of mycophenolic acid (MPA), its glucuronide metabolite, and daclizumab were measured after dosing on days 28 and 56."	( Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. Bumgardner, G; Gaston, RS; Kirkman, RL; Light, S; Nieforth, K; Patel, IH; Pescovitz, MD; Vincenti, F, 2003)	0.32
" Twenty patients received mega-dose methylprednisolone (MDMP) in a dosage of 30 mg/kg/d for three days and 20 mg/kg/d for four days."	( A randomized and comparative study of intravenous immunoglobulin and mega dose methylprednisolone treatments in children with acute idiopathic thrombocytopenic purpura. Aslan, Y; Erduran, E; Gedik, Y; Orhan, F, )	0.13
"The aim of this study was to compare the effectiveness of triamcinolone hexacetonide (THA) and methylprednisolone acetate (MPA), given via the intra-articular route at equipotent dosage to patients with symptomatic knee OA with effusion, in a double-blind randomized comparative trial."	( Intra-articular steroids in knee osteoarthritis: a comparative study of triamcinolone hexacetonide and methylprednisolone acetate. Bhanji, A; Ioannou, Y; Mootoo, R; Pyne, D, 2004)	0.32
" Decreasing the daily maximal dosage may be beneficial to the reduction of corticosteroid-induced of diabetes."	( [Glucocorticoid-induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy]. Gao, J; Jiao, JS; Li, GW; Ma, L; Xiao, JZ; Xing, XY; Yang, ZJ; Zhao, HC, 2004)	0.32
" Our results support the prophylactic administration of methylprednisolone in small dosage to prevent posttraumatic hypoxaemia and probably FES in patients with isolated lower limb long bone fractures, especially when early fracture stabilisation is not possible."	( Prevention of posttraumatic hypoxaemia in isolated lower limb long bone fractures with a minimal prophylactic dose of corticosteroids. Antonogiannakis, E; Babalis, GA; Karliaftis, K; Yiannakopoulos, CK, 2004)	0.32
"Clinical date of 30 SARS patients without other diseases in whom corticosteroid was used were reviewed including total dosage, duration of use, the highest dosage and its duration, and speed of reduction in dosage."	( [Analysis of relation between the usage of corticosteroid in treatment and arthralgia as a sequela of SARS patients]. Chen, LM; Gao, HS; Hui, WL; Jiao, ZS; Li, YM; Wang, SX; Yang, Z; Yuan, SL; Zhao, ZY, 2004)	0.32
"The average total dosage of methylprednisolone was (4 244."	( [Analysis of relation between the usage of corticosteroid in treatment and arthralgia as a sequela of SARS patients]. Chen, LM; Gao, HS; Hui, WL; Jiao, ZS; Li, YM; Wang, SX; Yang, Z; Yuan, SL; Zhao, ZY, 2004)	0.32
"There is a dosage- effect relation between the degree of arthralgia and the total dosage of corticosteroid, and a time-effect relation between the duration of arthralgia and length of the use of corticosteroids."	( [Analysis of relation between the usage of corticosteroid in treatment and arthralgia as a sequela of SARS patients]. Chen, LM; Gao, HS; Hui, WL; Jiao, ZS; Li, YM; Wang, SX; Yang, Z; Yuan, SL; Zhao, ZY, 2004)	0.32
"Early applying of CH-HZ treatment showed good effects in improving CK, LDH, oxygenation index and absolute value of neutrophils, and could reduce the daily maximal dosage of glucocorticoid needed for SARS patients."	( [Clinical observation on treatment of SARS with combination of chaihu droplet pill and huoxiang zhengqi droplet pill]. Li, H; Lu, CZ; Tang, KC, 2004)	0.32
"Early application of CH-HZ treatment in treating SARS could alleviate the injury in lung of SARS patients and the neutrophil dependent inflammatory reaction, and reduce the dosage of glucocorticoid used."	( [Clinical observation on treatment of SARS with combination of chaihu droplet pill and huoxiang zhengqi droplet pill]. Li, H; Lu, CZ; Tang, KC, 2004)	0.32
" These findings suggest that doses of glucocorticoids should be prescribed on a milligram/kilogram basis instead of empiric dosing schedules."	( Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. Farooqui, M; Gilliland-Johnson, KK; Reed, KA; Tornatore, KM; Venuto, RC, 2004)	0.32
"The average total dosage of methylprednisolone was (4949 +/- 2959) mg, and the average course of treatment was (24 +/- 5) days (16 to 30 days)."	( [Factors of avascular necrosis of femoral head and osteoporosis in SARS patients' convalescence]. Chen, LM; Gao, HS; Hui, WL; Jiao, ZS; Li, YM; Su, B; Wang, JG; Wang, SX; Wei, CS; Yang, Z; Yuan, SL, 2004)	0.32
" The influencing factors of femoral necrosis included the degree of healing activity, the dosage summation of corticosteroids, and length of ictus therapy."	( [Factors of avascular necrosis of femoral head and osteoporosis in SARS patients' convalescence]. Chen, LM; Gao, HS; Hui, WL; Jiao, ZS; Li, YM; Su, B; Wang, JG; Wang, SX; Wei, CS; Yang, Z; Yuan, SL, 2004)	0.32
" The average dosage of GCS was 160 mg/d in the first week, and then reduced to 80 mg/d and 40 mg/d in the second and the third weeks, respectively."	( [Side effects of glucocorticosteroids in the management of 1291 patients of SARS]. Chen, BW; Han, DM; Li, N; Wang, GF; Wang, YX; Wu, YF; Xiao, F; Xie, GQ, 2004)	0.32
"Hyperglycemia and hypokalemia are correlated with GCS dosage and duration."	( [Side effects of glucocorticosteroids in the management of 1291 patients of SARS]. Chen, BW; Han, DM; Li, N; Wang, GF; Wang, YX; Wu, YF; Xiao, F; Xie, GQ, 2004)	0.32
"Randomised trials comparing different routes of administration and dosage schemes of corticosteroid or adrenocorticotrophic hormone therapy versus a control group where no therapy considered effective for this condition was administered, unless it was also given in a similar way to the experimental group."	( Corticosteroids for Bell's palsy (idiopathic facial paralysis). Alvarez, G; Ferreira, J; Salinas, RA, 2004)	0.32
" These results suggest that there is an appropriate dosage as well as appropriate timing for MP administration to suppress PIH."	( Effects of preinjury administration of corticosteroids on pseudointimal hyperplasia and cytokine response in a rat model of balloon aortic injury. Kaneda, M; Kitajima, M; Matsumoto, K; Mukai, M; Murayama, T; Nagasaki, K; Shibutani, S; Shimazu, M; Shintani, T; Wakabayashi, G, 2004)	0.32
" The maximum daily dosage of steroid may significantly influence on the occurrence of avascular abnormalities."	( [Report on the investigation of lower extremity osteonecrosis with magnetic resonance imaging in recovered severe acute respiratory syndrome in Guangzhou]. Chen, JY; Chen, RC; Liang, BL; Liu, QY; Shen, J; Zeng, QS; Zhong, NS, 2004)	0.32
" The treatment regiments included oxygen, small dosage and short period of methylprednisolone (1 to 2 mg/kg), use of ventilator, psychological intervention, and treatment of underlying diseases, after which, all the 7 patients recovered."	( [Clinical experience from treatment of seven SARS patients]. Dong, QH; Guo, LM; Li, XH; Li, YR; Wang, XJ; Xiang, P; Yan, J; Yang, LQ; Yang, YY; Zhang, WY, 2004)	0.32
"IL-10+DC and IL-12+DC in peripheral blood are associated with time after transplantation and dosage of immunosuppression."	( Association of circulating interleukin (IL)-12- and IL-10-producing dendritic cells with time posttransplant, dose of immunosuppression, and plasma cytokines in renal-transplant recipients. Daniel, V; Hergesell, O; Naujokat, C; Opelz, G; Sadeghi, M; Wiesel, M, 2005)	0.33
"The CC16 was measured in plasma from 15 subjects exposed to LPS by inhalation, during which the kinetics and the dose-response relationship of LPS-induced CC16 were evaluated."	( Inhaled LPS induces blood release of Clara cell specific protein (CC16) in human beings. Bernard, A; Michel, O; Murdoch, R, 2005)	0.33
" The average lifetime dosage of MP was 75."	( Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Bosco, A; Bratina, A; Cazzato, G; Giuntini, D; Locatelli, L; Nasuelli, D; Rudick, RA; Tommasi, MA; Toncic, M; Zivadinov, R; Zorzon, M, 2005)	0.33
" Although there were no significant differences in the total dosage of cyclosporine A between the patients with living-relation donors and those with non-heart-beating donors, a significant increase in the total dosage of methylprednisolone was observed in patients with non-heart-beating donors compared with those in the patients with living-relation donors."	( Studies on post-transplant dyslipidemia in kidney transplant patients. Asahara, T; Dohi, K; Doi, S; Fukuda, Y; Hayamizu, K; Kawai, T; Marubayashi, S; Ohdan, H; Okumoto, S; Onoe, T; Taniguchi, Y; Tanji, C; Tashiro, H; Tokita, D, 2005)	0.33
" The employment of methotrexate attained decrease in the dosage of steroids temporarily."	( [Treatment with nebulized lidocaine in steroid-dependent asthma]. de Paz Arranz, S; Fernández Parra, B; Herrera Mozo, I; Pérez Pimiento, A; Rodríguez Mosquera, M; Santaolalla Montoya, M, )	0.13
"The rabbits were randomly divided into 11 groups: oleic acid group; control group; treatment groups including low, middle and high dosage groups of Qingkailing and MP alone and combined, respectively."	( [Therapeutic effect of Qingkailing and methylprednisolone injection alone or combined on the acute lung injury induced by oleic acid in rabbits]. Cui, HF; Du, GY; Gao, SR; Gao, W; He, R; Hui, LQ; Liang, RX; Wang, XR; Wu, ZL; Zhang, CY; Zhao, Y; Zhu, XX, 2005)	0.33
" (2) A dosage lower than the one recommended in the literature is effective."	( Benefits of low weekly doses of methotrexate in steroid-dependent asthmatic patients. A double-blind, randomized, placebo-controlled study. Amengual, MJ; Comet, R; Domingo, C; Larrosa, M; Marín, A; Morón, A; Rué, M, 2006)	0.33
" The observation indexes were time in hospital, pneumonia duration, mortality, glucocorticoid's gross dosage, glucocorticoid's average dosage of days and glucocorticoid use time."	( [Effect of glucocorticoid with traditional Chinese medicine in severe acute aespiratory syndrome (SARS)]. Gao, FZ; He, LY; Hu, JQ; Jiao, Q; Li, P; Liang, ZW; Liu, BY; Liu, WM; Liu, XM; Ni, Q; Tong, XY; Wen, TC; Xie, YM, 2005)	0.33
" The median of glucocorticoid' s gross dosage was 1,277."	( [Effect of glucocorticoid with traditional Chinese medicine in severe acute aespiratory syndrome (SARS)]. Gao, FZ; He, LY; Hu, JQ; Jiao, Q; Li, P; Liang, ZW; Liu, BY; Liu, WM; Liu, XM; Ni, Q; Tong, XY; Wen, TC; Xie, YM, 2005)	0.33
"Compared with the group of simplicity western mendicine, in the group of integratived Chinese and western mendicine, time in hospital shorten, pneumonia duration shorten, mortality fall, simultaneity, glucocorticoid's average dosage is decreased."	( [Effect of glucocorticoid with traditional Chinese medicine in severe acute aespiratory syndrome (SARS)]. Gao, FZ; He, LY; Hu, JQ; Jiao, Q; Li, P; Liang, ZW; Liu, BY; Liu, WM; Liu, XM; Ni, Q; Tong, XY; Wen, TC; Xie, YM, 2005)	0.33
"Glucocorticoid (GC) dosing is commonly based on body mass or surface area in children, although the drug effects appear to correlate with steroid exposure, rather than dose."	( Methylprednisolone exposure in pediatric renal transplant patients. Holmberg, C; Jänne, OA; Neuvonen, PJ; Raivio, T; Seikku, P, 2006)	0.33
" Fecal oocyst production could be perpetuated by dosing at 10-day intervals."	( Characterization of a single dose methylprednisolone acetate immune suppression model using Cryptosporidium muris and Cryptosporidium parvum. Miller, TA; Schaefer, FW, 2006)	0.33
" In this case, once the dosage of oral prednisone was increased and methotrexate was added to the therapeutic scheme, inflammation was controlled within 1 month."	( Combination of azathioprine and corticosteroids in the treatment of serpiginous choroiditis. Burnier, MN; Deschênes, J; Ozdal, PC; Vianna, RN, 2006)	0.33
" Reduction in dosage of CNI may delay the development of CAN, leading to longer graft survival."	( Stable graft function after reduction of calcineurin inhibitor dosage in paediatric kidney transplant patients. Amann, K; Benz, K; Dittrich, K; Dötsch, J; Klare, B; Nüsken, KD; Plank, C; Rascher, W; Sauerstein, K; Stuppy, A, 2006)	0.33
" Over a period of 9 months CNI dosage was stepwise reduced from CSA trough levels of 100-150 ng/ml to 50-70 ng/ml and Tac trough levels of 5-8 ng/ml to 2-3 ng/ml, respectively."	( Stable graft function after reduction of calcineurin inhibitor dosage in paediatric kidney transplant patients. Amann, K; Benz, K; Dittrich, K; Dötsch, J; Klare, B; Nüsken, KD; Plank, C; Rascher, W; Sauerstein, K; Stuppy, A, 2006)	0.33
" A good prospective multicenter trial of high-dose methylprednisolone for traumatic brain injury should be considered in which dosage and timing parameters similar to those enacted for the NASCIS studies are used."	( Are steroids really ineffective for severely head injured patients? Kamano, S, 2000)	0.31
" The norepinephrine dose-response curve displayed a shift to the left after incubation with methylprednisolone."	( Femoral artery constriction by norepinephrine is enhanced by methylprednisolone in a rat model. Drescher, W; Hassenpflug, J; Herdegen, T; Liebs, TR; Lohse, J; Pufe, T; Varoga, D, 2006)	0.33
"03), to have taken a mean dosage >7."	( Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. Ambler, G; Bessant, R; Duncan, R; Gordon, C; Isenberg, DA; Rahman, A; Swanton, J, 2006)	0.33
" At the age of 14 years, mycophenolate mofetil (MMF) was added to the maintenance therapy and the CSA dosage was reduced."	( Fifteen-year remission of a steroid-resistant nephrotic syndrome sustained by cyclosporine A. Drube, J; Ehrich, JH; Geerlings, C; Mengel, M; Taylor, R, 2007)	0.34
" Additionally, free hepatic cytosolic GR and its mRNA data from a chronic infusion dosing study of MPL (0."	( Assessing the dynamics of nuclear glucocorticoid-receptor complex: adding flexibility to gene expression modeling. Almon, RR; DuBois, DC; Hazra, A; Jusko, WJ, 2007)	0.34
" A comparison of datasets from the two different dosing regimens identified 358 genes that were regulated by MPL in response to both dosing regimens."	( A microarray analysis of the temporal response of liver to methylprednisolone: a comparative analysis of two dosing regimens. Almon, RR; DuBois, DC; Jusko, WJ, 2007)	0.34
" Dosage effects of immunosuppressive drugs (tacrolimus, cyclosporin A, sirolimus, mycophenolic acid, and methylprednisolone) were evaluated in vitro and the assay was applied successfully to dialysis, renal transplant, and liver transplant patients."	( Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. Böhler, T; Budde, K; Glander, P; Gurragchaa, P; Kamar, N; Klupp, J; Neumayer, HH; Nolting, J; Reisener, K, 2007)	0.34
" The use of bosentan for vasculitis had not been reported in children before the treatment of our patient, so its dosage was based on that used to produce vasodilation in children with pulmonary hypertension."	( Polyarteritis nodosa resistant to conventional treatment in a pediatric patient. García-Consuegra, J; González-Fernández, MA, 2007)	0.34
" The discovered dose-effect relationship allows confirmation of the treatment response, thereby establishing the first step towards optimising the inolimomab dosage in future trials."	( Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease. Darlavoix, I; Dartois, C; Freyer, G; Girard, P; Hénin, E; Michallet, M; Tranchand, B; Vermot-Desroches, C; You, B, 2007)	0.34
" Comparison of the two data sets yielded 196 genes identified as regulated by MPL in both dosing regimens."	( Microarray analysis of the temporal response of skeletal muscle to methylprednisolone: comparative analysis of two dosing regimens. Almon, RR; DuBois, DC; Ghimbovschi, S; Hoffman, EP; Jusko, WJ; Yao, Z, 2007)	0.34
") dosing for use in pharmacodynamic studies."	( Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats. Almon, RR; DuBois, DC; Hazra, A; Jusko, WJ; Pyszczynski, N, 2007)	0.34
"Methylprednisolone concentrations in the perilymph of patients during cochlear implantation were compared after 3 dosing strategies of methylprednisolone solution for injection (40 mg/ml): 1) IT administration of up to 40 mg was injected into the middle ear through the external auditory canal via a 27-gauge needle passed through a small anterosuperior myringotomy; 2) IV administration of 1 mg/kg was given as a single injection over 30 seconds; 3) IV administration of 10 mg/kg was infused over 30 minutes."	( Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. Balkany, TJ; Begg, EJ; Bird, PA; Keast, AT; Murray, DP; Zhang, M, 2007)	0.34
" The aim of this dosage finding study was to test the most promising corticosteroid protocol in a smaller but representative series, in order to optimize the settings of upcoming prospective and long-term multicenter studies."	( Postoperative high-dose steroids do not improve mid-term survival with native liver in biliary atresia. Becker, T; Harder, D; Leonhardt, J; Melter, M; Petersen, C; Ure, BM; Wasielewski, RV, 2008)	0.35
" Of these, 196 genes were controlled by MPL under both dosing conditions."	( Mathematical modeling of corticosteroid pharmacogenomics in rat muscle following acute and chronic methylprednisolone dosing. Almon, RR; Dubois, DC; Ghimbovschi, S; Hoffman, EP; Jusko, WJ; Yao, Z, )	0.13
" Serum was obtained from each patient with BP at least three times: before the initiation of treatment, during complete disease control just before the decrease in corticosteroid, and when the dosage of corticosteroid was successfully decreased to half the initial dose."	( Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Feng, S; Jin, P; Lin, L; Sang, H; Shao, C; Wu, Q; Zhou, W, 2008)	0.35
" Of the 24% who use steroids, the NASCIS II dosing regimen is most commonly followed."	( Methylprednisolone for acute spinal cord injury: 5-year practice reversal. Hamilton, MG; Hurlbert, RJ, 2008)	0.35
" Dosage was in accordance with their pharmacokinetic properties and experience gained with experimental SCI."	( Lack of neuroprotection with pharmacological pretreatment in a paradigm for anticipated spinal cord lesions. Franco-Bourland, RE; Grijalva, I; Guízar-Sahagún, G; Ibarra, A; Madrazo, I; Martínez-Cruz, A; Rodríguez-Balderas, CA, 2009)	0.35
" This study aimed to examine in rabbits the temporal relationships and dose-response effects of acute high-dose methylprednisolone succinate on diaphragmatic contractile and structural properties."	( Acute effects of high-dose methylprednisolone on diaphragm muscle function. Baker, MJ; Caiozzo, VJ; Fang, L; Nelson, RS; Pham, HT; Sassoon, CS; Zhu, E, 2008)	0.35
" On admission, he was administered intravenous immunoglobulins at a dosage of 400 mg/kg/day for 5 days yet continued to worsen."	( Corticosteroids can help distinguish between Guillain-Barré syndrome and first attack of chronic inflammatory demyelinating neuropathy: an illustrative case report. Alexander, KJ; Alshubaili, AF; Santhamoorthy, P; Sharafuddin, KM, 2008)	0.35
" Our aim was to determine the relationship between the dosage of steroids and the number and distribution of osteonecrotic lesions in patients treated with steroids during the SARS epidemic in Beijing, China in 2003."	( Steroid-induced osteonecrosis: the number of lesions is related to the dosage. Hernigou, P; Li, ZR; Liu, ZH; Wei, HY; Zhang, NF, 2008)	0.35
" However, long-term dosing caused continuous hyperglycemia during and after infusion."	( Pharmacodynamics of glucose regulation by methylprednisolone. II. normal rats. Jin, JY; Jusko, WJ, 2009)	0.35
" The results exemplify the importance of the steroid dosing regimen in mediating pharmacological and adverse metabolic effects."	( Pharmacodynamics of glucose regulation by methylprednisolone. I. Adrenalectomized rats. Jin, JY; Jusko, WJ, 2009)	0.35
" Data were extracted from the published articles relating to: outcome; MP dosing regimen; species/strain; number of animals; methodological quality; type of injury induction; use of anaesthesia; functional scale used; and duration of follow-up."	( Animal studies in spinal cord injury: a systematic review of methylprednisolone. Akhtar, AZ; Pippin, JJ; Sandusky, CB, 2009)	0.35
" IVIG resulted in a remarkable and durable response at decreased dosage (0."	( [Efficacy of intravenous immunoglobulin in Arndt-Gottron scleromyxedema]. Guillet, G; Lopez, L; Villers, A; Wierzbicka-Hainaut, E, 2009)	0.35
"Randomised trials comparing different routes of administration and dosage schemes of corticosteroid or adrenocorticotrophic hormone therapy versus a control group where no therapy considered effective for this condition was administered, unless it was also given in a similar way to the experimental group."	( WITHDRAWN: Corticosteroids for Bell's palsy (idiopathic facial paralysis). Alvarez, G; Ferreira, J; Salinas, RA, 2009)	0.35
" No excess of lipid accumulation could be detected with the dosage and exposure time used."	( The synthetic liver X receptor agonist GW3965 reduces tissue factor production and inflammatory responses in human islets in vitro. Collins, JL; Dahle, MK; Foss, A; Korsgren, O; Lund, T; Scholz, H; Wang, JE, 2009)	0.35
" With a suitable dosage addition of methylprednisolone to donor mice HSC mobilization regimen could avoid the increasing risk of graft rejection."	( [Influence of methylprednisolone on cell component of donor graft and on H-2 haploidentical hematopoietic stem cell transplantation in mice]. Ding, BH; Li, YF; Liu, JM; Xuan, HB; Zhang, LS, 2009)	0.35
" The present study compares the efficacy and safety of 2 different intravenous methylprednisolone (MTPiv) dosing regimens."	( Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone: a comparison of two dosing regimens. Alfayate Guerra, R; Arias Mendoza, N; González Sánchez, V; López Macia, A; Mauri Dot, M; Moreno-Pérez, O; Picó Alfonso, A; Sánchez-Ortiga, R, 2009)	0.35
" In contrast to the postdose reductions of IMPDH activity observed early posttransplant, IMPDH activity within both treatment groups was elevated throughout the dosing interval at week 13."	( Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study. Bergan, S; Bremer, S; Holdaas, H; Jørgensen, PF; Midtvedt, K; Rootwelt, H; Stenstrøm, J; Vethe, NT, 2009)	0.35
"The significant influence of MPA on IMPDH1 expression, possibly mediated through reduced guanine nucleotide levels, could explain the elevations of IMPDH activity within dosing intervals at week 13."	( Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study. Bergan, S; Bremer, S; Holdaas, H; Jørgensen, PF; Midtvedt, K; Rootwelt, H; Stenstrøm, J; Vethe, NT, 2009)	0.35
" The results of the traditional functional methods showed that administration of the NASCIS dosage of MPSS following acute spinal cord contusion did not lead to any significant differences in the functional recovery of MPSS- vs."	( Methylprednisolone fails to improve functional and histological outcome following spinal cord injury in rats. Cabrita, AM; Costa, LM; Couto, PA; Di Scipio, F; Filipe, VM; Fornaro, M; Geuna, S; Magalhães, LG; Maurício, AC; Pereira, JE; Varejão, AS, 2009)	0.35
" Mono-exponential kinetics after single intravenous dosing is considered."	( Mean residence time as estimated from cropped and truncated moments. Czock, D; Hartmann, B; Keller, F, 2009)	0.35
" Thirty minutes after ASCI, the subjects in experimental group received MP injection through intraperitoneal with dosage of 30 mg/kg."	( [Effects of high dose methylprednisolone on cell apoptosis and Bcl-2 expression after acute spinal cord injuries in rats]. Ma, LJ; Wu, HT; Zhang, JJ, 2009)	0.35
" The use of systemic corticosteroids in the treatment of TEN is controversial because of a lack of randomized, controlled, prospective studies, and because the effects of steroid therapy vary depending on the dosage and time of its administration during the course of TEN."	( Skin biopsies to assess response to systemic corticosteroid therapy in early-stage TEN: case report and review of the literature. Céspedes, YP; Nigra, TP; O'Donoghue, JM; Rockley, PF, 2009)	0.35
" Each group was divided into two subgroups by dosage of methylprednisolone (5 or 10 mg/kg body weight)."	( Low levels of steroid-metabolizing hepatic enzyme (cytochrome P450 3A) activity may elevate responsiveness to steroids and may increase risk of steroid-induced osteonecrosis even with low glucocorticoid dose. Azuma, T; Kadoya, Y; Kaneshiro, Y; Kim, M; Masada, T; Oda, Y; Takaoka, K; Tokuhara, Y; Wakitani, S, 2009)	0.35
" He was effectively managed with methylprednisolone pulse therapy (500 mg/day x 3 days) followed by progressive dosage tapering."	( [Case of microscopic polyangiitis presenting initially as prostatic vasculitis]. Akizawa, T; Ashikaga, E; Iyoda, M; Nagai, H; Shibata, T; Suzuki, H, 2009)	0.35
" In summary, modern immunosuppression today allows us to reduce the dosage of steroids and to avoid the prolonged use of cyclophosphamide."	( Induction and maintenance therapy in proliferative lupus nephritis. Glassock, RJ; Moroni, G; Ponticelli, C, )	0.13
" Due to lack of evidence, inclusion criteria was revised during the process of the review to include studies comparing different dosage of corticosteroids."	( Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantation. Banihosseini, S; Ferrara, JL; Rabbani-Anari, M; Rahimi Darabad, R; Rohanizadegan, M; Salmasian, H; Shakiba, A, 2010)	0.36
" Serum chromium levels were not assessed, so it is uncertain if the patient experienced chromium deficiency or if it was adequately treated with chromium supplementation, and a dose-response relationship could not be ascertained because the patient received a continuous infusion of chromium."	( Improved glucose control associated with i.v. chromium administration in two patients receiving enteral nutrition. Baker, WL; Bell, JL; Coleman, CI; Keating, K; Phung, OJ; Quercia, RA; White, CM, 2010)	0.36
"Randomised trials comparing different routes of administration and dosage schemes of corticosteroid or adrenocorticotrophic hormone therapy versus a control group where no therapy considered effective for this condition was administered, unless it was also given in a similar way to the experimental group."	( Corticosteroids for Bell's palsy (idiopathic facial paralysis). Alvarez, G; Daly, F; Ferreira, J; Salinas, RA, 2010)	0.36
" For five consecutively days, each patient received methylprednisolone by intravenous administration at a dosage of 15 mg/kg/day each 8 h, once a month for 3 months."	( Methylprednisolone for the treatment of children with refractory epilepsy. Diaz-Bustos, R; Mora-Puga, M; Palacios, GC; Ramirez-Campos, J; Sevilla-Castillo, RA, 2009)	0.35
"The dose-response relationship of intrathecal midazolam was not evaluated in our study, so further study should be conducted with different doses of intrathecal midazolam for management of PHN."	( Efficacy of intrathecal midazolam with or without epidural methylprednisolone for management of post-herpetic neuralgia involving lumbosacral dermatomes. Dureja, GP; Jamal, A; Khan, M; Tahseen, M; Usmani, H, )	0.13
" Fifty percent of the patients received tacrolimus (TRL) and the others cyclosporine (CsA), both dosed according to weight."	( Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience. Campanella, L; Cuomo, O; Esposito, C; Ioia, G; Perrella, A; Taglialatela, D, 2010)	0.36
" Our goal was to compare IL-1Ra activity in SLE patients with and without renal involvement and to determine the effect of different dosage of glucocorticosteroids used in 17 patients with active SLE without nephritis, 7 patients with inactive lupus nephritis (LN), and 8 patients with active LN, along with 10 healthy controls."	( Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease. Brugos, B; Dul, C; Gubisch, W; Kiss, E; Sipka, S; Szegedi, G; Zeher, M, 2010)	0.36
" Following reinduction, the appearance of another small new lesion made the patient ineligible, as per protocol, for further dosing despite stabilization of her remaining lesions."	( Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Binder, M; Erasim, C; Harmankaya, K; Hoos, A; Ibrahim, R; Koelblinger, C; Pehamberger, H, 2011)	0.37
" Equivalent daily MP dosing with MP-dendrimer conjugate further diminished these values, with decreases of 87% and 67%, respectively."	( In vivo efficacy of dendrimer-methylprednisolone conjugate formulation for the treatment of lung inflammation. Bassett, DJ; Gao, X; Guru, BR; Inapagolla, R; Kannan, RM; Kurtoglu, YE; Lieh-Lai, M, 2010)	0.36
" The dosage of immunosuppressive systemic therapy was reduced or able to be stopped in three patients (50%)."	( Periocular corticosteroid injection in the management of uveitis in children. Grigg, JR; Habot-Wilner, Z; Kabasele, PM; Lightman, S; McCluskey, P; Roufas, A; Sallam, A, 2010)	0.36
" This case suggests that reducing the dosage of immunosuppressive agents can be an effective strategy for GVHD after liver transplantation."	( Graft versus host disease after liver transplantation: a case report. Gao, J; Gao, PJ; Huang, L; Leng, XS; Li, GM; Wang, D; Zhu, JY, 2010)	0.36
" This review examines the role of a member of the newest class of TCs, the fourth-generation compound methylprednisolone aceponate (MPA) in AD management, with reference to the chemical structure, pharmacokinetics, efficacy in AD, safety assessed in preclinical and clinical trials and dosing considerations."	( Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. Luger, TA, 2011)	0.37
" The MPL treatments caused reduction of food consumption and body weights in all dosing groups."	( Dynamic modeling of methylprednisolone effects on body weight and glucose regulation in rats. Almon, RR; DuBois, DC; Fang, J; He, Y; Jusko, WJ, 2011)	0.37
" In particular, we tested the impact of dosing (1-10 μg/kg), mode of delivery (intravenous vs."	( Low dose estrogen prevents neuronal degeneration and microglial reactivity in an acute model of spinal cord injury: effect of dosing, route of administration, and therapy delay. Banik, NL; Das, A; Matzelle, DD; Ray, SK; Samantaray, S; Smith, JA; Varma, AK, 2011)	0.37
" The aims of this study were to investigate CYP3A5 polymorphism's effect on TAC dosing and the age dependency of TAC dosing by testing blood concentrations, and the interaction between steroids and TAC during the first year after tx."	( Influence of CYP3A5 polymorphism on tacrolimus maintenance doses and serum levels after renal transplantation: age dependency and pharmacological interaction with steroids. Argibay, PF; Belloso, WH; Coccia, PA; Costa, L; Ferraris, JR; Ferraris, V; Ghezzi, LF; Jimenez, G; Larriba, JM; Redal, MA, 2011)	0.37
" Intravenous methylprednisolone 30 mg/kg/d was given to all patients for 5 days in addition to a stable dosage of the regular antiepileptic drugs."	( Interictal encephalography can influence patient selection for methylprednisolone therapy in pediatric refractory epilepsy. Gandelman-Marton, R; Heyman, E; Lahat, E, 2012)	0.38
" A daily oral dose of atorvastatin calcium treatment for 70 days weakened the long bones of methylprednisolone acetate treated rabbits irrespective of the dosage (2, 10, or 20 mg)."	( Effect of atorvastatin on the cortical bones of corticosteroid treated rabbits. Braitman, LE; Goldstein, DT; Handal, JA; John, TK; Khurana, JS; Saing, M; Samuel, SP, 2012)	0.38
"The assessment of the dose-response relationship is important but not straightforward when the therapeutic agent is administered repeatedly with dose-modification in each patient and a continuous response is measured repeatedly."	( An autoregressive linear mixed effects model for the analysis of unequally spaced longitudinal data with dose-modification. Funatogawa, I; Funatogawa, T, 2012)	0.38
"Male Lewis rats were dosed with lipopolysaccharide (50 μg/kg LPS) alone or with methylprednisolone (10 and 50 mg/kg) and sacrificed at different time points."	( Pharmacokinetic/pharmacodynamic modeling of methylprednisolone effects on iNOS mRNA expression and nitric oxide during LPS-induced inflammation in rats. Almon, RR; DuBois, DC; Jusko, WJ; Lepist, EI; Sukumaran, S, 2012)	0.38
" LPS increased expression of iNOS mRNA in lung and increased plasma NO, while MPL dosing palliated this increase in a dose-dependent manner."	( Pharmacokinetic/pharmacodynamic modeling of methylprednisolone effects on iNOS mRNA expression and nitric oxide during LPS-induced inflammation in rats. Almon, RR; DuBois, DC; Jusko, WJ; Lepist, EI; Sukumaran, S, 2012)	0.38
" However, after treating with exogenous steroids, dose-response studies showed hGR-S1(-349A) had a substantial augmentation in activity at higher concentrations of hydrocortisone and methylprednisolone when compared with hGRα, whereas hGR-S1 did not."	( Enhanced steroid response of a human glucocorticoid receptor splice variant. Amini, A; Baker, AC; Chew, VW; Cho, K; Green, TL; Greenhalgh, DG; Lim, D; Tung, K, 2012)	0.38
" The incidence of calcineurin-inhibitor-induced pain syndrome was related to the dosage of tacrolimus (P > ."	( Immunosuppressant-related hip pain after orthotopic liver transplant. Chen, GH; Fu, BS; He, JW; Jiang, N; Li, H; Wang, GS; Wang, GY; Wang, K; Yang, Y; Zhang, J, 2013)	0.39
"Pharmacokinetics of MP may differ among IA MPA dosing protocols, and MP may be detected in plasma and urine for a longer time than previously reported."	( Pharmacokinetics of methylprednisolone acetate after intra-articular administration and subsequent suppression of endogenous hydrocortisone secretion in exercising horses. Bertone, AL; Hothem, EA; Menéndez, MI; Phelps, MA, 2012)	0.38
" Monitoring trough levels helps not only in reducing nephrotoxiicity but also in reducing the chances of acute rejection; although there is no international consensus, the trough concentration is used to determine dosing and the AUC for calculating the exposure of the patient to the drug."	( Pharmacokinetics of tacrolimus in adult renal transplant recipients. Madhavarapu, M; Mayur, P; Naik, P; Nayak, KS; Sritharan, V, 2012)	0.38
"Trough level determination and a C2, C4 two-point limited sampling strategy may be useful to plan the dosing strategy and estimate the exposure of renal transplant patients to tacrolimus."	( Pharmacokinetics of tacrolimus in adult renal transplant recipients. Madhavarapu, M; Mayur, P; Naik, P; Nayak, KS; Sritharan, V, 2012)	0.38
" Despite extensive scientific and clinical data on neurogenic osteoporosis, there is no consensus regarding the best pharmacotherapeutic agents, dosing regimens, or rehabilitative strategies for prevention and treatment of bone loss."	( The changing landscape of spinal cord injury. Cooper, JM; Juknis, N; Volshteyn, O, 2012)	0.38
" Time series experiments showed that both corticosteroids and LPS but not insulin dosing resulted in the transient down-regulation of GRα mRNA."	( Evidence for a glucocorticoid receptor beta splice variant in the rat and its physiological regulation in liver. Almon, RR; DuBois, DC; Jusko, WJ; Sukumaran, S, 2013)	0.39
" Immunologic studies suggest that unexpected lack of expansion of CD56(bright) NK cells and predictable decline in FoxP3+ T-regs combined with a transient interruption in daclizumab dosing may have contributed to this serious side effect."	( CNS vasculitis in a patient with MS on daclizumab monotherapy. Bielekova, B; Martin, J; McFarland, H; Oh, U; Ohayon, J; Richert, N; Vortmeyer, A, 2013)	0.39
"Each isoform had a unique dose-response curve with the optimal activity depending on concentration and type of steroid."	( Single nucleotide polymorphisms and type of steroid impact the functional response of the human glucocorticoid receptor. Baker, AC; Chew, VW; Cho, K; Green, TL; Greenhalgh, DG; Lim, D; Tung, K, 2013)	0.39
" Graded amounts of LPS (1-10,000 pg/ml) were spiked into normal blood to obtain dose-response curves: a good dose-response curve, from 1 to 1,000 pg/ml, was obtained for the LAL assay."	( Interleukin-8 induces an elevation in the endotoxin activity assay (EAA) level: does the EAA truly measure the endotoxin level? Endo, S; Inada, K; Inoue, Y; Kojika, M; Matsumoto, N; Suzuki, Y; Takahashi, G, 2013)	0.39
" However, the optimal dosing of corticosteroids is unknown and their administration varies considerably between different institutions."	( Methylprednisolone in neonatal cardiac surgery: reduced inflammation without improved clinical outcome. Andersson, S; Keski-Nisula, J; Neuvonen, PJ; Olkkola, KT; Peltola, K; Pesonen, E; Sairanen, H; Suominen, PK; Tuominen, N, 2013)	0.39
" However, no specific dosing recommendations have been made for children admitted to the PICU."	( Corticosteroid therapy in critically ill pediatric asthmatic patients. Canarie, MF; Carroll, CL; Faustino, EV; Giuliano, JS; Li, S; Pinto, MG, 2013)	0.39
" Country of practice, years of experience, and PICU size were not associated with corticosteroid dosing preference."	( Corticosteroid therapy in critically ill pediatric asthmatic patients. Canarie, MF; Carroll, CL; Faustino, EV; Giuliano, JS; Li, S; Pinto, MG, 2013)	0.39
" Future research is needed to determine the most appropriate corticosteroid dosage in this critically ill patient population."	( Corticosteroid therapy in critically ill pediatric asthmatic patients. Canarie, MF; Carroll, CL; Faustino, EV; Giuliano, JS; Li, S; Pinto, MG, 2013)	0.39
"This study, despite its retrospective design, demonstrated the therapeutic efficacy of IVCY for NMOSD in both the acute and chronic phases of the disease and determined the IVCY dosage for Japanese women with NMOSD."	( Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Maruo, Y; Nakamura, M; Nishimura, H; Sakushima, K; Sasaki, H; Takahashi, I; Takahashi, T; Tsuzaka, K; Yabe, I; Yaguchi, H; Yashima-Yamada, M, 2013)	0.39
" A dosage of 500 mg intravenous methylprednisolone once weekly for 6 weeks, followed by 250 mg intravenous methylprednisolone once weekly for 6 weeks, with a total treatment period of 12 weeks was given."	( Severe eyelid oedema in Graves' ophthalmopathy. Adamidou, F; Anagnostis, P; Karras, S; Poulasouchidou, M, 2013)	0.39
" This randomized trial was designed to prospectively evaluate the effect of specific glucocorticoid dosing protocols on inflammatory markers in neonatal cardiac surgery requiring cardiopulmonary bypass."	( Preoperative steroid treatment does not improve markers of inflammation after cardiac surgery in neonates: results from a randomized trial. Atz, AM; Baker, NL; Bradley, SM; Butts, RJ; Graham, EM; McGowan, FX; McHugh, KE; Reeves, ST; Spinale, FG; Stroud, RE, 2014)	0.4
" This dosage was continued until oxygenation improved, and the treatment was gradually tapered (by 20 mg every 2-3 days) to the previous maintenance dosage."	( Moderate-dose glucocorticoids as salvage therapy for severe pneumonia in renal transplant recipients: a single-center feasibility study. Han, Y; He, HY; Ju, MJ; Luo, Z; Rong, RM; Tu, GW; Xu, M; Xue, ZG; Zhu, TY, 2014)	0.4
" Assessed were dynamic changes of food intake and systemic factors (plasma glucose, insulin, free fatty acids (FFA) and leptin) and tissue-specific biomarkers (cAMP, phosphoenolpyruvate carboxykinase (PEPCK) mRNA and enzyme activity, leptin mRNA, interleukin 6 receptor type 1 (IL6R1) mRNA and Insulin receptor substrate-1 (IRS-1) mRNA) after acute and chronic dosing with MPL along with the GC receptor (GR) dynamics in each target organ."	( Meta-modeling of methylprednisolone effects on glucose regulation in rats. Almon, RR; Dubois, DC; Fang, J; Jusko, WJ; Sukumaran, S, 2013)	0.39
"Studies evaluating corticosteroid (CS) dosing for patients hospitalized with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) have largely excluded patients admitted directly to the intensive care unit (ICU), and none have evaluated the effect of CS dosing regimens on mortality."	( Outcomes associated with corticosteroid dosage in critically ill patients with acute exacerbations of chronic obstructive pulmonary disease. Allen, RR; Kiser, TH; Moss, M; Valuck, RJ; Vandivier, RW, 2014)	0.4
" Lower dosage strategies should be encouraged for patients admitted to the ICU and the optimum dose should be determined through clinical trials."	( Outcomes associated with corticosteroid dosage in critically ill patients with acute exacerbations of chronic obstructive pulmonary disease. Allen, RR; Kiser, TH; Moss, M; Valuck, RJ; Vandivier, RW, 2014)	0.4
" However, the clinical benefit is limited by side effects due to the chronic use and generally high dosage that is required for effective treatment."	( Systemic treatment with glutathione PEGylated liposomal methylprednisolone (2B3-201) improves therapeutic efficacy in a model of ocular inflammation. Appeldoorn, CC; de Boer, M; Gaillard, PJ; Reijerkerk, A; Rip, J, 2014)	0.4
"To analyze the clinical manifestations of refractory Mycoplasma pneumoniae pneumonia (RMPP) which unresponded to methylprednisolone in the dosage of 2 mg/(kg·d) for 3 days."	( [Clinical features and treatment of refractory Mycoplasma pneumoniae pneumonia unresponded to conventional dose methylprednisolone in children]. Chen, L; Liu, J; Wu, J; Yang, Y; Zhao, S, 2014)	0.4
" High dosage steroid treatment was started, with good response."	( Cytomegalovirus-related necrotising vasculitis mimicking Henoch-Schönlein syndrome. Buoncompagni, A; Coccia, MC; D'Alessandro, M; Martini, A; Minoia, F; Picco, P, )	0.13
" In summary, in the murine MOG-EAE model of MS, a glutathione PEGylated liposomal formulation of MP (2B3-201) is clinically and histologically as effective as free MP at one tenth of the dosage as well as at a lower application frequency and clearly more effective than the same dosage of free MP."	( Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis. Appeldoorn, CC; Gaillard, PJ; Gladdines, W; Lee, DH; Linker, RA; Reijerkerk, A; Rötger, C, 2014)	0.4
" Here, we describe a highly reproducible strategy, enabling a global, large-scale investigation of the expression dynamics of corticosteroid-regulated proteins in livers from adrenalectomized rats over 11 time points after drug dosing (0."	( Highly multiplexed and reproducible ion-current-based strategy for large-scale quantitative proteomics and the application to protein expression dynamics induced by methylprednisolone in 60 rats. Almon, RR; Duan, X; DuBois, DC; Jusko, WJ; Li, J; Nouri-Nigjeh, E; Qu, J; Shen, X; Sukumaran, S; Tu, C, 2014)	0.4
" On multivariable regression, greater number of corticosteroid doses but not cumulative corticosteroid dosage was significantly associated with low 48-hour AVP concentration (β=-4."	( Effect of corticosteroids on arginine vasopressin after pediatric cardiac surgery. Chen, H; Mastropietro, CW; Miletic, K; Rossi, NF, 2014)	0.4
" Further safety and dose-response studies are required to allow recommendations for general practice."	( Preoperative methylprednisolone enhances recovery after endovascular aortic repair: a randomized, double-blind, placebo-controlled clinical trial. Andersen, A; de la Motte, L; Groenvall, JB; Kehlet, H; Lönn, L; Nielsen, CH; Nielsen, HB; Schroeder, TV; Vogt, K, 2014)	0.4
"We evaluated histological changes occurring in renal biopsy specimens, between the time before initial induction therapy and after 12 months' maintenance therapy, as well as changes in laboratory parameters, SLE disease activity (SLEDAI), and dosage of corticosteroid (CS) in childhood-onset systemic lupus erythematosus (SLE) patients treated with mycophenolate mofetil (MMF)."	( Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis. Imagawa, T; Kikuchi, M; Kizawa, T; Miyamae, T; Mori, M; Nagahama, K; Nakamura, T; Nozawa, T; Okudela, K; Tsutsumi, H; Yokota, S, 2015)	0.42
"Monitoring MPA-C0 and individualized MMF dosing help to prevent acute graft rejection, reducing drug toxicity and complications, and improving graft survival rate after renal transplantation."	( [Therapeutic window of mycophenolate mofetil for preventing acute graft rejection following renal transplantation]. Luo, M; Yu, L; Zhou, M, 2014)	0.4
" Systemic treatment usually begins with high dosage corticosteroids."	( Atypical Cogan's syndrome: a case report and summary of current treatment options. Jančatová, D; Komínek, P; Matoušek, P; Zeleník, K, 2015)	0.42
" However, the dosing and the duration of immunosuppressive therapy have not been systematically studied in the setting of treating ipilimumab-induced irAEs."	( Ipilimumab-induced toxicities and the gastroenterologist. Bye, W; Cheng, R; Cooper, A; Kench, J; McNeil, C; Shackel, N; Watson, G, 2015)	0.42
"Thirty adult female SD rats were randomly divided into 5 equal groups, namely the sham-operated group, SCI group, SCI with MP treatment group (MP group, with intramuscular injection of 50 mg/kg MP within 8 hours after SCI and then dosage reduced 10 mg/kg daily), SCI with GB treatment group (GB group, with intragastric gavage of GB 50 mg/kg once daily for 7 days), and combined GB and MP treatment group."	( [Effect of Gold Belt combined with methylprednisolone on motor function and brain-derived neurotrophic factor expression in rats following traumatic spinal cord injury]. Li, C; Wang, T; Xu, Z, 2015)	0.42
" Dosage and treatment decisions were at the discretion of the physicians."	( Bortezomib-containing regimens are effective in multiple myeloma--results of a non-interventional phase IV study. Alkemper, B; Gaede, B; Knauf, W; Reschke, D; Schlag, R; Schmits, R; Schütz, S; Schwarzer, A; Tapprich, C, 2015)	0.42
" However, symptoms relapsed when the dosage of corticosteroid was tapered, and multiple lung nodules were found with the symptom of dyspnea in chest computed tomography scan during the follow-up period."	( Weber-Christian disease presenting with lung nodules dramatically improved with corticosteroid therapy: one case report and literature review. Ji, LL; Wang, Y; Zhang, S; Zhang, Z; Zhao, J, 2018)	0.48
" Heterogeneity was related in part to the dosing strategy."	( Corticosteroids for treating sepsis. Annane, D; Bellissant, E; Bollaert, PE; Briegel, J; Keh, D; Kupfer, Y, 2015)	0.42
" We conducted a retrospective review to compare efficacy of different dosing regimes of IVCS."	( Clinical Experience of Use of High-dose Intravenous Methylprednisolone in Children With Acute Moderate to Severe Colitis. Auth, MK; Baillie, C; Crook, K; Finnamore, HE; Krishnamurthy, B; Venkatesh, K; Vora, R; Whittle, E, 2016)	0.43
" Cases (1555 patients with SLE who developed HZ) and controls (3049 age- and sex-matched patients with SLE but without HZ) were analyzed for use of various immunosuppressive medications in the preceding 3-month period, and dose-response relationships were determined."	( Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study. Chen, GS; Hu, SC; Lin, CL; Lin, YC; Wang, TN; Yen, FL, 2016)	0.43
" The correct timing and corticosteroid dosage in the context of broad-spectrum antimicrobial therapy might further improve the outcomes of patients with LOSP."	( Late-onset severe pneumonia after allogeneic hematopoietic stem cell transplantation: prognostic factors and treatments. Chen, H; Chen, YH; Han, W; Huang, XJ; Liu, KY; Mo, XD; Wang, FR; Wang, JZ; Wang, Y; Xu, LP; Yan, CH; Zhang, XH, 2016)	0.43
" TCR was administered by oral route at the scheduled dosage while the 50% of oral dosage was used by SL route, taking into account the absence of liver first pass."	( Sublingual administration improves systemic exposure of tacrolimus in kidney transplant recipients: comparison with oral administration. Apicella, L; Balletta, MM; Capone, D; Carrano, R; Federico, S; Mosca, T; Nappi, R; Russo, L; Sabbatini, M; Santangelo, M; Tarantino, G, 2016)	0.43
" Because of the patient's susceptibility to infections, the attempt to gradually reduce glucocorticoid dosage induced a relapse of PH."	( A complicated case of primary hypophysitis with bilateral intracavernous carotid artery occlusion. Katsiveli, P; Kounadi, T; Lymperopoulos, K; Papanastasiou, L; Piaditis, G; Sfakiotaki, M; Voulgaris, N, 2016)	0.43
"The HPLC-MS analytical method is an alternative to HPLC-MS/MS methods, sensitive enough for identifying and quantifying steroids in vitreous humor at a therapeutic dosage scale."	( Determination of Three Corticosteroids in the Biologic Matrix of Vitreous Humor by HPLC-tandem Mass Spectrometry: Method Development and Validation. Fraile, JM; Garcia-Martin, E; Mayoral, JA; Otín-Mallada, S; Pablo, LE; Polo-Llorens, V; Prieto, E; Vispe, E, 2017)	0.46
" The average dosage of exogenous insulin is 5100 U/d."	( A systemic lupus erythematosus patient presenting as type B insulin resistance complicated with cryoglobulinemia. Huang, Q; Yan, Y; Zhao, H; Zuo, L, 2017)	0.46
"Randomised trials and quasi-randomised trials comparing different routes of administration and dosage schemes of corticosteroid or adrenocorticotrophic hormone therapy versus a control group receiving no therapy considered effective for this condition, unless the same therapy was given in a similar way to the experimental group."	( Corticosteroids for Bell's palsy (idiopathic facial paralysis). Daly, F; Gagyor, I; Gammie, F; Madhok, VB; Somasundara, D; Sullivan, F; Sullivan, M, 2016)	0.43
" Rituximab use resulted in a significant reduction in steroid dosage during follow-up."	( Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey. Akman Karakaş, A; Alpsoy, E; Bilgiç Temel, A; Bozkurt, S; Dicle, Ö; Erat, A; Ergün, E; Eskiocak, AH; Koç, S; Nazlım, B; Özkesici, B; Uğurlu, N; Uzun, S; Yılmaz, E, 2016)	0.43
" In spite of the temporary remission after re-initiation of oral steroid therapy, reduction of oral steroid dosage resulted in new lesion formation apart from the initial locations."	( An adult-onset multiphasic disseminated encephalomyelitis (MDEM) presenting favorable response to steroid therapy. Fujimura, H; Fukada, K; Hazama, T; Inoue, K; Kinoshita, M; Sugimura, Y, 2016)	0.43
" Requirement of mean daily dosage of prednisone was significantly lower in RTX group [p = 0."	( Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Babu, BG; Basu, B; Roy, B, 2017)	0.46
" Moreover, in vivo fluorescence molecular imaging showed that BSA633-MP was mainly accumulated in the liver and kidney after intravenous dosing for 24 h."	( Albumin-based nanoparticles as methylprednisolone carriers for targeted delivery towards the neonatal Fc receptor in glomerular podocytes. Chen, M; Mao, H; Qian, J; Wang, N; Wu, L; Xing, C; Zhang, B; Zhao, X, 2017)	0.46
" The results of pulmonary function tests, Asthma Control Test (ACT) and Asthma Health Questionnaire (AHQ)-33 scores, the dosage of methylprednisolone during the 12-month treatment period, and the number of emergency visits prior to the start of treatment with omalizumab were compared in patients pre- and post-treatment with omalizumab."	( Efficacy of long-term omalizumab therapy in patients with severe asthma. Arai, M; Mineshita, M; Miyazawa, T; Saji, J; Yamamoto, T, 2017)	0.46
"020) and the dosage of methylprednisolone (871."	( Efficacy of long-term omalizumab therapy in patients with severe asthma. Arai, M; Mineshita, M; Miyazawa, T; Saji, J; Yamamoto, T, 2017)	0.46
" While transcriptomic regulation following methylprednisolone (MPL) dosing has been temporally examined in rat liver, proteomic assessments are needed to better characterize the tissue-specific functional aspects of MPL actions."	( Functional proteomic analysis of corticosteroid pharmacodynamics in rat liver: Relationship to hepatic stress, signaling, energy regulation, and drug metabolism. Almon, RR; Ayyar, VS; DuBois, DC; Jusko, WJ; Qu, J; Sukumaran, S, 2017)	0.46
" After the publication of two randomized clinical trials in postherpetic neuralgia patients treated with similar intrathecal methylprednisolone acetate (MPA) dosing regimes with conflicting results; one showing significant pain reduction (Kotani N, Kushikata T, Hashimoto H, Kimura F, Muraoka M, Yodono M, Asai M, Matsuki A: Intrathecal methylprednisolone for intractable postherpetic neuralgia."	( Analgesic properties of intrathecal glucocorticoids in three well established preclinical pain models. Kalkman, CJ; Rijsdijk, M; Svensson, CI; Wijck, AJ; Yaksh, TL, 2016)	0.43
" The pharmacokinetic/pharmacodynamic/pharmacogenomic effects of acute and chronic methylprednisolone (MPL) dosing on the tissue-specific dynamics of GILZ expression were examined in rats."	( Mechanistic Multi-Tissue Modeling of Glucocorticoid-Induced Leucine Zipper Regulation: Integrating Circadian Gene Expression with Receptor-Mediated Corticosteroid Pharmacodynamics. Almon, RR; Ayyar, VS; DuBois, DC; Jusko, WJ, 2017)	0.46
"012), and controversy with other studies could be because of difference in corticosteroid dosage and small number of patients."	( Assessment of the Prevalence and Risk Factors Associated With Glucocorticoid-Induced Diabetes Mellitus in Pemphigus Vulgaris Patients. Alizadeh, N; Darjani, A; Eftekhari, H; Gharaei Nejad, K; Hedayati Emami, MH; Nickhah, N; Rafiei, R, 2017)	0.46
" Removal of infected teeth should be performed as soon as possible in order to reduce the dosage of corticosteroids and occcurence rate of OFG."	( Orofacial granulomatosis: A case report of three cases may be caused by apical periodontitis. Wang, J; Wang, W; Yu, X; Zhang, W, 2017)	0.46
" Transdermal drug delivery system is the main route with discrete, self-contained dosage forms when placed on the skin, transporting the medicament through the skin into the systemic circulation in a wellcontrolled manner."	( Design and Evaluation of Transdermal Patches of Timolol Maleate. Jamakandi, VG; Panchayya Hiremath, SS; Reddy, JJ, 2018)	0.48
" There was no significant correlation between age, body mass index, blood pressure, cumulative dosage, duration time of glucocorticoid, mean daily dosage and glucocorticoid-induced ocular hypertension (P>0."	( [Clinical characteristics of glucocorticoid-induced eye adverse reactions in children with primary nephrotic syndrome]. Ding, J; Liu, XY; Su, BG; Wang, F; Xiao, HJ; Zhang, HW; Zhao, Y, 2017)	0.46
" The effects of the Expanded Disability Status Scale (EDSS), duration of the disease, and cumulative dosage of medications on menopausal age were evaluated."	( Effects of multiple sclerosis and medications on menopausal age. Bilgiç, A; Bölük, C; Köseoğlu Toksoy, C; Taşdemir, M; Türk Börü, Ü, 2018)	0.48
" Both dose and dosing frequency can be reduced by incorporating free MP in glutathione-PEGylated liposomes, creating a slow-release formulation with reduced toxicity and prolonged peripheral efficacy."	( Glutathione-PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first-in-human study. Gaillard, PJ; Gladdines, W; Groeneveld, GJ; Kanhai, KMS; Klaassen, ES; Stavrakaki, I; Zuiker, RGJA, 2018)	0.48
" oral dexamethasone versus oral prednisone), with consideration for dosing and pharmacokinetic properties, to better identify the optimal IM or oral corticosteroid regimens to improve patient outcomes."	( Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma. Campbell, S; Cross, E; Kirkland, SW; Rowe, BH; Villa-Roel, C, 2018)	0.48
" Dosage and speed of infusion of Daratumumab have to be strictly controlled."	( [Infusion of Daratumumab in Combination Therapies - Practical Information for The Outpatient Area]. Engelhardt, M; Munder, M; Salwender, H; Scheid, C, 2018)	0.48
"0%) were treated by adjusting the dosage of immunosuppressive agents, and 6 (14."	( Acute allograft rejection in liver transplant recipients: Incidence, risk factors, treatment success, and impact on graft failure. Beckebaum, S; Cicinnati, VR; Dogan, N; Hüsing-Kabar, A; Kabar, I; Schmidt, HH, 2018)	0.48
" The PFIC2 patient had abnormal liver function 19 months after LT, and recovered after administration of increased dosage of immunosuppressant agents."	( Liver Transplantation for Progressive Familial Intrahepatic Cholestasis. Liu, Y; Qu, W; Sun, LY; Wei, L; Zeng, ZG; Zhu, ZJ, 2018)	0.48
" Dexamethasone (4 mg/mL) and methylprednisolone (20 mg/mL) were given transtympanically to 22 and 24 patients, respectively, one dosage per day for 5 consecutive days."	( Intratympanic Methylprednisolone versus Dexamethasone for the Primary Treatment of Idiopathic Sudden Sensorineural Hearing Loss. Çetik, F; Dağkıran, M; Doğrusöz, M; Kıroğlu, M; Özdemir, S; Sürmelioğlu, Ö; Tarkan, Ö; Tuncer, Ü, 2018)	0.48
" No significant statistical differences in the cumulative dosage of methylprednisolone or occurrence of restrictive myopathy, raised intraocular pressure, proptosis, and exposure keratopathy between the groups at 0, 3, 6, 12, and 18 months were found."	( Methotrexate as an Adjuvant in Severe Thyroid Eye Disease: Does It Really Work as a Steroid-Sparing Agent? Chng, CL; Choo, CT; Lang, S; Looi, A; Ming Sie, N; Seah, LL; Shen, S; Yang, M; Yong, KL, )	0.13
"Frequent injection of high-dose methylprednisolone (MP) is used to treat spinal cord injury (SCI), but free MP is associated with various side effects and its water solubility is low, limiting potential dosing regimes and administration routes."	( NEP Deng, R; Hao, N; Huang, J; Li, C; Li, J; Lin, Y; Lyu, J; Zhang, Q; Zhong, Z, 2019)	0.51
"Although steroids are effective for multiple types of acute facial palsies, an appropriate dosage remains to be established."	( Comparison of the efficacy of various doses of steroids for acute facial palsy. Choi, J; Han, MS; Jeong, YJ; Nam, KJ; Rah, Y, 2019)	0.51
" We also conducted a dose-response meta-analysis to analyze the cumulative dosage and SONFH risk in mutation carriers."	( Association between genetic polymorphisms and osteonecrosis in steroid treatment populations: a detailed stratified and dose-response meta-analysis. Jing, M; Yang, J; Yang, X, 2019)	0.51
" For patients with liver failure and HLH, the dosage of glucocorticoid should be reduced to avoid serious side effects."	( Clinical characteristics of liver failure with hemophagocytic lymphohistiocytosis. Dong, J; Hu, Z; Jia, L; Li, J; Meng, Q; Xie, F; Yao, Q; Yu, H; Zhao, Y; Zhu, Y, 2019)	0.51
" Potential time-dependent interplay between sex hormone and glucocorticoid signaling in vivo was assessed by comparing the enhancement of GILZ by MPL in the uterus [high estrogen receptor (ER) density] and in liver (lower ER density) from male and female rats dosed within the proestrus (high estradiol/progesterone) and estrus (low estradiol/progesterone) phases of the rodent estrous cycle."	( Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part III: Estrous Cycle and Estrogen Receptor-Dependent Antagonism of Glucocorticoid-Induced Leucine Zipper (GILZ) Enhancement by Corticosteroids. Almon, RR; Ayyar, VS; DuBois, DC; Jusko, WJ, 2019)	0.51
"Due to the continuing debates on the utility of high-dose methylprednisolone (MP) early after acute spinal cord injury (ASCI), we aimed to evaluate the therapeutic and adverse effects of high-dose MP according to the second National Acute Spinal Cord Injury Study (NASCIS-2) dosing protocol in comparison to no steroids in patients with ASCI by performing a meta-analysis on the basis of the current available clinical trials."	( High-dose methylprednisolone for acute traumatic spinal cord injury: A meta-analysis. He, L; Liu, B; Liu, Z; Luo, C; Pang, M; Rong, L; Yang, Y, 2019)	0.51
" The decreased recovery of mainly sufentanil and propofol could lead to suboptimal dosing of patients during cardiac surgery with CPB."	( In Vitro Recovery of Sufentanil, Midazolam, Propofol, and Methylprednisolone in Pediatric Cardiopulmonary Bypass Systems. Bogers, AJJC; Kinzig, M; Koch, BCP; Sörgel, F; Stolker, RJ; Tibboel, D; van Hoeven, MPJ; van Rosmalen, J; van Saet, A; Wildschut, ED; Zeilmaker-Roest, GA, 2020)	0.56
"Methylprednisolone is used in neonates to modulate cardiopulmonary bypass (CPB)-induced inflammation, but optimal dosing and exposure are unknown."	( Population Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone in Neonates Undergoing Cardiopulmonary Bypass. Cohen-Wolkowiez, M; Dumond, J; Gonzalez, D; Graham, EM; Hill, KD; Hornik, CP; Wu, H, 2019)	0.51
" Compared with conventional group, glucocorticoid dosage and the occurrence rate of hematuria and/or proteinuria within 3 months were lower in HP group."	( Changes of inflammatory mediators and oxidative stress indicators in children with Henoch-Schönlein purpura and clinical effects of hemoperfusion in the treatment of severe Henoch-Schönlein purpura with gastrointestinal involvement in children. Deng, F; Dong, Y; Wu, L; Zhu, Y, 2019)	0.51
" HP can reduce glucocorticoid dosage and the rate of renal involvement in children with severe HSP with GI involvement."	( Changes of inflammatory mediators and oxidative stress indicators in children with Henoch-Schönlein purpura and clinical effects of hemoperfusion in the treatment of severe Henoch-Schönlein purpura with gastrointestinal involvement in children. Deng, F; Dong, Y; Wu, L; Zhu, Y, 2019)	0.51
" However, to date, the use of glucocorticoid therapy in SMPP is limited to small case series, and the glucocorticoid dosage for children with SMPP has not been established."	( Meta-analysis of the Clinical Efficacy and Safety of High- and Low-dose Methylprednisolone in the Treatment of Children With Severe Mycoplasma Pneumoniae Pneumonia. Deng, ZZ; Sun, LL; Wang, CJ; Ye, C; Zhou, YL; Zuo, SR, 2020)	0.56
" Changes in serum thyroid hormone concentrations were evaluated in the short-term period (24 h and 7 days) and after a cumulative dosage of 400 and 800 mg equivalents of methylprednisolone; in addition, healing time and duration of exposure to GCs were calculated."	( Effect of high-dose intravenous glucocorticoid therapy on serum thyroid hormone concentrations in type 2 amiodarone-induced thyrotoxicosis: an exploratory study. Bartalena, L; Bogazzi, F; Cappellani, D; Manetti, L; Martino, E; Urbani, C, 2020)	0.56
"We report the case of a patient suffering from duplicity of myotonic dystrophy type 1 and ulcerative colitis whose treatment for ulcerative colitis included repeated administrations of descending doses of methylprednisolone and in whom we found an association between methylprednisolone dosing and cessation of myotonia."	( The Association of methylprednisolone dosing to cessation of myotonia in a patient with myotonic dystrophy type 1. Bednařík, J; Horák, T; Horáková, M; Voháňka, S, 2020)	0.56
" Because of suboptimal response after 2 doses, manifested by increasing drowsiness, further fall in platelets and rising ferritin, methylprednisolone dosage was increased to 30 mg/kg/day with the addition of oral cyclosporine (4 mg/kg/day)."	( Experience with Cidofovir as an adjunctive therapy in a patient of adenovirus-induced macrophage activation syndrome in systemic arthritis. Bose, N; Chowdhury, K; Pal, P; Poddar, A; Saha, A, 2020)	0.56
" During surgery, MP was administered at a dose of 500 mg; thereafter, the dosage was tapered rapidly, and the drug was discontinued on day 14 post transplant."	( Early Steroid Withdrawal Protocol With Basiliximab and Rituximab in ABO-Incompatible Kidney Transplant Recipients. Koyama, I; Nakajima, I; Shirai, H; Tojimbara, T; Yamazaki, T; Yashima, J, )	0.13
" The patient benefited from a back-titrated regimen of methylprednisolone with the initial dosage of 2 mg/kg and anti-fibrotic effect of nintedanib and was successfully weaned from the ventilator."	( Pulmonary fibrosis and cytokine release syndrome after hyperactivation with sintilimab. Chen, X; Hu, J; Li, Y; Luo, C; Zuo, X, 2020)	0.56
" For the treatment of COVID-19 pneumonia, systemic and in-depth investigation is needed to determine the timing and dosage of glucocorticoids needed to inhibit overwhelming inflammatory response and not the protective immune response to COVID-19 pneumonia."	( Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience. Hu, Y; Hu, Z; Li, L; Peng, P; Wang, T; Wang, X; Zhang, Z, 2020)	0.56
" Discontinuation or dosage reduction of immunosuppressives and other treatment information was documented."	( Clinical course of COVID-19 disease in immunosuppressed renal transplant patients Ateş, ÖF; Çetin, ES; Dheir, H; Fırat, N; Genç, AB; Karabay, O; Köroğlu, M; Muratdağı, G; Özmen, K; Sipahi, S; Tomak, Y; Yaylacı, S, 2021)	0.62
"A total of 262 patients were grouped as receiving usual care (n = 75), methylprednisolone dosed at least at 1mg/kg/day for ≥ 3 days (n = 104), or dexamethasone dosed at least at 6 mg for ≥7 days (n = 83)."	( A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19. Ko, JJ; Mehta, N; Qiao, R; Wald-Dickler, N; Wu, C; Yang, W, 2021)	0.62
"In COVID-19 patients requiring mechanical ventilation, sufficiently dosed methylprednisolone can lead to a further decreased mortality as compared to dexamethasone."	( A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19. Ko, JJ; Mehta, N; Qiao, R; Wald-Dickler, N; Wu, C; Yang, W, 2021)	0.62
"Currently, no consensus exists on the dosing regimen of corticosteroids in relation to disease severity in pemphigus vulgaris."	( Comparison of three different dose regimens of methylprednisolone as initial therapy for pemphigus vulgaris of moderate severity: A single-center retrospective study from Turkey. Babuna Kobaner, G; Kiliç Sayar, S; Küçükoğlu, R; Polat Ekinci, A, 2021)	0.62
" Finally, increased Axon miRs dosage with methylprednisolone, significantly promotes functional recovery and remyelination."	( A 3D Fiber-Hydrogel Based Non-Viral Gene Delivery Platform Reveals that microRNAs Promote Axon Regeneration and Enhance Functional Recovery Following Spinal Cord Injury. Chew, EGY; Chew, SY; Chin, JS; Foo, JN; Lian, MM; Lin, J; Lin, VPH; Milbreta, U; Wu, W; Zhang, K; Zhang, N, 2021)	0.62
" GC hormone that can specifically target the lung might decrease the effective dosage and thus reduce GC-associated side effects."	( Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody. Chen, SS; Chen, T; He, X; Li, HP; Li, N; Lu, LQ; Qiu, H; Song, JC; Tang, DL; Weng, D; Wu, Q; Yin, ZF; Zhao, MM; Zhou, NY, 2021)	0.62
" However, whether higher dosing of steroids results in better outcomes has been debated."	( Do high-dose corticosteroids improve outcomes in hospitalized COVID-19 patients? Dalton, D; Guddati, AK; Hererra, M; Jefferies, D; Kumar, G; Meersman, M; Nanchal, R; Patel, D; Sakhuja, A, 2022)	0.72
" We examined the effect of corticosteroid dosing on time to alanine aminotransferase (ALT) normalization, need for additional immunosuppression, and steroid-related complications."	( Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. Grover, S; Hodi, FS; Li, M; Rahma, OE; Sack, JS; Vogel, AS; Wong, D; Zucker, SD, 2022)	0.72
" Effects on eGFR slope and albuminuria will also be assessed overall, as well as by the steroid dosing regimen."	( The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. Agarwal, R; Barbour, S; Billot, L; Cass, A; Cattran, D; Chan, TM; Feehally, J; Floege, J; Glassock, R; Hladunewich, MA; Hooi, LS; Jardine, MJ; Jha, V; Johnson, DW; Levin, A; Liu, ZH; Lv, J; Monaghan, H; Perkovic, V; Reich, HN; Remuzzi, G; Wheeler, DC; Wong, MG; Woodward, M; Wu, Y; Zhang, H; Zhao, M, 2021)	0.62
"Although the most recent systematic review and meta-analyses on acute respiratory distress syndrome (ARDS) have shown that the use of steroids decreases mortality in adult patients, its benefits and risks may differ depending on the type and dosage of the steroid."	( Steroid treatment in patients with acute respiratory distress syndrome: a systematic review and network meta-analysis. Hongo, T; Ihara, S; Ishikawa, J; Kaneko, T; Ohki, S; Sakaguchi, M; Taito, S; Yatabe, T; Yoshihiro, S, 2022)	0.72
" Dosage of methylprednisolone (1000 mg/day or 500 mg/day) did not significantly influence treatment efficacy (Z = 0."	( Factors influencing intravenous methylprednisolone pulse therapy in Chinese patients with isolated optic neuritis associated with AQP4 antibody-seropositive neuromyelitis optica. Guo, S; Jiang, H; Jiang, L; Liu, H; Peng, J; Wang, J; Wei, W, 2021)	0.62
"Repeat dosing poses a major hurdle for the development of an adeno-associated virus (AAV)-based gene therapy for cystic fibrosis, in part because of the potential for development of an immune reaction to the AAV1 capsid proteins."	( Short-Term Steroid Treatment of Rhesus Macaque Increases Transduction. Cebotaru, CV; Cebotaru, L; Guggino, WB; Tomar, V; Yanda, MK, 2022)	0.72
" Dosing in each group occurred at baseline and on day 15 (week 2)."	( Intravenous pegylated liposomal prednisolone outperforms intramuscular methylprednisolone in treating rheumatoid arthritis flares: A randomized controlled clinical trial. Bijlsma, JWJ; Bos, R; Kothekar, M; Lammers, T; Metselaar, JM; Middelink, LM; Raut, A; van Laar, JM; Vonkeman, HE; Westhovens, R; Wortel, CH; Yao, SL, 2022)	0.72
" Early recognition of ICI-associated myocarditis and sufficient dosage and time course of glucocorticoid therapy are critical for severe cases."	( Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries. Hu, X; Shuai, X; Wei, Y, 2021)	0.62
" The dosage of adrenal glucocorticoids was reduced by more than half compared with that before chemotherapy."	( Clinical observation of low-dose combination chemotherapy in refractory/recurrent paroxysmal nocturnal hemoglobinuria patients: A single-center retrospective analysis. Chen, Y; Fu, R; Li, L; Liu, C; Liu, H; Liu, Z; Shao, Z; Wang, H; Zhao, X, 2022)	0.72
" Hormone dosage was related to the duration of remission in patients, and the cumulative dose of methylprednisolone≥8 mg/kg showed a poor prognosis."	( [Efficacy of Chimeric Antigen Receptor T Cell in the Treatment of Refractory/Recurrent B Acute Lymphocytic Leukemia in Children]. DU, WW; He, HL; Hu, SY; Li, BS; Lu, J; Lu, Y; Wang, TY; Xiao, PF; Yang, F, 2022)	0.72
" Additionally, the control dose and cumulative dosage of steroids, Bullous Pemphigoid Disease Area Index (BPDAI) scores, pruritus scores, and adverse events were assessed."	( Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid. Chen, S; Chen, Z; Gao, H; He, S; Hu, Y; Liu, S; Luo, X; Ma, L; Tang, C; Tang, L; Wang, L; Xu, Y; Yang, F; Yang, J; Zhang, Z; Zhao, Y, 2022)	0.72
" Clinical response in short-term follow-up was independent of prednisone dosage and underlying etiology."	( Cohort study of infantile epileptic spasms syndrome: etiological analysis and treatment of corticosteroids. Cheng, M; Hong, S; Jiang, L; Jiang, Y; Li, T; Liang, X; Liao, S; Luo, Y; Zhong, M; Zou, N, 2022)	0.72
" The IVIG dosage for the patients in group I was 2 gr/kg, whereas the IVIG dosage for the patients in group II was 2 gr/kg + 2 mg/kg/day of methylprednisolone."	( A retrospective comparative analysis of factors affecting the decision and outcome of initial intravenous immunoglobulin alone or intravenous immunoglobulin plus methylprednisolone use in children with the multisystem inflammatory syndrome. Ağın, H; Arıkan, KÖ; Bayram, N; Besin, D; Böncüoğlu, E; Çelebi, MY; Cem, E; Devrim, İ; Düzgöl, M; Kara, AA; Kıymet, E; Meşe, T; Şahinkaya, Ş; Seven, P; Vuran, G, 2022)	0.72
" Systemic administration of methylprednisolone (MP) at a higher dosage though can reduce neurological deficits following acute SCI."	( A Bibliometric Analysis of Publications on Spinal Cord Injury Treatment With Glucocorticoids Using VOSviewer. Li, AA; Liu, JM; Liu, ZL; Tong, WL; Wang, SJ; Xiao, SN; Zhang, Y; Zhong, NS, 2022)	0.72
" Although the United States has made a significant global contribution to this important field of research, it requires rigorous clinical trials designed to verify the therapeutic role of MP in SCI and its appropriate dosage to find solutions for neurological recovery."	( A Bibliometric Analysis of Publications on Spinal Cord Injury Treatment With Glucocorticoids Using VOSviewer. Li, AA; Liu, JM; Liu, ZL; Tong, WL; Wang, SJ; Xiao, SN; Zhang, Y; Zhong, NS, 2022)	0.72
" The early-onset pulmonary events (EOPEs) of brigatinib are associated with high dosage and older age."	( Early-Onset Pulmonary Events with Combined Brigatinib and Afatinib Treatment of L858/cisT790M/cisC797S NSCLC: A Case Report. Chang, HT; Lee, BJ; Lim, CK; Zhang, JH, 2022)	0.72
", a hyperimmune anti-COVID-19 intravenous immunoglobulin), methylprednisolone, interferon-beta/standard-of-care (SOC), interferon-beta-1b, convalescent plasma, remdesivir, lopinavir/ritonavir, immunoglobulin gamma, high dosage sarilumab (HS), auxora, and imatinib were effective when compared with placebo or SOC group."	( Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials. Chen, J; Cheng, Q; Fang, Z; Jia, Q; Zhao, G, 2022)	0.72
"To reveal the recurrence rate of Graves ophthalmopathy (GO) presenting as diplopia in the primary position for 1 year after varied doses of intravenous methylprednisolone (IVMP) followed by oral prednisolone, with dosing based on the magnetic resonance imaging (MRI) findings."	( One-year recurrence rate of Graves ophthalmopathy presenting as diplopia in the primary position after varied doses of intravenous methylprednisolone followed by oral prednisolone with dosing based on the magnetic resonance imaging findings. Fukuchi, T; Hasegawa, Y; Hatase, T; Kiyokawa, M; Ueki, S, 2023)	0.91
"This study showed that in 20% of patients, GO recurred within 1 year of administration of varied doses of IVMP, with the dosing based on the MRI findings."	( One-year recurrence rate of Graves ophthalmopathy presenting as diplopia in the primary position after varied doses of intravenous methylprednisolone followed by oral prednisolone with dosing based on the magnetic resonance imaging findings. Fukuchi, T; Hasegawa, Y; Hatase, T; Kiyokawa, M; Ueki, S, 2023)	0.91
"The use of pulse dose corticosteroid therapy (PDCT) in children for treatment of alopecia areata (AA) has been reported, but dosing regimens are not well-established."	( Pediatric pulse dose corticosteroid therapy dosing and administration in the treatment of alopecia areata: A review of literature. Carrillo, B; Gallaga, NM; Good, A; Munoz-Gonzalez, A; Ross, L, 2023)	0.91
"The results of our study suggest that intravenous methylprednisolone showed dose-response efficiencies, and pulse therapy may benefit critically ill patients with acute COVID-19, such as those requiring iMV."	( Intravenous methylprednisolone pulse therapy and the risk of in-hospital mortality among acute COVID-19 patients: Nationwide clinical cohort study. Moromizato, T; Sakaniwa, R; Shibuya, K; Taniguchi, K; Tokuda, Y, 2023)	0.91
" As the dosage of corticosteroids was decreased, he developed impaired dorsiflexion of the left ankle, tingling and numbness in his feet, consistent with vasculitis neuropathy."	( Thrombocytopenia during avacopan administration: A case report. Akagi, Y; Ando, F; Fujiki, T; Hanioka, A; Iimori, S; Mandai, S; Mori, K; Mori, T; Mori, Y; Morimoto, N; Naito, S; Sakai, K; Shioji, S; Sohara, E; Susa, K; Uchida, S; Watanabe, H; Yamamura, A, 2023)	0.91
" Overall, the TESTING trial provided more data regarding the treatment dosage and safety of corticosteroids, a cost-effective therapy, in IgAN, which have important implications for pediatric patients with IgAN."	( Corticosteroids in the treatment of IgA nephropathy: lessons from the TESTING trial. Hu, YT; Lv, JC; Zhang, H; Zhang, Y, 2023)	0.91
" Further research is needed to establish guidelines on dosage regimens."	( Efficacy and safety of intravenous glucocorticoid therapy for IgG4-related ophthalmic disease. Choi, YA; Kim, GJ; Sa, HS; Yang, MK, 2023)	0.91
" The initial dosage of corticosteroid therapy should be decided according to the severity of the disease."	( Clinical features and "early" corticosteroid treatment outcome of pediatric He, R; Liu, J; Liu, L; Wang, H; Zhang, X; Zhao, F; Zhao, S, 2023)	0.91
" Patients who received steroids for irAEs at a dosage of < 2 mg/kg had comparable prognosis to those who did not receive steroids; however, patients who received methylprednisolone pulse therapy, primarily for severe pneumonitis and hepatitis, had shorter overall survival than those who did not receive steroids (7."	( Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes. Egashira, N; Hata, K; Hirota, T; Ieiri, I; Matsuda, K; Matsukane, R; Minami, H; Nakao, S; Suetsugu, K; Watanabe, H, 2023)	0.91
"Previous evaluations of medication dosing variance for children in the prehospital setting have been limited regionally or to specific conditions."	( Deviation From National Dosing Recommendations for Children Having Out-of-Hospital Emergencies. Martin-Gill, C; Ramgopal, S, 2023)	0.91
" We investigated dosing deviations (defined as being ≥20% of the weight-appropriate dose from national guidelines) for the following: lorazepam, diazepam, and midazolam for seizures; fentanyl, hydromorphone, morphine, and ketorolac; intramuscular epinephrine and diphenhydramine for children with allergy or anaphylaxis; intravenous epinephrine; and methylprednisolone."	( Deviation From National Dosing Recommendations for Children Having Out-of-Hospital Emergencies. Martin-Gill, C; Ramgopal, S, 2023)	0.91
" Appropriate dosing was most common with methylprednisolone (75."	( Deviation From National Dosing Recommendations for Children Having Out-of-Hospital Emergencies. Martin-Gill, C; Ramgopal, S, 2023)	0.91
"We identified variance in weight-based dosing from national guidelines for common pediatric medications in the prehospital setting, which may be attributable to protocol differences or dosing errors."	( Deviation From National Dosing Recommendations for Children Having Out-of-Hospital Emergencies. Martin-Gill, C; Ramgopal, S, 2023)	0.91

Role	Description
anti-inflammatory drug	A substance that reduces or suppresses inflammation.
neuroprotective agent	Any compound that can be used for the treatment of neurodegenerative disorders.
antiemetic	A drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centres (the vomiting centre and the chemoreceptive trigger zone) or affect the peripheral receptors.
adrenergic agent	Any agent that acts on an adrenergic receptor or affects the life cycle of an adrenergic transmitter.
xenobiotic	A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminant	Any minor or unwanted substance introduced into the environment that can have undesired effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
6-methylprednisolone
primary alpha-hydroxy ketone	An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a -CH2 (methylene) group.
tertiary alpha-hydroxy ketone	An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Drug induction of bile acid pathway	0	25

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
acetylcholinesterase	Homo sapiens (human)	Potency	89.3584	0.0025	41.7960	15,848.9004	AID1347395
hypoxia-inducible factor 1 alpha subunit	Homo sapiens (human)	Potency	9.5205	3.1890	29.8841	59.4836	AID1224846
PPM1D protein	Homo sapiens (human)	Potency	0.0083	0.0052	9.4661	32.9993	AID1347411
GLI family zinc finger 3	Homo sapiens (human)	Potency	9.8895	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	0.1907	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID1259381; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)	Homo sapiens (human)	Potency	0.0501	0.0013	7.7625	44.6684	AID914; AID915
progesterone receptor	Homo sapiens (human)	Potency	26.2147	0.0004	17.9460	75.1148	AID1346784; AID1346795; AID1347036
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	0.3162	0.2818	9.7212	35.4813	AID2326
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	0.0419	0.0002	14.3764	60.0339	AID720691; AID720692; AID720719
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	24.5412	0.0008	17.5051	59.3239	AID1159527
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	30.6379	0.0015	30.6073	15,848.9004	AID1224849
pregnane X nuclear receptor	Homo sapiens (human)	Potency	30.6379	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	1.8387	0.0002	29.3054	16,493.5996	AID743069; AID743078; AID743080; AID743091
G	Vesicular stomatitis virus	Potency	34.6713	0.0123	8.9648	39.8107	AID1645842
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	0.7079	0.7079	36.9043	89.1251	AID504333
IDH1	Homo sapiens (human)	Potency	29.0929	0.0052	10.8652	35.4813	AID686970
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	0.0336	0.0017	23.8393	78.1014	AID743083
nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus (Norway rat)	Potency	1.5849	0.1000	9.1916	31.6228	AID1346983
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	0.0293	0.0041	9.9848	25.9290	AID504444; AID720524
geminin	Homo sapiens (human)	Potency	0.5012	0.0046	11.3741	33.4983	AID624297
muscleblind-like protein 1 isoform 1	Homo sapiens (human)	Potency	100.0000	0.0041	9.9625	28.1838	AID2675
Interferon beta	Homo sapiens (human)	Potency	6.9422	0.0033	9.1582	39.8107	AID1347407; AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	34.6713	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	34.6713	0.0123	8.9648	39.8107	AID1645842
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	0.0344	0.0119	17.9420	71.5630	AID651632
Ataxin-2	Homo sapiens (human)	Potency	0.0344	0.0119	12.2221	68.7989	AID651632
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	34.6713	0.0123	8.9648	39.8107	AID1645842
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	0.6012	0.0601	10.7453	37.9330	AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	40.9700	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	100.3433	0.1100	7.1903	10.0000	AID1443980; AID1449628; AID1473738
Glucocorticoid receptor	Homo sapiens (human)	IC50 (µMol)	0.0110	0.0000	0.4953	10.0000	AID625263
Glucocorticoid receptor	Homo sapiens (human)	Ki	0.0050	0.0001	0.3863	7.0010	AID625263
Glycine receptor subunit alpha-1	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0110	0.0015	0.7600	5.0740	AID625263
Glycine receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Ki	0.0050	0.0007	0.7653	7.0010	AID625263
Androgen receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	26.6800	0.0010	1.9794	14.1600	AID625228
Androgen receptor	Rattus norvegicus (Norway rat)	Ki	17.7860	0.0003	1.2185	8.9270	AID625228
Glycine receptor subunit beta	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0110	0.0015	0.7600	5.0740	AID625263
Glycine receptor subunit beta	Rattus norvegicus (Norway rat)	Ki	0.0050	0.0007	0.7846	7.0010	AID625263
Glycine receptor subunit alpha-2	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0110	0.0015	0.8044	5.0740	AID625263
Glycine receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Ki	0.0050	0.0007	0.7846	7.0010	AID625263
Glycine receptor subunit alpha-3	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0110	0.0015	0.7600	5.0740	AID625263
Glycine receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Ki	0.0050	0.0007	0.7846	7.0010	AID625263
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)	EC50 (µMol)	12.6000	0.0020	3.5196	10.0000	AID1215087
Nuclear receptor subfamily 1 group I member 2	Rattus norvegicus (Norway rat)	EC50 (µMol)	4.0000	0.0100	4.1394	10.0000	AID1215090
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
negative regulation of DNA-templated transcription	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
regulation of DNA-templated transcription	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
xenobiotic metabolic process	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
signal transduction	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
steroid metabolic process	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
positive regulation of gene expression	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
intracellular receptor signaling pathway	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
xenobiotic catabolic process	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
xenobiotic transport	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
cell differentiation	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
regulation of gluconeogenesis	Glucocorticoid receptor	Homo sapiens (human)
chromatin organization	Glucocorticoid receptor	Homo sapiens (human)
regulation of DNA-templated transcription	Glucocorticoid receptor	Homo sapiens (human)
apoptotic process	Glucocorticoid receptor	Homo sapiens (human)
chromosome segregation	Glucocorticoid receptor	Homo sapiens (human)
signal transduction	Glucocorticoid receptor	Homo sapiens (human)
glucocorticoid metabolic process	Glucocorticoid receptor	Homo sapiens (human)
gene expression	Glucocorticoid receptor	Homo sapiens (human)
microglia differentiation	Glucocorticoid receptor	Homo sapiens (human)
adrenal gland development	Glucocorticoid receptor	Homo sapiens (human)
regulation of glucocorticoid biosynthetic process	Glucocorticoid receptor	Homo sapiens (human)
synaptic transmission, glutamatergic	Glucocorticoid receptor	Homo sapiens (human)
maternal behavior	Glucocorticoid receptor	Homo sapiens (human)
intracellular glucocorticoid receptor signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
glucocorticoid mediated signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of neuron apoptotic process	Glucocorticoid receptor	Homo sapiens (human)
negative regulation of DNA-templated transcription	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
astrocyte differentiation	Glucocorticoid receptor	Homo sapiens (human)
cell division	Glucocorticoid receptor	Homo sapiens (human)
mammary gland duct morphogenesis	Glucocorticoid receptor	Homo sapiens (human)
motor behavior	Glucocorticoid receptor	Homo sapiens (human)
cellular response to steroid hormone stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to glucocorticoid stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to dexamethasone stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Glucocorticoid receptor	Homo sapiens (human)
neuroinflammatory response	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Glucocorticoid receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell population proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of B cell proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nuclear DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
signal transduction in response to DNA damage	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
isotype switching	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of isotype switching to IgG isotypes	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloading	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of cell cycle G2/M phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
nuclear receptor activity	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
protein binding	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
zinc ion binding	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
nuclear receptor binding	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
core promoter sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Glucocorticoid receptor	Homo sapiens (human)
RNA binding	Glucocorticoid receptor	Homo sapiens (human)
nuclear receptor activity	Glucocorticoid receptor	Homo sapiens (human)
nuclear glucocorticoid receptor activity	Glucocorticoid receptor	Homo sapiens (human)
steroid binding	Glucocorticoid receptor	Homo sapiens (human)
protein binding	Glucocorticoid receptor	Homo sapiens (human)
zinc ion binding	Glucocorticoid receptor	Homo sapiens (human)
TBP-class protein binding	Glucocorticoid receptor	Homo sapiens (human)
protein kinase binding	Glucocorticoid receptor	Homo sapiens (human)
identical protein binding	Glucocorticoid receptor	Homo sapiens (human)
Hsp90 protein binding	Glucocorticoid receptor	Homo sapiens (human)
steroid hormone binding	Glucocorticoid receptor	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Glucocorticoid receptor	Homo sapiens (human)
estrogen response element binding	Glucocorticoid receptor	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
nucleoplasm	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
transcription regulator complex	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
nuclear body	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
intermediate filament cytoskeleton	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
chromatin	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
nucleus	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nucleus	Glucocorticoid receptor	Homo sapiens (human)
nucleus	Glucocorticoid receptor	Homo sapiens (human)
nucleoplasm	Glucocorticoid receptor	Homo sapiens (human)
cytoplasm	Glucocorticoid receptor	Homo sapiens (human)
mitochondrial matrix	Glucocorticoid receptor	Homo sapiens (human)
centrosome	Glucocorticoid receptor	Homo sapiens (human)
spindle	Glucocorticoid receptor	Homo sapiens (human)
cytosol	Glucocorticoid receptor	Homo sapiens (human)
membrane	Glucocorticoid receptor	Homo sapiens (human)
nuclear speck	Glucocorticoid receptor	Homo sapiens (human)
synapse	Glucocorticoid receptor	Homo sapiens (human)
chromatin	Glucocorticoid receptor	Homo sapiens (human)
protein-containing complex	Glucocorticoid receptor	Homo sapiens (human)
plasma membrane	Glycine receptor subunit beta	Rattus norvegicus (Norway rat)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1211792	Hepatic clearance in human	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1221962	Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID176988	In vivo anti-inflammatory activity in the rat, alpha-tocopherol filled pouch peroral dose	1993	Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22	Non-steroidal glucocorticoid-like substances: receptor binding and in vivo activity.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID91224	Antiinflammatory activity measured by using McKenzie-Stoughton human vasoconstrictor assay	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Computer-aided studies of the structure-activity relationships between the structure of some steroids and their antiinflammatory activity.
AID19006	Calculated membrane partition coefficient (Kmemb)	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID689046	Antiinflammatory activity in oxazolone-induced Sprague-Dawley rat chronic dermatitis model at 0.5 to 5 mg/kg, po qd administered after 7 days of oxazolone sensitization measured after 4 to 5 hrs last post treatment on day 14	2011	Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24	Discovery of selective glucocorticoid receptor modulator MK-5932.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1215088	Competitive binding affinity to human PXR LBD (111 to 434) up to 46 uM by TR-FRET assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Identification of clinically used drugs that activate pregnane X receptors.
AID496831	Antimicrobial activity against Cryptosporidium parvum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID29811	Oral bioavailability in human	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID74386	Relative binding affinity against glucocorticoid receptor.	1993	Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22	Non-steroidal glucocorticoid-like substances: receptor binding and in vivo activity.
AID679086	TP_TRANSPORTER: transepithelial transport of Methylprednisolone at a concentration of 20 uM in MDR1-expressing MDCK cells	2003	Pharmaceutical research, Aug, Volume: 20, Issue:8	Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.
AID1221958	Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID496826	Antimicrobial activity against Entamoeba histolytica	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1211791	Fraction unbound in human hepatocytes	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496827	Antimicrobial activity against Leishmania amazonensis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID409954	Inhibition of mouse brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1211797	Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1215091	Activation of human PXR expressed in human HepG2 (DPX-2) cells up to 46 uM after 24 hrs by luciferase reporter gene based luminescent analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Identification of clinically used drugs that activate pregnane X receptors.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1215087	Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Identification of clinically used drugs that activate pregnane X receptors.
AID172538	In vivo glucocorticoid profile, depression of thymus weight in rat at 1 mg/kg peroral dose	1993	Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22	Non-steroidal glucocorticoid-like substances: receptor binding and in vivo activity.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1215090	Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Identification of clinically used drugs that activate pregnane X receptors.
AID1687199	Activation of adipogenic cocktail-induced PPARgamma mRNA expression in mouse 3T3-L1 cells at 1 uM by RT-qPCR analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Tigliane Diterpenoids as a New Type of Antiadipogenic Agents Inhibit GRα-Dexras1 Axis in Adipocytes.
AID373867	Hepatic clearance in human hepatocytes in absence of fetal calf serum	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	First-principle, structure-based prediction of hepatic metabolic clearance values in human.
AID496818	Antimicrobial activity against Trypanosoma brucei brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID188016	Anti-inflammatory effect in rat granuloma assay, activity relative to hydrocortisone and hydrocortisone 21-acetate	1983	Journal of medicinal chemistry, Mar, Volume: 26, Issue:3	Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
AID496828	Antimicrobial activity against Leishmania donovani	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID91481	Binding constant against human serum albumin (HSA)	2001	Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25	Cheminformatic models to predict binding affinities to human serum albumin.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID682043	TP_TRANSPORTER: transepithelial transport (basal to apical), inhibited by Verapamil in Caco-2 cells	2002	Biological & pharmaceutical bulletin, Mar, Volume: 25, Issue:3	Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells.
AID679087	TP_TRANSPORTER: transepithelial transport of Methylprednisolone at a concentration of 20 uM in Caco-2 cells	2003	Pharmaceutical research, Aug, Volume: 20, Issue:8	Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1221965	Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1443980	Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch	2010	Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID26304	Partition coefficient (logD6.5)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID496820	Antimicrobial activity against Trypanosoma brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID90104	Potency relative to fluocinolone 16,17-acetonide in the human vasoconstictor test	1983	Journal of medicinal chemistry, Mar, Volume: 26, Issue:3	Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
AID29360	Ionization constant (pKa)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496817	Antimicrobial activity against Trypanosoma cruzi	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID172531	In vivo glucocorticoid profile, depression of adrenal weight in rat at 5 mg/kg peroral dose	1993	Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22	Non-steroidal glucocorticoid-like substances: receptor binding and in vivo activity.
AID409956	Inhibition of mouse brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID22293	Delta logD (logD6.5 - logD7.4)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID197376	In vivo glucocorticoid profile, depression of body weight gain without altered food consumption in rat at 1 mg/kg peroral dose	1993	Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22	Non-steroidal glucocorticoid-like substances: receptor binding and in vivo activity.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1687203	Activation of GR-alpha in mouse 3T3-L1 cells assessed as increase in adipogenic cocktail-induced Dexras1 mRNA expression at 10 uM incubated for 4 hrs by RT-qPCR analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Tigliane Diterpenoids as a New Type of Antiadipogenic Agents Inhibit GRα-Dexras1 Axis in Adipocytes.
AID1221982	Fraction absorbed in human	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID7783	Unbound fraction (plasma)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID476929	Human intestinal absorption in po dosed human	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID197379	In vivo glucocorticoid profile, depression of body weight gain without altered food consumption in rat at 5 mg/kg peroral dose	1993	Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22	Non-steroidal glucocorticoid-like substances: receptor binding and in vivo activity.
AID1221961	Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID8002	Observed volume of distribution	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1215097	Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis relative to dexamethasone	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Identification of clinically used drugs that activate pregnane X receptors.
AID327509	Agonist activity at glucocorticoid receptor-mediated luciferase reporter gene assay assessed as ratio of firefly luciferase activity to renilla luciferase activity at 10 uM	2008	Journal of natural products, Jan, Volume: 71, Issue:1	Microbial transformation of isosteviol and bioactivities against the glucocorticoid/androgen response elements.
AID1687198	Lipid increasing activity in mouse 3T3-L1 cells assessed as increase in adipogenic cocktail induced triglyceride levels at 1 uM incubated for 6 days by GPO-POD assay	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Tigliane Diterpenoids as a New Type of Antiadipogenic Agents Inhibit GRα-Dexras1 Axis in Adipocytes.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496824	Antimicrobial activity against Toxoplasma gondii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496829	Antimicrobial activity against Leishmania infantum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID689047	Toxicity in oxazolone-induced Sprague-Dawley rat chronic dermatitis model assessed as increase in plasma insulin level at 0.5 to 5 mg/kg, po qd administered after 7 days of oxazolone sensitization measured after 4 to 5 hrs last post treatment on day 14	2011	Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24	Discovery of selective glucocorticoid receptor modulator MK-5932.
AID1215089	Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis relative to rifampicin	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Identification of clinically used drugs that activate pregnane X receptors.
AID681354	TP_TRANSPORTER: transepithelial transport in MDR1-expressing LLC-PK1 cells	2003	Pharmaceutical research, Nov, Volume: 20, Issue:11	Structural determinants of P-glycoprotein-mediated transport of glucocorticoids.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1211793	Lipophilicity, log P of the compound	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1221960	Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID496823	Antimicrobial activity against Trichomonas vaginalis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID26380	Dissociation constant (pKa)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID379153	Agonist activity at glucocorticoid receptor transfected in mouse RAW264.7 cells assessed as firefly/renilla luciferase ratio at 10 uM by dual liciferase reporter assay	2006	Journal of natural products, Oct, Volume: 69, Issue:10	Transformation of steviol-16alpha,17-epoxide by Streptomyces griseus and Cunninghamella bainieri.
AID497005	Antimicrobial activity against Pneumocystis carinii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496832	Antimicrobial activity against Trypanosoma brucei rhodesiense	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496825	Antimicrobial activity against Leishmania mexicana	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1221957	Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID172541	In vivo glucocorticoid profile, depression of thymus weight in rat at 5 mg/kg peroral dose	1993	Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22	Non-steroidal glucocorticoid-like substances: receptor binding and in vivo activity.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496821	Antimicrobial activity against Leishmania	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID172528	In vivo glucocorticoid profile, depression of adrenal weight in rat at 1 mg/kg peroral dose	1993	Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22	Non-steroidal glucocorticoid-like substances: receptor binding and in vivo activity.
AID592681	Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	QSAR-based permeability model for drug-like compounds.
AID496830	Antimicrobial activity against Leishmania major	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1221963	Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1221964	Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1211794	Fraction unbound in blood (not specified)	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1221956	Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1211798	Intrinsic clearance in human using well stirred liver model by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347414	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347415	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: tertiary screen by RT-qPCR	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1224864	HCS microscopy assay (F508del-CFTR)	2016	PloS one, , Volume: 11, Issue:10	Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4777 (25.45)	18.7374
1990's	3745 (19.96)	18.2507
2000's	4436 (23.64)	29.6817
2010's	4502 (23.99)	24.3611
2020's	1307 (6.96)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	2,602 (12.85%)	5.53%
Reviews	1,343 (6.63%)	6.00%
Case Studies	7,091 (35.02%)	4.05%
Observational	104 (0.51%)	0.25%
Other	9,107 (44.98%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (952)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Phase 3, Controlled, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate (MTX) Compared to MTX Alone, in Methotrexate-Naive Patients With Active Rheumatoid Arthrit [NCT00299104]	Phase 3	755 participants (Actual)	Interventional	2006-01-31	Completed
A Pilot Study of Intensified Lymphodepletion Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Systemic Lupus Erythematosus [NCT00076752]	Phase 2	9 participants (Actual)	Interventional	2004-01-30	Completed
The Safety and Efficacy of Belatacept, Antithymocyte Globulin, and Sirolimus in Recipients of Non-HLA-identical Living-donor Renal Transplants (ITN023ST) [NCT00346151]	Phase 2	5 participants (Actual)	Interventional	2006-12-31	Terminated(stopped due to Stopping rule-acute rejection threshold-was met based on local biopsy results)
Electroretinographic Changes in Healthy Young Men Before and After Induction of Glucose Intolerance by Glucocorticoids Treatment, Hyperphagia and Lack of Exercise [NCT01140932]		10 participants (Actual)	Interventional	2010-02-28	Completed
EuroPainClinics® Study II (Prospective Randomized Double Blinded Trial) [NCT02459392]		300 participants (Actual)	Interventional	2021-12-31	Completed
Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification [NCT01193504]	Phase 4	100 participants (Anticipated)	Interventional	2010-09-30	Recruiting
Efficacy and Tolerability of Systemic Methylprednisolone in Children and Adolescents With Chronic Rhinosinusitis [NCT01205984]	Phase 4	48 participants (Actual)	Interventional	2007-07-31	Completed
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis [NCT00282347]	Phase 3	144 participants (Actual)	Interventional	2006-01-31	Completed
Vestibular Prognosis Assessment of the Idiopathic Sudden Sensorineural Hearing Loss With Vestibular Dysfunction Treated With Oral or Intratympanic Glucocorticoids [NCT03974867]		72 participants (Anticipated)	Interventional	2019-07-31	Not yet recruiting
Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome: Open-label, Multi-center, Single Arm, Phase 4 Trial (DoSAKOM) [NCT03794492]	Phase 4	169 participants (Actual)	Interventional	2018-03-31	Active, not recruiting
Effect of Preoperative Administration of Dexamethasone Versus Methylprednisolone in Surgical Extraction of Retained Lower Third Molars [NCT05752305]	Phase 2/Phase 3	84 participants (Actual)	Interventional	2022-01-15	Completed
A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL) [NCT04127578]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2020-01-03	Recruiting
Anti-CD20 Antibody Rituximab in Addition to Prednisolone in Treatment of Warm Antibody Related Autoimmune Hemolytic Anemia. A Randomised Danish Multicenter Trial. [NCT01134432]	Phase 3	65 participants (Actual)	Interventional	2005-03-31	Completed
[NCT01137084]		300 participants (Anticipated)	Interventional	2005-01-31	Completed
Steroid Treatment as Anti-inflammatory and Neuroprotective Agent Following Out-of-Hospital Cardiac Arrest. A Randomized Trial [NCT04624776]	Phase 2	158 participants (Actual)	Interventional	2020-10-10	Completed
An Investigator Initiated Open Study to Evaluate the Efficacy and Safety of Intra Arterial Infusion for Treatment of Steroid Resistant Acute Hepatic Graft Versus Host Disease (AGVHD) [NCT01140984]		2 participants (Actual)	Interventional	2010-09-30	Terminated(stopped due to technical issues)
Role of Add-on Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis [NCT05842681]		30 participants (Anticipated)	Interventional	2023-06-01	Not yet recruiting
Three-dimensional Evaluation of Postoperative Edema After Third Molar Surgery: a Randomized Clinical Trial [NCT05941130]	Phase 4	40 participants (Anticipated)	Interventional	2022-07-01	Recruiting
A Bidimensional Early Intervention Strategy of Standard of Care Combined With Host Immunomodulation in Elderly Patients With Mild or Moderate COVID-19: A Multicentre, Randomized, Controlled, Adaptive Platform Study [NCT05855395]		5,815 participants (Anticipated)	Interventional	2023-05-26	Recruiting
Intravenous Methylprednisolone Versus High Dose Oral Prednisolone for the Treatment of Infantile Spasms: a Randomized Open-labelled Trial [NCT03876444]	Phase 2/Phase 3	128 participants (Anticipated)	Interventional	2019-04-01	Recruiting
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP: a Randomized, Open, Multicenter Clinical Study [NCT05280626]	Phase 2	100 participants (Anticipated)	Interventional	2022-03-25	Not yet recruiting
Effect of Corticosteroids On MyocardiaL Injury Among Patients Hospitalized for Community-AcquirEd PneUMonia - COLOSSEUM TRIAL [NCT03745664]	Phase 3	122 participants (Anticipated)	Interventional	2021-01-10	Recruiting
Establishment of CST1 Predictive Model of Oral Glucocorticoid Therapy Sensitivity for Chronic Rhinosinusitis With Polyps [NCT05598424]	Phase 4	150 participants (Anticipated)	Interventional	2022-11-22	Recruiting
A Single-Center, Randomized, Double-Masked, Vehicle and Active-Controlled, Dose-Ranging Phase 2 Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis Using the Conjunctival Allergen Challenge M [NCT03320434]	Phase 2	120 participants (Actual)	Interventional	2017-10-13	Completed
Ruxolitinib and Methylprednisolone as First Line Therapy for Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation [NCT03701698]	Phase 2	30 participants (Anticipated)	Interventional	2018-11-01	Not yet recruiting
A Double-Blind, Placebo -Controlled, Randomized Study to Assess the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation. [NCT00048165]	Phase 4	434 participants (Actual)	Interventional	1999-08-31	Completed
Efficacy and Safety of Subacromial Corticosteroid Injection in Type-2 Diabetic [NCT03652480]		20 participants (Actual)	Observational	2013-03-31	Completed
The Effect of a Preoperative Single-dose Methylprednisolone on the Postoperative Rehabilitation After Abdominal Hysterectomy: A Prospective, Double Blinded, Placebo Controlled Study [NCT01106547]	Phase 4	55 participants (Anticipated)	Interventional	2009-08-31	Completed
Sonographic Assessment in Severe Ulcerative Colitis Patients Admitted for Intravenous Corticosteroids and Eligible for Infliximab Rescue Therapy; a Prospective Clinician-blinded Observational Study Protocol. [NCT03942861]		50 participants (Anticipated)	Observational	2019-02-21	Recruiting
A Randomized Clinical Trial Comparing Hyaluronic Acid (Hylan G-F 20) and Corticosteroid (Methylprednisolone Acetate) for Knee Osteoarthritis [NCT01132677]		78 participants (Anticipated)	Interventional	2010-05-31	Enrolling by invitation
Preemptive Therapy Study of Cetuximab(Erbitux®)Induced Skin Rash Using Doxycycline, Sunscreen, Hydrocortisone and Moisturizer in Colorectal and Head and Neck Cancer Patients [NCT01874860]	Phase 2	24 participants (Actual)	Interventional	2013-08-31	Completed
Comparison Between Intra-articular Pulsed Radiofrequency With Steroids Injection Versus Intra-articular Steroids Injection in Chronic Sacroiliac Joint Arthritis [NCT03564106]	Phase 2/Phase 3	40 participants (Actual)	Interventional	2019-03-01	Completed
"Maximizing Outcome of Multiple Sclerosis Transplantation: MOST Trial" [NCT03342638]	Phase 3	66 participants (Actual)	Interventional	2017-11-08	Terminated(stopped due to PI Sabbatical)
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease [NCT03584516]	Phase 2/Phase 3	155 participants (Actual)	Interventional	2019-01-17	Active, not recruiting
High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma [NCT01177371]	Phase 2	13 participants (Actual)	Interventional	1988-03-31	Completed
Effect of Preoperative Intravenous High Dose Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Patients Scheduled for Total Hip-arthroplasty [NCT02445898]	Phase 2/Phase 3	64 participants (Actual)	Interventional	2015-09-30	Completed
Randomized Clinical Trial Comparing Conventional Conservative Treatment for Plantar Fasciopathia With Endoscopic Surgery With Fascial Release. [NCT02448316]	Phase 4	30 participants (Actual)	Interventional	2015-04-01	Completed
Prospective Evaluation of Perioperative Steroid Dosing on Postsurgical Edema in Orthognathic Surgery [NCT03190642]	Phase 4	180 participants (Actual)	Interventional	2018-01-01	Completed
Single Dose Oral Dexamethasone Versus Multi-dose Prednisolone in the Treatment of Acute Exacerbations of Asthma in Children Who Attend the Emergency Department [NCT03698630]	Phase 4	250 participants (Actual)	Interventional	2011-07-06	Completed
Analgesic Efficacy of Liposomal Bupivacaine in Total Knee Arthroplasty [NCT02426164]	Phase 4	0 participants (Actual)	Interventional	2015-06-30	Withdrawn(stopped due to Could not receive facility approval)
Efficacy and Tolerance of Ultrasound-guided Needling and Lavage of Calcific Tendinitis of the Rotator Cuff Performed With or Without Subacromial Corticosteroid Injection: A Double Blind Controlled Study [NCT02403856]	Phase 4	136 participants (Actual)	Interventional	2015-04-04	Completed
Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease [NCT02392780]	Phase 2	10 participants (Anticipated)	Interventional	2015-04-30	Not yet recruiting
DEXTENZA Compared to Topical Steroid Therapy Prior to Cataract Surgery in Patients Who Receive Premium Intraocular Lenses [NCT04479748]	Phase 4	13 participants (Actual)	Interventional	2020-10-01	Completed
A Randomised Phase II Evaluation of Molecular Guided Therapy for Diffuse Large B-Cell Lymphoma With Acalabrutinib [NCT04546620]	Phase 2	453 participants (Anticipated)	Interventional	2021-10-19	Recruiting
Can Injection of Methylprednisoloneacetate 80 mg, in the Cavity After Mastectomy for Primary Breast Cancer, at the Time of Removal of the Drain, Prevent Seroma Formation? [NCT01380912]		160 participants (Anticipated)	Observational	2010-08-31	Recruiting
Evaluating Clinical and Immunological Effects of Rituximab With Cyclophosphamide Compared to Rituximab Alone in AAV Patients [NCT03942887]	Phase 3	100 participants (Anticipated)	Interventional	2019-05-03	Recruiting
To Study the Effect of Adjunctive Oral Methylprednisolone Therapy in Pediatric Urinary Tract Infection [NCT02331862]	Phase 3	160 participants (Anticipated)	Interventional	2015-01-31	Not yet recruiting
VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial [NCT05139849]	Phase 3	1,276 participants (Anticipated)	Interventional	2021-11-17	Recruiting
A Single-center, Prospective, Non-comparative Clinical Trial of Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome [NCT05137496]	Phase 3	40 participants (Anticipated)	Interventional	2022-06-01	Not yet recruiting
Safety and Efficacy of Thymus Transplantation in Complete DiGeorge Anomaly, IND#9836 [NCT01220531]		0 participants	Expanded Access		Approved for marketing
Evaluation of Effects, Safety, Viral Load and Antibody Level of Functional Food Dietary Supplement Containing Grape Products in Controlled, Randomized Study Using SARSCoV-2 RT-PCR Positive Covid-19 Patients. [NCT05417997]	Phase 3	71 participants (Actual)	Interventional	2021-05-29	Completed
MP3-pulses-COVID-19. Methylprednisolone Pulses Versus Dexamethasone According RECOVERY Protocol in Patients With Pneumonia Due to SARS-COV-2 Coronavirus Infection [NCT04780581]	Phase 4	127 participants (Actual)	Interventional	2021-02-01	Terminated(stopped due to Impossibility of reaching the sample size established by protocol)
Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease [NCT04224558]	Phase 1/Phase 2	15 participants (Anticipated)	Interventional	2020-12-15	Recruiting
Efficacy of CST1-Guided Oral Glucocorticoid Therapy for Chronic Rhinosinusitis With Polyps [NCT05598411]	Phase 4	90 participants (Anticipated)	Interventional	2022-10-17	Not yet recruiting
An Open-Label, Single-Arm, Multiple Center Extension Study to Evaluate One Year of Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer With YONSA™ 500 mg (4 x 125 mg qd) With Methylprednisolone (4 mg Bid) [NCT02962284]	Phase 2	20 participants (Actual)	Interventional	2016-11-30	Completed
Corticosteroids for Acute Migraine. An ED-based, Randomized, Comparative Effectiveness Trial [NCT02847494]	Phase 4	220 participants (Actual)	Interventional	2016-09-01	Completed
Health Related Quality of Life and Pain Managment Using Infiltration or Suprascapular Nerve Block Ultrasound Guided in Patients With Glenohumeral Arthirtis [NCT03794505]	Phase 3	40 participants (Actual)	Interventional	2018-04-01	Completed
Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis [NCT01305837]	Phase 2	30 participants (Actual)	Interventional	2011-04-30	Completed
A Multi-centre Randomised Double Blind Placebo Controlled Study Comparing Two Regimens of Combination Therapy in Early DMARD Naive Rheumatoid Arthritis. [NCT01308255]	Phase 4	112 participants (Actual)	Interventional	2006-09-30	Completed
A Randomised Phase II Study Comparing LEnalidomide Plus Rituximab, GEmcitabine and Methylprednisolone (LR-GEM) to Rituximab, Gemcitabine, Methylprednisolone and cisplatiN (R-GEM-P) in Second-line Treatment of Diffuse Large B-cell Lymphoma (DLBCL). [NCT02060656]	Phase 2	92 participants (Anticipated)	Interventional	2013-09-30	Active, not recruiting
Clinical Study of Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of Checkpoint Inhibitor-related Pneumonitis [NCT05280873]	Phase 1	48 participants (Anticipated)	Interventional	2021-10-10	Recruiting
Efficacy and Cost-effectiveness of Intra-Articular Ketorolac Injection for Knee Osteoarthritis: A Randomized, Controlled, Double-Blinded Study [NCT03694821]	Phase 4	18 participants (Actual)	Interventional	2018-07-05	Terminated(stopped due to Low enrollment)
Everolimus in Association With Very Low-dose Tacrolimus Versus Enteric-coated Mycophenolate Sodium With Low-dose Tacrolimus in de Novo Renal Transplant Recipients - A Prospective Single Center Study [NCT02084446]	Phase 4	120 participants (Actual)	Interventional	2012-12-31	Completed
The Efficacy of Steroid Therapy in Vestibular Neuritis Confirmed by Head Impulse Test: Prospective Randomized Controlled Study [NCT02098330]	Phase 3	40 participants (Actual)	Interventional	2014-03-31	Completed
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis: Two-arm, Open, Single-center Study [NCT06119490]	Early Phase 1	30 participants (Anticipated)	Interventional	2023-07-05	Recruiting
Corticosteroid(CS) Injections for the Treatment of Common Upper Extremity Pathologies, With or Without Lidocaine [NCT03704584]	Phase 4	62 participants (Actual)	Interventional	2019-05-14	Terminated(stopped due to Enrollment and study activities were initially suspended due to COVID-19. The investigator has also left Emory and the study will not resume.)
Phase II Study of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine and Methylprednisolone for Relapsed/Refractory Myeloma [NCT01332617]	Phase 2	0 participants (Actual)	Interventional	2011-04-30	Withdrawn(stopped due to Investigators no longer interested in activating study)
Feasibility and Safety of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord: an Open-Labeled, Dose-Escalating Clinical Trial [NCT01354483]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2011-09-30	Completed
CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease [NCT02061800]	Phase 1/Phase 2	15 participants (Anticipated)	Interventional	2013-06-03	Recruiting
The Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients, and the Effect of ABCB1、CYP3A4、CYP3A5、PORGenetic Polymorphism on the Two Drugs [NCT02077556]	Phase 4	14 participants (Actual)	Interventional	2014-04-30	Completed
Double-blind, Placebo-controlled, Randomized Study of the Safety and Tolerability of Isoxsuprine HCL Combined With High Dose Steroid Treatment of Multiple Sclerosis (MS) Relapse [NCT03752307]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2019-02-15	Completed
Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis. [NCT01941589]	Phase 4	149 participants (Actual)	Interventional	2013-09-30	Completed
Subcutaneous Injection of TNFα Monoclonal Antibody for Treating Traumatic Acute Spinal Cord Injury [NCT04988425]	Phase 1/Phase 2	90 participants (Anticipated)	Interventional	2022-09-01	Not yet recruiting
A Comparative Study of Strategies for Management of Duchenne Myopathy in Assiut University Children Hospital [NCT03633565]	Phase 4	45 participants (Anticipated)	Interventional	2018-09-30	Not yet recruiting
Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (PEGS) in Peripheral T-Cell Non-Hodgkin's Lymphoma [NCT00109928]	Phase 2	34 participants (Actual)	Interventional	2005-09-30	Completed
A Phase II, Open-labeled, Ophthalmological External Investigator-blinded, Single-center, Randomized, Superiority, Non Profit, Pilot Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO) in Hypercholesterolemic Patients With Mo [NCT03110848]	Phase 2	88 participants (Actual)	Interventional	2020-06-01	Completed
Manipulation Versus Steroid Injection in the Treatment of Morton's Neuroma [NCT05707572]		62 participants (Actual)	Interventional	2014-09-30	Completed
Randomized, Double-blind, Placebo- and Active Comparator- Controlled Crossover Study in Healthy Male Subjects and an Open Label Study in Healthy Subjects and MS Patients to Assess the Safety, Pharmacokinetics and Pharmacodynamics of 2B3-201 [NCT02048358]	Phase 1	47 participants (Actual)	Interventional	2013-11-30	Terminated
Does Injection Site Matter? A Randomized Controlled Trial to Evaluate Efficacy of Knee Intraarticular Injections on Improval of Patient Reported Outcomes. [NCT02176304]	Phase 4	60 participants (Actual)	Interventional	2014-06-30	Completed
[NCT01281748]	Phase 4	83 participants (Actual)	Interventional	2005-07-31	Terminated(stopped due to Low rate of enrollment)
Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata [NCT01167946]	Phase 4	42 participants (Actual)	Interventional	2003-01-31	Completed
DELTA Study Dutch Evaluation in Liver Transplantation To Assess the Efficacy of Cyclosporine A Microemulsion With C-2h Monitoring Versus Tacrolimus With Trough Monitoring in de Novo Liver Transplant Recipients [NCT00149994]	Phase 4	171 participants (Actual)	Interventional	2002-12-31	Completed
Cyclophosphamide and Hydroxychloroquine for the Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus [NCT02444728]	Phase 3	50 participants (Actual)	Interventional	2015-07-31	Terminated(stopped due to Because of insufficient enrollement)
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipi [NCT02763761]	Phase 2	0 participants (Actual)	Interventional	2016-08-16	Withdrawn(stopped due to Insufficient enrollment)
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas [NCT01189864]		3,493 participants (Actual)	Observational	2010-02-01	Terminated(stopped due to Terminated to initiate FDA IND-cleared study protocol)
Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study Low Dose Study [NCT01560052]		503 participants (Actual)	Interventional	2012-05-05	Completed
Investigating New Onset Diabetes Mellitus in Kidney Transplant Recipients Receiving an Advagraf-Based Immunosuppressive Regimen With or Without Corticosteroids - A Multicenter, Two Arm, Randomized, Open Label Clinical Study [NCT01304836]	Phase 4	1,166 participants (Actual)	Interventional	2011-01-22	Completed
Oral Megadose Corticosteroid Therapy of Acute Exacerbations of Multiple Sclerosis (OMEGA) [NCT00418145]	Phase 3	16 participants (Actual)	Interventional	2003-09-30	Terminated(stopped due to low enrollment - data was not analyzed for this study)
A Randomized, International, Multi Centre Study to Assess the Efficacy and Safety of Intravenous PEG-liposomal Prednisolone Sodium Phosphate (Nanocort®) vs Intravenous Methylprednisolone (Solu-Medrol®) Treatment in Patients With Acute Exacerbation of Rela [NCT01039103]	Phase 2	15 participants (Actual)	Interventional	2009-12-31	Terminated
Corticosteroid Treatment in the Acute Phase of Caustic Ingestion Management for the Prevention of Refractory Stenosis of the Esophagus and Pharynx- The CORTICAU Study [NCT03760354]	Phase 2	30 participants (Anticipated)	Interventional	2019-02-15	Not yet recruiting
Ultrasound-guided Medial Lumbar Bundle Branch Block by Caudal-cranial Approach: Radiographic Comparison of a New Ultrasound-guided Method [NCT05930236]		40 participants (Anticipated)	Interventional	2023-04-21	Recruiting
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1) [NCT02953678]	Phase 2	71 participants (Actual)	Interventional	2016-12-30	Completed
A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab [NCT00379431]	Phase 2	9 participants (Actual)	Interventional	2006-11-27	Completed
Evaluation of clINical reCovery After a Relapse: a Pilot Study assEssing the Neuronal Effects of D-Aspartate in RR-MS Subjects Treated With IntErferon Beta 1a 44 mcg TIW (INCREASE) [NCT03387046]	Phase 2	7 participants (Actual)	Interventional	2018-03-26	Terminated(stopped due to Study was terminated early due to slow recruitment rate.)
A Prospective, Randomized, Controlled, Open Label, Assessor-blinded, Parallel-group Phase III Clinical Trial to Evaluate the Impact of Tapering Systemic Immunosuppressive Therapy in a Treat-to-target Approach on Maintaining Minimal Disease Activity in Adu [NCT04610476]	Phase 3	270 participants (Anticipated)	Interventional	2020-10-19	Recruiting
A Multicentre Double-blind Randomised Controlled Trial to Assess the Clinical- and Cost-effectiveness of Facet-joint Injections in Selected Patients With Non-specific Low Back Pain: a Feasibility Study [NCT03339362]	Phase 4	9 participants (Actual)	Interventional	2015-07-31	Completed
Impact of Local Steroid Application in Extreme Lateral Lumbar Interbody Fusion [NCT03327272]	Phase 3	0 participants (Actual)	Interventional	2018-05-22	Withdrawn(stopped due to Did not enroll, PI decided not to proceed.)
Phase II Trial Of Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin's Lymphoma [NCT00732498]	Phase 2	28 participants (Actual)	Interventional	2006-05-15	Completed
Single Arm Study To Assess Comprehensive Infusion Guidance For The Management Of The Infusion- Associated Reactions (IARs) In Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With LEMTRADA [NCT02205489]	Phase 4	58 participants (Actual)	Interventional	2014-10-31	Completed
A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR) [NCT05436652]	Phase 2	48 participants (Anticipated)	Interventional	2022-07-22	Recruiting
Evaluation of Intraoperative Use of Dexycu on the Signs and Symptoms of Dry Eye [NCT04184999]	Phase 4	40 participants (Actual)	Interventional	2019-08-10	Completed
A Prospective, Randomized, Double-Blind Study to Compare the Effects of Dexamethasone Versus Depo-Medrol When Used in Lumbar Epidural Injections [NCT01397552]		8 participants (Actual)	Interventional	2009-09-30	Terminated(stopped due to Low enrollment, too many subjects getting second injection)
Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study) [NCT00792948]	Phase 2	97 participants (Actual)	Interventional	2009-09-01	Active, not recruiting
MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE [NCT03355482]	Phase 2	40 participants (Anticipated)	Interventional	2017-04-10	Suspended(stopped due to recruitment, funding)
Prognostic Value of Single-dose Glucocorticoid After Endovascular Repair for Aortic Dissection [NCT02523300]		240 participants (Anticipated)	Interventional	2015-10-31	Not yet recruiting
Effects of Intraoperative Local Steroid Utilization in a Single-Level Minimally Invasive Transforaminal Lumbar Interbody Fusion [NCT03308084]	Phase 3	105 participants (Actual)	Interventional	2015-11-13	Completed
A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract [NCT05191706]	Phase 4	60 participants (Anticipated)	Interventional	2022-01-04	Recruiting
A Phase IIA, Open-label Study Designed to Evaluate Efficacy and Safety of BL-8040 Followed by Anti-Thymocyte Globulin (hATG), Cyclosporine and Methylprednisolone in Adult Subjects With Aplastic Anemia (AA) or Hypoplastic Myelodysplastic Syndrome (MDS) [NCT02462252]	Phase 2	11 participants (Actual)	Interventional	2015-10-31	Completed
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD [NCT00562497]	Phase 3	192 participants (Actual)	Interventional	2008-01-31	Completed
Glucocorticoid Inflammation Paradox in Human Skeletal Muscle [NCT03529929]	Phase 3	0 participants (Actual)	Interventional	2019-06-01	Withdrawn(stopped due to withdrawn)
The Effect of High Dose Steroid and Normobaric Oxygen Therapy on Recent Onset Non-arteritic Anterior Ischemic Optic Neuropathy(NAION); a Randomized Clinical Trial [NCT02439866]	Phase 3	90 participants (Anticipated)	Interventional	2014-02-28	Recruiting
Using A Novel Classification System in Intravenous Glucocorticoids Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial [NCT03107078]	Phase 4	200 participants (Anticipated)	Interventional	2016-10-01	Recruiting
A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin (IVIg) Versus Standard Therapy for the Treatment of Transverse Myelitis in Adults and Children [NCT02398994]	Phase 3	2 participants (Actual)	Interventional	2015-03-31	Terminated(stopped due to Continued effort did not successfully increase recruitment into the study.)
A Randomized, Parallel Group, Double-masked, Active-controlled Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of Dexamethasone Sodium Phosphate Visulex System for the Treatment of Non-infectious Anterior Uveitis [NCT02309385]	Phase 1/Phase 2	44 participants (Actual)	Interventional	2014-10-31	Completed
Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy. [NCT03500133]	Phase 4	500 participants (Anticipated)	Interventional	2017-10-06	Recruiting
Targeting Steroid Resistance During Acute Exacerbations of Chronic Obstructive Pulmonary Disease With Respiratory Failure - The AECOPD Resistance Study [NCT03680495]		46 participants (Anticipated)	Observational [Patient Registry]	2017-07-21	Recruiting
CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid [NCT03492255]		49 participants (Actual)	Interventional	2018-04-12	Terminated(stopped due to Significative difference between percentage of renal response (primary outcome) between the two study arms.)
Evaluation of Ultrasound Guided Platelet Rich Plasma Injection Versus Steroids Injection for Pain Relief in Cases of Partial Rotator Cuff Tears [NCT05317624]	Early Phase 1	60 participants (Actual)	Interventional	2021-08-10	Completed
Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study [NCT03674099]	Phase 2	200 participants (Anticipated)	Interventional	2018-10-01	Recruiting
Calcific Tendinitis: Comparing Minimally Invasive Modalities [NCT02367560]		60 participants (Anticipated)	Interventional	2015-07-31	Recruiting
Moscow-Berlin 2015 Multicenter Randomized Study for Treatment of Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults [NCT03390387]		4,000 participants (Anticipated)	Interventional	2015-11-30	Recruiting
Effect of Preoperative Intravenous High Dose Methylprednisolone on Complement Activation in Patients Scheduled for Total Knee-arthroplasty [NCT02332616]	Phase 3	70 participants (Actual)	Interventional	2015-01-31	Completed
Early and Late Prognosis in Patients With Guillain-Barre Syndrome [NCT06041451]	Phase 4	450 participants (Anticipated)	Interventional	2013-01-02	Recruiting
An Open-label, Phase 1/2 Study to Evaluate the Safety and Efficacy of Single-dose LY3884961 in Infants With Type 2 Gaucher Disease [NCT04411654]	Phase 1/Phase 2	15 participants (Anticipated)	Interventional	2021-06-29	Recruiting
Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis: a Multinational, Randomised, Open Label, Phase III Trial - The iCaD Study [NCT05947669]	Phase 3	195 participants (Anticipated)	Interventional	2023-08-22	Recruiting
[NCT02591953]		22 participants (Actual)	Interventional	2015-11-30	Terminated(stopped due to Unable to meet enrollment and follow up criteria)
Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction [NCT05462730]	Phase 2	530 participants (Actual)	Interventional	2022-11-14	Active, not recruiting
Oral Prednisolone for Acute Rhinovirus Induced Wheezing in Children Less Than 2 Years of Age: a Point-of-care Testing Guided Randomized, Double-blind, Placebo-controlled Trial [NCT05444699]	Phase 4	210 participants (Anticipated)	Interventional	2022-10-11	Recruiting
Transforaminal Epidural Injection in Acute Sciatica [NCT03924791]		142 participants (Anticipated)	Interventional	2019-06-01	Recruiting
Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Untreated CLL/SLL The HiLOG Trial [NCT01496976]	Phase 2	45 participants (Actual)	Interventional	2012-03-30	Active, not recruiting
A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) For the Treatment of Acute GVHD in Patients Who Receive Allogeneic Hematopoietic Stem Cell Transplantation [NCT00136903]	Phase 2	32 participants (Actual)	Interventional	2005-04-27	Completed
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis [NCT00676832]	Phase 2	190 participants (Actual)	Interventional	2008-05-31	Completed
The Usage of Neuropsychological Tests and Multi-mode Magnetic Resonance Imaging in Patients With Autoimmune Encephalitis for Cognitive Neural Mechanism [NCT03530462]		22 participants (Actual)	Observational	2017-04-07	Completed
Ultrasound Guided Continuous Suprascapular Nerve Block With Oral Gabapentin For Pain Management In Patients With Frozen Shoulder [NCT05037994]		40 participants (Actual)	Interventional	2021-04-01	Completed
A Phase 3, Multicenter, Randomized, Evaluator-blinded Clinical Trial to Assess the Safety and Efficacy of Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% Compared to Prednisolone Acetate, 1% in the Treatment of Inflammation After Cataract Surgery in [NCT05724446]	Phase 3	60 participants (Anticipated)	Interventional	2022-12-12	Recruiting
Chidamide Combines With Etoposide and Methylprednisolone in the Treatment of Hemophagocytic Lymphohistiocytosis [NCT05137522]		20 participants (Anticipated)	Interventional	2021-07-01	Recruiting
Local Steroid Injection vs Wrist Splinting for Carpal Tunnel Syndrome: A Randomized Clinical Trial [NCT02140632]	Phase 4	50 participants (Actual)	Interventional	2013-12-31	Completed
[NCT02253966]	Phase 2	48 participants (Actual)	Interventional	2014-10-31	Completed
"Efficacy of Infliximab as Bridging Therapy in the Treatment of Patients Affected by Corticodependent Crohn's Disease Under Standard Treatment With Azathioprine" [NCT00796250]	Phase 3	9 participants (Actual)	Interventional	2003-11-01	Terminated(stopped due to Due to poor patient recruitment, a decision was made to terminate this trial.)
Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial. [NCT02160132]	Phase 2	180 participants (Anticipated)	Interventional	2014-06-30	Recruiting
Efficacy of Steroids on Functional Outcomes After Musculoskeletal Injuries of the Hand [NCT05003596]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2021-09-01	Not yet recruiting
Effect of High-dose Glucocorticoids on Markers of Inflammation and Bone Metabolism in Patients With Primary Glomerular Disease [NCT04987450]		40 participants (Anticipated)	Observational	2018-10-01	Recruiting
A Parallel-arm, Single Blind Randomised Controlled Trial Comparing 'AIRWAY PRESSURE RELEASE VENTILATION' and 'LOW-TIDAL VOLUME VENTILATION' in Children With Acute Respiratory Distress Syndrome [NCT02167698]		52 participants (Actual)	Interventional	2014-02-28	Terminated(stopped due to Increased mortality in the intervention arm at 50% enrolment)
Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy in Biliary Atresia: a Randomized Controlled Trial [NCT05925309]		356 participants (Anticipated)	Interventional	2023-07-01	Recruiting
Stop LCNP: High Dose Steroid Therapy for Late Radiation-Associated Lower Cranial Neuropathy: A Phase I/II Dose Finding Trial and Data Registry [NCT04151082]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2019-10-31	Active, not recruiting
Efficacy and Safety of Methylprednisolone Versus Dexamethasone in Caudal Block for Children Undergoing Hypospadias Surgical Repair: A Bi-center Randomized Controlled Study [NCT05717374]		80 participants (Anticipated)	Interventional	2023-02-13	Recruiting
The Efficacy and Safety of 36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent Drug-Induced Liver Injury [NCT03266146]	Phase 1/Phase 2	90 participants (Actual)	Interventional	2017-09-02	Completed
The Prospective Evaluation of Peri-Operative Glucocorticoid Use in the Management of Cervicofacial Infections of Odontogenic Origin [NCT05951504]	Phase 2/Phase 3	29 participants (Actual)	Interventional	2022-06-22	Completed
Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome：a Prospective, Multicenter, Non-randomized Controlled Intervention Study [NCT05604859]	Phase 4	350 participants (Anticipated)	Interventional	2022-08-19	Recruiting
Corticosteroid Pulse Therapy Effects on MRI Asymptomatic Gadolinium-enhancing Lesions Conversion to a Non-enhancing Black Hole With or Without Treatment in MS Clinic of Booalisina Hospital Sari 2021-2023 [NCT04979650]	Phase 2	104 participants (Anticipated)	Interventional	2021-05-22	Enrolling by invitation
The Impact of Dexamethasone Versus Methylprednisolone Upon Neutrophil/Lymphocyte Ratio (NLR) in COVID-19 Diseased Patients Admitted in ICU [NCT04909918]	Phase 3	60 participants (Actual)	Interventional	2021-05-28	Completed
Prevention of Development of Transcutaneous Sensitization in Children With Atopic Dermatitis During Their First Year of Life: an Observational Study [NCT04900948]	Phase 4	108 participants (Actual)	Interventional	2017-12-10	Completed
Evaluation Of Vision Recovery And Comfort Index In Patients With Borderline/Mild Dry Eyes Undergoing Femtosecond Laser-Assisted Cataract Surgery With Premium Intraocular Lens - The ENHANCE Study [NCT04863742]	Phase 4	30 participants (Anticipated)	Interventional	2021-04-26	Recruiting
Single-blind, Investigator-initiated, Randomized, Controlled Trial to Assess the Safety and Efficacy of Intravenous Corticosteroid Therapy to Treat Patients With Acute Myocarditis With Mildly Reduced Left Ventricular Ejection Fraction [NCT05974462]	Phase 3	174 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
Evaluation of the Feasibility of Depomedrol Added to Bupivacaine in Ultrasound-guided Genicular Nerve Block in the Combination With Adductor Canal Block for Postoperative Analgesia and Rehabilitation After Reconstructive Knee Surgery. [NCT05893771]		48 participants (Actual)	Interventional	2023-06-07	Completed
Mechanisms of Neurodynamic Treatments (MONET) [NCT05859412]		108 participants (Anticipated)	Interventional	2023-04-13	Recruiting
Methylprednisolone Taper After Total Knee Replacement: A Prospective Randomized Trial [NCT05859269]	Phase 4	200 participants (Anticipated)	Interventional	2023-10-16	Recruiting
A Pilot Randomized Controlled Trial of De Novo Belatacept-Based Immunosuppression in Lung Transplantation [NCT03388008]	Phase 2	27 participants (Actual)	Interventional	2019-12-17	Completed
Hypertonic Dextrose Versus Corticosteroid Intra-Articular Injections for the Treatment of Trapeziometacarpal Arthritis: A Prospective Double-blind Randomized Controlled Clinical Trial [NCT04791202]	Phase 3	130 participants (Anticipated)	Interventional	2021-04-01	Not yet recruiting
Lateral Elbow Tendinopathy: A Randomized Controlled Trial Examining The Treatment Effect Of Strength Training Combined With Cortico-Steroid Injection, Dry-Needling Or Placebo [NCT02521298]		60 participants (Actual)	Interventional	2015-10-31	Completed
Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (Belatacept)-Based Immunosuppression [NCT02137239]	Phase 2	58 participants (Actual)	Interventional	2015-12-31	Completed
Clinical and Laboratory Evaluation of Acute Rejection, Myocyte Growth, Repair, and Oxidative Stress Following de Novo Cardiac Transplant: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens With MPA TDM [NCT00157014]	Phase 3	111 participants (Actual)	Interventional	2004-05-10	Completed
Procollagen-3 Driven Corticosteroids for Persistent Acute Respiratory Distress Syndrome [NCT03371498]	Phase 3	356 participants (Anticipated)	Interventional	2018-12-27	Recruiting
High-dose Intravenous Methylprednisolone Therapy in Patients With Graves' Orbitopathy is Associated With the Increased Activity of Factor VIII [NCT03535090]		26 participants (Actual)	Observational	2011-01-01	Completed
Methylprednisolone Taper to Treat Delayed Post-Operative Recovery After Total Knee Arthroplasty: a Double-Blind Randomized Controlled Trial [NCT05113901]	Phase 4	4 participants (Actual)	Interventional	2022-03-03	Terminated(stopped due to Extremely low participation, decided to focus on similar study instead)
Benefit of a Flash Dose of Corticosteroids in Digestive Surgical Oncology: a Randomized, Double Blind, Placebo-controlled Trial [NCT03875690]	Phase 3	1,200 participants (Anticipated)	Interventional	2019-07-02	Recruiting
Comparative Study Between the Uses of High Dose Corticosteroid Therapy for Short Duration Versus Low Dose Corticosteroid for Long Duration in Severe Lung Contusion With ARDS [NCT04467892]	Phase 2	240 participants (Actual)	Interventional	2018-01-02	Completed
A Sequential Multiple Assignment Randomized Trial (SMART) Developing and Optimizing Patient-Tailored Adaptive Treatment Strategies (ATS) for Acute Severe Ulcerative Colitis [NCT05867329]	Phase 4	162 participants (Anticipated)	Interventional	2023-09-30	Recruiting
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones [NCT03007147]	Phase 3	475 participants (Anticipated)	Interventional	2017-08-08	Recruiting
Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura [NCT03647852]		150 participants (Anticipated)	Interventional	2019-09-01	Recruiting
A Randomised Controlled Trial to Compare the Clinical Effectiveness of Lower Extremity Manipulation to That of Steroid Injection in the Treatment of Morton's Neuroma [NCT02304094]		64 participants (Anticipated)	Interventional	2015-10-31	Recruiting
GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease [NCT03139604]	Phase 3	439 participants (Actual)	Interventional	2017-07-19	Completed
The Efficacy of Nasal Steroids in Treatment of Otitis Media With Effusion: Acomparative Study [NCT03491098]	Early Phase 1	60 participants (Anticipated)	Interventional	2018-05-15	Not yet recruiting
Mycophenolate Mofetil and Prednisolone Versus Prednisolone Alone in Fibrotic Hypersensitivity Pneumonitis: a Randomized Controlled Trial [NCT05626387]	Phase 4	144 participants (Anticipated)	Interventional	2022-11-23	Recruiting
A Prospective, Randomized, Controlled Phase Ⅱ Study of Preventively Use of Methylprednisolone After Split-course Chemoradiotherapy to Reduce the Risk of Radiation-induced Pulmonary Injury For Bulky Local Advanced None-small Cell Lung Cancer [NCT03661567]	Phase 2	52 participants (Actual)	Interventional	2018-08-09	Terminated(stopped due to slow enrollment)
A Double-masked, Methylprednisolone-control, Efficacy and Safety Study of 99Tc-MDP for Thyroid Associated Ophthalmopathy. [NCT03948191]	Phase 4	50 participants (Actual)	Interventional	2017-10-16	Completed
A Prospective, Open-label Trial of Methylprednisolone Pulse Macrolide Therapy for Refractory Mycoplasma Pneumoniae Pneumonia in Children [NCT01217099]		47 participants (Actual)	Interventional	2007-05-31	Terminated(stopped due to terminated)
Double-Masked, Randomized, Parallel Group Study for Evaluation of Non-Inferiority of 0.3%Gatifloxacin/1.0% Prednisolone Association Compared With Their Isolated Administration in the Prevention of Ocular Infection/Inflammation After LASIK Surgery [NCT01218737]	Phase 3	101 participants (Actual)	Interventional	2009-01-31	Completed
A Phase 2 Trial of Standard of Care Treatment Versus Mesenchymal Stromal Cell Therapy Together With Standard of Care for the Treatment of de Novo Acute Graft Versus Host Disease Following Allogeneic Bone Marrow Transplantation [NCT01589549]	Phase 2	66 participants (Anticipated)	Interventional	2012-04-30	Recruiting
Young Adult Acute Lymphoid Leukemia (ALL): Intensification of Pediatric AIEOP LLA-2000 Treatment [NCT01156883]		76 participants (Actual)	Interventional	2010-04-30	Completed
Evaluation of Corticosteroid as Modulators of Humeral and Cellular Immune Response in Open Heart Surgery in Egyptian Population [NCT03876041]	Phase 4	60 participants (Actual)	Interventional	2019-09-01	Completed
The LIPMAT Study: Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation [NCT02495662]	Phase 2	30 participants (Actual)	Interventional	2015-11-30	Terminated(stopped due to Slow inclusion)
Clinical Trial of Belimumab Combined With Multi-target Induction Therapy in Adult Patients With Severe Lupus Nephritis [NCT05863936]	Phase 3	15 participants (Anticipated)	Interventional	2023-04-01	Recruiting
Steroid Metabolism in Obese and Non-Obese Pediatric Patients Hospitalized for Status Asthmaticus [NCT04874610]		15 participants (Actual)	Observational	2021-08-16	Completed
A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed by Ofatumumab-Alemtuzumab in 17p Deletion CLL [NCT01465334]	Phase 2	30 participants (Actual)	Interventional	2011-12-31	Terminated(stopped due to Terminated early due to change in practice.)
The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease, a Double Blind Placebo Controlled Randomized Clinical Trial [NCT02422368]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2022-09-01	Withdrawn(stopped due to Do not access to the drug)
A Phase I, Single Center, Placebo-Controlled, Blinded Pilot Study of Ipratropium Bromide in Children Admitted to the Intensive Care Unit With Status Asthmaticus [NCT02872597]	Phase 1	30 participants (Actual)	Interventional	2016-09-05	Completed
A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Double and Triple Hit Lymphoma, Double Expressor Lymphoma and High-Gr [NCT04479267]	Phase 2	49 participants (Anticipated)	Interventional	2020-08-21	Recruiting
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY) [NCT04221477]	Phase 3	252 participants (Anticipated)	Interventional	2020-08-10	Active, not recruiting
An Open Label Study to Evaluate the Safety and Efficacy of Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Prior Treatment With Methotrexate [NCT01000610]	Phase 4	18 participants (Actual)	Interventional	2008-03-17	Completed
Phase 4, Randomized Study of Oral Glucocorticosteroid Administration in the Treatment of Acute Severe Asthma Exacerbation in Hospitalized Patients [NCT00627731]	Phase 4	50 participants (Actual)	Interventional	2007-06-30	Completed
Open-Label, Randomized, Multicenter, Parallel-Group Efficacy and Safety Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation [NCT00717379]	Phase 4	50 participants (Actual)	Interventional	2007-05-31	Completed
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) for Stage IV Indolent Lymphoma [NCT00577993]	Phase 3	210 participants (Actual)	Interventional	1998-03-16	Completed
Impact of the Administration of Systemic Glucocorticoids on Inflammatory Response and Clinical Evolution of Patients Diagnosed With Moderate- Severe Bronchiolitis [NCT02571517]	Phase 4	94 participants (Actual)	Interventional	2011-11-30	Completed
Viral Inception of Asthma: Prospective Study From Infancy to School-age. [NCT00731575]		200 participants (Anticipated)	Interventional	2007-06-30	Active, not recruiting
Immunomodulatory Effect of Extracorporeal Cytokine Adsorption in Cardiac Surgery [NCT02666703]	Phase 3	60 participants (Actual)	Interventional	2016-02-01	Completed
Comparison of Intravenous Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Proliferative Lupus Nephritis [NCT02645565]	Phase 4	75 participants (Actual)	Interventional	2015-12-31	Completed
Effectiveness of Hydrolyzed Collagen Peptide Injection for the Treatment of Collateral Ligament Pain: A Randomized Controlled Trial [NCT05971004]		62 participants (Actual)	Interventional	2022-04-13	Completed
Phase II Pilot Cohort Study to Investigate the Safety and Efficacy of Infliximab as Additional Therapy in the Treatment if Anti-Neutrophil Cytoplasm Antibody Associated Vasculitis [NCT00753103]	Phase 2	37 participants (Actual)	Interventional	2003-01-31	Completed
Treatment With Methylprednisolone in Acute Exacerbations of Multiple Sclerosis: Enhanced Effect With Nighttime Treatment? [NCT00764413]		57 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to Low inclusion frequency and not enough human resources for completing study)
Efficacy of Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation. A Randomized Controlled Trial [NCT02584738]	Phase 4	152 participants (Anticipated)	Interventional	2015-09-30	Recruiting
Subacromial Injection of Methylprednisolone Versus Ketorolac to Treat Shoulder Impingement: a Double-blind Randomized Controlled Trial [NCT03913702]	Phase 2	1 participants (Actual)	Interventional	2019-09-09	Terminated(stopped due to Inadequate patient enrollment)
Phase 2/3 Study of Rituximab for Graves' Ophthalmopathy [NCT00595335]	Phase 2/Phase 3	25 participants (Actual)	Interventional	2008-04-30	Completed
Intra-articular Doxycycline: A Novel Treatment of Adhesive Capsulitis [NCT03479502]	Phase 4	1 participants (Actual)	Interventional	2018-01-05	Terminated(stopped due to Lack of personnel to help with recruiting)
A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis [NCT01838174]	Phase 4	37 participants (Actual)	Interventional	2013-05-31	Terminated(stopped due to Sponsor requested)
Efficacy and Safety of Prednisolone and Chloroquine Add on Therapy in Osteoarthritis of the Knee Treated With Fixed Dose Combination of Glucosamine and Chondroitin Sulfate. [NCT00805519]	Phase 4	230 participants (Actual)	Interventional	2009-02-28	Completed
A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study To Evaluate The Safety And Efficacy Of TRU-015 In Subjects With Active Seropositive Rheumatoid Arthritis On A Stable Background Of Methotrexate [NCT00634933]	Phase 2	222 participants (Actual)	Interventional	2008-03-31	Terminated(stopped due to The study was terminated on 21 June 2010 due to results not meeting the primary endpoint. No safety reasons contributed to the termination of the study.)
Multicenter, Randomized, Double-blind Clinical Trial to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse. [NCT01986998]	Phase 4	49 participants (Actual)	Interventional	2013-10-31	Completed
Personalized Variable Versus Fixed Dose Corticosteroids Therapy in Hospitalized Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease [NCT02147015]		248 participants (Actual)	Interventional	2014-06-30	Completed
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of a BI 653048 BS H3PO4 Capsule Formulation Administered as Multiple Doses of 25 mg to 200 mg Once Daily (qd) for 3 Days Assessing Pharmacodynamics as Endotoxin-induced Inflammatory Response of a [NCT02224105]	Phase 1	56 participants (Actual)	Interventional	2010-03-31	Completed
Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia MT2002-02 [NCT00258427]	Phase 2	14 participants (Actual)	Interventional	2002-03-26	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled TRial Evaluating Immunosuppressive Treatment in Patients With Chronic Virus-Negative Inflammatory cardiomyopaThY (TRINITY Trial) [NCT05570409]	Phase 2/Phase 3	130 participants (Anticipated)	Interventional	2023-03-28	Recruiting
Assessment of the Efficacy of Medrol Dose Pack for Post-Concussive Headaches [NCT04685772]		25 participants (Anticipated)	Observational [Patient Registry]	2021-04-01	Recruiting
Methylprednisolone Pulse Therapy for Coronary Artery Dilatation or Aneurysm Formation in Kawasaki Disease [NCT04509219]	Phase 1	10 participants (Anticipated)	Interventional	2020-04-15	Recruiting
The Effect on Wrist Range of Motion With Perioperative Glucocorticoid Administration in the Treatment of Adult Distal Radius Fractures: A Randomized Controlled Trial [NCT03898154]	Phase 4	200 participants (Anticipated)	Interventional	2019-07-10	Recruiting
The Outcome of Dexamethasone and Methylprednisolone Treatment for Patients With ARDS Caused by COVID-19 [NCT04499313]	Phase 3	60 participants (Anticipated)	Interventional	2020-08-02	Recruiting
A Feasibility Study to Undertake a Definitive Randomised Multi-centre, Double-blind, Double-dummy Controlled Study of a Novel Agent Anakinra vs. Depo-Medrone for Acute Gout Attacks in Patients With Moderate Chronic Kidney Disease [NCT02578394]	Phase 2/Phase 3	21 participants (Actual)	Interventional	2016-04-30	Completed
Effects of Methylprednisolone Plus Ropivacaine Infiltration Before Wound Closure on Laminoplasty or Laminectomy [NCT04493463]	Phase 4	132 participants (Actual)	Interventional	2020-07-31	Completed
The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS) Applied on Cardiac Surgery With Cardiopulmonary Bypass: a Single Center, Randomized, Controlled Clinical Study [NCT02479581]	Phase 2	226 participants (Actual)	Interventional	2015-07-31	Completed
Syndrome du Tunnel Carpien - Essai Clinique randomisé évaluant l'efficacité de l'Utilisation de l'échographie Lors de l'Infiltration de corticostéroïdes [NCT02036125]		50 participants (Anticipated)	Interventional	2013-10-31	Recruiting
Zonisamide and Methylprednisolone to Prevent Noise-induced Temporary Hearing Loss [NCT02049073]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2017-10-31	Withdrawn(stopped due to new data makes this trial unethical)
Randomised Trial of Intra-articular Injection of Lidocaine Versus Placebo in Inflammatory Arthritis [NCT05302232]		80 participants (Anticipated)	Interventional	2022-04-18	Not yet recruiting
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia [NCT03913559]	Phase 2	32 participants (Anticipated)	Interventional	2019-05-14	Recruiting
A Prospective, Multi-center, Single-arm, Interventional Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant in China [NCT03099122]	Phase 4	115 participants (Actual)	Interventional	2017-08-16	Completed
Comparison of High-dose, Short-term Steroid and Low-dose Long-term Steroid Use in ARDS Caused by COVID-19 - Retrospective Cross-sectional Study [NCT05047874]		200 participants (Anticipated)	Observational	2021-09-20	Recruiting
An Open-Label, Parallel Group, Controlled Study in Healthy Subjects to Characterize Biological Responses to Immunological Challenges and to Measure the Effect of Marketed Anti-Inflammatory Agents on Those Responses [NCT02252809]	Early Phase 1	51 participants (Actual)	Interventional	2008-11-30	Completed
Comparative Evaluation of Preoperative Methylprednisolone or Ibuprofen on Anesthetic Efficacy of Inferior Alveolar Nerve Blocks in Patients With Symptomatic Irreversible Pulpitis [NCT04157036]	Phase 3	3 participants (Actual)	Interventional	2020-02-01	Terminated(stopped due to COVID halted recruitment for 2 years. A majority of patients eligible for the study had already taken preoperative analgesics, which disqualified them for the study.)
A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome [NCT04933292]	Phase 4	78 participants (Anticipated)	Interventional	2021-06-16	Recruiting
Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia: A Randomized, Controlled, 2x2 Factorial Study [NCT04485429]	Phase 3	0 participants (Actual)	Interventional	2020-07-20	Withdrawn(stopped due to It was not possible to perform the study due to the availability and logistics of porcine heparin)
A Single Center Open Label Pilot Study of Alpha1-Antitrypsin: A Novel Treatment to Mitigate Neuromyelitis Optica Attacks [NCT02087813]	Phase 1	0 participants (Actual)	Interventional	2014-03-31	Withdrawn
Phase 2a, Double-blind, Randomized, Placebo-controlled Trial of Methylprednisolone Versus Placebo in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS) [NCT05986422]	Phase 2	418 participants (Anticipated)	Interventional	2023-10-01	Recruiting
Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Crescents : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial. [NCT04833374]	Phase 3	200 participants (Anticipated)	Interventional	2021-05-24	Recruiting
Open-label Pilot Study of Methylprednisolone for the Treatment of Patients With Friedreich Ataxia (FRDA) [NCT02424435]	Early Phase 1	11 participants (Actual)	Interventional	2015-06-30	Completed
Comparison Of Efficacy Of Hydrocortisone And Methyl Prednisolone In Acute Severe Asthma [NCT06171932]		60 participants (Anticipated)	Observational [Patient Registry]	2023-11-26	Enrolling by invitation
A Pilot Study Examining Selinexor's Ability to Overcome Resistance in Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. [NCT04519476]	Phase 1	22 participants (Anticipated)	Interventional	2020-11-01	Recruiting
Evaluation of the Efficacy of 2% Cyclosporine in Preventing Graft Rejection [NCT02206789]		200 participants (Anticipated)	Interventional	2012-02-29	Recruiting
Using SMART Design to Develop Dynamic Treatment Regimens for Glucocorticoid Tapering [NCT06072768]	Phase 2	200 participants (Anticipated)	Interventional	2023-03-09	Recruiting
Impact of Cyclosporine or Steroid Withdrawal at 3 Months Post Transplantation on Graft Function, Patient Survival and Cardiovascular Surrogate Markers the First 5 Years After Renal Transplantation. [NCT00903188]	Phase 4	152 participants (Anticipated)	Interventional	2008-10-31	Recruiting
Comparative Evaluation of the Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in the Treatment of Pediatric and Adult Dermatosis [NCT01011621]	Phase 3	170 participants (Anticipated)	Interventional	2010-02-28	Not yet recruiting
A Multicentric, Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion (SDI) in Patients With Previously Untreated Advanced Follicular Lymphoma [NCT03817853]	Phase 4	114 participants (Actual)	Interventional	2019-02-26	Completed
Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI) [NCT00104299]	Phase 2/Phase 3	197 participants (Actual)	Interventional	2005-01-31	Completed
Randomised Double-blinded Trial Comparing Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis Relapses [NCT00984984]	Phase 3	200 participants (Anticipated)	Interventional	2008-03-31	Recruiting
To Assess the Role of Sphingosine-1-phosphate in the Pathobiology of Pneumonia: Generate a New Strategy for Treatment of Severe Community-acquired Pneumonia [NCT04007328]	Phase 2/Phase 3	400 participants (Anticipated)	Interventional	2019-06-15	Recruiting
(REASON) Double-blind, Randomized Phase II Study to Evaluate the Safety and Efficacy of Acetyl-l-carnitine in the Prevention of Sagopilone-induced Peripheral Neuropathy. [NCT00751205]	Phase 2	150 participants (Actual)	Interventional	2008-08-31	Completed
A Randomized Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Idiopathic Pneumonia Syndrome Following Allogeneic Cell Transplantation (BMTCTN0403) [NCT00421174]	Phase 3	37 participants (Actual)	Interventional	2007-08-31	Completed
A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus [NCT00539838]	Phase 3	33 participants (Actual)	Interventional	2007-12-19	Terminated(stopped due to The study was terminated prematurely when the decision was made that ocrelizumab was not likely to benefit this patient population.)
Evaluation of a New Formulation Useful for the Osteoarthrosis Treatment [NCT00977444]	Phase 2/Phase 3	114 participants (Actual)	Interventional	2007-11-30	Active, not recruiting
A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB T [NCT00057811]	Phase 2	97 participants (Actual)	Interventional	2004-06-30	Completed
Phase II Study of Cyclophosphamide, Prednisone and Rituximab (CPR) in Children, Adolescents and Young Adults With B-lymphocyte Antigen CD20 (CD20) Positive Post-Transplant Lymphoproliferative Disease (PTLD) Following Solid Organ Transplantation (SOT) [NCT00066469]	Phase 2	55 participants (Actual)	Interventional	2004-04-30	Completed
A Phase II Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease [NCT01028313]	Phase 2	0 participants (Actual)	Interventional		Withdrawn(stopped due to A decision was made to not move forward with the study. No participants were enrolled or treated.)
Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag. [NCT00888901]	Phase 4	30 participants (Actual)	Interventional	2009-05-31	Completed
Prospective Donor-specific Cellular Alloresponse Assessment for Immunosuppression Minimization in de Novo Renal Transplantation [NCT02540395]		184 participants (Actual)	Interventional	2015-03-31	Completed
A Randomized Pilot Trial of a Steroid-free Immunosuppressant Regimen in Pediatric Liver Transplantation [NCT00694408]	Phase 3	15 participants (Actual)	Interventional	2008-06-30	Terminated(stopped due to Study terminated due to withdrawal from market of Daclizumab)
Impact of Obesity on the Pharmacokinetics of Anticancer Therapy in Children With High Risk Acute Lymphoblastic Leukemia (ALL) [NCT00900445]		0 participants (Actual)	Observational	2008-03-24	Withdrawn
Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis [NCT00908089]	Phase 4	100 participants (Actual)	Interventional	2003-03-31	Active, not recruiting
Corticoids in Severe Community-acquired Pneumonia [NCT00908713]	Phase 4	120 participants (Actual)	Interventional	2004-01-31	Completed
Targeting Inflammation and Alloimmunity in Heart Transplant Recipients With Tocilizumab (RTB-004) [NCT03644667]	Phase 2	200 participants (Anticipated)	Interventional	2018-12-20	Recruiting
The Impact of Early Protocol Biopsy in Kidney Transplant Recipients Receiving TAC and MMF; a Prospective Observational Study [NCT02733510]		200 participants (Anticipated)	Observational	2016-04-30	Recruiting
ACP Max™ PRP System for Knee Osteoarthritis: A Feasibility Trial [NCT05765266]		45 participants (Anticipated)	Interventional	2023-08-12	Not yet recruiting
Clinical Treatment of Traumatic Optic Neuropathy: Optic Nerve Decompression Randomized Controlled Study [NCT02711982]		2 participants (Anticipated)	Interventional	2010-01-31	Recruiting
Greater Occipital Nerve Block for Migraine Prophylaxis [NCT00915473]	Phase 4	70 participants (Actual)	Interventional	2009-06-30	Completed
A Pilot Randomized Controlled Trial of Efficacy of Perineural Local Anesthetics and Steroids for Chronic Post-traumatic Neuropathic Pain in the Ankle and the Foot: The PREPLAN Study [NCT02680548]	Early Phase 1	8 participants (Actual)	Interventional	2015-11-30	Completed
Ultrasound Guided Platelet Rich Plasma Injections for Post Traumatic Greater Occipital Neuralgia: A Randomized Controlled Pilot Study [NCT04051203]	Phase 1	35 participants (Anticipated)	Interventional	2019-02-01	Active, not recruiting
Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial [NCT04244591]	Phase 2/Phase 3	80 participants (Actual)	Interventional	2020-01-26	Completed
Phenol Neurolysis of Genicular Nerves for Chronic Knee Pain Following Total Knee Arthroplasty: a Pilot Prospective, Randomized, Crossover Trial [NCT03973177]	Phase 4	0 participants (Actual)	Interventional	2019-05-24	Withdrawn(stopped due to Covid restrictions on recruitment)
An Open, Multicentre, Randomised, Parallel Group Pilot-Study to Compare Safety and Efficacy of Discontinuation of Mycophenolate Mofetil From a Tacrolimus/MMF/Steroid Triple Regimen Following Kidney Transplantation [NCT00693381]	Phase 3	152 participants (Actual)	Interventional	2003-02-28	Completed
A Prospective Study to Assess the Safety and Effectiveness of Medrol® in Acute Asthma in Indian Patients [NCT00971893]		0 participants (Actual)	Observational	2009-10-31	Withdrawn
A Phase Ib Feasibility Study of Personalized Kinase Inhibitor Therapy Combined With Induction in Acute Leukemias Who Exhibit In Vitro Kinase Inhibitor Sensitivity [NCT02779283]	Phase 1	7 participants (Actual)	Interventional	2016-01-13	Completed
Cadaveric Organ Donor Management: Thyroid and Adrenocortical Hormone Replacement [NCT04528797]		199 participants (Actual)	Interventional	2010-09-02	Completed
Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism and Beta-Cell Dysfunction in Males With the Metabolic Syndrome X: A Randomized, Placebo-controlled, Double-blind Intervention Study With a 2x2 Factorial Design [NCT00721552]		82 participants (Actual)	Interventional	2008-10-31	Completed
An Open-label, Prospective, Randomized, Controlled Clinical Trial of the Use of Reduced Duration Versus Standard Duration Steroid Replacement Therapy for Acute Adrenal Insufficiency in Patients With Septic Shock [NCT00842933]	Phase 4	32 participants (Anticipated)	Interventional	2007-05-31	Terminated(stopped due to Unable to meet enrollment goal prior to PI transfer)
DFCI ALL Adult Consortium Protocol: Adult ALL Trial [NCT01005758]	Phase 2	180 participants (Anticipated)	Interventional	2009-01-31	Not yet recruiting
Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) [NCT04918147]	Phase 2	75 participants (Anticipated)	Interventional	2021-10-13	Recruiting
Effects of Volume and Dose of Local Anaesthetic Solution in Epidural Steroidal Injections for Patients With Chronic Lower Back Pain [NCT00887003]		252 participants (Actual)	Interventional	2005-05-31	Completed
TAP Block With Dexamethasone Versus TAP Block With Methyl-prednisolone as a Pain Treatment Modality After Total Abdominal Hysterectomy Procedures: Randomized Controlled Trial [NCT06131593]		50 participants (Anticipated)	Interventional	2023-07-01	Recruiting
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma [NCT05675410]	Phase 3	1,875 participants (Anticipated)	Interventional	2023-05-11	Recruiting
A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis [NCT04548999]	Phase 3	770 participants (Actual)	Interventional	2020-12-03	Active, not recruiting
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphom [NCT03914625]	Phase 3	6,720 participants (Anticipated)	Interventional	2019-07-03	Recruiting
Transplantation of Umbilical Cord Blood for Myeloid Leukemia Patients Not in CR With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen and UCB NK Cells [NCT00354172]	Phase 2	16 participants (Actual)	Interventional	2006-02-28	Terminated(stopped due to Competing study was started.)
A Comparison of Three Different Formulations of Topical Prednisolone Acetate 1% for Control of Post Glaucoma and/or Cataract Surgery Inflammation. [NCT00345046]	Phase 4	60 participants (Actual)	Interventional	2002-09-30	Completed
Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome in In-vitro Fertilization Cycles: A Randomized Controlled Trial [NCT01014104]	Phase 1/Phase 2	218 participants (Actual)	Interventional	2009-10-31	Completed
Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia [NCT00301834]	Phase 2	35 participants (Actual)	Interventional	2005-01-31	Completed
Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis (TREAT in JIA) [NCT00443430]	Phase 4	85 participants (Actual)	Interventional	2007-05-31	Completed
Effects of Pre-operative Methylprednisolone (125mg iv) After Total Hip Arthroplasty: A Prospective, Randomized, Double-blind, Placebo-controlled Trail [NCT00968903]	Phase 4	48 participants (Actual)	Interventional	2010-04-30	Completed
Comparison of Monthly Pulse ACTH (Acthar Gel) Therapy With Methylprednisolone (MP, Solumedrol) for Long-Term Treatment of Multiple Sclerosis (MS) as an Add on Therapy to Beta-interferons (Avonex, Betaseron or Rebif) [NCT01049451]	Phase 1	23 participants (Actual)	Interventional	2009-11-30	Completed
Methylprednisolone Combined Electric-acupuncture Treatment Effects on Cognitive Function After Surgery for Elderly Patients With General Anesthesia [NCT02535039]	Phase 1/Phase 2	80 participants (Anticipated)	Interventional	2015-10-31	Recruiting
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma [NCT00481832]	Phase 2	50 participants (Actual)	Interventional	2007-01-31	Terminated(stopped due to Accrual Factor)
Comparison of the Efficacy and Safety of Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19. A Prospective Randomized Controlled Phase II Trial [NCT04377503]	Phase 2	30 participants (Actual)	Interventional	2020-05-01	Terminated(stopped due to The number of critically ill patients wirh COVID-19 decrease abruptly)
Preoperative Methylprednisolone in Endovascular Aortic Repair - a Randomized Double Blind Placebo Controlled Clinical Trial [NCT00989729]		150 participants (Actual)	Interventional	2009-10-31	Completed
SIMPLE Study: A Prospective and Randomized Trial of a Simplified Immunosuppressive Protocol Utilizing Low Dose EnvarsusXR [NCT04773392]	Phase 4	80 participants (Anticipated)	Interventional	2021-11-23	Recruiting
Phase 2 Clinical Trial for Comprehensive Treatment Program for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Tagraxofusp (SL-401) in Combination With HCVAD/Mini-CVD and VENETOCLAX [NCT04216524]	Phase 2	40 participants (Anticipated)	Interventional	2020-05-29	Recruiting
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study [NCT00574288]	Phase 2	104 participants (Actual)	Interventional	2008-03-26	Completed
A Prospective, Randomized Single-Masked Clinical Trial Comparing OCT and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone [NCT00698724]	Phase 4	200 participants (Anticipated)	Interventional	2008-06-30	Completed
The MAGIC Algorithm Probability Guided Preemption of Steroid-refractory Graft-versus-host Disease With Methylprednisolone [NCT05368181]	Phase 2	56 participants (Anticipated)	Interventional	2022-05-01	Recruiting
A Multicenter, Three Arm, Randomized, Open Label Clinical Study to Compare Renal Function in Liver Transplant Recipients Receiving an Immunosuppressive Regimen of Advagraf (Immediately or Delayed Post-transplant) and MMF With or Without a Monoclonal Anti- [NCT01011205]	Phase 3	893 participants (Actual)	Interventional	2009-09-30	Completed
Comparing Subacromial Injection of Platelet-rich Plasma Versus Methylprednisolone in the Treatment of Shoulder Subacromial Impingement Syndrome [NCT02669303]		19 participants (Actual)	Interventional	2015-09-30	Terminated(stopped due to low recruitment rate and high rate of loss-to-followup)
Incidence of Flare Reaction Following Shoulder Steroid Injections: Comparison of Depo-medrol (Methylprednisolone) and Kenalog (Triamcinolone) [NCT05438277]	Phase 4	421 participants (Actual)	Interventional	2020-01-01	Completed
PreOperative Steroid in Abdominal Wall Reconstruction: A Double-blinded Randomized Clinical Trial [NCT02594241]		42 participants (Actual)	Interventional	2016-03-31	Completed
High-Dose Methotrexate Plus Steroid Followed by Concurrent Whole Brain Chemoradiation With Temozolomide for Immunocompetent Patients With Primary Central Nervous System Lymphoma - a Phase II Study [NCT00455286]	Phase 2	25 participants	Interventional	2006-11-30	Recruiting
Renal Allograft Tolerance Through Mixed Chimerism [NCT00801632]	Phase 2	5 participants (Actual)	Interventional	2008-12-31	Completed
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen [NCT05626478]	Phase 4	100 participants (Anticipated)	Interventional	2023-06-01	Recruiting
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Prednisolone Acetate 1% Treating Pain, and inflamMation Following Corneal Transplant Surgery Compared to Topical Prednisolone Acetate 1%. [NCT04521140]	Phase 4	36 participants (Actual)	Interventional	2020-10-16	Completed
A Prospective, Multicenter, Randomized Controlled Trial of Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN) [NCT00657059]	Phase 3	151 participants (Actual)	Interventional	2007-09-30	Completed
Low Dose Versus High Dose Steroids in Treatment of Viral Encephalitis [NCT04103684]	Phase 4	100 participants (Anticipated)	Interventional	2020-03-30	Not yet recruiting
Prospective Observational Trial to Evaluate Clinical Prognosis and the Risk Factors for Progression for Myasthenia Gravis Patients [NCT04101578]		2,000 participants (Anticipated)	Observational	2017-02-08	Recruiting
Effectiveness of Transtympanic Steroids in Unilateral Ménière's Disease: a Randomised Controlled Double-Blind Trial [NCT00802529]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2009-04-30	Completed
"Are Steroids Efficacious in Hospitalized Patients With Bronchiolitis Who Show an Objective Clinical Improvement After Albuterol (Albuterol Responders)?" [NCT00798616]		0 participants (Actual)	Interventional		Withdrawn(stopped due to We were unable to enroll a sufficient number of patients due to manpower.)
Assessment of Clinical Efficacy of 1% Prednisolone Acetate (Ster ®), Produced by união química, Compared to 1% Prednisolone Acetate (Pred ® Fort), Produced by Allergan, in the Control of Postoperative Inflammation in Cataract Surgery. [NCT01227876]	Phase 3	106 participants (Actual)	Interventional	2011-01-31	Completed
Prospective Comparison of Sirolimus Against Corticosteroids in Treatment of Patients With Active Thyroid Eye Disease [NCT04936854]	Phase 2	60 participants (Anticipated)	Interventional	2023-01-01	Recruiting
A Phase 1, Exploratory, Randomized, Open-label, 2-Arm Study to Characterize the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Alemtuzumab 12mg Administered Subcutaneously or Intravenously in Patients With Progressive Multiple Sclerosis [NCT02583594]	Phase 1	24 participants (Actual)	Interventional	2015-12-06	Completed
A Phase 2 Study in Poor Risk Diffuse Large B-cell Lymphoma of Total Lymphoid Irradiation & Antithymocyte Globulin Followed by Matched Allogeneic Hematopoietic Transplantation as Consolidation to Autologous Hematopoietic Cell Transplantation [NCT00482053]	Phase 2	3 participants (Actual)	Interventional	2006-10-31	Terminated(stopped due to Low accrual)
Corticosteroids and Azathioprine Versus Corticosteroids Alone in IgA Nephropathy: a Randomized Controlled Trial. [NCT00755859]	Phase 4	206 participants (Actual)	Interventional	1998-05-31	Completed
Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery [NCT00758199]	Phase 4	49 participants (Actual)	Interventional	2008-07-31	Completed
An Observational, Retrospective, Single-center, Clinical Study to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO) [NCT05345119]		30 participants (Actual)	Observational	2020-01-15	Completed
A Multicentre Randomised Controlled Trial to Assess the Efficacy of Adding Rituximab to Standard of Care in Treating Acute Antibody-mediated Rejection in Kidney Transplantation [NCT03994783]	Phase 3	3 participants (Actual)	Interventional	2019-07-17	Active, not recruiting
Phase I/II Study of Hyper-CVAD Plus RAD001 (Everolimus) for Patients With Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) [NCT00968253]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2009-11-30	Completed
An Open-label Extension (OLE), Expanded Access Study, to Assess Long-term Safety of SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) With Methylprednisolone (4mg Bid) in Patients Who Completed Study Number CHL-AA-201 [NCT02887976]	Phase 3	2 participants (Actual)	Interventional	2016-09-30	Completed
The Effect of Steroid Pulse Therapy for the Reduction of Acute Rejection Episode in Subclinical Borderline Changes: An Open-Label, Randomized Clinical Trial [NCT02664493]		154 participants (Anticipated)	Interventional	2016-02-29	Recruiting
Treatment of Chronic Subdural Hematoma by Corticosteroids [NCT02650609]	Phase 3	202 participants (Actual)	Interventional	2016-06-24	Completed
Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men [NCT00957801]	Phase 4	29 participants (Actual)	Interventional	2009-03-31	Completed
A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients [NCT00782717]	Phase 2	263 participants (Actual)	Interventional	2008-11-30	Completed
A Multicenter, Four Arm, Randomized, Open Label Clinical Study Investigating Optimized Dosing in a Prograf®-/Advagraf®-Based Immunosuppressive Regimen in Kidney Transplant Subjects (OSAKA Study) [NCT00717470]	Phase 4	1,252 participants (Actual)	Interventional	2008-05-14	Completed
Phase 4, Randomized Study of Three Months-prednisolone Therapy in the Treatment of Chronic Eosinophilic Pneumonia [NCT00632554]	Phase 4	50 participants (Anticipated)	Interventional	2008-06-30	Completed
Phase II Trial of the Addition of PEG-Asparaginase to the Hyper-CVAD Regimen in Adult Newly-Diagnosed Acute Lymphoblastic Leukemia [NCT01005914]	Phase 2	11 participants (Actual)	Interventional	2009-06-30	Terminated(stopped due to Increased rate of bacterial infections)
Effect of Anti-inflammatory Topical Prednisolone Acetate 1%, Nepafenac of 0.1% and Ketorolac Tromethamine 0.4% in Intra-operative Mydriasis in Facetectomies [NCT00865540]	Phase 4	30 participants (Actual)	Interventional	2009-03-31	Active, not recruiting
Intra-discal Steroid Injection for MODIC I Discopathy: A Randomized Control Trial [NCT00804531]	Phase 4	137 participants (Actual)	Interventional	2009-04-30	Completed
A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis [NCT05232825]	Phase 3	236 participants (Actual)	Interventional	2022-05-03	Active, not recruiting
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis [NCT03952637]	Phase 1/Phase 2	17 participants (Actual)	Interventional	2019-08-19	Active, not recruiting
Vasopressin, Epinephrine, and Corticosteroids for Inhospital Cardiac Arrest: A Multicenter Randomized Controlled Trial [NCT00729794]	Phase 3	300 participants (Actual)	Interventional	2008-09-30	Completed
Role of Doxycycline in the Management of Patients With Chronic Rhinosinusitis With Nasal Polyps [NCT05157412]	Phase 3	60 participants (Anticipated)	Interventional	2022-03-01	Not yet recruiting
The Role of Anterior Segment Optical Coherence Tomography in Management of Acquired Punctal Stenosis [NCT04318652]	Phase 4	80 participants (Actual)	Interventional	2018-09-02	Completed
L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis [NCT02631109]	Phase 3	120 participants (Anticipated)	Interventional	2015-12-31	Recruiting
Randomized, Prospective Single-center Study Comparing a Rapid Discontinuation of Corticosteroids (Steroid Withdrawal) With Corticosteroid Therapy in Kidney Transplantation Using Mycophenolate Mofetil and Tacrolimus Maintenance Therapy [NCT00596947]	Phase 4	18 participants (Actual)	Interventional	2005-10-31	Terminated(stopped due to due to low study enrollment)
The Effects of Treatment of Subclinical Rejection on Renal Histology and Graft Function in Renal Transplant Patients Receiving Tacrolimus and Mycophenolate Mofetil [NCT00885820]	Phase 4	240 participants (Actual)	Interventional	2001-09-30	Completed
Evaluation of High-dose Corticosteroids on Microcirculation Alterations in Cardiac Surgery, by FMD (Flow Mediated vasoDilation), Near Infrared Spectrophotometry (NIRS) and Biological Analysis (Syndecan-1) [NCT02798068]	Phase 4	60 participants (Anticipated)	Interventional	2016-05-31	Recruiting
Evaluation of Efficacy in the Resolution of Post-Operative Inflammation and Pain in Patients Receiving Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery [NCT04316936]	Phase 4	15 participants (Actual)	Interventional	2019-12-10	Completed
GON-injection for a Sooner and Better Treatment of Cluster Headache: a Double-blind Randomized Controlled Trial [NCT04014634]	Phase 4	80 participants (Anticipated)	Interventional	2019-08-01	Recruiting
A Phase I, Randomised, Single-blind Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567 in Healthy Volunteers Using Prednisolone as Positive Control [NCT02760316]	Phase 1	64 participants (Anticipated)	Interventional	2016-05-02	Completed
Budesonide Inhalation Suspension for Acute Asthma in Children [NCT00393367]	Phase 4	179 participants (Actual)	Interventional	2006-12-31	Completed
An Open Label, Multicenter, Phase I/II Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease [NCT04220632]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2020-06-18	Terminated(stopped due to Adverse events of the first patient)
A Phase IIIB, Multicenter, Randomized, Double-Masked, Parallel-Group, Active-Controlled Study of the Safety and Efficacy of Difluprednate Ophthalmic Emulsion, 0.05% (Durezol™) 4 Times Daily (QID) and Prednisolone Acetate Ophthalmic Suspension, 1.0% (Pred [NCT01124045]	Phase 3	80 participants (Actual)	Interventional	2010-08-31	Completed
Intrathecal Rituximab in Progressive Multiple Sclerosis [NCT02545959]	Phase 2	10 participants (Actual)	Interventional	2015-11-30	Completed
Randomized, Placebo-Controlled Trial of Bilateral 3rd/4th Common Digital Foot Nerve Injections to Treat Restless Legs Syndrome [NCT00656110]		60 participants (Anticipated)	Interventional	2008-04-30	Recruiting
Topical Epidural Steroid Usage in Patients Undergoing Posterior Lumbar Decompression: A Randomized Control Trial [NCT05058287]	Phase 3	150 participants (Anticipated)	Interventional	2021-11-05	Recruiting
Multicenter, Randomized, Double Blind, Clinical Trial to Compare the Clinical and Radiological Efficacy of Equivalent Doses of Methylprednisolone Administered Orally or Intravenously in Patients With Multiple Sclerosis During Relapse [NCT00753792]	Phase 4	49 participants (Actual)	Interventional	2008-11-30	Completed
Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II：A Randomized Controlled Open-label Clinical Trial [NCT04617561]	Phase 4	90 participants (Anticipated)	Interventional	2020-11-01	Recruiting
Steroid Injection for the Treatment of Greater Trochanteric Pain Syndrome: A Randomized Controlled Trial [NCT00863889]	Phase 4	0 participants (Actual)	Interventional	2009-03-31	Withdrawn
An Unusual Association Between Pancreatic Cancer and Purtscher-like Retinopathy: Presentation of a Unique Case [NCT05350384]		1 participants (Actual)	Observational	2021-06-18	Completed
Steroids and Azathioprine in Early and Advanced IgA Nephropathy: Amendments to a Prospective Randomised Multicenter Trial [NCT01392833]	Phase 3	46 participants (Actual)	Interventional	1999-12-31	Completed
Phase I Study of Escalating Doses of Carfilzomib With Hyper-CVAD in Patients With Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma [NCT02293109]	Phase 1	10 participants (Actual)	Interventional	2015-12-17	Completed
Phase 1, Open-label, Randomized, Single-dose, 2-treatment, Crossover Be Study Comparing Constituted Methylprednisolone Powder For Oral Suspension 4 Mg/ml To Methylprednisolone 16 Mg Tablet Under Fasting Conditions [NCT01405157]	Phase 1	0 participants (Actual)	Interventional	2012-01-01	Withdrawn
Phase 1, Open-label, Randomized, Single-dose, 2-treatment, Crossover Be Study Comparing Constituted Methylprednisolone Powder For Oral Suspension 4 Mg/ml To Methylprednisolone 32 Mg Tablet Under Fed Conditions [NCT01405170]	Phase 1	0 participants (Actual)	Interventional	2011-10-14	Withdrawn
A Phase IV Single Blind Placebo-controlled Cross Over Study to Investigate the Efficacy of Greater Occipital Nerve Block With Local Anesthetic and Steroid in Patients With Chronic Migraine [NCT04017741]	Phase 4	8 participants (Actual)	Interventional	2018-02-14	Completed
Randomised Trial of Plasma Exchange or High Dose Methyl Prednisolone as Adjunctive Therapy for Severe Renal Vasculitis [NCT01408836]	Phase 2/Phase 3	150 participants (Actual)	Interventional	1995-03-31	Terminated(stopped due to Completed)
Comparison Between Standard Dose Methyl Prednisolone and Megadose Methyl Prednisolone as Regards Outcome in SARS.COV.2 Patients in Intensive Care Unit : Retrospective Study [NCT05279482]		104 participants (Actual)	Observational	2022-01-19	Completed
The Treatment of Hematologic Malignancies With Single or Double Umbilical Cord Blood Unit Transplantation Followed by Graft-versus-Host Prophylaxis With Tacrolimus and Mycophenolate Mofetil [NCT00608517]		6 participants (Actual)	Interventional	2005-09-30	Terminated(stopped due to slow accrual)
A Randomized Phase II Study for the Evaluation of Extracorporeal Photopheresis (ECP) in Combination With Corticosteroids for the Initial Treatment of Acute Graft-Versus-Host Disease (GVHD) [NCT00609609]	Phase 2	81 participants (Actual)	Interventional	2008-01-31	Completed
Effects of Pre-operative Methylprednisolone (125mg iv) After Total Knee Arthroplasty: A Prospective, Randomized, Double-blind, Placebo-controlled Trail [NCT00968578]	Phase 4	48 participants (Actual)	Interventional	2009-08-31	Completed
Study Characterizing the Impact of Different Therapeutic Strategies on Event Occurrence at 2 Years, 5 Years, 10 Years, and 15 Years, According to Prognostic Groups in Patients With Hodgkin Lymphoma [NCT00920153]	Phase 3	442 participants (Actual)	Interventional	2008-05-31	Terminated(stopped due to Other new drugs)
A Prospective Study on the Modified DEP Regimen Induction Therapy in Lymphoma Induced Hemophagocytic Lymphohistiocytosis [NCT04077905]	Phase 3	160 participants (Anticipated)	Interventional	2019-08-31	Recruiting
Phase II Study of Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOX) for Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma [NCT00336583]	Phase 2	27 participants (Actual)	Interventional	2006-06-30	Completed
Phase II Study of The Modified Hyper-CVAD Program for Acute Lymphoblastic Leukemia [NCT00671658]	Phase 2	220 participants (Actual)	Interventional	2002-11-30	Completed
Effect of Preoperative Intravenous High Dose Methylprednisolone on Immune Signaling in Patients Scheduled for Total Hip-arthroplasty [NCT02542592]	Phase 2/Phase 3	64 participants (Actual)	Interventional	2015-09-30	Completed
Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies [NCT01093586]	Phase 2	14 participants (Actual)	Interventional	2007-09-30	Completed
An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia [NCT04263402]	Phase 4	100 participants (Anticipated)	Interventional	2020-02-01	Recruiting
A Randomized, Parallel-Cohort Phase 1 Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute Graft Versus Host Disease [NCT02614612]	Phase 1	31 participants (Actual)	Interventional	2015-12-31	Completed
Prednisolone-induced Impairment of Glucose Metabolism and Beta-cell Dysfunction and the Protective Effects of Exenatide: a Single-center, Randomized, Double-blind, Placebo-controlled Crossover Study in Healthy Volunteers [NCT00744224]		8 participants (Anticipated)	Interventional	2009-02-28	Completed
A Comparison of Effects of Standard Dose vs. Low Dose Advagraf® With IL-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB - Based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response [NCT00933231]	Phase 3	281 participants (Actual)	Interventional	2009-08-17	Completed
[NCT02603575]		60 participants (Anticipated)	Interventional	2015-11-30	Recruiting
Treatment of Acute Graft vs. Host Disease With Steroids Plus Daclizumab (Zenapax) or Placebo [NCT00053976]	Phase 3	105 participants (Actual)	Interventional	2001-01-31	Completed
Phase III Randomised Study on Liposomal Cytarabine (DepoCyte®) vs. Intrathecal Triple for CNS-Treatment During Maintenance Therapy in High-Risk Acute Lymphoblastic Leukemia Patients in NOPHO ALL 2008 Treatment Protocol [NCT00991744]	Phase 3	100 participants (Anticipated)	Interventional	2009-01-31	Suspended(stopped due to Sterility problems in DepoCyte production)
Efficacy of Vigabatrin With High Dose Prednisolone Combination Therapy Versus Vigabatrin Alone for Infantile Spasm: a Randomized Trial [NCT04302116]		250 participants (Anticipated)	Interventional	2020-05-18	Recruiting
Pilot Randomized, Placebo-Controlled Trial to Evaluate The Effect of Oral Pulsed Methylprednisolone on Seizure Frequency in Pediatric Patients With Idiopathic Intractable Convulsive Epilepsy [NCT04219995]	Phase 1/Phase 2	10 participants (Anticipated)	Interventional	2020-02-03	Recruiting
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation [NCT00309907]	Phase 2	39 participants (Actual)	Interventional	2006-04-30	Completed
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults [NCT02166463]	Phase 3	600 participants (Actual)	Interventional	2015-03-19	Active, not recruiting
A Prospective Randomized Controlled Study to Compare Efficacy of Caspofungin Combined With Trimethoprim-sulfamethoxazole Versus Trimethoprim/Sulfamethoxazole as First-line Therapy in Non-HIV Patients With Severe Pneumocystis Pneumonia [NCT03978559]	Phase 4	122 participants (Anticipated)	Interventional	2019-08-14	Recruiting
Swiss PACK-CXL (Photoactivated Chromophore for Infectious Keratitis Cross-linking) Multicenter Trial for the Treatment of Infectious Keratitis [NCT02717871]	Phase 3	35 participants (Actual)	Interventional	2016-03-31	Completed
A PHASE II RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMBINATION WITH METHOTREXATE, COMPARED TO INFLIXIMAB PLUS METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS CURRENTLY RESPONDING INADE [NCT00808210]	Phase 2	28 participants (Actual)	Interventional	2009-03-05	Terminated(stopped due to Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.)
Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) [NCT00720109]	Phase 2/Phase 3	63 participants (Actual)	Interventional	2008-07-14	Completed
Relative Efficacy of Repeat Course of Intravenous methyLprednisolone and Intramuscular ACTH in the Treatment of Acute Relapse of Multiple Sclerosis After Sub Response to Initial Course of Intravenous Methylprednisolone (RECLAIM): a Single Center Pilot Stu [NCT00947895]	Phase 2/Phase 3	30 participants (Actual)	Interventional	2009-10-31	Terminated(stopped due to Study reached halfway point in approximately one year time period and was halted to analyze data.)
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases [NCT00623766]	Phase 2	99 participants (Actual)	Interventional	2008-07-31	Completed
A Phase I Open-Label, Safety Study of Haploidentical Bone Marrow Transplantation (BMT) After Ex Vivo Treatment of Bone Marrow With Anti-B7.1 and Anti-B7.2 Antibodies [NCT00005988]	Phase 1	5 participants (Actual)	Interventional	2000-02-29	Completed
[NCT00006054]		0 participants	Interventional	2000-03-31	Terminated
[NCT00006055]		10 participants	Interventional	2000-03-31	Active, not recruiting
T-cell Depletion In Unrelated Donor Marrow Transplantation [NCT00006451]	Phase 3	0 participants (Actual)	Interventional	1996-04-30	Withdrawn(stopped due to Terminated (due to no accrual))
Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation [NCT00008307]	Phase 2	52 participants (Anticipated)	Interventional	1998-04-30	Active, not recruiting
[NCT00000147]		0 participants	Interventional	1988-07-31	Active, not recruiting
Acute Respiratory Distress Syndrome Clinical Network (ARDSNet) [NCT00000579]	Phase 3	0 participants	Interventional	1994-09-30	Completed
A Controlled Randomized Trial to Study the Efficacy of Adjunctive Methylprednisolone for the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Pediatric AIDS Patients [NCT00000741]	Phase 3	0 participants (Actual)	Interventional		Withdrawn
Allogeneic Bone Marrow Transplantation for Marrow Failure States [NCT00005852]	Phase 2	0 participants	Interventional	1996-06-30	Terminated(stopped due to low accrual)
Assessment of the Operative Course in Connection With Removal of Lower Third Molars With Particular Consideration to the Occurence of Pain and Swelling [NCT00805298]		154 participants (Actual)	Interventional	2008-08-31	Completed
Intérêt de la corticothérapie Dans la Pneumocystose Grave du Patient immunodéprimé Non VIH. Essai Prospectif Multicentrique Randomisé Contrôlé : PIC [NCT02944045]	Phase 3	222 participants (Anticipated)	Interventional	2017-02-15	Recruiting
Efficacy of Methylprednisolone in Severe Community-acquired Pneumonia，A Multi-center Randomized Controlled Trial [NCT02552342]	Phase 4	610 participants (Anticipated)	Interventional	2015-05-31	Recruiting
A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients With Anterior Uveitis [NCT02406209]	Phase 2	45 participants (Actual)	Interventional	2015-03-31	Completed
Acute Unilateral Vestibulopathy and Corticosteroid Treatment [NCT02912182]	Phase 4	78 participants (Actual)	Interventional	2015-12-31	Terminated(stopped due to Placebo medication expired)
An Open-label Study to Assess the Efficacy and Safety of Alipogene Tiparvovec (AMT-011), Human LPL [S447X], Expressed by an Adeno-Associated Viral Vector After Intramuscular Administration in LPL-deficient Adult Subjects [NCT00891306]	Phase 2/Phase 3	5 participants (Actual)	Interventional	2009-02-28	Completed
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas [NCT01024322]		1,189 participants (Actual)	Observational	2009-10-01	Terminated(stopped due to Terminated to initiate FDA IND-cleared study protocol)
Hematopoietic Stem Cell Transplant For Patients With Dyskeratosis Congenita and Severe Aplastic Anemia [NCT00455312]	Phase 2/Phase 3	36 participants (Actual)	Interventional	2007-08-31	Completed
The Research of Standard Diagnosis and Treatment for Henoch-Schonlein Purpura Nephritis in Children [NCT02532777]	Phase 2	100 participants (Anticipated)	Interventional	2015-08-31	Recruiting
Utility of Intramuscular Corticosteroids for Radicular Low Back Pain [NCT00290589]	Phase 3	82 participants (Actual)	Interventional	2003-06-30	Completed
Randomized Trial of Plasma Exchange as Adjunctive Therapy for Severe Crescentic GlomerUlonephritis of IgA NEphropathy (RESCUE Study) [NCT02647255]	Phase 2/Phase 3	10 participants (Actual)	Interventional	2016-03-31	Terminated(stopped due to Due to the rarity and rapid progressive course of the disease, patients were less likely to participate in randomization.)
Local Injection of Ozone Versus Methylprednisolone Acetate in Carpal Tunnel Syndrome of Scleroderma Patients. A Single-blind Randomized Clinical Trial [NCT03742466]		50 participants (Actual)	Interventional	2018-11-10	Completed
A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib [NCT01324596]	Phase 3	1,132 participants (Actual)	Interventional	2011-04-30	Completed
A Randomized, Multicenter, Open-label, 6-month Study to Explore the Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare [NCT00423098]	Phase 2	81 participants (Actual)	Interventional	2007-02-28	Completed
An Open-label, Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft Versus Host Disease After TLI/ARG Nonmyeloablative Allogeneic Stem Cell Transplantation [NCT00186628]	Phase 2	36 participants (Actual)	Interventional	2005-06-30	Completed
A Phase II Trial of T-Cell Depleted Marrow Grafts Combined With Infusions of G-CSF Stimulated, CD34 Ceprate Stem Cell Column Selected, E-Rosette Depleted Peripheral Blood Progenitor Cells Derived From HLA Haplotype Matched Related Donors for Patients With [NCT00002718]	Phase 2	31 participants (Actual)	Interventional	1995-11-30	Completed
Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord: an Open-Labeled, Dose-Escalating Clinical Tiral [NCT01046786]	Phase 1/Phase 2	8 participants (Actual)	Interventional	2010-01-31	Completed
An Oral Methylprednisolone Taper Within a Multimodal Analgesic Regimen After Total Knee Arthroplasty: a Double-Blind Randomized Placebo-Controlled Trial [NCT05097976]	Phase 4	420 participants (Anticipated)	Interventional	2022-03-01	Recruiting
Rituximab Plus Short-term Methylprednisolone Versus Standard Dose Methylprednisolone in Newly Diagnosed Participants With Immune Thrombocytopenia (ITP): A Multicenter, Randomized Phase II Study in China [NCT02757196]	Phase 2	112 participants (Anticipated)	Interventional	2016-05-31	Not yet recruiting
Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis [NCT00332696]	Phase 2	64 participants (Actual)	Interventional	2005-09-30	Completed
A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy in Infants With Biliary Atresia [NCT00294684]		141 participants (Actual)	Interventional	2005-11-30	Completed
A Randomized, Placebo Controlled, Double-blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate, Compared to Methotrexate Monotherapy, in Patients With Active Rheumatoid Arthritis [NCT00299130]	Phase 3	511 participants (Actual)	Interventional	2005-10-31	Completed
A Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Tolerability and Safety of Rituximab When Given in Combination With Methotrexate and Etanercept (Enbrel) or Methotrexate and Adalimumab (Humira) in Subjects With Active Rheumatoid Arth [NCT00298272]	Phase 2	54 participants (Actual)	Interventional	2006-05-31	Terminated(stopped due to Sponsor decided to end long term extension phase for business reasons unrelated to safety.)
Steroid Free Immunosuppression in Liver Transplantation [NCT00296244]	Phase 4	40 participants (Actual)	Interventional	2006-02-28	Completed
A Randomized Trial of Rituximab in Induction Therapy for Living Donor Renal Transplantation [NCT01095172]	Phase 4	100 participants (Actual)	Interventional	2010-11-30	Active, not recruiting
High Dose Cyclophosphamide & ATG With Hematopoietic Stem Cell Transplantation in Patients With Refractory Idiopathic Inflammatory Myopathy Diseases: A Phase I Trial [NCT00278564]	Phase 1	7 participants (Actual)	Interventional	2005-09-30	Terminated(stopped due to high relapse rate)
Pain Relief and Functional Improvement Provided by ESWT in Plantar Fasciitis is Better Than Corticosteroid Injection and Kinesiotherapy: A Randomized Trial [NCT05647291]		90 participants (Actual)	Interventional	2021-10-15	Completed
An Open-Label, Phase 1 Study to Examine the Pharmacokinetic Interactions Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects [NCT01886209]	Phase 1	28 participants (Anticipated)	Interventional	2013-06-30	Completed
Evaluation of Inhaled Corticosteroid Treatment in Sinusitis [NCT01907204]	Phase 2/Phase 3	50 participants (Actual)	Interventional	2013-07-31	Completed
A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis [NCT04544436]	Phase 3	865 participants (Anticipated)	Interventional	2020-11-26	Active, not recruiting
Assessing the Efficacy of DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert, When Placed Within the Lower Eye Lid Canaliculus in Comparison to Topical Prednisolone Acetate Following Bilateral Small Incision Lenticule Extraction (SMILE) [NCT04380857]	Phase 4	20 participants (Actual)	Interventional	2020-06-18	Completed
Regulatory T Cell Modulation in Kidney Transplantation With Biologic Blockade of Dual Effector Pathways, CD28 and IL-6 (CTOT-24) [NCT04066114]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2019-12-11	Completed
A Phase II Study to Evaluate Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease [NCT00410657]	Phase 2	53 participants (Anticipated)	Interventional	2006-07-31	Completed
Maintenance in Autologous Stem Cell Transplant for Crohn's Disease (MASCT - CD) [NCT03219359]	Phase 2	50 participants (Anticipated)	Interventional	2017-07-12	Recruiting
Macular Edema Nepafenac vs. Difluprednate Uveitis Trial [NCT01939691]	Phase 4	9 participants (Actual)	Interventional	2018-09-12	Terminated(stopped due to Difficulty enrolling)
Autologous Blood or Marrow Transplantation for Aggressive Non-Hodgkin's Lymphoma Based on Early [18F] FDG-PET Scanning [NCT00238368]	Phase 2	59 participants (Actual)	Interventional	2004-02-29	Completed
Efficiency of Multi-Modal Anesthesia (MMA) Protocol in Pain Control and Analgesia in Patients Undergoing Posterior Lumbar Spinal Fusion Surgery [NCT05413902]	Phase 4	100 participants (Actual)	Interventional	2021-04-05	Completed
A Double-blind, Two-arm, Multicenter, Randomized Trial to Evaluate Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Recent Secondary Progressive Multiple Sclerosis: P.R.OM.E.S.S Study [NCT00241254]	Phase 3	138 participants (Actual)	Interventional	2005-12-31	Completed
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Itolizumab in Subjects With Newly Diagnosed Acute Graft Versus Host Disease [NCT05823675]	Phase 1	44 participants (Anticipated)	Interventional	2023-05-19	Recruiting
Phase II Study of High-dose Methylprednisolone and Rituximab in Previously Treated Patients With High Risk Chronic B Lymphocytic Leukemia [NCT00558181]	Phase 2	29 participants (Actual)	Interventional	2007-09-30	Completed
European Multicenter and Open-Label Controlled Randomized Trial to Evaluate the Efficacy of Sequential Treatment With Tacrolimus-Rituximab Versus Steroids Plus Cyclophosphamide in Patients With Primary Membranous Nephropathy (The STARMEN Study) [NCT01955187]	Phase 3	86 participants (Actual)	Interventional	2014-01-31	Completed
Steroid Injections vs. Platelet Rich Plasma Injections in Patients With Plantar Fasciitis: A Comparison of Clinical and Ultrasound Findings [NCT01957631]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2013-06-30	Withdrawn(stopped due to Lack of funding)
A Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy [NCT01969019]	Phase 4	70 participants (Anticipated)	Interventional	2010-01-31	Recruiting
Antiemetic Corticosteroid Rotation From Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated With Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial [NCT01974024]	Phase 3	65 participants (Actual)	Interventional	2013-10-01	Completed
A Prospective Randomized 3-arm Trial Comparing Intra-articular Corticosteroid Injection vs Arthrographic Distention vs Arthrographic Distention Plus Intra-articular Corticosteroid Injection in the Treatment of Adhesive Capsulitis [NCT01983527]		132 participants (Anticipated)	Interventional	2013-12-31	Not yet recruiting
Comparing the Effectiveness of Steroid Injection Versus Placebo and Immobilization Versus no Immobilization in Treating Patients With Lateral Epicondylitis [NCT01986465]	Phase 2/Phase 3	78 participants (Actual)	Interventional	2013-05-31	Completed
Optimal Treatment of Plantar Fasciitis: A Randomized Clinical Trial Using Physical Training, Glucocorticoid Injections or a Combination Thereof. [NCT01994759]	Phase 4	90 participants (Actual)	Interventional	2013-09-01	Completed
Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease [NCT04603729]	Phase 3	100 participants (Actual)	Interventional	2020-05-30	Completed
PhaseIV Study of Intra-articular Methylprednisolone in TMJ Arthralgia [NCT01995019]	Phase 4	56 participants (Actual)	Interventional	2013-12-10	Completed
Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars) [NCT04593706]		40 participants (Anticipated)	Interventional	2020-11-01	Not yet recruiting
Preoperative Glucocorticoid Use in Major Hepatectomy - A Randomized Controlled Trial [NCT01997658]	Phase 2/Phase 3	200 participants (Actual)	Interventional	2014-10-31	Completed
High Doses of Methylprednisolone in the Management of Caustic Esophageal Burns in Children [NCT02002078]	Phase 4	83 participants (Actual)	Interventional	2007-02-28	Completed
Efficacy of the Intralesional Infusion of Local Anesthetic and Steroids After Major Abdominal Surgery: a Randomized Double Blind Phase III Trial [NCT02002663]	Phase 3	120 participants (Actual)	Interventional	2013-08-31	Completed
A Phase I Randomized, Double-blind, Placebo-controlled, Dose-increasing Single Dose Study Evaluating the Safety, Tolerability，Pharmacokinetics and Pharmacodynamics Analysis of Pegloticase in Subjects With Asymptomatic Hyperuricemia [NCT05302388]	Phase 1	45 participants (Actual)	Interventional	2022-04-11	Completed
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving KRYSTEXXA® (Pegloticase) (MIRROR Randomized Controlled Trial [RCT]) [NCT03994731]	Phase 4	152 participants (Actual)	Interventional	2019-06-13	Completed
Randomised, Multicentre, Open Label, Parallel Group Pragmatic Clinical Trial of Local Steroid Injection Versus Night Splinting in Mild to Moderate Carpal Tunnel Syndrome (CTS) [NCT02038452]	Phase 4	234 participants (Actual)	Interventional	2014-04-30	Completed
Influence of Corticoids on Renal Function in Cardiac Surgery [NCT00879931]	Phase 2	80 participants (Actual)	Interventional	2013-01-31	Completed
Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass [NCT00934843]		77 participants (Actual)	Interventional	2007-03-31	Completed
Do Intraoperative Topical Corticosteroids Aid in the Prevention of Postoperative Dysphagia Following Elective Anterior Cervical Discectomy and Fusion? A Randomized, Controlled, Double Blinded Clinical Trial [NCT02539394]		128 participants (Actual)	Interventional	2015-08-31	Completed
[NCT00005898]	Phase 1/Phase 2	30 participants	Interventional	2000-02-29	Completed
Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis: a Randomized Controlled Trial [NCT03265405]	Phase 4	86 participants (Actual)	Interventional	2017-04-01	Completed
Steroid Administration for Articular Fractures of the Elbow (SAFE Trial): A Randomized, Controlled Trial of Perioperative Glucocorticoids During Treatment of Intraarticular Elbow Fractures [NCT04738318]	Phase 4	3 participants (Actual)	Interventional	2022-06-16	Terminated(stopped due to Switched to observational study type.)
Efficacy and Safety of Difluprednate Ophthalmic Emulsion vs. a Fixed-Combination of Prednisolone Acetate - Phenylephrine Ophthalmic Suspension on Post-operative Inflammation Following Cataract Surgery. [NCT04631315]	Phase 4	255 participants (Actual)	Interventional	2019-03-24	Completed
Study on the Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica and Gene Polymorphism: a Cohort Study [NCT04601142]		350 participants (Anticipated)	Observational	2020-10-31	Recruiting
Peking University Third Hospital Medical Science Research Ethics Committee [NCT04590183]		30 participants (Anticipated)	Interventional	2020-10-01	Recruiting
Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Glucocorticoid Infusion in Acute Respiratory Distress Syndrome (ARDS) [NCT00562835]	Phase 2/Phase 3	400 participants (Anticipated)	Interventional	2008-02-29	Not yet recruiting
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combination With Standard of Care (Mycophenolate Mofetil and Steroid [NCT01085097]	Phase 2	46 participants (Actual)	Interventional	2010-09-01	Completed
The Efficacy Of Magnesium In Radicular Lower Limb Pain When It Is Added To Local Anesthetics And Steroids In The Transforaminal Epidural Injections. A Comparative Study [NCT04532775]	Phase 1	100 participants (Anticipated)	Interventional	2020-08-30	Not yet recruiting
Comparison of Methylprednisolone or Methotrexate With Standard Treatment in the Maintenance Treatment of Medically and Surgically Treated Chronic Rhinosinusitis With Nasal Polyposis [NCT04532736]	Phase 2	41 participants (Actual)	Interventional	2017-09-02	Completed
A Phase 3 Multicenter, Randomized, Double-Masked Study of the Safety and Efficacy of Difluprednate 0.05% Ophthalmic Emulsion Compared to Prednisolone Acetate 1% Ophthalmic Suspension in the Treatment of Endogenous Anterior Uveitis [NCT01201798]	Phase 3	111 participants (Actual)	Interventional	2010-10-31	Completed
Comparison of the Efficacy Between Ultrasound-guided Dextrose Injection Versus Dextrose With Methylprednisolone Injection in Patients With Carpal Tunnel Syndrome: a Prospective, Randomized Double-blind Clinical Trial. [NCT06045013]	Phase 3	70 participants (Anticipated)	Interventional	2023-09-13	Recruiting
A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifyi [NCT03368664]	Phase 3	16 participants (Actual)	Interventional	2017-10-24	Active, not recruiting
Ultrasound Guided Sacroiliac Joint Injections With Ketorolac Versus Corticosteroid: A Prospective Non-inferiority Study [NCT06081101]	Early Phase 1	80 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Lessdrops™ Prophylactic Treatment After Routine Phacoemulsification Compared to Standard Drops Regimen [NCT03578276]	Phase 4	35 participants (Actual)	Interventional	2018-06-22	Completed
Risk Stratification-directed Low-dose Glucocorticoid Prophylaxis for Acute GVHD After Unmanipulated Haploidentical Blood and Marrow Transplantation--a Randomized, Controlled, Clinical Trial [NCT01607580]		145 participants (Actual)	Interventional	2012-06-30	Completed
Evaluation of the Bioavailability of Methylprednisolone Succinate Administered Intranasally [NCT05649878]		8 participants (Actual)	Interventional	2021-11-05	Completed
Non-Invasive Mechanical Ventilation in Elderly Patients Affected by Acute Hypercapnic Respiratory Failure:A Randomized Control Study vs Standard Medical Therapy A Multicentric Randomized Controlled Trial [NCT00600639]	Phase 4	82 participants (Actual)	Interventional	2004-01-31	Terminated
Comparison Between Prednisolone and Dexamethasone on D28 Mortality in Patients on Oxygen Therapy, With CoViD-19: Multicenter, Randomized, Open-label Non-inferiority Study [NCT04765371]	Phase 3	89 participants (Actual)	Interventional	2021-03-03	Completed
Local Steroid Injection in the Treatment of Idiopathic Carpal Tunnel Syndrome: A Randomized Double-blind Placebo-controlled Trial Among Patients Planned for Surgical Treatment [NCT00806871]	Phase 2/Phase 3	112 participants (Actual)	Interventional	2008-11-30	Completed
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis [NCT00424489]	Phase 1	9 participants (Actual)	Interventional	2002-02-28	Terminated(stopped due to No participants enrolled for more than two years. No plan to continue study.)
Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammation and Pain- The LINK Study [NCT04168112]	Phase 4	20 participants (Actual)	Interventional	2020-02-12	Completed
Incretin Physiology and Beta-Cell Function Before and After Treatment With Steroid Hormone in Healthy Individuals [NCT00713440]		10 participants (Actual)	Interventional	2008-07-31	Completed
Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest - A Randomized, Double-Blind, Placebo-Controlled Trial [NCT03640949]	Phase 2/Phase 3	501 participants (Actual)	Interventional	2018-09-17	Completed
A Phase 2 Study of SNDX-5613 in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia [NCT05761171]	Phase 2	78 participants (Anticipated)	Interventional	2023-11-20	Recruiting
Abatacept for Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: a Sickle Transplant Alliance for Research Trial [NCT02867800]	Phase 1	24 participants (Actual)	Interventional	2016-07-31	Active, not recruiting
Preoperative Methylprednisolone to Patients Suspected of Appendicitis Undergoing Laparoscopy [NCT02711449]	Phase 2	78 participants (Actual)	Interventional	2016-04-30	Completed
An Open-label Multicenter Trial to Study the Efficacy and Safety of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura [NCT04074187]	Phase 2/Phase 3	21 participants (Actual)	Interventional	2019-10-21	Completed
A Randomized Controlled Clinical Trial on the Efficacy and Safety of Glucocorticosteroid in the Patients With Chronic Recurrent Drug-induced Liver Injury [NCT02651350]	Phase 1/Phase 2	80 participants (Actual)	Interventional	2015-12-31	Completed
Efficacy of Intra-operative Subacromial Corticosteroid Injections on Surgical Outcomes After Arthroscopic Shoulder Surgery [NCT02867904]	Phase 4	12 participants (Actual)	Interventional	2016-03-31	Terminated(stopped due to It was difficult to recruit patients to get the appropriate sample size.)
"Screening Protein Predictive of Response to Tumor Necrosis Factor-α Inhibitors Treatment in Chinese Rheumatoid Arthritis From Real World and Investigating Its Mechanism Through Signal Pathway" [NCT02878161]	Phase 4	240 participants (Anticipated)	Interventional	2016-01-31	Enrolling by invitation
Comparison of Corticosteroids Versus Placebo on Duration of Ventilatory Support During Severe Acute Exacerbations of COPD Patients in the Intensive Care Unit: a Multicentre Randomized Controlled Trial [NCT04163536]	Phase 3	440 participants (Anticipated)	Interventional	2021-10-25	Recruiting
Selective CD28 Blockade With Lulizumab Compared to CNI Inhibition With Tacrolimus in Renal Transplant Recipients [NCT04903054]	Phase 2	0 participants (Actual)	Interventional	2022-01-10	Withdrawn(stopped due to Limited period of availability of a supply of the study drug and difficulties in enrollment)
Desensitization for Preformed Anti-HLA Antibodies in Kidney Transplantation [NCT00908583]	Phase 4	44 participants (Actual)	Interventional	2009-05-31	Completed
Corticosteroids for Cancer Pain [NCT00676936]	Phase 3	50 participants (Actual)	Interventional	2008-04-30	Completed
Phase 1, Open-label, Randomized, Single-dose, 2-treatment, 2 Period Crossover Bioequivalence Study Comparing Constituted Methylprednisolone Powder For Oral Suspension 4 Mg/ml To Methylprednisolone 32 Mg Tablet Under Fasted Conditions [NCT01405131]	Phase 1	0 participants (Actual)	Interventional	2012-01-01	Withdrawn
Early Short Course Corticosteroids in Hospitalized Patients With COVID-19 [NCT04374071]		250 participants (Actual)	Observational	2020-03-12	Completed
Assessment of Corticosteroid Effect in the Prevention of Facial Palsy After Cerebella-pontine Angle Surgery [NCT00438087]	Phase 3	313 participants (Actual)	Interventional	2007-03-31	Completed
A Phase I Study to Examine the Toxicity of Killer IG-Like Receptor (KIR) Mismatched Umbilical Cord Blood for Pediatric Patients With Malignant Solid Tumors [NCT00436761]	Phase 1	20 participants (Anticipated)	Interventional	2004-05-31	Active, not recruiting
Retrospective Study of Intrapleural Methylprednisolone Injection for Multiple Organ Failure With Acute Respiratory Distress Syndrome [NCT01423864]	Phase 2	29 participants (Actual)	Interventional	2005-06-30	Completed
A Randomized, Multicentre, Double-blind Study to Evaluate the Efficacy of High-dose Administration of Methylprednisolone in Addition to Standard Treatment, in SARS-CoV2 (COVID-19) Pneumonia Patients [NCT04673162]	Phase 3	260 participants (Actual)	Interventional	2020-12-17	Completed
Efficacy of High-dose Corticosteroid Pulses Added to Conventional Oral Corticosteroid Course for Moderate Flares of Ulcerative Colitis. [NCT02921555]	Phase 4	75 participants (Actual)	Interventional	2018-10-11	Completed
Assessing the Efficacy and Safety of DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert, When Placed Within the Lower Eye Lid Canaliculus in Pseudo Phakic Patients Undergoing Gas Bubble Repair and Laser Following Retinal Detachment [NCT04464629]	Phase 4	7 participants (Actual)	Interventional	2020-07-14	Terminated(stopped due to Poor enrollment)
Randomized Treatment Interruption of Natalizumab [NCT01071083]	Phase 2	175 participants (Actual)	Interventional	2010-03-31	Completed
The Ideal Management of Crohn's Disease: Top Down Versus Step Up Strategies. A Prospective Controlled Trial in the Benelux [NCT00554710]	Phase 4	129 participants (Actual)	Interventional	2001-05-31	Completed
Evaluation of the Tolerability and Efficacy of Erythropoietin (EPO) Treatment in Spinal Shock: Comparative Study VS Methylprednisolone (MP) [NCT00561067]	Phase 3	10 participants (Actual)	Interventional	2008-04-30	Terminated(stopped due to Italian Medicines Agency decision)
Double-Blind, Placebo Controlled, Randomized, Multicenter, Parallel-Group Study to Compare the Efficacy and Safety of Advantan Cream Twice Weekly With Advabase Cream During a Maintenance Phase of 16 Weeks After Successful Treatment of Atopic Dermatitis Wi [NCT00185510]	Phase 4	250 participants (Actual)	Interventional	2005-03-31	Completed
Can Montelukast Shorten Corticosteroid Therapy In Children With Mild To Moderate Acute Asthma? [NCT00213252]	Phase 2	130 participants (Actual)	Interventional	2005-09-30	Completed
Multisystem Inflammatory Syndrome Therapies in Children (MISTIC) Comparative Effectiveness Study [NCT04898231]	Phase 2/Phase 3	180 participants (Anticipated)	Interventional	2020-12-22	Active, not recruiting
A Phase 2b, Double-Blind, Three Arm, Randomized, Placebo Controlled Trial With Restricted Response Adaptive Randomization Testing the Efficacy and Safety of High Dose Methylprednisolone or Equine Anti-Thymocyte Globulin as Treatment for Acute Liver Failur [NCT04862221]	Phase 2	163 participants (Anticipated)	Interventional	2022-02-09	Recruiting
T Cell Receptor Alpha/Beta T Cell Depleted (α/β TCD) Hematopoietic Cell Transplantation in Patients With Fanconi Anemia (FA) [NCT03579875]	Phase 2	48 participants (Anticipated)	Interventional	2018-11-13	Recruiting
Treatment of Acute Lymphoblastic Leukemia in Children [NCT00400946]	Phase 3	800 participants (Actual)	Interventional	2005-04-30	Completed
Comparison of Three Different Treatment Regimes in Early Rheumatoid Arthritis: A Randomized Open-labelled Trial [NCT01870128]	Phase 3	60 participants (Actual)	Interventional	2009-08-31	Completed
Comparison of the Efficacy and Safety of Two Corticosteroid Regimens in the Treatment of Diffuse Lung Disease After Coronavirus Disease 2019 (COVID-19) Pneumonia [NCT04657484]		130 participants (Actual)	Interventional	2020-12-01	Completed
Phase II, Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Effects and Safety of Infusion of Low-Doses of Methylprednisolone in Early ALI and ARDS in Children [NCT01757899]	Phase 2	0 participants (Actual)	Interventional	2014-01-31	Withdrawn(stopped due to Technical problems)
Comparison of the Effectiveness of the Ultrasound Guided Subacromial, Acromioclavicular With Subacromial Injection and Suprascapular Nerve Block in Patients With Shoulder Impingement Syndrome ; A Randomized Controlled, Single Blind, Clinical Trial [NCT05015322]	Phase 4	88 participants (Actual)	Interventional	2017-01-01	Completed
Use of Topical Euphrasia, a Homeopathic Remedy in Ophthalmology [NCT02416128]		0 participants (Actual)	Interventional	2015-04-30	Withdrawn(stopped due to No participants enrolled)
A Two-Part, Multi-Center, Prospective, Phase 2/3 Clinical Study to Evaluate the Safety and Efficacy of GLASSIA as an Add-On Biopharmacotherapy to Conventional Steroid Treatment in Subjects With Acute Graft-Versus-Host Disease With Lower Gastrointestinal I [NCT02956122]	Phase 2/Phase 3	1 participants (Actual)	Interventional	2017-04-26	Terminated(stopped due to The decision to discontinue the study was based on business reasons.)
[NCT00000138]	Phase 3	0 participants	Interventional	1989-05-31	Active, not recruiting
[NCT00004482]	Phase 2	40 participants	Interventional	1999-12-31	Completed
The Efficacy of Exercise Therapy Followed by Ultrasound Guided Injection in Patients With a Painful Shoulder - a Randomised Controlled Study With Blinded Observer [NCT01506804]		99 participants (Actual)	Interventional	2010-11-30	Completed
Phase IV Study of Perioperative Steroid's Effects on Death or MI in High-Risk Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass [NCT00427388]	Phase 4	7,507 participants (Actual)	Interventional	2007-06-30	Active, not recruiting
[NCT00480675]		65 participants (Actual)	Interventional	2007-03-31	Completed
A Multi-Centre, Open Label Study to Investigate the Recovery of IFN-beta Efficacy in Relapsing-Remitting Multiple Sclerosis Patients With Neutralising IFN-beta Antibodies and Reduced Bioavailability [NCT00493116]	Phase 4	20 participants (Actual)	Interventional	2003-10-31	Completed
[NCT00469781]	Phase 4	95 participants (Actual)	Interventional	2007-05-31	Completed
[NCT00501579]	Phase 3	0 participants	Interventional		Completed
A Randomized, Masked Multi-center Safety & Efficacy Study of the Effects of Preoperative & Postoperative Cataract Surgery Use of Difluprednate Ophthalmic Emulsion, 0.05% Compared to Prednisolone Acetate Ophthalmic Suspension 1% on Visual Acuity & Corneal [NCT01244334]	Phase 4	52 participants (Actual)	Interventional	2009-03-31	Completed
Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY) [NCT04826588]	Phase 3	76 participants (Actual)	Interventional	2021-05-23	Completed
A Multicenter, Double-blinded, Randomized, Placebo-controlled Trial to Compare the Effectiveness of Intratympanic Injections methylPREDnisolon Versus Placebo in the Treatment of Vertigo Attacks in MENière's Disease (PREDMEN Trial). [NCT05851508]	Phase 3	148 participants (Anticipated)	Interventional	2023-10-01	Recruiting
Prednisolone and Vitamin B1, B6, and B12 in Patients With Post-COVID-19-Syndrome (PC19S) - a Randomized Controlled Trial in Primary Care [NCT05638633]	Phase 3	340 participants (Anticipated)	Interventional	2022-11-11	Recruiting
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement [NCT02828358]	Phase 2	78 participants (Actual)	Interventional	2017-04-01	Active, not recruiting
Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance [NCT00752479]	Phase 1/Phase 2	4 participants (Actual)	Interventional	2008-05-31	Terminated(stopped due to Necessity of major revision of the protocol)
NON-T-CELL DEPLETED HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING [NCT00521430]		30 participants (Anticipated)	Interventional	2004-04-30	Completed
Remission Induction in Very Early Rheumatoid Arthritis: a Comparison of Etanercept Plus Methotrexate Plus Steroid With Standard Therapy [NCT00523692]	Phase 4	20 participants (Anticipated)	Interventional	2007-09-30	Not yet recruiting
A Multicentre Placebo-Controlled Evaluation of Prednisolone and/or Valaciclovir for the Treatment of Bell's Palsy [NCT00510263]	Phase 4	839 participants (Actual)	Interventional	2001-05-31	Completed
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer (VA STARPORT) [NCT04787744]	Phase 2/Phase 3	464 participants (Anticipated)	Interventional	2021-07-01	Recruiting
Timing of Corticosteroids in COVID-19, II. Post COVID-19 Follow-up [NCT04530409]	Phase 4	752 participants (Actual)	Interventional	2021-03-20	Active, not recruiting
Non-interventional Clinical Trial to Establish a Glucocorticoid-induced Osteoporosis Databank for Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis and Therapy With Glucocorticoids [NCT02719314]		10,000 participants (Anticipated)	Observational [Patient Registry]	2015-12-31	Recruiting
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care [NCT01431326]		3,520 participants (Actual)	Observational	2011-11-30	Completed
A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807) [NCT00557193]	Phase 3	218 participants (Actual)	Interventional	2008-01-15	Active, not recruiting
Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants [NCT02935101]	Phase 2	4 participants (Actual)	Interventional	2016-10-31	Terminated(stopped due to difficulties in recruiting study participants)
Pilot Study Investigating the Utility of Epidural AlloGen-LI Injection for Treatment of Spinal Stenosis Symptoms [NCT02932020]		0 participants (Actual)	Interventional	2016-10-31	Withdrawn
A Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, Crossover Bioavailability Study Comparing Constituted Methylprednisolone Powder For Oral Suspension 4 Mg/Ml to Methylprednisolone 32 Mg Tablet Under Fasted Conditions [NCT01267201]	Phase 1	24 participants (Actual)	Interventional	2010-11-30	Completed
Clinical and Radiological Comparison of the Efficacy of Hyaluronic Acid, PRP and Steroid Injections in Partial Rotator Cuff Tears: A Prospective Randomized Study [NCT04681937]		80 participants (Anticipated)	Interventional	2021-06-01	Not yet recruiting
High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab [NCT01211665]	Phase 4	3 participants (Actual)	Interventional	2010-09-30	Terminated(stopped due to This study was stopped prematurely due to lack of enrollment within a 1-5-year period.)
DEXTENZA for the Treatment of Post-Surgical Pain and Inflammation ComparEd to StandaRd of Care Topical Cortico-Steroid Treatment In PatientS Who Undergo BilaTeral Pterygium Surgery PERSIST Study [NCT04351737]	Phase 4	20 participants (Anticipated)	Interventional	2020-07-15	Active, not recruiting
A PedAL/EuPAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory Leukemia [NCT05320380]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2023-08-01	Withdrawn(stopped due to Withdrawn per CS0150757)
Effects of Peri-Operative Glucosteroid Administration on Outcomes Following Distal Radius Fracture [NCT05655130]	Phase 1	60 participants (Anticipated)	Interventional	2018-11-06	Active, not recruiting
An Open-label, Single-arm Study to Describe Glucocorticoid Use in Rheumatoid Arthritis Patients Treated With Tocilizumab in Daily Clinical Practice and to Evaluate Systematic Glucocorticoid Dose Reduction Once Low Disease Activity is Reached (ACT-ALONE) [NCT01219933]	Phase 4	68 participants (Actual)	Interventional	2011-01-31	Completed
A Randomized Controlled Trial of L-DEP as an Initial Treatment for Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis [NCT02912702]	Phase 3	120 participants (Anticipated)	Interventional	2016-09-30	Recruiting
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma [NCT00882895]	Phase 2	18 participants (Actual)	Interventional	2009-05-05	Active, not recruiting
Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm [NCT04355247]	Phase 2	20 participants (Anticipated)	Interventional	2020-04-14	Recruiting
Treatment Of Giant Cell Arteritis Patients With Ultra-short Glucocorticosteroids And tociliZumab: Role of Imaging in a Observational Study [NCT05394909]		20 participants (Actual)	Observational	2020-02-07	Active, not recruiting
A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With Severe Aplastic Anemia, Inborn Errors in Metabolism, or Inherited Hematologic Stem Cell Disorders [NCT00003336]	Phase 2	6 participants (Actual)	Interventional	1998-01-31	Completed
Matched Unrelated and Haploidentical Bone Marrow Transplantation for Hematologic Malignancies [NCT00003960]	Phase 2	36 participants (Anticipated)	Interventional	1998-04-30	Completed
Effect of Steroids on Cerebrospinal Fluid Markers of Inflammation and Neuronal Damage After Surgical Aortic Valve Replacement [NCT01755338]		30 participants (Actual)	Interventional	2012-12-31	Completed
A Phase II Study to Evaluate Efficacy and Tolerability of Methotrexate in Combination With Glucocorticoids for the Treatment of Newly Diagnosed Acute Graft-Versus-Host Disease After Nonmyeloablative Hematopoietic Cell Transplantation [NCT00357084]	Phase 2	53 participants (Anticipated)	Interventional	2006-05-31	Completed
Phase I-II Clinical Trial for the Evaluation of Brentuximab Vedotin Plus Etoposide, Solumoderin (Methylprednisolone), High Dose ARA-C (Cytarabine) and Cisplatin in the Transplant and Post-transplant Management for Relapsed or Refractory Classical Hodgkin [NCT02243436]	Phase 1/Phase 2	67 participants (Actual)	Interventional	2014-11-11	Completed
Research on the Treatment of Severe Community-acquired Pneumonia in Children [NCT05768204]	Phase 4	160 participants (Anticipated)	Interventional	2023-03-10	Recruiting
Open Randomized Study on the Efficacy of corticoïd Infiltration Versus Physiological Solution Infiltration Versus Feigning of Infiltration Via Sacro-coccygien Hiatus Versus Natural Evolution in Discal Sciatica [NCT01482897]	Phase 3	13 participants (Actual)	Interventional	2011-12-31	Terminated(stopped due to Enrolment stopped on December 01, 2014 since after 3 years, only 13 patients were included (instead of 274) (Date of last visit last patient : October 3, 2013).)
A Randomized, Open Label, Phase II Multicenter Study of Non-Myeloablative Autologous Transplantation With Auto-CD34+HPC Versus Currently Available Immunosuppressive/Immunomodulatory Therapy for Treatment of Systemic Lupus Erythematosus [NCT00230035]	Phase 2	0 participants (Actual)	Interventional	2005-09-30	Withdrawn(stopped due to Recommended by DSMB due to lack of accrual)
A Randomized Study To Compare The Safety And Efficacy Of Two Immunosuppressive Regimens In De Novo Renal Allograft Recipients:Sirolimus Plus Mycophenolate Mofetil Plus Corticosteroids Following A Rabbit Anti-Human Thymocyte Globulin Induction (RATG) Vs Ta [NCT00261820]	Phase 4	160 participants	Interventional		Completed
Urinary Aquaporin 2 Excretion After Methylprednisolone in Fasting Healthy Humans [NCT00281710]	Phase 4	20 participants	Interventional	2005-10-31	Completed
REPLACE: Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids [NCT00284947]	Phase 4	7 participants (Actual)	Interventional	2006-01-31	Completed
Prospective Phase II Study of Early Low Dose Steroid Therapy of Acute Respiratory Distress Syndrome (ARDS) After Thoracic Surgery (E-START) [NCT00290602]	Phase 2	40 participants	Interventional	2004-02-29	Completed
Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma [NCT00307606]	Phase 4	40 participants (Anticipated)	Interventional	2005-12-31	Recruiting
Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis [NCT00307645]	Phase 3	160 participants	Interventional	2003-05-31	Terminated
The Efficacy and Safety of Intravenous Pulse Steroids Compared to Standard Oral Steroids in the Treatment of Problematic Hemangiomas in Infants: A Randomized Controlled Trial [NCT00312520]	Phase 3	20 participants	Interventional	2002-07-31	Completed
Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus [NCT04233164]	Early Phase 1	47 participants (Actual)	Interventional	2020-03-04	Active, not recruiting
The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells [NCT00084695]	Phase 2	25 participants (Anticipated)	Interventional	2003-09-30	Recruiting
A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of Treatment [NCT05665270]	Phase 4	40 participants (Anticipated)	Interventional	2023-01-30	Enrolling by invitation
[NCT00433225]	Phase 4	0 participants	Interventional		Completed
A Masked Comparison of Acular LS Plus Steroid Versus Steroid Alone for the Prevention of Macular Leakage in Cataract Patients [NCT00348244]	Phase 4	0 participants	Interventional		Completed
A Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX Compared With AVONEX in Combination With Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects With Relapsing Remitting MS Who Have Breakthrough Disease on AVONEX Monothe [NCT00112034]	Phase 4	350 participants	Interventional	2003-06-30	Completed
Double-Blind Randomized Placebo-Controlled Trial on Clinical and Biological Effects of Oral Corticosteroids or Doxycyclin in Patients With Nasal Polyposis [NCT00480298]	Phase 2	48 participants	Interventional	2002-11-30	Completed
A Multicenter, Randomized, Open Label, Parallel Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Combination With MMF and Steroids in Patients Undergoing Kidney Transplantation and a Pharmacokinetics Study. [NCT00481819]	Phase 3	240 participants (Actual)	Interventional	2007-07-31	Completed
A Multicentre, Open Label, Non-Comparative Trial Investigating the Recovering of INF-Beta Efficacy in Breakthrough Relapsing-Remitting Multiple Sclerosis Patients With Neutralizing Interferon-Beta Antibodies [NCT00492466]	Phase 4	14 participants (Actual)	Interventional	2003-03-31	Completed
The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome [NCT00127985]	Phase 4	240 participants (Anticipated)	Interventional	2005-08-31	Recruiting
A Randomised, Placebo-controlled, Parallel Group Single Dose Study of SB681323 in Patients With Active RA to Investigate the CRP Dose Response Relationship [NCT00134693]	Phase 2	77 participants (Actual)	Interventional	2005-06-21	Completed
Medication Overuse Headache: A Randomised Double Blind Study of Prednisolone or Placebo in Withdrawal Therapy (Phase 3), and a Randomised 1 Year Follow up by Neurologist or General Physician After Successful Withdrawal Therapy [NCT00135122]	Phase 3	100 participants (Actual)	Interventional	2003-09-30	Completed
A Phase I/II Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases [NCT05789589]	Phase 1/Phase 2	46 participants (Anticipated)	Interventional	2023-08-16	Recruiting
Assessment of the Efficacy of Glucocorticoids in Improving Post-operative Organ Dysfunction in Patients With Acute Type A Aortic Dissection(GLAD): a Randomized Controlled Trial [NCT05329740]	Phase 4	212 participants (Actual)	Interventional	2022-02-07	Completed
Repeated Corticosteroid Injections Around the Greater Occipital Nerve (GON) as Prophylactic Treatment in Chronic Cluster Headache [NCT05324748]	Phase 3	50 participants (Anticipated)	Interventional	2022-11-07	Recruiting
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma [NCT04759586]	Phase 3	244 participants (Anticipated)	Interventional	2021-10-05	Recruiting
The Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques: An Investigator-Blinded Study [NCT02784210]	Phase 2	30 participants (Anticipated)	Interventional	2016-10-05	Recruiting
A Randomized, Multicenter, Open-Label Study of Single Dose Filgrastim-SD/01 Versus Daily Filgrastim Following ESHAP Chemotherapy for Non-Hodgkin's Lymphoma [NCT00004192]	Phase 2	60 participants (Anticipated)	Interventional	2000-05-01	Completed
An Open-label, Single-arm, Multicenter Phase II/III Extension Study to Evaluate the Safety of Rituximab Re-treatment in Subjects With Moderate to Severe Systemic Lupus Erythematosus Previously Enrolled in Protocol U2971g [NCT00381810]	Phase 3	31 participants (Actual)	Interventional	2006-06-22	Terminated(stopped due to During a safety review of studies U2970g and U2971g, the Data Monitoring Committee recommended that enrollment in this extension trial be terminated.)
A Multi-center Randomized Controlled Trial of Efficacy and Safety of Perineural Local Anesthetics and Steroids for Chronic Peripheral Post-traumatic Neuropathic Pain: The Resperist Study [NCT03009500]	Phase 3	3 participants (Actual)	Interventional	2017-01-31	Completed
Trial of High Dose Immunosuppressive Therapy With Hematopoietic Stem Cell Support in Devic's Disease [NCT00787722]	Phase 1/Phase 2	13 participants (Actual)	Interventional	2009-10-10	Completed
Phase II Study of Combination of Thymoglobulin, Cyclosporine, Methylprednisone, and Granulocyte Colony-stimulating Factor (GCSF) in Patients With Newly Diagnosed Aplastic Anemia or With Hypoplastic or Low/Intermediate-1 Risk Myelodysplastic Syndrome [NCT00806598]	Phase 2	53 participants (Actual)	Interventional	2005-05-31	Completed
A Prospective Randomized Controlled Trial of Early Non-Invasive Positive Pressure Ventilation in Patients With Hypoxemic Respiratory Failure and Malignancies [NCT02464696]		256 participants (Anticipated)	Interventional	2015-10-06	Recruiting
Lymphodepleting Chemotherapy and T-Cell Suppression Followed By Allogeneic Natural Killer Cells and IL-2 in Patients With Recurrent Ovarian, Fallopian Tube, Primary Peritoneal Cancer and Advanced Metastatic Breast Cancer (MT2009-30) [NCT01105650]	Phase 2	13 participants (Actual)	Interventional	2010-07-31	Completed
Injection of Dorsal Scapular n at Different Levels, Dose it Make Difference? [NCT04693312]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2020-01-01	Completed
Multi-center, Randomized, Double Masked, Vehicle Controlled Phase IV Study to Compare the Efficacy, Ocular Safety and Tolerability of a Two Day Treatment With Eye Drops (0.5% Prednisolone Acetate, One Drop Four Times Per Day) in Patients With Intraocular [NCT00170729]	Phase 4	62 participants (Actual)	Interventional	2004-08-17	Completed
The Impact of Pre-emptive Large Doses of Methylprednisolone Combined With Gabapentin on Pain Treatment and Convalescence After Total Knee Arthroplasty in Elderly: A Double-blind Randomized Study [NCT04653415]	Phase 4	160 participants (Actual)	Interventional	2019-06-01	Completed
Gene Transfer for Patients With Fanconi Anemia Complementation Group A (FANCA) [NCT01331018]	Phase 1	3 participants (Actual)	Interventional	2012-02-22	Active, not recruiting
A Phase III Study to Determine Efficacy and Safety of Low-Dose Glucocorticoids for Initial Treatment of Acute Graft-versus-Host Disease [NCT00929695]	Phase 3	164 participants (Actual)	Interventional	2009-06-30	Completed
CSP #574 - Evaluate the Safety and Efficacy of Methylprednisolone in Hospitalized Veterans With Severe Community-Acquired Pneumonia [NCT01283009]	Phase 3	584 participants (Actual)	Interventional	2012-01-09	Completed
Comparison of Efficacy and Safety of Intravenous Pulsed Methylprednisolone and Oral Methotrexate Versus Intravenous Pulsed Methylprednisolone and Oral Placebo in the Treatment of Active Moderate and Severe Thyroid Eye Disease - a Prospective, Randomized, [NCT00348413]		80 participants (Anticipated)	Interventional	2003-06-30	Completed
A Randomized Controlled Trial to Evaluate the Efficacy and Safety of Docetaxel Combined With Platinum-based Drugs Compared With Docetaxel Alone for Metastatic Hormone-sensitive Prostate Cancer Patients Carrying DNA Repair Mutation [NCT05461261]	Phase 2	50 participants (Anticipated)	Interventional	2022-07-01	Recruiting
Intradiscal Gelified Ethanol Versus Intradiscal Steroid in Refractory Lumbar Discogenic Pain: a Randomized Single-blind Study [NCT03415828]		83 participants (Actual)	Interventional	2018-05-29	Active, not recruiting
Pilot, Phase I, Single Blind Trial to Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers. (PRURITUS- Nimpa Study). [NCT01529320]	Phase 1	18 participants (Actual)	Interventional	2012-02-29	Completed
Non-Myeloablative Allogeneic Hematopoietic Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies and Disorders [NCT00053989]	Phase 2	41 participants (Actual)	Interventional	2002-01-29	Completed
A RANDOMIZED TRIAL OF UNMODIFIED VERSUS T-CELL DEPLETED ALLOGENEIC HLA-IDENTICAL BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF ACUTE LEUKEMIAS [NCT00002534]	Phase 3	0 participants	Interventional	1993-05-31	Completed
A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Severe Type of Hand, Foot, and Mouth Disease [NCT01554930]		230 participants (Actual)	Interventional	2010-05-31	Completed
A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Children and Adults With Hematologic Malignancies [NCT00003661]	Phase 2	3 participants (Actual)	Interventional	1998-06-30	Completed
The Unrelated Donor Marrow Transplantation Trial [NCT00003187]	Phase 2/Phase 3	19 participants (Actual)	Interventional	1995-05-31	Completed
Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease [NCT00109993]	Phase 2	34 participants (Actual)	Interventional	2005-01-31	Completed
A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Pediatric Solid Tumors With Relapsed or Therapy Refractory Disease [NCT00112645]	Phase 1	10 participants (Anticipated)	Interventional	2005-04-30	Completed
Transplantation of Unrelated Donor Hematopoietic Stem Cells for the Treatment of Hematological Malignancies [NCT00281879]	Phase 2	200 participants (Actual)	Interventional	2006-02-28	Terminated
A Study of Modified Augmented BFM Therapy for Infants With Acute Lymphoblastic Leukemia [NCT00022126]	Phase 2	6 participants (Actual)	Interventional	2002-11-30	Completed
[NCT00000146]	Phase 3	0 participants	Interventional	1988-07-31	Active, not recruiting
[NCT02115997]	Phase 4	30 participants (Actual)	Interventional	2015-07-06	Completed
[NCT00017628]	Phase 1	20 participants	Interventional	2001-04-30	Completed
A Phase III, Randomized, Placebo-Controlled, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Oral Beclomethasone 17, 21-Dipropionate (BDP) in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Gr [NCT00043147]	Phase 3	0 participants	Interventional	2002-04-30	Completed
Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study [NCT00135967]	Phase 2/Phase 3	30 participants	Interventional	2002-05-31	Completed
Randomised, Double-Arm, Controlled, Open-Label Study Comparing Calcineurin Inhibitor-Free Immunosuppression (Zenapax®, CellCept® and Prednisolone) and Cyclosporine A Based Immunosuppression (Sandimmun Neoral®, CellCept® and Prednisolone) on the Outcome of [NCT00138970]	Phase 4	70 participants	Interventional	2002-01-31	Completed
A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Tacrolimus and Corticosteroid as Immunosuppressive Treatment for Lupus Membra [NCT00404794]	Phase 3	20 participants (Anticipated)	Interventional	2005-11-30	Completed
A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS) [NCT00404833]	Phase 3	16 participants (Anticipated)	Interventional	2003-01-31	Completed
[NCT00017654]		3 participants	Interventional	2001-04-30	Active, not recruiting
A Double-Blind Randomized Trial of Steroid Withdrawal in Sirolimus- and Cyclosporine-Treated Primary Transplant Recipients [NCT00023244]	Phase 2	274 participants (Actual)	Interventional	2001-01-31	Terminated(stopped due to Effective August 13, 2004: Unanticipated high incidence of post-transplant lymphoproliferative disorder)
Phase IV Study of Early RA: a Randomized Magnetic Resonance Imaging Study Comparing the Effects of Methotrexate Alone or in Combination With Infliximab or Intravenous Pulse Methylprednisolone [NCT00396747]	Phase 4	45 participants (Actual)	Interventional	2003-06-30	Completed
A Phase IV, Randomized, Multi-center Clinical Trial to Compare the Efficacy of Orbital Radiotherapy in Association With Intravenous Glucocorticoids vs Intravenous Glucocorticoids Alone for Moderately Severe and Active Graves' Orbitopathy [NCT03098225]	Phase 4	120 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
Induction Therapy for Lupus Nephritis With no Added Oral Steroids: An Open Label Randomised Multicentre Controlled Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF [NCT04702256]	Phase 3	196 participants (Anticipated)	Interventional	2021-12-09	Recruiting
Calcineurin Inhibitor Sparing Protocol in Living Donor Pediatric Kidney Transplantation [NCT00023231]		35 participants (Actual)	Interventional	2001-02-28	Completed
Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation [NCT00055653]	Phase 2	0 participants	Interventional	2003-01-31	Completed
An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMP [NCT00037115]	Phase 4	0 participants (Actual)	Interventional	2002-05-31	Withdrawn(stopped due to Lack of funding)
A Phase II Trial of BBR 2778 in Combination With Cytarabine, Methylprednisolone and Cisplatin (BSHAP) as Salvage in Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma [NCT00069966]	Phase 2	0 participants	Interventional	2003-04-30	Active, not recruiting
Pilot Study Of T-Cell-Depleted Peripheral Blood Stem Cell Transplantation From Partially Matched Related Donors For Patients With High-Risk Leukemia [NCT00066417]	Phase 2	51 participants (Anticipated)	Interventional		Terminated(stopped due to Trial was withdrawn for drug availability issues.)
Immunomodulation by Ultraviolet B-Irradiation (UVB) to Facilitate Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies [NCT00068523]		10 participants (Actual)	Interventional	2003-06-30	Completed
Single-Center, Randomized, Double Masked, Two-Period Cross-Over, Three Days Per Period, Phase IV Study to Compare Ocular Safety and Tolerability of Prednisolone Acetate 0.5% Eye Drops Versus Vehicle in Healthy Volunteers [NCT00134992]	Phase 4	30 participants	Interventional	2004-08-31	Completed
The Role of Topical Prednisolone Acetate Following Selective Laser Trabeculoplasty [NCT00406042]		25 participants	Interventional	2005-09-30	Completed
Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease [NCT00152620]		40 participants	Interventional	2004-06-30	Terminated(stopped due to study completed)
A Phase I Trial of BBR 2778 in Combination With Cytarabine, Methylprednisolone and Cisplatin in the Treatment of Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma [NCT00053105]	Phase 1	0 participants	Interventional	2002-02-28	Active, not recruiting
Pilot Study Of Multiple Umbilical Cord Blood Unit Transplantation Following Non-Myeloablative Conditioning In Patients With Hematologic Disorders Or Severe Aplastic Anemia [NCT00054236]	Phase 1	55 participants (Actual)	Interventional	2002-05-31	Completed
A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Investigating Methylprednisolone in Combination With Interferon-beta-1a for the Treatment of Patients With Relapsing-remitting Multiple Sclerosis [NCT00168766]	Phase 4	345 participants (Actual)	Interventional	2003-01-31	Completed
[NCT00854061]	Phase 3	172 participants (Actual)	Interventional	2009-02-28	Completed
A Multi-Center, Randomized, Double Masked, Bioequivalence Study of Tobramycin and Prednisolone Acetate (0.3/1.0%, ISTA) Ophthalmic Suspension Compared to PredForte (1.0% Prednisolone Acetate, Allergan) Ophthalmic Suspension [NCT00198523]	Phase 3	132 participants	Interventional	2005-07-31	Completed
Prevention of Post-Extubation Laryngeal Edema With Intravenous Corticosteroids: a Prospective, Double-Blind, Placebo-Controlled Trial. [NCT00199576]	Phase 3	670 participants	Interventional	2000-12-31	Completed
the Effect of Single Dose of Etomidate Used During Emergency Intubation on Hemodynamics and Adrenal Cortex: a Randomized Clinical Trial [NCT01792037]	Phase 4	90 participants (Actual)	Interventional	2012-12-31	Completed
Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery [NCT04200651]	Phase 4	25 participants (Actual)	Interventional	2020-01-13	Completed
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy [NCT01381874]	Phase 2	297 participants (Actual)	Interventional	2011-08-24	Completed
Peri-articular Injections Containing a Corticosteroid During Total Knee Arthroplasty [NCT00492973]		101 participants (Actual)	Interventional	2006-03-31	Completed
Danish Non-inferiority Study of Ocrelizumab and Rituximab in MS (DanNORMS): A Randomized Study Comparing the Efficacy of Ocrelizumab and Rituximab in Active Multiple Sclerosis [NCT04688788]	Phase 3	594 participants (Anticipated)	Interventional	2021-04-28	Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of CRx-102 in Subjects With Symptomatic Knee Osteoarthritis and Optional One-Year Extension [NCT00521989]	Phase 2	279 participants (Actual)	Interventional	2007-08-31	Terminated(stopped due to CRx-102-006 study results, negative)
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Superiority of CRx-102 Over Each of Its Components When Given to Subjects With Active Rheumatoid Arthritis (RA) [NCT00551707]	Phase 2	51 participants (Actual)	Interventional	2007-10-31	Completed
A California Cooperative Clinical Study Comparing Allogeneic Hematopoietic Cell Transplantation Using Nonmyeloablative Host Conditioning With Total Lymphoid Irradiation and Anti-thymocyte Globulin Versus Best Standard of Care in Acute Myeloid Leukemia (AM [NCT00568633]	Phase 3	58 participants (Actual)	Interventional	2007-08-31	Terminated(stopped due to Poor accrual)
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation [NCT00609739]	Phase 1/Phase 2	1 participants (Actual)	Interventional	1999-06-30	Terminated(stopped due to Low accrual)
A Randomized, Placebo Controlled, Multicenter Clinical Study Investigating Efficacy of Rituximab in the Inhibition of Joint Structural Damage Assessed by Magnetic Resonance Imaging in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrex [NCT00578305]	Phase 3	185 participants (Actual)	Interventional	2007-11-30	Completed
A Study of Cyclophosphamide, Fludarabine, and Antithymocyte Globulin Followed by Matched Sibling Donor Hematopoietic Cell Transplantation in Patients With Fanconi Anemia [NCT00630253]	Phase 1/Phase 2	31 participants (Actual)	Interventional	2000-02-17	Completed
Adrenal Cortical Function and Vitamin A Deficiency in Sepsis, Severe Sepsis and Septic Shock: Prospective Randomized, Double Blind Placebo Controlled Clinical Trials [NCT03152474]	Phase 4	300 participants (Actual)	Interventional	1993-02-28	Completed
Effect of Intraarticular Steroids on Bone Turnover in Osteoarthritis [NCT00682357]		25 participants (Actual)	Interventional	2008-05-31	Completed
Pilot Study of Methylprednisolone Replacement for Dexamethasone-induced Hiuup Patients [NCT01277731]		0 participants (Actual)	Interventional	2010-07-31	Withdrawn
Yale Steroid Enhanced Versus Exparel Nerveblock TKA Part 2 [NCT05736549]	Phase 2	66 participants (Anticipated)	Interventional	2023-02-07	Recruiting
Effect of Preoperative Low-dose of Methylprednisolone on Postoperative Pain and Immune Functions After Video-assisted Thoracoscopic Surgery: A Prospective Randomized Controlled Trial [NCT03393949]	Phase 4	112 participants (Actual)	Interventional	2015-07-01	Completed
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Pediatric Subjects [NCT03721965]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2019-12-31	Terminated(stopped due to The study was terminated due to insufficient efficacy in a separate phase III study)
[NCT00699803]	Phase 2	64 participants (Actual)	Interventional	2008-05-31	Completed
Azithromycin for Preventing the Development of Upper Respiratory Tract Illness Into Lower Respiratory Tract Symptoms in Children and Oral Corticosteroids for Treating Episodes of Significant Lower Respiratory Tract Symptoms in Children [NCT01272635]	Phase 3	607 participants (Actual)	Interventional	2011-03-31	Completed
An Open-label, Randomized, Cross-over Interventional Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression [NCT04345445]	Phase 3	310 participants (Anticipated)	Interventional	2020-04-15	Not yet recruiting
Phase II Randomized Double Blind Trial of Methylprednisolone and N-acetylcysteine in Hepatic Resections. [NCT01726465]	Phase 2	50 participants (Actual)	Interventional	2012-11-30	Terminated(stopped due to The first phase was completed)
Efficacy and Safety Evaluation of Rapamycin Combined With Methylprednisolone in the Treatment of Hyperthyroidism Exophthalmos: A Randomized, Controlled, Multicenter Clinical Trial. [NCT05532072]	Early Phase 1	140 participants (Anticipated)	Interventional	2022-09-30	Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) [NCT01086540]	Phase 2	57 participants (Actual)	Interventional	2011-06-24	Completed
Non-myeloablative Hematopoietic Stem Cell Transplantation for Stiff Person Syndrome (SPS) and Anti-GAD Antibody Variants: Progressive Encephalomyelitis With Rigidity and Myoclonus (PERM), and Adult Onset Autoimmune Anti-GAD Positive Cerebellar Ataxia [NCT02282514]	Phase 1/Phase 2	23 participants (Actual)	Interventional	2014-10-31	Terminated(stopped due to Could not predict who would respond, relapse or go into remission)
B-Cell Targeted Therapy for Acute Renal Allograft Rejection With an Antibody Mediated Component: A Prospective, Randomized, Open-Label Study [NCT00771875]	Phase 2	30 participants (Actual)	Interventional	2008-09-30	Completed
Intraorbital Injection Versus Oral Steroid in Patients With Anterior Idiopathic Orbital Inflammation: A Randomized Clinical Trial [NCT03958344]	Phase 3	120 participants (Anticipated)	Interventional	2022-01-01	Recruiting
Extended Follow-up of a Randomized Placebo-controlled Trial of Local Steroid Injection in Carpal Tunnel Syndrome [NCT02652390]	Phase 4	111 participants (Actual)	Interventional	2016-02-29	Completed
Multicenter, PrOspective, Randomized, Controlled Trial Comparing GenIcular Artery EmbOlization Using Embosphere Microspheres to Corticosteroid iNjections for the Treatment of Symptomatic Knee Osteoarthritis: MOTION Study [NCT05818150]		264 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Addition of Pyridoxine to Prednisolone in the Treatment of Infantile Spasms: A Randomized Controlled Trial [NCT01828437]	Phase 3	62 participants (Actual)	Interventional	2012-11-30	Completed
"RANDOMIZED COMPARISON OF ALTERNATING TRIPLE THERAPY (ATT) VERUS CHOP IN PATIENTS WITH INTERMEDIATE GRADE LYMPHOMAS AND IMMUNOBLASTIC LYMPHOMAS WITH INTERNATIONAL INDEX 2-5" [NCT00002565]	Phase 3	61 participants (Actual)	Interventional	1994-05-25	Completed
Perks of Methylprednisolone for Hospitalized COVID-19 Patients: A Clinical Trial [NCT04559113]		200 participants (Anticipated)	Interventional	2020-05-01	Recruiting
Maternal Epidural Steroids to Prevent Neonatal Exposure to Hyperthermia and Inflammation [NCT02212210]	Early Phase 1	135 participants (Actual)	Interventional	2012-02-29	Terminated(stopped due to PI permanently closed accrual for the study based on FDA warning issued in April 2014. Study is closed)
The Use of Intra-articular Corticosteroid Injection to Treat Osteoarthritis of the Carpometacarpal Joint: A Randomized Control Trial [NCT04177433]	Phase 4	90 participants (Anticipated)	Interventional	2020-12-02	Recruiting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (Biomarkers) of BI 653048 BS H3PO4 Capsule Formulation Administered as Multiple Doses of 25 mg to 200 mg qd for 10 Days. A Randomised, Double-blind Within Dose Groups, Placebo-controlled, Multipl [NCT02217631]	Phase 1	140 participants (Actual)	Interventional	2009-10-31	Completed
Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection. A Multicenter, Interventional, Randomized, Three Arms Study Design [NCT04528888]	Phase 3	210 participants (Anticipated)	Interventional	2020-11-25	Recruiting
A Proof of Concept Study to Determine the Local Delivery and Efficacy of Intravenously Injected PEG-liposomal Prednisolone Sodium Phosphate (Nanocort) in Atherosclerotic Tissue in Subjects With Peripheral Artery Disease. [NCT01647685]	Phase 1/Phase 2	21 participants (Anticipated)	Interventional	2012-05-31	Recruiting
Transplantation of Umbilical Cord Blood From Related and Unrelated Donors [NCT00290628]		43 participants (Actual)	Interventional	1999-10-31	Terminated(stopped due to Replaced with another study)
Efficacy of Moxifloxacin 0.5%/Prednisolone 1% Fixed Combination Compared With Individual Administration of Moxifloxacin 0.5% and Prednisolone 1% in the Prevention of Post Operative Inflammation in Patients Having Lasik Surgery [NCT01603030]	Phase 3	66 participants (Anticipated)	Interventional	2012-06-30	Not yet recruiting
Preemptive Effect of Dexamethasone and Methylprednisolone on Pain, Swelling and Trismus After Third Molar Surgery: a Split-mouth Randomized Triple-blind Clinical Trial [NCT01603498]		18 participants (Actual)	Interventional	2011-04-30	Completed
A Multicentre, Randomised, Double Blind, Double Dummy, Active Comparator Controlled, Parallel Group Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis [NCT00299013]	Phase 3	796 participants (Actual)	Interventional	2006-03-31	Completed
Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants [NCT00307671]	Phase 4	108 participants (Actual)	Interventional	2005-07-31	Completed
Phase II Study of Induction Therapy Comprising Etoposide, Methylprednisolone, Cytarabine, and Cisplatin (ESHAP) Followed by Consolidation Therapy Comprising Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Relapsed or Refractory AIDS-Relat [NCT00310128]	Phase 2	0 participants (Actual)	Interventional	2006-02-28	Withdrawn(stopped due to Drug supply unavailable)
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy With THERAKOS* UVADEX* for the Treatment of Patients With Newly Diagnosed Acute Graft Versus-Host Disease [NCT00282503]	Phase 3	19 participants (Actual)	Interventional	2006-01-31	Terminated(stopped due to Lack of recruitment)
A Comparison of Intravenous Versus Oral Administration of Prednisolone in the Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease [NCT00311961]	Phase 4	256 participants	Interventional	2001-06-30	Completed
Long Term Tapering or Standard Steroids for Nephrotic Syndrome [NCT00308321]	Phase 4	50 participants (Anticipated)	Interventional	2003-09-30	Recruiting
Multicenter, Open-label, Randomized Study on Steroid-free Immunosuppression, in Comparison With Daily Steroid Therapy, in Children With Stable Renal Transplant Function Under Cyclosporine (CyA) and Mycophenolate Mofetil (MMF) [NCT00309218]	Phase 3	42 participants (Actual)	Interventional	1999-03-31	Completed
Comparison of Efficacy of Intra-articular Morphine vs Methylprednisolone in Patients With Knee Osteoarthritis. A Single - Blind, Randomized-controlled Study [NCT06163755]	Phase 2	0 participants (Actual)	Interventional	2018-01-01	Withdrawn(stopped due to Lack of funding)
A Phase III, International, Multicenter, Randomised Open Label Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Patients With Childhood Onset Idiopathic Nephrotic Syndrome [NCT05627557]	Phase 3	80 participants (Anticipated)	Interventional	2023-03-29	Recruiting
A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours [NCT05489211]	Phase 2	670 participants (Anticipated)	Interventional	2022-09-06	Recruiting
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety of Obinutuzumab in Patients With Systemic Lupus Erythematosus [NCT04963296]	Phase 3	300 participants (Anticipated)	Interventional	2021-10-26	Recruiting
Epidural Steroid Following Discectomy for Herniated Lumbar Disc Reduces Neurological Impairment and Enhances Recovery. A Randomized Study With Two-year Follow-up [NCT01499641]		200 participants (Actual)	Interventional	2001-05-31	Completed
A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspen [NCT01505088]	Phase 3	193 participants (Actual)	Interventional	2011-12-31	Completed
Standard Chemotherapy (CHOP Regimen) Versus Sequential High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas and Poor Prognostic Factors: A Randomized Phase III Study (MISTRAL) [NCT00003215]	Phase 3	400 participants (Anticipated)	Interventional	1997-04-30	Completed
[NCT01627236]		120 participants (Anticipated)	Interventional	2012-12-31	Recruiting
Biomarkers of Lupus Disease: Study of Biomarker Changes Before and After Treatment With Depomedrol and Background Medication Withdrawal in Patients With Mild to Moderate SLE Disease Activity [NCT00987831]	Phase 1/Phase 2	158 participants (Actual)	Interventional	2009-05-31	Completed
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation: a Randomized Study [NCT01640743]		58 participants (Actual)	Interventional	2010-03-31	Completed
Randomized, Multicentric Study Evaluating the Efficacy and the Safety of Methylprednisolone Bolus in the Treatment of Renal Sarcoidosis [NCT01652417]		40 participants (Actual)	Interventional	2012-10-31	Terminated(stopped due to insufficient recruitment)
Clinical Study of Chemoimmunotherapy With Fresh Frozen Plasma, High Dose Methylprednisolone and Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia [NCT01670812]	Phase 3	100 participants (Anticipated)	Interventional	2012-01-31	Recruiting
The Effect of Different Intra-articular Injections on Pain and Function in Primary Gonarthrosis [NCT05291793]		80 participants (Actual)	Interventional	2020-04-01	Completed
Single Center, Randomized, Double-Masked Evaluation of the Efficacy of PredAcetate 1% Ophthalmic Suspension Compared to Pred Acetate 0.12% Ophthalmic Suspension, Lot Etab 0.2% Ophthalmic Suspension, and Placebo in a Modified CAC Model [NCT00689078]	Phase 4	36 participants (Actual)	Interventional	2008-05-31	Completed
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen [NCT02199041]	Phase 2	24 participants (Actual)	Interventional	2014-07-11	Terminated(stopped due to The study was halted early due to slow accrual.)
Phase I/II Trial of Thymus Transplantation With Immunosuppression, #950 [NCT00579527]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2005-12-19	Completed
Assessment of the Efficacy of an Intradiscal Injection of Corticoids in Modic I Discopathies. [NCT01694134]	Phase 3	50 participants (Actual)	Interventional	2012-07-12	Completed
Alternative Treatment Paradigm for Natalizumab Trial [NCT01710228]	Phase 2	0 participants (Actual)	Interventional	2013-07-31	Withdrawn(stopped due to sponsor stopped)
CHEMO-T: Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (CHOP) Versus Gemcitabine, Cisplatin and Methyl Prednisolone (GEM-P) in the First Line Treatment Of T-cell Lymphoma,a Multicentre Randomised Phase II Study [NCT01719835]	Phase 2	87 participants (Actual)	Interventional	2012-03-31	Active, not recruiting
Determining Optimal Dose of Corticosteroids in COPD Exacerbations: A Pilot Study [NCT01742338]	Phase 4	125 participants (Anticipated)	Interventional	2012-05-03	Suspended(stopped due to The study has been suspended to address research staffing and the feasibility of continued recruitment)
A Double-Blind, Randomized, Multicenter, Phase II Study of the Safety and Efficacy of Two Rituximab Regimens in Subjects With Moderate to Severe Active Rheumatoid Arthritis Receiving Stable Doses of Methotrexate [NCT00243412]	Phase 2	42 participants (Actual)	Interventional	2005-08-31	Completed
A Randomised, Single Blind, Placebo-Controlled, Cross-over, Phase 1 Methodology Study to Validate the Cantharidin Blister Model in Healthy Male Volunteers [NCT01762787]	Phase 1	40 participants (Actual)	Interventional	2010-08-17	Completed
Phase 3 Open Label Randomised Multicentre Controlled Trial of Rituxmab and Mycophenolate Mofetil Without Oral Steroids for the Treatment of Lupus Nephritis [NCT01773616]	Phase 3	24 participants (Actual)	Interventional	2015-04-30	Terminated(stopped due to Study assessments for patients recruited continuing per protocol so patients receive a minimum of 6 months follow up. No safety concerns have been raised.)
FDG PET/CT: Reducing False Positive Mediastinal Uptake by Premedicating With Methylprednisolone [NCT01789892]		0 participants (Actual)	Interventional	2011-06-30	Withdrawn(stopped due to no patient accrual)
Safety and Efficacy of Nonsteroidal Antiinflammatory Drug and Glucocorticoids in Acute Sciatica [NCT01816334]	Phase 4	50 participants (Actual)	Interventional	2013-01-31	Completed
Kidney Graft Function Under the Immunosuppression Strategies With Low Dose of Neoral®(Cyclosporine) and Standard Dose of Myfortic®(Enteric-Coated Mycophenolate Sodium) vs. With Conventional Dose of Neoral®(Cyclosporine) and Reduced Dose of Myfortic®(Enter [NCT01817322]	Phase 4	140 participants (Actual)	Interventional	2011-06-30	Completed
Lymphodepleting Chemotherapy With Rituximab and Allogeneic Natural Killer Cells for Patients With Refractory Lymphoid Malignancies (MT2009-15) [NCT01181258]	Phase 2	16 participants (Actual)	Interventional	2010-08-31	Completed
Study of Visual Recovery After Erythropoietin (EPO) Injection, in Patients With Traumatic Optic Neuropathy (TON) [NCT01783847]	Phase 1/Phase 2	117 participants (Actual)	Interventional	2015-02-28	Completed
Phase 2 Study of Rituximab and ESHAP (Etoposide, Methylprednisolone, Cytarabine, and Cisplatin) in Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma [NCT00367497]	Phase 2	5 participants (Actual)	Interventional	2005-08-31	Terminated(stopped due to The stopping rule was applied because of low response rates.)
Cord Blood Transplantation for Hematologic Malignancies and Bone Marrow Failure Syndromes [NCT00003270]	Phase 2	20 participants (Actual)	Interventional	1997-09-04	Completed
Predicting Response to Intra-Articular Corticosteroid Injection in Patients With Osteoarthritis of the Glenohumeral Joint [NCT03232749]	Phase 4	25 participants (Actual)	Interventional	2018-04-18	Terminated(stopped due to The physician in charge is leaving the University of Florida)
Double-blind Randomized Controlled Trial of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis [NCT01809132]	Phase 2/Phase 3	104 participants (Actual)	Interventional	2013-09-30	Completed
A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Rapidly Augmenting Platelet Counts in Childhood ITP. [NCT00376077]	Phase 3	32 participants (Actual)	Interventional	2005-08-31	Completed
SMART Trial: Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia [NCT03852537]	Phase 2	44 participants (Actual)	Interventional	2019-12-02	Completed
Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncolo [NCT00553202]	Phase 2	158 participants (Actual)	Interventional	2008-01-31	Completed
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients With Active Class III or IV Lupus Nephritis, Including an Evaluation of Open Label Sa [NCT05039619]	Phase 2	40 participants (Anticipated)	Interventional	2022-05-12	Recruiting
Towards a Self-Administered Hearing Protection Regimen [NCT04826237]	Phase 4	100 participants (Anticipated)	Interventional	2023-02-09	Recruiting
Efficacy of Injectable Methylprednisolone Sodium Succinate in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome Under the New Coronavirus (SARS-CoV2): a Phase IIb, Randomized, Double-blind, Placebo-controlled, Clinical Trial. [NCT04343729]	Phase 2	416 participants (Actual)	Interventional	2020-04-18	Completed
A Randomized, Controlled, Open-Label Study to Evaluate the Efficacy of Extracorporeal Photopheresis (ECP) Versus Corticosteroids in the Treatment of Patients With Secondary Progressive Multiple Sclerosis (SPMS) [NCT02296346]		13 participants (Actual)	Interventional	2014-10-31	Terminated(stopped due to Low enrollment/PI relocated. New site couldn't reach agreement with manufacturer)
A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% [NCT01437982]	Phase 4	140 participants (Anticipated)	Interventional	2010-08-05	Completed
Efficacy of Peripheral Nerve Blocks for Episodic Migraine Treatment and Prophylaxis [NCT05734625]	Phase 2	60 participants (Anticipated)	Interventional	2023-07-10	Recruiting
The Evaluation of the Safety and Efficacy of Sustained Release Dexamethasone Intracanalicular Insert (DEXTENZA) in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia (TENDER) [NCT05620901]	Early Phase 1	30 participants (Anticipated)	Interventional	2023-02-01	Recruiting
Focal Cerebral Arteriopathy Steroid Trial [NCT06040255]	Phase 4	80 participants (Anticipated)	Interventional	2023-10-01	Not yet recruiting
Single Blind Randomized Controlled Trial to Assess the Safety and Efficacy of High Dose Pulse Intravenous Corticosteroid Therapy to Treat Patients With Complicated/Fulminant Acute Myocarditis [NCT05150704]	Phase 3	288 participants (Anticipated)	Interventional	2021-10-07	Recruiting
Randomized Multicenter Phase 3 Single-blind Trial Comparing the Efficacy of Corticosteroid Control to Mesenchymal Stem Cell Preparations From Autologous Bone Marrow Concentrate (BMAC), Adipose-derived Stem Cells in the Form of Stromal Vascular Fraction (S [NCT03818737]	Phase 3	475 participants (Actual)	Interventional	2019-03-28	Completed
Glucocorticoid Treatment in Patients Undergoing TAVR to Reduce the Incidence of Atrioventricular Block and Pacemaker Implantation [NCT06076824]	Phase 4	100 participants (Anticipated)	Interventional	2023-08-12	Recruiting
Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung Disease [NCT04988282]	Phase 4	262 participants (Actual)	Interventional	2021-05-24	Completed
Medrol® In Contact Dermatitis: A Prospective Study To Assess The Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Subjects [NCT00929981]		80 participants (Actual)	Observational	2009-09-30	Completed
A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy [NCT03018535]	Phase 3	76 participants (Actual)	Interventional	2012-01-31	Active, not recruiting
The Effect of 4.5 Gram Methylprednisolone Administered Once Weekly for 12 Weeks on Bone Metabolism in Graves´ Ophthalmopathy [NCT03122847]		30 participants (Anticipated)	Observational	2017-06-07	Active, not recruiting
Delayed Infusion of Ex Vivo Anergized Peripheral Blood Mononuclear Cells Following CD34 Selected Peripheral Blood Stem Cell Transplantation From a Haploidentical Donor for Patients With Acute Leukemia and Myelodysplasia [NCT00376480]	Phase 1	19 participants (Actual)	Interventional	2005-06-30	Completed
Phase 2/Phase 3 of the Randomized Control Trial to Evaluate the Efficacy of Autologous Blood Injection Versus Local Corticosteroid Injection for Treatment of Lateral Epicondylitis. [NCT00947765]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2007-01-31	Completed
Autologous Hematopoietic Stem Cell Transplant for Patients With Systemic Sclerosis and Cardiac Dysfunction [NCT03593902]	Phase 2/Phase 3	9 participants (Actual)	Interventional	2018-05-17	Terminated(stopped due to PI Sabbatical)
Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone [NCT04744623]	Phase 2/Phase 3	10 participants (Actual)	Interventional	2020-09-30	Active, not recruiting
Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome [NCT04323592]		173 participants (Actual)	Observational [Patient Registry]	2020-03-23	Completed
Low Dose Versus High Dose Methylprednisolone for Children With Severe Mycoplasma Pneumoniae Pneumonia : a Multicenter Randomized Blinded Trial [NCT02303587]		424 participants (Actual)	Interventional	2014-12-31	Completed
Clinical Effectiveness of Symptomatic Therapy Compared to Standard Step up Care for the Treatment of Low Impact Psoriatic Oligoarthritis: a 2 Arm Parallel Group Feasibility Study [NCT03797872]	Phase 4	1 participants (Actual)	Interventional	2019-04-17	Completed
Effect of Preoperative Intravenous High Dose Methylprednisolone on Endothelial Function in Patients Scheduled for Total Knee-arthroplasty [NCT02332629]	Phase 3	70 participants (Actual)	Interventional	2015-01-31	Completed
A Randomized, Comparative Trial of Trimetrexate With Leucovorin Rescue Versus Standard Anti-Pneumocystis Therapy Versus Standard Anti-Pneumocystis Therapy With High Dose Steroids for AIDS Patients With Pneumocystis Pneumonia Who Appear to Be Refractory to [NCT00000730]	Phase 3	240 participants	Interventional		Terminated
Phase 2 Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy [NCT02167217]	Phase 2	25 participants (Actual)	Interventional	2014-04-17	Completed
Pilot Study in AIDS-Related Lymphomas [NCT00002524]	Phase 2	46 participants (Actual)	Interventional	1993-06-30	Completed
A Prospective Randomized Double-blinded Controlled Single Center Clinical Study of the Efficacy and Safety for Tofacitinib Compared With Glucocorticoid in the Remission-reduction Treatment of Active Takayasu's Arteritis [NCT05749666]	Phase 3	50 participants (Anticipated)	Interventional	2023-01-20	Recruiting
Treatment of Metastatic Prostate Cancer That is Hormone-Independent: Evaluation of the Role of Chemotherapy on the Quality of Life of Patients. Phase II Study [NCT00003682]	Phase 3	160 participants (Anticipated)	Interventional	1998-10-31	Terminated(stopped due to lack of inclusions)
Sudden Hearing Loss Multicenter Treatment Trial [NCT00097448]	Phase 3	255 participants (Actual)	Interventional	2004-12-31	Completed
Phase II Trial of Natalizumab (Tysabri®) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract [NCT02176031]	Phase 2	21 participants (Actual)	Interventional	2015-01-31	Completed
STeroids to REduce Systemic Inflammation After Infant Heart Surgery (STRESS) [NCT03229538]	Phase 3	1,263 participants (Actual)	Interventional	2017-10-18	Completed
A Randomised, Comparator Controlled, Two Part, Open-label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Doses of Otelixizumab in Patients With Thyroid Orbitopathy [NCT01114503]	Phase 2	2 participants (Actual)	Interventional	2010-07-07	Terminated(stopped due to Clinical study in Graves' ophthalmopathy terminated until there is a better understanding of an efficacious dose with Otelixizumab from other clinical studies.)
Single Center, Randomized, Double-Blind, Placebo-Controlled Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab [NCT01144143]	Phase 4	16 participants (Actual)	Interventional	2007-07-31	Completed
Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma [NCT01621880]	Phase 2	112 participants (Actual)	Interventional	2012-06-30	Completed
Intratympanic Dexamethasone or Methylprednisolone for Sudden Hearing Loss as a Salvage Treatment: a Randomized, Double-blind, Multi-center Study [NCT04129697]		30 participants (Anticipated)	Interventional	2020-01-01	Not yet recruiting
Comparison of the Efficacy of Two Different Glucocorticoid Regimens for Treatment of Active Moderate-to-severe Graves' Orbitopathy [NCT05793359]		62 participants (Actual)	Observational [Patient Registry]	2017-07-25	Completed
Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails [NCT04273321]		86 participants (Actual)	Interventional	2020-02-14	Completed
Retrobulbar Methylprednisolone as Adjunctive Treatment in Optic Neuritis. Randomized Controlled Trial. [NCT04942002]	Phase 2/Phase 3	50 participants (Anticipated)	Interventional	2021-06-15	Recruiting
Safety and Efficacy of Topical Loteprednol Etabonate 0.5%, Versus Prednisolone Acetate 1%, for the Treatment of Intraocular Inflammation Following Surgery for Childhood Cataract [NCT01475643]	Phase 3	107 participants (Actual)	Interventional	2013-06-30	Completed
Glucocorticosteroid Therapy on Drug-induced Liver Injury: a Prospective Non-randomized Concurrent Control Trial [NCT04553003]	Phase 4	80 participants (Anticipated)	Interventional	2020-08-01	Recruiting
Hyper-CVAD With Liposomal Vincristine (Hyper-CMAD) in Acute Lymphoblastic Leukemia [NCT01319981]	Phase 2	31 participants (Actual)	Interventional	2013-03-05	Completed
The Use of Campath-1H, Tacrolimus, and Sirolimus Followed by Sirolimus Withdrawal in Renal Transplant Patients [NCT00078559]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2003-11-30	Completed
Evaluation of DEXTENZA on the Management of Pain and Inflammation in Patients With Anterior Uveitis Compared to Standard of Care Topical Corticosteroids [NCT04426734]	Phase 4	30 participants (Anticipated)	Interventional	2020-07-01	Not yet recruiting
Treatment of Refractory Gout With Adrenocorticotropic Hormone or Methylprednisolone [NCT04808856]		60 participants (Anticipated)	Interventional	2021-04-01	Recruiting
Corticosteriods vs. Saline vs. Air Placebo Intra-articular Injections for Knee Osteoarthritis: A Single Blinded Prospective Randomized Trial [NCT02995083]	Early Phase 1	0 participants (Actual)	Interventional	2017-06-30	Withdrawn(stopped due to Study deemed not feasible)
Yale Steroid Enhanced Versus Exparel Nerveblock TKA Randomized Controlled Trial (RCT) Study [NCT05279092]	Phase 2	250 participants (Anticipated)	Interventional	2022-09-08	Recruiting
Oral Prednisolone Dosing in Children Hospitalized With Asthma [NCT00257933]	Phase 4	152 participants (Actual)	Interventional	2006-02-28	Completed
Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial. [NCT05748561]	Phase 2/Phase 3	18 participants (Anticipated)	Interventional	2022-04-05	Recruiting
Musculoskeletal Ultrasound Changes in the Plantar Fascia After a Single Injection of Platelet Rich Plasma Compared to Steroid [NCT05339542]		98 participants (Actual)	Interventional	2022-03-10	Completed
Randomized Controlled Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery [NCT01559675]		121 participants (Actual)	Interventional	2010-09-30	Completed
Dextenza vs Prednisolone Acetate After Cataract Surgery for Patients With Diabetes [NCT04977427]	Phase 4	200 participants (Anticipated)	Interventional	2021-07-31	Not yet recruiting
A Pilot Study Investigating the Feasibility and Efficacy of Locoregional Intra-arterial Administration of Methylprednisolone as a Bridge Therapy to Treat Symptomatic Flares in Inflammatory Bowel Disease. [NCT05587673]	Phase 1	30 participants (Anticipated)	Interventional	2022-10-06	Recruiting
Comparison of Efficacy and Safety of Two Different Ultrasound-Guided Suprascapular Nerve Block Techniques in Chronic Shoulder Pain: A Prospective Double-Blinded Randomized Controlled Study [NCT04938037]		80 participants (Anticipated)	Interventional	2021-06-01	Recruiting
A Feasibility Randomised Placebo-controlled Trial With Objective Outcome Measures to Evaluate the Efficacy of Biosimilar Rituximab in Musculoskeletal and Mucocutaneous Systemic Lupus Erythematosus [NCT03054259]	Phase 2	30 participants (Anticipated)	Interventional	2017-09-21	Recruiting
Transverse Abdominis Plane Block Using Liposomal Bupivacaine for Post-operative Cesarean Delivery Analgesia- Walking Towards Recovery [NCT04393207]	Phase 4	300 participants (Anticipated)	Interventional	2022-02-01	Recruiting
Intracanalicular Dexamethasone Insert for Management of Post-operative Pain and Inflammation in Patients Undergoing Vitreoretinal Surgery [NCT04371445]	Phase 4	30 participants (Anticipated)	Interventional	2020-12-01	Enrolling by invitation
Evaluation of Sleep EEG Changes in Paediatric Patients With Language Dysfunction: A Follow up Study. Evaluation of Sleep EEG Changes in Paediatric Patients With Language Dysfunction: A Follow up Study. Evaluation of Sleep EEG Changes in Pediatric Patients [NCT05487521]	Phase 3	93 participants (Actual)	Interventional	2020-02-20	Completed
Clinical Study of the Effect of Methylprednisolone Combined With Two Hydroxypropyl Theophylline on Respiratory Dynamics During Thoracoscopic Lobectomy [NCT04810819]		110 participants (Anticipated)	Interventional	2021-07-01	Not yet recruiting
Comparison of Dropless Prophylaxis After Routine Phacoemulsification to Standard Drops Regimen [NCT02515045]	Phase 4	59 participants (Actual)	Interventional	2015-01-31	Completed
Efficacy and Safety of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 Chronic Kidney Disease [NCT05510323]	Phase 3	208 participants (Anticipated)	Interventional	2022-08-31	Not yet recruiting
The Effectiveness of Pulsed Radiofrequency of the Suprascapular Nerve and Shoulder Joint Compared to Intra-articular Corticosteroid Injection for Hemiplegic Shoulder Pain Management and Functional Improvement. [NCT05563571]		20 participants (Anticipated)	Interventional	2022-04-01	Recruiting
DEXTENZA VS. PREDNISOLONE ACETATE 1% in the Incidence of Pseudophakic Macular Edema in Patients With Diabetic Retinopathy Undergoing Cataract Surgery [NCT04362241]	Phase 4	30 participants (Anticipated)	Interventional	2020-08-07	Recruiting
The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy [NCT01579539]	Phase 3	18 participants (Actual)	Interventional	2013-06-27	Completed
Pre-operative Intravenous Steroid in Unilateral Primary Total Knee Replacement for Pain Relief and Recovery: A Double-Blind Randomized Controlled Trial [NCT03082092]	Phase 4	60 participants (Actual)	Interventional	2017-06-01	Completed
Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD) [NCT03829566]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2019-11-30	Withdrawn(stopped due to Discontinued by Investigator)
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment [NCT02283996]	Phase 4	260 participants (Anticipated)	Interventional	2014-11-30	Recruiting
Efficacy and Safety of Granulocyte-colony Stimulating Factor in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid: A Randomized, Double-blind, Placebo-controlled, Nationwide Multi-center Study [NCT02442180]	Phase 3	64 participants (Actual)	Interventional	2015-07-31	Terminated(stopped due to failure to recruit eligible patients)
Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL) - a 12-week, Prospective, Open-label, Pilot Study [NCT01790022]	Phase 2	20 participants (Actual)	Interventional	2012-07-31	Active, not recruiting
A Phase 2a Single-arm, Prospective, Open-label Pilot Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant [NCT04046549]	Phase 2	25 participants (Actual)	Interventional	2019-10-30	Completed
Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery [NCT01872611]	Phase 3	819 participants (Actual)	Interventional	2013-06-30	Completed
A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy [NCT04629248]	Phase 3	140 participants (Anticipated)	Interventional	2021-06-25	Recruiting
[NCT00425724]	Phase 4	20 participants (Anticipated)	Interventional	2000-01-31	Completed
Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Relapsed or Refractory CLL/SLL The HiLOG Trial [NCT01497496]	Phase 2	29 participants (Actual)	Interventional	2012-01-26	Completed
Dextenza in Pterygium Surgery [NCT04403516]	Phase 4	30 participants (Actual)	Interventional	2020-10-01	Completed
Randomized Controlled Trial of Infliximab (Remicade®) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19) [NCT02495077]	Phase 2	290 participants (Actual)	Interventional	2015-11-02	Completed
Prospective, Randomized Clinical Trial of Meibomian Gland Probing Versus Sham Procedure for Refractory Meibomian Gland Dysfunction [NCT02256969]	Phase 4	45 participants (Actual)	Interventional	2014-10-31	Completed
MYELOMA VII MEDICAL RESEARCH COUNCIL WORKING PARTY ON LEUKEMIA IN ADULTS: MYELOMATOSIS THERAPY TRIAL [NCT00002599]	Phase 3	750 participants (Anticipated)	Interventional	1994-09-30	Active, not recruiting
Phase III Study of Combination Chemotherapy in Children With T Cell and Pre-B Cell Non-Hodgkin's Lymphoma [NCT00003650]	Phase 3	179 participants (Actual)	Interventional	1997-02-28	Completed
A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Adults and Children With Bone Marrow Failure Syndromes or Inherited Metabolic or Hematologic Diseases [NCT00003662]	Phase 2	90 participants (Anticipated)	Interventional	1998-08-31	Completed
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Infants Less Than 1 Year of Age. [NCT00002785]	Phase 2	0 participants	Interventional	1996-07-31	Completed
Augmenting Bone Marrow With CD34 Enriched Peripheral Blood Hematopoietic Stem Cells for Allogeneic Transplantation of Hematologic Malignancies [NCT00004232]	Phase 1	0 participants	Interventional	1999-10-31	Completed
The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenanc [NCT00003728]	Phase 3	1,500 participants (Anticipated)	Interventional	1998-12-31	Active, not recruiting
"Phase I Study of T Cell Depleted (TCD) Partially Matched Related Donor (PMRD) Hematopoietic Stem Cell Transplantation for High Risk Hematologic Diseases Using Intense Pre and Post Transplant Immunosuppression and Megadose CD34 Veto Cells" [NCT00004904]	Phase 1	0 participants	Interventional	1999-10-31	Completed
Use of G-CSF Stimulated HLA-Identical Allogeneic Peripheral Blood Stem Cells for Patients With High Risk Acute Myelogenous Leukemia or CML in Blast Crisis [NCT00002833]	Phase 2	53 participants (Actual)	Interventional	1994-10-31	Completed
Safety and Effectiveness of Single-dose Subconjunctival Triamcinolone Compared to Topical Prednisolone Eye Drops in Manual Small Incision Cataract Surgery [NCT05248139]		100 participants (Anticipated)	Interventional	2022-10-31	Not yet recruiting
A Multicenter Study of Unrelated Umbilical Cord Blood as an Alternate Source of Stem Cells for Transplantation [NCT00003913]	Phase 2	390 participants (Anticipated)	Interventional	1998-12-31	Completed
A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia [NCT00004255]	Phase 2/Phase 3	0 participants	Interventional	2000-03-31	Completed
Phase II Study of Prednisolone/Methylprednisolone Absorption in Children With Juvenile Dermatomyositis [NCT00004357]	Phase 2	6 participants (Actual)	Interventional	1997-09-30	Completed
T-Cell Depletion for Graft-Versus-Host Disease (GVHD) Prevention in High Risk Matched and Mismatched Allogeneic Bone Marrow Transplantation [NCT00005641]	Phase 2	0 participants	Interventional	1997-09-30	Terminated(stopped due to low study accrual)
Phase III Randomized, Double-Blind Study of Methylprednisolone by 24- Versus 48-Hour Infusion Versus Tirilazad for Acute Spinal Cord Injury [NCT00004759]	Phase 3	497 participants	Interventional	1991-12-31	Completed
Bone Marrow Transplantation and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance (ITN054ST) [NCT02029638]	Phase 2	4 participants (Actual)	Interventional	2014-01-07	Terminated(stopped due to Slow accrual)
Phase II Trial of Intensive, Short-Course Combination Chemotherapy in the Treatment of Newly Diagnosed Patients With Poor-Risk Nonlymphoblastic Lymphoma and Acute B-Lymphoblastic Leukemia and in Patients With Recurrent Non-Hodgkin's Lymphoma [NCT00002471]	Phase 2	0 participants	Interventional	1990-02-28	Completed
De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study [NCT02909335]	Phase 3	0 participants (Actual)	Interventional	2016-11-30	Withdrawn
Does Anesthetic Contribute to Symptomatic Relief in Corticosteroid Injections for Knee Osteoarthritis? A Double-Blind Randomized Trial Comparing Corticosteroid/Ropivacaine Versus Corticosteroid/Saline Injections [NCT02576249]	Phase 4	29 participants (Actual)	Interventional	2015-10-31	Completed
A Multicenter, Randomized, Open-label, Blinded-assessor, Follow-up, Phase 4 Study in Patients With Rheumatoid Arthritis Who Have Completed the Initial Treatment Part in the NORD-STAR Study and Have Reached Stable Low Disease Activity [NCT02466581]	Phase 4	25 participants (Actual)	Interventional	2015-02-03	Active, not recruiting
Preoperative Methylprednisolone on Thoracic Endovascular Repair for Reducing Post-implantation Syndrome [NCT05349071]		158 participants (Anticipated)	Interventional	2022-05-01	Not yet recruiting
Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease [NCT01977781]	Phase 1	40 participants (Actual)	Interventional	2013-12-31	Completed
A Prospective, Randomized Trial Comparing the Efficacy of Body-weight Based Versus Fixed Corticosteroid Dosage on Remission in Patients With Moderate to Severe Crohn's Disease Flares [NCT02392286]	Phase 4	15 participants (Actual)	Interventional	2015-03-31	Terminated(stopped due to insufficient enrollment)
Efficacy and Safety of Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis. [NCT05990894]		248 participants (Actual)	Observational	2018-01-01	Completed
High Dose Steroids for Liver Resection - Effect on Complications and Endothelial Function in the Immediate Postoperative Phase - a Randomized, Doubleblind, Controlled Trial [NCT03403517]	Phase 4	174 participants (Actual)	Interventional	2017-12-11	Completed
A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab (SAR650984) in Patients Awaiting Kidney Transplantation [NCT04294459]	Phase 1/Phase 2	23 participants (Actual)	Interventional	2020-06-18	Terminated(stopped due to Terminated due to non-safety reasons)
Safety and Efficacy of KPI-121 1% Ophthalmic Suspension Versus Prednisolone Acetate Ophthalmic Suspension 1% for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age [NCT03596723]	Phase 3	2 participants (Actual)	Interventional	2018-07-03	Terminated(stopped due to NDA #210565 did not trigger the need for a Pediatric Research Equity Act study.)
Post-operative Methylprednisolone Taper Course for Orthopedic Surgery [NCT03661645]	Phase 4	1,000 participants (Anticipated)	Interventional	2018-09-07	Enrolling by invitation
A Randomized Prospective Study of Early Intensification Versus Alternating Triple Therapy for Patients With Poor Prognosis Lymphoma [NCT00002835]	Phase 3	116 participants (Actual)	Interventional	1995-10-30	Completed
[NCT00004323]	Phase 2	10 participants	Interventional	1995-02-28	Completed
[NCT00004785]	Phase 3	54 participants	Interventional	1995-11-30	Completed
Phase I/II Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) [NCT02464657]	Phase 1/Phase 2	44 participants (Actual)	Interventional	2015-07-31	Completed
Open Randomized Single Centre Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With Severe Lung Injury Secondary to COVID-19 [NCT04341038]	Phase 3	84 participants (Anticipated)	Interventional	2020-04-01	Recruiting
Physiologic Effects of Stress Dose Corticosteroids in the Management of Inhospital Cardiac Arrest - CORTICA [NCT02790788]	Phase 1/Phase 2	100 participants (Actual)	Interventional	2016-11-04	Completed
Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients [NCT02954198]		40 participants (Actual)	Interventional	2016-12-01	Completed
Efficacy and Safety of Loteprednol 0.5% Gel for Routine Prophylaxis After Photorefractive Keratectomy Compared to Prednisolone Acetate 1% Suspension and Fluorometholone 0.1% Suspension [NCT03123614]	Phase 4	131 participants (Actual)	Interventional	2014-09-19	Completed
Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients Converted From Twice-daily Tacrolimus [NCT02953873]	Phase 4	25 participants (Actual)	Interventional	2017-05-05	Completed
Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease [NCT02133924]	Phase 2	76 participants (Actual)	Interventional	2016-08-31	Completed
A Phase 4, Randomized, Double-Masked, Single Center, Placebo-Controlled Adaptive Clinical Trial, Using Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, in Subjects With Allergic Conjunctivitis to Evaluate a Modified Conjunctival Allergen Challenge ( [NCT01534195]	Phase 4	11 participants (Actual)	Interventional	2012-01-31	Completed
Treatment of COVID-19 Pneumonia With Glucocorticoids. A Randomized Controlled Trial [NCT04438980]	Phase 3	72 participants (Actual)	Interventional	2020-05-15	Completed
Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease [NCT02339142]	Phase 4	100 participants (Anticipated)	Interventional	2015-01-31	Not yet recruiting
Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI) [NCT03111810]	Phase 2	32 participants (Actual)	Interventional	2017-05-25	Completed
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Obinutuzumab in Patients With ISN/RPS 2003 Class III or IV Lupus Nephritis [NCT02550652]	Phase 2	126 participants (Actual)	Interventional	2015-11-13	Completed
A Multicenter, Open-Label Study to Estimate the Effect Sizes of HRCT Endpoints in Response to GLUCOCORTICOID Induction Therapy in Subjects With Pulmonary Sarcoidosis [NCT03324503]		8 participants (Actual)	Interventional	2017-12-08	Completed
Intra-articular Injections of Platelet-rich Plasma, Hyaluronic Acid, or Corticosteroids for Knee Osteoarthritis, Which is Better? A Prospective Study of a Single-blind Randomized Control Trial RCT From the Iraqi Population [NCT04980105]	Phase 3	150 participants (Actual)	Interventional	2020-03-02	Active, not recruiting
Hit Hard and Early. The Effect of High Dose Methylprednisolone on Nailfold Capillary Changes and Biomarkers in Early SSc: a 12-week Randomised Explorative Double-blind Placebo-controlled Trial. [NCT03059979]	Early Phase 1	30 participants (Anticipated)	Interventional	2017-01-31	Recruiting
Second Affiliated Hospital, College of Medicine, Zhejiang University [NCT04918953]	Phase 2	90 participants (Anticipated)	Interventional	2021-06-02	Not yet recruiting
The Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma [NCT03045471]		50 participants (Anticipated)	Observational	2017-03-01	Not yet recruiting
Study of the Excretion of Orally Administered Corticosteroids for the Improval of the Detection of Said Substances in Anti-doping Controls [NCT04791345]	Phase 1	50 participants (Anticipated)	Interventional	2021-02-26	Recruiting
Autologous Platelet Rich Fibrin Versus Steroid in Ultrasound-Guided Sacroiliac Joint Injection for Joint Dysfunction (Randomized Comparative Study) [NCT04757740]	Phase 4	94 participants (Anticipated)	Interventional	2021-03-01	Recruiting
The Role of Doxycycline in Management of Moderate to Severe Chronic Rhinosinusitis With Nasal Polyps [NCT02569437]	Phase 2	49 participants (Actual)	Interventional	2014-09-30	Terminated(stopped due to A high percentage of patients were dropping out of the study and were not able to complete the protocol.)
Topical Use of Corticosteroid to Prevent Epiretinal Membrane Formation in Eyes With Retinal Tear Undergoing Laser Retinopexy: a Pilot Prospective Clinical Study [NCT02412059]		200 participants (Actual)	Interventional	2015-08-31	Completed
An Open-label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera®/Rituxan®) in Patients With Active Rheumatoid Arthritis [NCT02093026]	Phase 2	465 participants (Actual)	Interventional	2002-08-31	Completed
Triamcinolone Versus Methylprednisolone in Ultrasound Guided Transversus Abdominis Plane Block in Major Open Abdominal Surgery [NCT04480775]	Phase 2/Phase 3	84 participants (Actual)	Interventional	2020-07-15	Completed
Safety and Efficacy of Steroids in the Management of Fulminant Hepatic Failure Due to Hepatitis A Virus in the Pediatric Age Group [NCT02375867]	Phase 4	33 participants (Actual)	Interventional	2015-01-31	Completed
Once a Month High-dose Methylprednisolone During Wash-out Period Between Natalizumab and Fingolimod Treatments in Patients With Multiple Sclerosis: a Randomised, Controlled, Double-blind Trial (NTZ2FTY) [NCT02769689]	Phase 4	56 participants (Anticipated)	Interventional	2019-06-12	Recruiting
Intra-Arterial Steroid Administration of De Novo Acute Graft-vs-Host Disease of the Gastrointestinal Tract: A Phase II Study [NCT02425813]	Phase 2	0 participants (Actual)	Interventional	2015-10-31	Withdrawn(stopped due to Slow Accrual)
An Open-label Study to Evaluate the Effect of MabThera in Combination With Methotrexate on Disease Activity in Patients With Active Rheumatoid Arthritis After DMARD Treatment Failure [NCT02006706]	Phase 3	15 participants (Actual)	Interventional	2006-08-10	Completed
Intra-articular and Intravenous Infliximab in the Treatment of Resistant Seronegative Oligoarthritis of the Knee [NCT01216631]	Phase 2	1 participants (Actual)	Interventional	2010-09-30	Terminated(stopped due to Unable to recruit)
Comparison of the Treatment Efficacy of High-Dose Corticosteroid and Tocilizumab During Clinical Worsening in Patients With COVID-19 Pneumonia [NCT05133635]	Phase 4	0 participants (Actual)	Interventional	2021-02-01	Withdrawn(stopped due to A recent study suggested a new corticosteroid regime for intensive care unit patients.)
A Randomized Multi-Center Treatment Study (COALL 08-09) to Improve the Survival of Children With Acute Lymphoblastic Leukemia on Behalf of the German Society of Pediatric Hematology and Oncology [NCT01228331]	Phase 2/Phase 3	745 participants (Actual)	Interventional	2010-10-31	Active, not recruiting
Corticosteroids in Severe Alcoholic Hepatitis Patients With Early Spontaneous Improvement [NCT03160651]		140 participants (Anticipated)	Interventional	2018-02-09	Recruiting
Comparison Between Ultrasound Guided Ozone, Platelet-Rich Plasma or Steroid Injection in the Treatment of Sacroiliitis; a Randomized Double Blinded Controlled Study [NCT05914350]		105 participants (Anticipated)	Interventional	2023-06-23	Recruiting
Investigating Differences in Flare Reaction Incidence and Intensity Following Trigger Finger Injections Using Betamethasone and Methylprednisolone [NCT04900220]	Phase 4	66 participants (Actual)	Interventional	2021-09-15	Completed
Genomic Response of Human Immune and Non-Immune Cells to Glucocorticoids [NCT02798523]	Phase 1	33 participants (Actual)	Interventional	2017-01-24	Completed
Steroid Versus Platelet Rich Plasma in Ultrasound Guided Sacroiliac Joint Injection for Chronic Low Back Pain [NCT02334475]		40 participants (Actual)	Interventional	2013-07-31	Completed
Effect of Preoperative Intravenous High Dose Methylprednisolone on Glucose Homeostasis in Patients Scheduled for Total Hip- and Knee-arthroplasty [NCT02332603]	Phase 3	134 participants (Actual)	Interventional	2015-01-31	Completed
Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab Against Systemic Corticotherapy in Patients Admitted by Covid-19 With Bilateral Pneumonia and Poor Evolution [NCT05002517]	Phase 3	60 participants (Anticipated)	Interventional	2020-09-03	Active, not recruiting
Antiviral Treatment in Facial Palsy. Randomized Control Trial [NCT02328079]		50 participants (Actual)	Interventional	2013-04-30	Completed
Comparison Of Two Corticosteroid Dosing Regimens For Prevention Of Corneal Transplant Rejection Episodes After Descemet's Membrane Endothelial Keratoplasty [NCT01448213]	Phase 2	264 participants (Actual)	Interventional	2011-10-31	Completed
Optimization of NULOJIX® (Belatacept) Usage as a Means of Avoiding CNI and Steroids in Renal Transplantation (CTOT-10) [NCT01436305]	Phase 2	19 participants (Actual)	Interventional	2011-09-30	Terminated(stopped due to Secondary to safety concerns plus change in Campath® (alemtuzumab) availability.)
A Two-Part, Phase I Randomized, Double-Blind, Active-Comparator Controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of MK-8808 and to Compare the Pharmacokinetics of MK-8808 With EU-approved MabThera® and US-licensed [NCT01390441]	Phase 1	100 participants (Actual)	Interventional	2011-07-31	Terminated(stopped due to The study was terminated early by the Sponsor for business reasons.)
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Methylprednisolone as a Treatment for Presumed Hantavirus Cardiopulmonary Syndrome [NCT00128180]	Phase 2	66 participants (Actual)	Interventional	2003-01-31	Completed
Randomized Study of Different Non-myeloablative Conditioning Regimens With Hematopoietic Stem Cell Support in Patients With Scleroderma (Autologous Systemic Sclerosis Immune Suppression Trial - II ASSIST-IIb) [NCT01445821]	Phase 3	44 participants (Actual)	Interventional	2011-09-15	Terminated(stopped due to Developed a better regimen: DIAD. Cast. 2018 NCT03593902)
A Phase II Study of Rituximab and Temozolomide in Recurrent Primary CNS Lymphoma [NCT00248534]	Phase 2	16 participants (Actual)	Interventional	2005-09-30	Terminated(stopped due to slow accrual/lack of resources/low priority due to combining 2 consortia)
Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to a Single Intrabursal Injection of Corticosteroids in Patients With Shoulder Calcific Tendinopathy [NCT01652495]	Phase 4	44 participants (Actual)	Interventional	2012-03-31	Completed
A Phase 1/2 Trial Evaluating Treatment of Emergent Graft Versus Host Disease (GvHD) With AP1903 After Planned Donor Infusions (DLIs) of T-cells Genetically Modified With the iCasp9 Suicide Gene in Patients With Hematologic Malignancies [NCT01875237]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2013-12-27	Terminated
Prospective, Randomized Comparison of Corticosteroid Dosing Regimens Following Endothelial Keratoplasty [NCT01853696]	Phase 4	167 participants (Actual)	Interventional	2013-03-31	Completed
Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery [NCT01853072]	Phase 3	881 participants (Actual)	Interventional	2013-06-30	Completed
Blood Pressure Profile and NT-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy [NCT03590080]		32 participants (Actual)	Observational	2011-01-01	Completed
Impact of Preoperative Single Corticosteroid Flash on Morbidity After Colorectal Resection: Monocentric Prospective Pilot Study [NCT03437746]	Phase 2	78 participants (Actual)	Interventional	2018-03-01	Terminated(stopped due to insufficient rate of inclusion)
Effect of Depo-Medrol Application on the Psoas Muscle After Transpsoas LLIF on Post-operative Hip Flexor Weakness, Thigh Pain and Numbness [NCT05929755]	Phase 4	80 participants (Anticipated)	Interventional	2023-05-12	Recruiting
Effect of Methylprednisolone on Systemic Inflammatory Response and Clinical Parameters During Pediatric Congenital Open-Heart Surgery: A Randomized Controlled Trial [NCT05927233]	Phase 4	60 participants (Anticipated)	Interventional	2023-04-01	Recruiting
The D3 Study: Drug Delivery vs Drops - A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1% in Controlling Post-operative Pain and Inflammation in Patients Undergoing Sequential Cataract Surgery [NCT04273282]	Phase 4	31 participants (Actual)	Interventional	2019-12-16	Completed
A Novel Immunosuppression Intervention for the Treatment of Amyotrophic Lateral Sclerosis (ALS) [NCT01884571]	Phase 2	31 participants (Actual)	Interventional	2013-10-31	Completed
A 12-Month, Open Label Study of Extended Release Tacrolimus (Envarsus XR®, LCPT) With Mycophenolate, Rabbit Antithymocyte Globulin (rATG) and Early Steroid Withdrawal in de Novo Kidney Transplant Recipients [NCT03828682]	Phase 4	60 participants (Anticipated)	Interventional	2019-06-21	Recruiting
The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy [NCT01451710]		30 participants (Actual)	Interventional	2011-03-31	Completed
Double-Blind, Randomized, Parallel Group, Multicenter Study of Durolane Compared to Methylprednisolone in Subjects With Osteoarthritis of the Knee [NCT01209364]	Phase 3	442 participants (Actual)	Interventional	2007-03-31	Completed
High Dose Steroids in Children With Stroke and Unilateral Focal Arteriopathy: Paediatric Arteriopathy Steroid Aspirin (PASTA) Project. A Multicentre Randomized Trial. [NCT03249844]	Phase 3	0 participants (Actual)	Interventional	2022-09-01	Withdrawn(stopped due to discontinuation of the trial)
Allogeneic Hematopoietic Cell Transplantation of Positively Selected CD34+ Cells and Defined Inoculum of T Cells From Related Haploidentical Donors for Older Patients With Indolent Hematologic Malignancies [NCT00185692]	Phase 2	16 participants (Actual)	Interventional	2000-08-31	Completed
Evaluation of a Strategy Based on the 3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation: the I4BiS Study [NCT02444429]	Phase 3	346 participants (Anticipated)	Interventional	2015-09-30	Recruiting
Proteomics Combined With Metabolomics Studies on the Efficacy of Telitacicept in Chinese Patients of Systemic Lupus Erythematosus [NCT05666336]	Phase 4	30 participants (Anticipated)	Interventional	2022-12-31	Recruiting
Optimization of NULOJIX® (Belatacept) Usage as a Means of Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation (CTOT-15) [NCT01790594]	Phase 2	46 participants (Actual)	Interventional	2013-02-28	Terminated(stopped due to Slow accrual within enrollment time period: projected accrual goal not achieved.)
Phase II Study of Adult Acute Lymphoblastic Leukaemia (ALL): Imatinib in Combination With Chemotherapy in Ph+ Patients, and Post-remissional Treatment Intensification in High-risk Ph- Patients, With Minimal Residual Disease Monitoring. [NCT00458848]	Phase 2	470 participants (Actual)	Interventional	2004-10-31	Completed
Steroid and Tacrolimus Avoidance Using NULOJIX® (Belatacept) in Renal Transplantation (CTOT-16) [NCT01856257]	Phase 2	71 participants (Actual)	Interventional	2013-07-31	Terminated(stopped due to Safety: Stopping rule not met.)
Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics in Kidney Transplant Recipients [NCT06044558]		507 participants (Actual)	Observational	2022-09-01	Completed
[NCT00733096]	Phase 2/Phase 3	84 participants (Actual)	Interventional	2008-08-31	Completed
Steroids in Pediatric Acute Lung Injury/ARDS Trial: A Blinded, Placebo-controlled, Randomized Clinical Trial [NCT01274260]	Phase 2	100 participants (Anticipated)	Interventional	2010-10-31	Active, not recruiting
SAAB: Randomized, Double Blind STudy of Corticosteroid Pulse After Ablation [NCT00807586]	Phase 4	119 participants (Actual)	Interventional	2008-12-31	Completed
A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic Leukemia [NCT06124157]	Phase 3	680 participants (Anticipated)	Interventional	2024-01-22	Not yet recruiting
A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients With Fronto-Temporal Dementia With Progranulin Mutations (FTD-GRN) [NCT04408625]	Phase 1/Phase 2	23 participants (Anticipated)	Interventional	2020-11-09	Recruiting
The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis: A Pilot Study [NCT03511625]	Phase 3	6 participants (Anticipated)	Interventional	2018-10-02	Active, not recruiting
Phase II Study of Infliximab for the Treatment of Ipilimumab Colitis [NCT04305145]	Phase 2	42 participants (Anticipated)	Interventional	2020-08-31	Recruiting
High Dose Methylprednisolone Verses Low Dose in Correction of Congenital Acynotic Heart Disease [NCT05103397]	Phase 4	75 participants (Anticipated)	Interventional	2021-10-16	Recruiting
Patient PReference, Efficacy, and SaFety of an Intracanalicular DExamenthasone InseRt comparEd to Topical PrednisoloNe in PatienTs UndergoIng SequentiAl PhacoemuLsification With Intraocular Lens Surgery OR Combined Phacoemulsification With IOL and a Minim [NCT04563559]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2020-11-30	Withdrawn(stopped due to PI decided not to open study)
Health Sciences University Bursa Yüksek Ihtisas Training and Research Hospital [NCT04847687]		300 participants (Actual)	Observational	2021-03-01	Completed
Is the Effect of Systemic Steroids Treating Pollen Induced Allergic Rhinitis Mainly Due to a Placebo Effect [NCT04622917]	Phase 4	44 participants (Actual)	Interventional	2019-04-10	Active, not recruiting
Randomized Controlled Trial on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow [NCT05062681]	Phase 4	60 participants (Anticipated)	Interventional	2021-09-15	Recruiting
Methylprednisolone and Hyaluronic Acid Versus Each Agent Alone to Control Post-extraction Complications of Impacted Mandibular Third Molar [NCT04816253]		72 participants (Actual)	Interventional	2021-02-10	Completed
Analgesia After Total Knee Arthroplasty: Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI). A Double-Blinded Randomized Controlled Trial [NCT03094663]		86 participants (Anticipated)	Interventional	2017-02-28	Recruiting
[NCT03067753]	Phase 2	28 participants (Anticipated)	Interventional	2016-12-31	Recruiting
A Phase I/II Study of High-Dose Deoxyazacytidine, Busulfan, and Cyclophosphamide With Allogeneic Stem Cell Transplantation for Hematologic Malignancies [NCT00002831]	Phase 1/Phase 2	24 participants (Actual)	Interventional	1995-08-01	Completed
A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With High Risk Hematologic Malignancies [NCT00003335]	Phase 2	44 participants (Actual)	Interventional	1998-01-31	Completed
Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections [NCT04563299]	Phase 4	10 participants (Actual)	Interventional	2020-12-09	Terminated(stopped due to Subject Enrollment)
Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids for Treatment of Minnesota High-Risk Acute GVHD (aGVHD): A Phase I/II Study [NCT05123040]	Phase 1/Phase 2	55 participants (Anticipated)	Interventional	2023-06-05	Recruiting
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis [NCT01382940]	Phase 4	351 participants (Actual)	Interventional	2011-07-26	Completed
Niacin (as a Vasodilator), and a Topical Steroid (for Macular Edema), Non-Ischemic CRVO,HRVO,BRVO [NCT00493064]	Phase 2/Phase 3	63 participants (Actual)	Interventional	2006-10-31	Completed
A Phase II, Randomized, Clinical Trial Assessing Efficacy And Safety Of Oral Prednisolone vs Intravenous Vincristine In The Treatment Of Infantile [NCT00555464]	Phase 2	8 participants (Actual)	Interventional	2007-11-30	Terminated(stopped due to The introduction of oral propranolol as a highly efficacious agent for infantile hemangiomas)
Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass [NCT01579513]		190 participants (Actual)	Interventional	2012-06-30	Completed
A Pilot Study: Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas [NCT00624416]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2007-10-31	Completed
The Effect of Moderate-Dose Steroid Therapy in Sepsis: A Placebo-Controlled, Randomized Study [NCT01275638]	Phase 4	55 participants (Actual)	Interventional	2005-04-30	Completed
A Phase II, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Withdrawal Design Trial Using Adaptive Randomization Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis [NCT01369745]	Phase 2	294 participants (Actual)	Interventional	2011-06-30	Completed
A Phase 1, Three-Part, Open-Label, Parallel-Cohort Safety and Tolerability Study of Relugolix in Combination With Abiraterone Acetate Plus a Corticosteroid, Apalutamide, or Docetaxel With or Without Prednisone in Men With Metastatic Castration-Sensitive P [NCT04666129]	Phase 1	72 participants (Anticipated)	Interventional	2021-02-18	Recruiting
Effect of Drop-less Surgery Compared to Topical NSAID Alone and Combination of Steroid and NSAID on Central Macular Thickness After Cataract Surgery, a Randomized Controlled Trial [NCT03383328]	Phase 4	470 participants (Actual)	Interventional	2018-02-01	Completed
Randomized Controlled Trial of Ultrasound-guided Steroid Injection Versus Wrist Splint in Patients With Carpal Tunnel Syndrome [NCT04515966]	Phase 4	70 participants (Anticipated)	Interventional	2020-12-01	Recruiting
Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO [NCT02378298]	Phase 4	26 participants (Actual)	Interventional	2011-12-31	Active, not recruiting
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma [NCT05800366]	Phase 2	40 participants (Anticipated)	Interventional	2023-04-06	Recruiting
High Dose Steroids in Children With Stroke and Unilateral Focal Arteriopathy: A Multicentre Randomized Controlled Trial PASTA (Paediatric Arteriopathy Steroid Aspirin) Trial [NCT04873583]	Phase 3	70 participants (Anticipated)	Interventional	2021-11-16	Recruiting
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy [NCT03959085]	Phase 3	4,772 participants (Anticipated)	Interventional	2019-10-31	Recruiting
Improvement in Function and Pain Due to Subacromial Bursitis in Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone [NCT02242630]		61 participants (Actual)	Interventional	2014-09-30	Completed
A Single-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of Prednisolone Sodium Phosphate Ophthalmic Solution, 1% Compared to Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model [NCT01730872]	Phase 4	16 participants (Actual)	Interventional	2012-11-30	Completed
The Utility of feNO in the Differential Diagnosis of Chronic Cough: The Response to Anti-inflammatory Therapy With Prednisolone and Montelukast [NCT02479074]	Phase 4	49 participants (Actual)	Interventional	2016-01-31	Completed
First Line Treatment of Familiar Lymphohistiocytosis by Alemtuzumab (CAMPATH®) [NCT02472054]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2015-06-29	Completed
Increased Heart Rhythm in Response to High-dose Intravenous Methylprednisolone Pulse Therapy of Moderate-to-severe Graves' Orbitopathy [NCT04391439]		40 participants (Actual)	Observational	2011-01-01	Completed
A Randomized, Open-label, Mutli-centre Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgki [NCT01724021]	Phase 3	743 participants (Actual)	Interventional	2012-12-31	Completed
The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI) [NCT02292082]	Phase 4	111 participants (Actual)	Interventional	2014-11-30	Completed
Zoledronic Acid or Methylprednisolone in the Management of Active Charcot's Neuroarthropathy of Foot in Patients With Diabetes Mellitus: A Randomized, Double-blind, Placebo Controlled Trial [NCT03289338]	Phase 2/Phase 3	36 participants (Actual)	Interventional	2016-06-01	Completed
The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol [NCT04349410]	Phase 2/Phase 3	1,800 participants (Actual)	Interventional	2020-04-11	Completed
A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults With Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia [NCT05303792]	Phase 2	66 participants (Anticipated)	Interventional	2023-02-27	Recruiting
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients [NCT03110822]	Phase 1	134 participants (Anticipated)	Interventional	2017-02-01	Recruiting
A Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib [NCT02294357]	Phase 2	45 participants (Anticipated)	Interventional	2014-12-31	Terminated(stopped due to Early termination due to the difficulties to enroll subjects.)
The Effect of Positive Airway Pressure on Idiopathic Sudden Sensorineural Hearing Loss Comorbided With Obstructive Sleep Apnea: A Clinical Randomized Controlled Study [NCT04192656]	Phase 4	102 participants (Anticipated)	Interventional	2019-11-01	Recruiting
Effect of Preoperative Intravenous High Dose Methylprednisolone on Quadriceps Muscle Function in Patients Scheduled for Total Knee-arthroplasty [NCT02319343]	Phase 3	70 participants (Actual)	Interventional	2015-01-31	Completed
Phase III Study to Evaluate the Efficacy and Safety of NPB-01 in Patients With Autoimmune Encephalitis Refractory to Steroid Pulse Therapy [NCT05177939]	Phase 3	40 participants (Anticipated)	Interventional	2022-03-03	Recruiting
Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. [NCT04662723]	Phase 4	878 participants (Anticipated)	Interventional	2023-05-01	Recruiting
Multicenter, Randomized, Observer-blind, Controlled Study of the Anti-IL-6 Receptor Antibody Tocilizumab (TCZ) or Methylprednisolone (MP) Treatment in Patients With Active Moderate-severe Graves' Orbitopathy [NCT04876534]	Phase 2	64 participants (Anticipated)	Interventional	2019-12-18	Recruiting
A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Co-Administration of FOV1101-00 (Cyclosporine 0.01% or 0.02%) and Prednisolone Acetate 0.12% (PredMild®) Compared to Prednisolone Acetate 1% Alone or Vehicle Alone in Patients With Mi [NCT00833495]	Phase 2	155 participants (Actual)	Interventional	2009-01-31	Completed
Parasitic Ulcer Treatment Trial Pilot [NCT03484507]	Phase 2	49 participants (Actual)	Interventional	2018-01-01	Active, not recruiting
A National Prospective Study of Patients With Hepatitis Induced by Immune Checkpoint Inhibitors; Characterization of Liver Injury, Outcome of Therapy and Randomization to Either Prednisolone or Mycophenolate Mofetil Treatment in Case of Relapse [NCT04810156]	Phase 2	60 participants (Anticipated)	Interventional	2021-04-07	Recruiting
Prednisolone vs. Vigabatrin in the First-line Treatment of Infantile Spasms [NCT02299115]	Phase 3	0 participants (Actual)	Interventional	2017-09-05	Withdrawn(stopped due to Most centres are now using oral steroids as 1st line treatment so question of efficacy is no longer of high interest.)
Randomized, Open-Label Trial of Tacrolimus/Everolimus vs. Tacrolimus/Enteric-Coated Mycophenolate Sodium to Prevent Biopsy-Proven Acute Rejection and Chronic Allograft Injury in Adult, Primary Kidney Transplantation [NCT01680861]	Phase 3	32 participants (Actual)	Interventional	2012-11-30	Completed
Pre-emptive Scalp Infiltration With Ropivacaine Plus Methylprednisolone vs Ropivacaine Alone for Relief of Postoperative Pain After Craniotomy in Children (RP/MP vs RP) [NCT03636165]	Phase 4	90 participants (Anticipated)	Interventional	2022-09-01	Not yet recruiting
Preoperative Single-high Dose Glucocorticoid for Patients Undergoing Hip Fracture Surgery and the Effect on Postoperative Delirium. [NCT02317601]	Phase 4	122 participants (Actual)	Interventional	2014-12-31	Completed
Randomized Controlled Trial of Methylprednisolone Versus Dexamethasone in COVID-19 Pneumonia (MEDEAS Trial) [NCT04636671]	Phase 3	690 participants (Actual)	Interventional	2021-04-14	Completed
A Prospective, Multi-Center, Randomized, Double-Masked, Positive Controlled, Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspe [NCT02517619]	Phase 3	251 participants (Actual)	Interventional	2016-01-16	Completed
Effectiveness and Safety of Efgartigimod in the Acute Phase of Neuromyelitis Optica Spectrum Disorders-a Multicentric, Controlled, Retrospective, Real-Word Study [NCT06118398]		24 participants (Anticipated)	Observational	2023-11-05	Not yet recruiting
Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisolone, and GCSF (Filgrastim or Pegfilgrastim) in Patients With Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS) [NCT01624805]	Phase 2	100 participants (Anticipated)	Interventional	2012-06-25	Recruiting
CORTERAS STUDY: The Effect of Corticosteroids on Early Recovery After Major Surgery in Elderly Patients [NCT05220319]	Phase 4	672 participants (Anticipated)	Interventional	2022-02-03	Recruiting
An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or Are Double Refractory to a [NCT01985126]	Phase 2	124 participants (Actual)	Interventional	2013-09-27	Completed
A Randomized Study Comparing the Incidence of Acute Clinical or Subclinical Rejection With Two Dosing Regimens of CellCept in de Novo Renal Transplant Recipients Receiving Induction, Cyclosporine and Brief Steroid Therapy [NCT02005562]	Phase 3	252 participants (Actual)	Interventional	2006-05-31	Completed
Comparison of Follow-up and Steroid Treatment Results in Intussusception in Children [NCT05640375]	Phase 1/Phase 2	120 participants (Anticipated)	Interventional	2019-12-24	Recruiting
A Randomized Controlled Pilot Trial of Cyclosporine vs Steroids in DRESS [NCT04988256]	Early Phase 1	50 participants (Anticipated)	Interventional	2021-09-27	Enrolling by invitation
The Effects of Intraoperative Local and Systemic Corticosteroid Administration on Postoperative Dysphagia After Anterior Cervical Fusion [NCT03311425]	Phase 3	140 participants (Actual)	Interventional	2014-08-01	Completed
Effects of a Multiple Sclerosis Relapse Therapy With Methylprednisolone (MP) During Pregnancy on Offspring Cognitive Function, Stress Sensitivity, Behaviour and Functional and Structural Brain Development [NCT04832269]		80 participants (Anticipated)	Observational	2020-10-19	Recruiting
Randomized, Double-blinded, Comparison Between Ultrasound-Guided Genicular Nerve Phenol Neurolysis and Intra-articular Steroid Injections [NCT06000709]	Phase 4	40 participants (Anticipated)	Interventional	2023-10-20	Not yet recruiting
A 24 Month, Multicenter, Randomized, Open-label Safety and Efficacy Study of Concentration-controlled Everolimus With Reduced Calcineurin Inhibitor vs Mycophenolate With Standard Calcineurin Inhibitor in de Novo Renal Transplantation [NCT01950819]	Phase 4	2,037 participants (Actual)	Interventional	2013-12-03	Completed
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI) [NCT02260934]	Phase 2	43 participants (Actual)	Interventional	2015-07-09	Completed
A Randomized Clinical Trial of Efficacy and Safety on the Use of Belatacept as Compared to Tacrolimus in the Setting of Rabbit Antithymocyte Globulin Induction and Rapid Steroid Discontinuation in Deceased Donor Renal Transplant Recipients With a Focus on [NCT02152345]	Phase 4	57 participants (Actual)	Interventional	2014-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00003270 (1) [back to overview]	Progression-free Survival
NCT00048165 (14) [back to overview]	Number of Participants With Marked Laboratory Abnormalities: Hematology Parameters
NCT00048165 (14) [back to overview]	Median Change From Baseline for Lipid Profile (Total Cholesterol, Low Density Lipoproteins, High Density Lipoproteins, and Triglycerides)
NCT00048165 (14) [back to overview]	Median Time to First Acute Rejection Episode Within the First 6 Months and 12 Months PT
NCT00048165 (14) [back to overview]	Number of Acute Rejection Episodes Per Participant Within the First 6 Months and 12 Months PT
NCT00048165 (14) [back to overview]	Number of Participant Who Died Within 6 Months 12 Months and 3 Years PT
NCT00048165 (14) [back to overview]	Number of Participants Using Monomurab Cluster of Differentiation 3, Orthoclone Polyclonal Antithymocyte Globulin or Antilymphocyte Globulin in the First 6 Months and 12 Months PT
NCT00048165 (14) [back to overview]	Number of Participants With Any Adverse Events and Any Serious Adverse Event, and Adverse Events Leading to Premature Withdrawal
NCT00048165 (14) [back to overview]	Number of Participants With Malignancies and Opportunistic Infections
NCT00048165 (14) [back to overview]	Number of Participants With Marked Laboratory Abnormalities: Biochemistry Parameters
NCT00048165 (14) [back to overview]	Number of Participants With Worst ISHLT Biopsy Grade Within First 6 Months and 12 Months PT
NCT00048165 (14) [back to overview]	Median Change From Baseline for LDL/HDL Ratio
NCT00048165 (14) [back to overview]	Mean Maintenance Doses of Mycophenolate Mofetil, Cyclosporine, and Cumulative Dose of Corticosteroids at 6 and 12 Months PT
NCT00048165 (14) [back to overview]	Number of Participants Who Developed Acute Rejection Episode Within the 12 Months PT
NCT00048165 (14) [back to overview]	Number of Participants Who Developed Acute Rejection Episode Within 6 Months Post-Transplant
NCT00053989 (4) [back to overview]	PFS
NCT00053989 (4) [back to overview]	OS
NCT00053989 (4) [back to overview]	Acute GvHD
NCT00053989 (4) [back to overview]	Day 100 TRM
NCT00057811 (4) [back to overview]	Minimal Residual Disease
NCT00057811 (4) [back to overview]	Response Rate
NCT00057811 (4) [back to overview]	Grade ≥ 3 Stomatitis
NCT00057811 (4) [back to overview]	Toxic Death
NCT00066469 (1) [back to overview]	Event-free Survival
NCT00076752 (16) [back to overview]	Cluster of Differentiation 8 (CD8) + Cells
NCT00076752 (16) [back to overview]	Extractable Nuclear Antigen (ENA)
NCT00076752 (16) [back to overview]	Natural Killer Cells
NCT00076752 (16) [back to overview]	Platelet Count
NCT00076752 (16) [back to overview]	Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)
NCT00076752 (16) [back to overview]	White Blood Cells
NCT00076752 (16) [back to overview]	Cluster of Differentiation 4 (CD4) + Cells
NCT00076752 (16) [back to overview]	Number of Participants With Adverse Events
NCT00076752 (16) [back to overview]	Absolute Lymphocyte Count
NCT00076752 (16) [back to overview]	Absolute Neutrophil Count
NCT00076752 (16) [back to overview]	Anti-Double Stranded Deoxyribonucleic Acid (DNA) Antibody
NCT00076752 (16) [back to overview]	Anti-Nuclear Antibody
NCT00076752 (16) [back to overview]	Anti-Smith-Ribonuclear Protein Antibody
NCT00076752 (16) [back to overview]	Cluster of Differentiation 19 (CD19) + Cells
NCT00076752 (16) [back to overview]	Cluster of Differentiation 3 (CD3) + Cells
NCT00076752 (16) [back to overview]	Relapse-free Complete Clinical Response
NCT00078559 (14) [back to overview]	Number of Alemtuzumab Associated Adverse Events, Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]	Number of Deaths Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]	Number of Acute Rejections in All Enrolled Participants
NCT00078559 (14) [back to overview]	Number of Participants Requiring Anti-lymphocyte Therapy for an Acute Rejection, Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]	Number of Participants Who Experienced Graft Loss Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]	Number of Severe Acute Rejections Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]	Number of Side Effects of Conventional Immunosuppression, Stratified by Withdrawal Status
NCT00078559 (14) [back to overview]	Number of Acute Rejections Between Initiation of Sirolimus Withdrawal and End of Study
NCT00078559 (14) [back to overview]	Time From Transplantation to Acute Rejection in Participants for Whom Acute Rejection Occurred During the 1 Year Post-transplant Period
NCT00078559 (14) [back to overview]	Change in Renal Function as Measured by Serum Creatinine, Stratified by Withdrawal Status
NCT00078559 (14) [back to overview]	Time From Transplantation to Acute Rejection in Participants for Whom Sirolimus Withdrawal Was Not Initiated
NCT00078559 (14) [back to overview]	Number of Sirolimus Associated Adverse Events, Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]	Number of Tacrolimus Associated Adverse Events, Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]	Number of Acute Rejections in All Enrolled Participants Following Sirolimus Withdrawal
NCT00097448 (1) [back to overview]	Hearing Improvement
NCT00104299 (8) [back to overview]	Number of Subjects Experiencing Serious Adverse Events
NCT00104299 (8) [back to overview]	Time to Remission (BVAS=0) From the Visit 1 Baseline Visit in the Two Treatment Groups
NCT00104299 (8) [back to overview]	Time to Complete Remission (BVAS=0, Off Glucocorticoids) From the Visit 1 Baseline Visit in the Two Treatment Groups
NCT00104299 (8) [back to overview]	The Duration of Remission (BVAS=0), the Time to Limited and/or Severe Flare After Remission in the Two Treatment Groups
NCT00104299 (8) [back to overview]	The Duration of Complete Remission (BVAS=0, Off Glucocorticoids), the Time to Limited and/or Severe Flare After Remission in the Two Treatment Groups
NCT00104299 (8) [back to overview]	Disease Remission
NCT00104299 (8) [back to overview]	Percentage of Participants Who Have a BVAS/WG Score of 0 and Have Successfully Completed the Glucocorticoid Taper by 6 Months Post-randomization
NCT00104299 (8) [back to overview]	Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy
NCT00109928 (4) [back to overview]	2-year Overall Survival Rate
NCT00109928 (4) [back to overview]	Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT00109928 (4) [back to overview]	Response Rate
NCT00109928 (4) [back to overview]	2-year Progression-free Survival Rate
NCT00128180 (10) [back to overview]	Duration of Shock and/or Pressor/Inotropic Support
NCT00128180 (10) [back to overview]	Length of Time on a Ventilator
NCT00128180 (10) [back to overview]	Number of Participants Intubated and Placed on a Ventilator After Study Entry.
NCT00128180 (10) [back to overview]	Number of Participants on Extracorporeal Membrane Oxygenation (ECMO)
NCT00128180 (10) [back to overview]	Duration of ICU Stays
NCT00128180 (10) [back to overview]	Development of Serum Creatinine Greater Than or Equal to 3.0 mg/dL After Study Entry
NCT00128180 (10) [back to overview]	Duration of Hospital Stay in Days
NCT00128180 (10) [back to overview]	Number of Participants With SAEs
NCT00128180 (10) [back to overview]	The Proportion of Subjects Who Develop Death, PaO2/FiO2 Ratio Less Than or Equal to 55, Cardiac Index Less Than or Equal to 2.2, Pulseless Electrical Activity, Ventricular Tachycardia or Fibrillation
NCT00128180 (10) [back to overview]	Number of Participants Who Developed Refractory Shock Despite Fluid Resuscitation After Study Entry
NCT00149994 (1) [back to overview]	Percentage of Participants With an Occurrence of Biopsy Proven Acute Rejection (BPAR) During the First 3 Months Post de Novo Liver Transplantation.
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: s-ICAM
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: T-bars
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: Troponin T
NCT00157014 (36) [back to overview]	Number of Acute Rejection Episodes by International Society of Heart and Lung Transplantation (ISHLT) Criteria
NCT00157014 (36) [back to overview]	Number of Acute Rejection Episodes by International Society of Heart and Lung Transplantation (ISHLT) Criteria (Pediatric Population)
NCT00157014 (36) [back to overview]	Number of Patients With Successful Steroid Taper or Withdrawal at Weeks 26 and 52
NCT00157014 (36) [back to overview]	Number of Patients With Successful Steroid Taper or Withdrawal at Weeks 26 and 52 (Pediatric Population)
NCT00157014 (36) [back to overview]	Number of Patients With Treatment Failure and Crossover for Treatment Failure
NCT00157014 (36) [back to overview]	Number of Patients With Treatment Failure and Crossover for Treatment Failure (Pediatric Population)
NCT00157014 (36) [back to overview]	The Change in the Markers of Growth, Apoptosis, Inflammation and Oxidation Measured in Endomyocardial Biopsies
NCT00157014 (36) [back to overview]	The Change in the Markers of Growth, Apoptosis, Inflammation and Oxidation Measured in Endomyocardial Biopsies (Pediatric Population)
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation and Oxidation: Cystatin-C (Pediatric Population)
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: Osteopontin
NCT00157014 (36) [back to overview]	Mean Cases of Acute Rejection (MCAR) Per Patient
NCT00157014 (36) [back to overview]	Mean Cases of Acute Rejection (MCAR) Per Patient (Pediatric Population)
NCT00157014 (36) [back to overview]	Number of Cardiac Rejection Episodes Requiring Treatment
NCT00157014 (36) [back to overview]	Number of Cardiac Rejection Episodes Requiring Treatment (Pediatric Population)
NCT00157014 (36) [back to overview]	Number of Patients Requiring Antilymphocyte Antibodies or Steroids for Treatment of Severe Acute Rejection
NCT00157014 (36) [back to overview]	Number of Patients Requiring Antilymphocyte Antibodies or Steroids for Treatment of Severe Acute Rejection (Pediatric Population)
NCT00157014 (36) [back to overview]	Time to First Acute Rejection Episode Following de Novo Cardiac Transplant
NCT00157014 (36) [back to overview]	Time to First Acute Rejection Episode Following de Novo Cardiac Transplant (Pediatric Population)
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation and Oxidation: F2 Isoprostanes (Pediatric Population)
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation and Oxidation: hsCRP (Pediatric Population)
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation and Oxidation: Nitrotyrosine (Pediatric Population)
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: BNP
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: Cystatin-C
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: E-selectin
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: F2 Isoprostanes
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: Fibrinogen
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: GSH/GSSG
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: Homocysteine
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: hsCRP
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: IL-18
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: IL-6
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: MCP-1
NCT00157014 (36) [back to overview]	Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: Nitrotyrosine
NCT00185692 (2) [back to overview]	Acute Graft-versus-Host Disease (GVHD) Grade 2-4 Risk From Time of Transplant Until Day 90 Post-transplant
NCT00185692 (2) [back to overview]	Engraftment of Haploidentical CD34+ Selected Blood Stem Cells in Older Patients or Those With Medical Co-morbidities Following Total Lymphoid Irradiation and Antithymocyte Globulin Transplant Conditioning
NCT00186628 (4) [back to overview]	Mortality
NCT00186628 (4) [back to overview]	Overall Survival
NCT00186628 (4) [back to overview]	Incidence of Relapse
NCT00186628 (4) [back to overview]	Chronic Graft-vs-Host Disease (cGvHD)
NCT00243412 (10) [back to overview]	Number of Participants With American College of Rheumatology (ACR) Major Clinical Response and/or Remission
NCT00243412 (10) [back to overview]	DAS28-4 Erythrocyte Sedimentation Rate(ESR)
NCT00243412 (10) [back to overview]	Change From Baseline in Short Form 36 (SF 36) Summary and Subscale Scores
NCT00243412 (10) [back to overview]	Number of Participants With European League Against Rheumatism (EULAR) Response and Remission Using Disease Activity Score 28-4 (DAS28-4)C-reactive Protein (CRP)
NCT00243412 (10) [back to overview]	Number of Participants With Either an Infection or a Grade III or IV Adverse Event (National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI CTCAE], Version 3.0)
NCT00243412 (10) [back to overview]	Change From Baseline in Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F)
NCT00243412 (10) [back to overview]	Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)
NCT00243412 (10) [back to overview]	Number of Participants With American College of Rheumatology Responses (ACR20, ACR50, and ACR70)
NCT00243412 (10) [back to overview]	Change From Baseline in Rheumatoid Factor (RF)
NCT00243412 (10) [back to overview]	Change From Baseline in Disease Activity Score 28-4 C-reactive Protein (DAS28-4(CRP))
NCT00248534 (4) [back to overview]	Number of Participants Alive at 3 Years
NCT00248534 (4) [back to overview]	1 Year Overall Survival Rate
NCT00248534 (4) [back to overview]	6-month Progression-free Survival
NCT00248534 (4) [back to overview]	Percentage of Participants With Objective Response
NCT00257933 (1) [back to overview]	Time Measured From the Administration of the Loading Dose of Prednisolone (2mg/kg up to Max 60mg) in the Emergency Department (ED) Until the Home Dose of Albuterol is Administered
NCT00258427 (8) [back to overview]	Number of Participants Experiencing Acute Graft-Versus-Host Disease
NCT00258427 (8) [back to overview]	Number of Participants Experiencing Chronic Graft-Versus-Host Disease
NCT00258427 (8) [back to overview]	Number of Participants Experiencing Acute Graft-Versus-Host Disease
NCT00258427 (8) [back to overview]	Number of Participants Experiencing Relapse
NCT00258427 (8) [back to overview]	Number of Participants Experiencing Chronic Graft-Versus-Host Disease
NCT00258427 (8) [back to overview]	Number of Participants Experiencing Graft Failure
NCT00258427 (8) [back to overview]	Number of Participants Experiencing Major Infections
NCT00258427 (8) [back to overview]	Number of Participants Experiencing Overall Survival
NCT00278564 (1) [back to overview]	Survival
NCT00282347 (9) [back to overview]	Percentage of Participants Who Achieved a Complete Renal Response at Week 24 and Maintained it to Week 52
NCT00282347 (9) [back to overview]	Percentage of Participants Who Achieved a Complete Renal Response at Week 52
NCT00282347 (9) [back to overview]	Percentage of Participants With a Baseline Urine Protein to Creatinine Ratio of > 3.0 Who Achieved a Urine Protein to Creatinine Ratio of < 1.0 at Week 52
NCT00282347 (9) [back to overview]	Percentage of Participants Who Achieved a Complete Renal Response (CRR), a Partial Renal Response (PRR), or no Renal Response (NRR) at Week 52
NCT00282347 (9) [back to overview]	Time to Achieve a Complete Renal Response
NCT00282347 (9) [back to overview]	Change From Baseline in C3 and C4 Complement Levels at Week 52
NCT00282347 (9) [back to overview]	British Isles Lupus Assessment Group (BILAG) Index Score Over 52 Weeks
NCT00282347 (9) [back to overview]	Change From Baseline in Anti-double-stranded DNA at Week 52
NCT00282347 (9) [back to overview]	Change From Baseline in the Systemic Lupus Erythematosus Expanded Health Survey Physical Function Score at Week 52
NCT00290589 (3) [back to overview]	Numerical Rating Scale (0-10), an Interval Pain Scale, on Which 0 Indicates no Pain and 10 Indicates the Worst Pain Imaginable
NCT00290589 (3) [back to overview]	Number of Patients Using Analgesics
NCT00290589 (3) [back to overview]	Functional Disability Scales
NCT00294684 (9) [back to overview]	Weight Z-Score
NCT00294684 (9) [back to overview]	Total Bilirubin Concentration at 24 Months of Age
NCT00294684 (9) [back to overview]	The Percentage of Patients With Serum Total Bilirubin <1.5 mg/dL and With Native Liver at 6 Months After Portoenterostomy
NCT00294684 (9) [back to overview]	Survival With Native Liver at 24 Months of Age
NCT00294684 (9) [back to overview]	Serum Total Bilirubin Concentration
NCT00294684 (9) [back to overview]	Presence of Ascites at 24 Months
NCT00294684 (9) [back to overview]	Presence of Ascites at 12 Months
NCT00294684 (9) [back to overview]	Height Z-Score
NCT00294684 (9) [back to overview]	Total Bilirubin Concentration at 12 Months
NCT00296244 (6) [back to overview]	New-onset Diabetes Mellitus (NODM) as Secondary Outcome
NCT00296244 (6) [back to overview]	Infection as an Adverse Effect of Steroids
NCT00296244 (6) [back to overview]	Acute Rejection Rate
NCT00296244 (6) [back to overview]	Incidence and Severity of HCV Recurrence Post-OLT
NCT00296244 (6) [back to overview]	Patient Survival Rate
NCT00296244 (6) [back to overview]	Graft Survival Rate
NCT00298272 (8) [back to overview]	Proportion of Participants With at Least One Serious Infection Through Week 24
NCT00298272 (8) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Through Week 24
NCT00298272 (8) [back to overview]	Number of Participants With Any Infections or Any Grade 3/4 Infections Through Week 24
NCT00298272 (8) [back to overview]	Proportion of Participants Achieving an American College of Rheumatology 70 (ACR70) Response at Week 24
NCT00298272 (8) [back to overview]	Proportion of Participants Achieving an American College of Rheumatology 50 (ACR50) Response at Week 24
NCT00298272 (8) [back to overview]	Proportion of Participants Achieving an American College of Rheumatology 20 (ACR20) Response at Week 24
NCT00298272 (8) [back to overview]	Number of Participants With Clinically Significant Immunological and Laboratory Assessment Findings
NCT00298272 (8) [back to overview]	Maximum Duration of Infections Through Week 24
NCT00299104 (30) [back to overview]	The Percentage of Participants With Major Clinical Response at Week 52
NCT00299104 (30) [back to overview]	Change From Baseline in the SF-36 Mental Health Component Summary Score at Week 52 and Week 104
NCT00299104 (30) [back to overview]	Change From Baseline in the SF-36 Physical Health Component Summary Score at Week 52 and Week 104
NCT00299104 (30) [back to overview]	Percentage of Participants With Categorical Change in Health Assessment Questionnaire- Disability Index (HAQ-DI) From Baseline at Week 52
NCT00299104 (30) [back to overview]	Percentage of Participants With European League Against Rheumatism (EULAR) Good Response at Week 52
NCT00299104 (30) [back to overview]	Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 104
NCT00299104 (30) [back to overview]	Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52
NCT00299104 (30) [back to overview]	Change From Baseline in Modified Joint Space Narrowing (JSN) Score at Week 24
NCT00299104 (30) [back to overview]	Change From Baseline in Modified Joint Space Narrowing (JSN) Score at Week 52
NCT00299104 (30) [back to overview]	Change From Baseline in Modified Sharp Erosion Score at Week 52
NCT00299104 (30) [back to overview]	Change From Baseline in Modified Total Sharp Score (mTSS) From Screening at Week 52
NCT00299104 (30) [back to overview]	Change From Baseline in the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 52
NCT00299104 (30) [back to overview]	Change From Baseline in the Modified Total Sharp Score at Week 104
NCT00299104 (30) [back to overview]	Change From Baseline in the Modified Total Sharp Score at Week 24
NCT00299104 (30) [back to overview]	Change From Baseline in the Total Erosion Score at Week 104
NCT00299104 (30) [back to overview]	Change From Baseline in the Total Erosion Score at Week 24
NCT00299104 (30) [back to overview]	Change in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Score From Baseline at Week 52
NCT00299104 (30) [back to overview]	Percentage of Participants With American College of Rheumatology (ACR) ACR20 Response at Week 52
NCT00299104 (30) [back to overview]	Percentage of Participants With American College of Rheumatology (ACR) ACR50 Response at Week 52
NCT00299104 (30) [back to overview]	Percentage of Participants With American College of Rheumatology (ACR) ACR70 Response at Week 52
NCT00299104 (30) [back to overview]	Percentage of Participants With American College of Rheumatology (ACR) ACR90 Response at Week 52
NCT00299104 (30) [back to overview]	Percentage of Participants With DAS28-ESR Low Disease Activity at Week 52
NCT00299104 (30) [back to overview]	Percentage of Participants With DAS28-ESR Remission at Week 52
NCT00299104 (30) [back to overview]	Percentage of Participants Without Radiographic Progression at Week 104
NCT00299104 (30) [back to overview]	Percentage of Participants Without Radiographic Progression at Week 24
NCT00299104 (30) [back to overview]	Percentage of Participants Without Radiographic Progression in the Total Erosion Score at Week 104
NCT00299104 (30) [back to overview]	Percentage of Patients With Minimally Clinically Important Difference (MCID) in the SF-36 Mental Health Component Score at Week 52
NCT00299104 (30) [back to overview]	Percentage of Patients With Minimally Clinically Important Difference (MCID) in the SF-36 Physical Health Component Score at Week 52
NCT00299104 (30) [back to overview]	Percentage of Patients Without Radiographic Progression at Week 52
NCT00299104 (30) [back to overview]	Percentage of Patients Without Radiographic Progression in Total Erosion Score at Week 52
NCT00299130 (32) [back to overview]	Percent Change From Baseline in Erythrocyte Sedimentation Rate
NCT00299130 (32) [back to overview]	Percentage of Participants With European League Against Rheumatism (EULAR) Response at Week 24
NCT00299130 (32) [back to overview]	Percentage of Participants With DAS28-ESR Low Disease Activity Score and Clinical Remission at Week 48
NCT00299130 (32) [back to overview]	Change From Baseline in Short Form 36 Health Survey (SF-36) Social Functioning Domain Score
NCT00299130 (32) [back to overview]	Change From Baseline in Short Form 36 Health Survey (SF-36) Physical Role Limitations Domain Score
NCT00299130 (32) [back to overview]	Percentage of Participants With an ACR70 Response at Week 48
NCT00299130 (32) [back to overview]	Percent Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score
NCT00299130 (32) [back to overview]	Change From Baseline in Short Form 36 Health Survey (SF-36) Bodily Pain Domain Score
NCT00299130 (32) [back to overview]	Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Scores
NCT00299130 (32) [back to overview]	Time to Repletion of Peripheral CD19+ B-cells
NCT00299130 (32) [back to overview]	Percentage of Participants With DAS28-ESR Low Disease Activity Score and Clinical Remission at Week 24
NCT00299130 (32) [back to overview]	Percentage of Participants With an ACR70 Response at Week 24
NCT00299130 (32) [back to overview]	Percentage of Participants With an ACR50 Response at Week 48
NCT00299130 (32) [back to overview]	Percentage of Participants With an ACR50 Response at Week 24
NCT00299130 (32) [back to overview]	Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24
NCT00299130 (32) [back to overview]	Change From Baseline in Disease Activity Score (DAS28-ESR) at Week 24
NCT00299130 (32) [back to overview]	Percent Change From Baseline in Patient's Global Assessment of Disease Activity
NCT00299130 (32) [back to overview]	Percent Change From Baseline in Patient's Pain Assessment
NCT00299130 (32) [back to overview]	Change From Baseline in Short Form 36 Health Survey (SF-36) Physical Functioning Domain Score
NCT00299130 (32) [back to overview]	Change From Baseline in Short Form 36 Health Survey (SF-36) Mental Health Domain Score
NCT00299130 (32) [back to overview]	Change From Baseline in Short Form 36 Health Survey (SF-36) General Health Domain Score
NCT00299130 (32) [back to overview]	Change From Baseline in Short Form 36 Health Survey (SF-36) Emotional Role Limitations Domain Score
NCT00299130 (32) [back to overview]	Change From Baseline in Short Form 36 Health Survey (SF-36) Vitality Domain Score
NCT00299130 (32) [back to overview]	Percent Change From Baseline in Physician's Global Assessment of Disease Activity
NCT00299130 (32) [back to overview]	Percent Change From Baseline in Short Form 36 Health Survey (SF-36) Summary Scores (Physical and Mental Components)
NCT00299130 (32) [back to overview]	Percent Change From Baseline in Tender Joint Count
NCT00299130 (32) [back to overview]	Percent Change From Baseline in C-Reactive Protein
NCT00299130 (32) [back to overview]	Percent Change From Baseline in Swollen Joint Count
NCT00299130 (32) [back to overview]	Percentage of Participants With HAQ-DI Improved, Unchanged or Worsened at Week 48
NCT00299130 (32) [back to overview]	Percentage of Participants With HAQ-DI Improved, Unchanged or Worsened at Week 24
NCT00299130 (32) [back to overview]	Percentage of Participants With Low Immunoglobulin Concentrations Pre- and Post-Rituximab Treatment
NCT00299130 (32) [back to overview]	Percentage of Participants With European League Against Rheumatism (EULAR) Response at Week 48
NCT00301834 (5) [back to overview]	Number of Participants Achieving Durable Engraftment (Presence of Donor Cells) at 6 Weeks Post Transplantation
NCT00301834 (5) [back to overview]	Cytomegalovirus (CMV) Viral Infection and Disease Symptoms
NCT00301834 (5) [back to overview]	Toxicity Grade ≥ 3 From Start of Conditioning Through the First Year Post Transplantation
NCT00301834 (5) [back to overview]	Treatment-related Mortality at 100 Days and 1 Year Post Transplantation
NCT00301834 (5) [back to overview]	Disease-free Survival With Correction of Disease at One Year Post Transplantation
NCT00309907 (6) [back to overview]	Survival Rate
NCT00309907 (6) [back to overview]	Toxicity of Etanercept Plus Corticosteroid Therapy Using the Common Terminology Criteria Version 4.0
NCT00309907 (6) [back to overview]	Estimate Percentage Pulmonary Response in Patients With IPS Treated With Etanercept + Corticosteroid Therapy
NCT00309907 (6) [back to overview]	Response of IPS (Idiopathic Pneumonia Syndrome) to Etanercept Plus Corticosteroid Therapy by Day 28.
NCT00309907 (6) [back to overview]	Plasma Cytokine IL6 Level
NCT00309907 (6) [back to overview]	C-reactive Protein Levels
NCT00332696 (11) [back to overview]	Participant's Quality of Life Using the Edmonton Scale
NCT00332696 (11) [back to overview]	Number of Vomiting Episodes Per Day at Day1, Day 2 and Day 14
NCT00332696 (11) [back to overview]	Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 1
NCT00332696 (11) [back to overview]	Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 14
NCT00332696 (11) [back to overview]	Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 7
NCT00332696 (11) [back to overview]	Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 1
NCT00332696 (11) [back to overview]	Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 2
NCT00332696 (11) [back to overview]	Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 3
NCT00332696 (11) [back to overview]	Number of Participants With Relief From Obstruction at Day 7 and Day 14
NCT00332696 (11) [back to overview]	Number of Participants With Treatment Success From Day 10 to Day 13
NCT00332696 (11) [back to overview]	Number of Participants With Treatment Success From Day 5 to Day 7
NCT00336583 (2) [back to overview]	Worst Toxicity Grade by Patient
NCT00336583 (2) [back to overview]	Overall Response Rate
NCT00345046 (1) [back to overview]	Percent Change in Flare at Resolution
NCT00346151 (15) [back to overview]	Acute Rejection at 12-Months
NCT00346151 (15) [back to overview]	Acute Rejection at 6-Months
NCT00346151 (15) [back to overview]	Graft Survival at 12 Months Post-transplant
NCT00346151 (15) [back to overview]	Participant Survival at 12 Months Post-Transplant
NCT00346151 (15) [back to overview]	Proportion of Participants Requiring Antilymphocyte Therapy for Acute Rejection
NCT00346151 (15) [back to overview]	Proportion of Participants With a Sirolimus Associated Adverse Event
NCT00346151 (15) [back to overview]	Proportion of Participants With Chronic Allograft Nephropathy
NCT00346151 (15) [back to overview]	Proportion of Participants With Delayed Graft Function
NCT00346151 (15) [back to overview]	Proportion of Participants With Malignancies
NCT00346151 (15) [back to overview]	Proportion of Participants With Post-transplant Diabetes Mellitus
NCT00346151 (15) [back to overview]	Proportion of Participants With Post-transplant Infections
NCT00346151 (15) [back to overview]	Proportion of Participants With Wound Complications
NCT00346151 (15) [back to overview]	Renal Function as Measured by Glomerular Filtration Rate (GFR) at 24 Weeks
NCT00346151 (15) [back to overview]	Time From Transplant to Acute Rejection
NCT00346151 (15) [back to overview]	Tolerance Induction
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Experienced Relapse by 12 Months
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Attained Neutrophil Engraftment
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Were Disease-free and Alive at 6 Months
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Were Disease-free and Alive at 12 Months
NCT00354172 (15) [back to overview]	Number of Participants (Patients) With Acute Graft-versus-host Disease (GVHD) Grade II-IV
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Experienced Relapse by 24 Months
NCT00354172 (15) [back to overview]	Chimerism After Double Umbilical Cord Blood Transplant (UCBT)
NCT00354172 (15) [back to overview]	Number of Patients Who Were Disease-free and Alive at 24 Months
NCT00354172 (15) [back to overview]	Number of Participants (Patients) With Chronic Graft-Versus-Host Disease
NCT00354172 (15) [back to overview]	Number of Participants (Patients) With Acute Graft-versus-Host Disease at Grade III-IV
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Attained Platelet Engraftment
NCT00354172 (15) [back to overview]	Number of Participants (Patients) With Successful Natural Killer Cell Expansion
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Died by 12 Months
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Died by 24 Months
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Died Due to Transplant.
NCT00381810 (1) [back to overview]	Percentage of Participants With at Least 1 Serious Adverse Event
NCT00393367 (12) [back to overview]	Serious Adverse Events
NCT00393367 (12) [back to overview]	Number of Participants With Adverse Events (Non-serious).
NCT00393367 (12) [back to overview]	Number of Subjects Moving From the Severe Asthma to Moderate Asthma Category
NCT00393367 (12) [back to overview]	Median Change in Asthma Score 2 Hours After Intervention
NCT00393367 (12) [back to overview]	Mean Change in Respiratory Rate.
NCT00393367 (12) [back to overview]	Mean Change in Asthma Score at 2 Hours
NCT00393367 (12) [back to overview]	Change in Mean Heart Rate
NCT00393367 (12) [back to overview]	Oxygen Saturation.
NCT00393367 (12) [back to overview]	Number of Subjects Moving From the Severe Asthma to Mild Asthma Category
NCT00393367 (12) [back to overview]	Number of Patients Hospitalized
NCT00393367 (12) [back to overview]	Number of Subjects Remaining in the Severe Asthma Category
NCT00393367 (12) [back to overview]	Relapse / Readmission Numbers.
NCT00400946 (10) [back to overview]	Post-Induction Nadir Serum Asparaginase Activity Level
NCT00400946 (10) [back to overview]	Induction Therapeutic Nadir Serum Asparaginase Activity Rate
NCT00400946 (10) [back to overview]	Induction Serum Asparaginase Activity Level
NCT00400946 (10) [back to overview]	Post-Induction Therapeutic Nadir Serum Asparaginase Activity Rate
NCT00400946 (10) [back to overview]	Asparaginase-Related Toxicity Rate
NCT00400946 (10) [back to overview]	5-Year Disease-Free Survival by MRD Day 32 Status
NCT00400946 (10) [back to overview]	5-year Disease-Free Survival by CNS Directed Treatment Group
NCT00400946 (10) [back to overview]	Induction Infection Toxicity Rate
NCT00400946 (10) [back to overview]	5-Year Disease-Free Survival
NCT00400946 (10) [back to overview]	5-Year Disease-Free Survival by Bone Marrow Day 18 Status
NCT00421174 (10) [back to overview]	Discontinuation of Supplemental Oxygen
NCT00421174 (10) [back to overview]	Overall Mortality
NCT00421174 (10) [back to overview]	Incidence of Relapse
NCT00421174 (10) [back to overview]	Incidence of Infection
NCT00421174 (10) [back to overview]	Incidence of Graft-vs-Host-Disease (GVHD)
NCT00421174 (10) [back to overview]	Corticosteroid Dose
NCT00421174 (10) [back to overview]	Response to Therapy
NCT00421174 (10) [back to overview]	Response Rate
NCT00421174 (10) [back to overview]	Incidence of Toxicity
NCT00421174 (10) [back to overview]	Overall Survival
NCT00423098 (10) [back to overview]	Number of Patients With Complete Remission
NCT00423098 (10) [back to overview]	Number of Patients With Moderate to Severe Flares
NCT00423098 (10) [back to overview]	Number of Patients With Partial Remission
NCT00423098 (10) [back to overview]	Number of Patients With Treatment Failure
NCT00423098 (10) [back to overview]	Cumulative Dose of Prednisone Equivalent Corticosteroids (CS)
NCT00423098 (10) [back to overview]	Number of Patients With Adverse Events and Infections
NCT00423098 (10) [back to overview]	Change From Baseline in Overall Disease Activity With Systematic Lupus Erythematosus Disease Activity Index (SLEDAI)
NCT00423098 (10) [back to overview]	Change From Baseline in Overall Disease Activity With British Isles Lupus Assessment Group (BILAG)
NCT00423098 (10) [back to overview]	Duration of Exposure to Study Medication
NCT00423098 (10) [back to overview]	Number of Patients With Complete Remission
NCT00424489 (1) [back to overview]	Survival
NCT00443430 (3) [back to overview]	Safety Profiles, Including the Number of Treatment-emergent, Serious, or Unexpected Adverse Events and Other Important Medical Events
NCT00443430 (3) [back to overview]	Proportion of Participants Who Attain Inactive Disease by 6 Months
NCT00443430 (3) [back to overview]	Clinical Remission on Medication
NCT00455312 (10) [back to overview]	Overall Survival
NCT00455312 (10) [back to overview]	Neutrophil Engraftment
NCT00455312 (10) [back to overview]	Incidence of Regimen Related Mortality at 100 Days
NCT00455312 (10) [back to overview]	Incidence of Pulmonary Complications
NCT00455312 (10) [back to overview]	Incidence of Grade 3-4 Acute Graft Versus Host Disease (GVHD)
NCT00455312 (10) [back to overview]	Incidence of Late Secondary Malignancies
NCT00455312 (10) [back to overview]	Incidence of Grade 2-4 Acute Graft Versus Host Disease (GVHD)
NCT00455312 (10) [back to overview]	Incidence of Chronic GVHD
NCT00455312 (10) [back to overview]	Incidence of Chronic GVHD
NCT00455312 (10) [back to overview]	Overall Survival
NCT00458848 (3) [back to overview]	Percentage of Participants Reaching Overall Survival
NCT00458848 (3) [back to overview]	Number of Patients Reaching Complete Hematological Response After Induction Therapy
NCT00458848 (3) [back to overview]	Percentage of Participants Reaching Disease Free Survival
NCT00481832 (10) [back to overview]	Relapse Rate
NCT00481832 (10) [back to overview]	Incidence of Chemotherapy-associated Pneumonitis
NCT00481832 (10) [back to overview]	Incidence of Acute Graft Versus Host Disease (GvHD)
NCT00481832 (10) [back to overview]	Achieving Full Donor Chimerism
NCT00481832 (10) [back to overview]	Event-free Survival (EFS)
NCT00481832 (10) [back to overview]	Incidence of Chronic Graft Versus Host Disease (GvHD)
NCT00481832 (10) [back to overview]	Overall Mortality Rate
NCT00481832 (10) [back to overview]	Median Time to Platelet Engraftment
NCT00481832 (10) [back to overview]	Median Time to Neutrophile Engraftment
NCT00481832 (10) [back to overview]	Overall Survival (OS)
NCT00482053 (7) [back to overview]	Median Time to Platelet Engraftment After Allogeneic Transplant
NCT00482053 (7) [back to overview]	Overall Survival (OS)
NCT00482053 (7) [back to overview]	Median Time to Platelet Engraftment After Autologous Transplant
NCT00482053 (7) [back to overview]	Median Time to Neutrophil Engraftment After Autologous Transplant
NCT00482053 (7) [back to overview]	Median Time to Neutrophil Engraftment After Allogeneic Transplant
NCT00482053 (7) [back to overview]	Incidence of Chronic Graft vs Host Disease (GvHD)
NCT00482053 (7) [back to overview]	Event-free Survival (EFS) Per Protocol
NCT00492973 (5) [back to overview]	Amount of Pain Medication Taken Per Day
NCT00492973 (5) [back to overview]	Complications, Such as Infections, Hospital Readmissions, Manipulations Under Anesthesia, Etc.
NCT00492973 (5) [back to overview]	Knee Range of Motion
NCT00492973 (5) [back to overview]	Length of Hospital Stay
NCT00492973 (5) [back to overview]	Knee Society Scores
NCT00493064 (1) [back to overview]	Number of Participants With An Improvement in Vision, as Measured by an Increase of 15 Letters on the Early Treatment Diabetic Retinopathy Study (EDTRS) Vision Chart.
NCT00521989 (1) [back to overview]	Change From Baseline to Day 98 Using the WOMAC Pain Question #1
NCT00551707 (2) [back to overview]	Percent Change From Baseline to Day 98 in C-reactive Protein (CRP) Values - As Treated Population
NCT00551707 (2) [back to overview]	Absolute C-reactive Protein (CRP) Values at Day 98 - As Treated Population
NCT00553202 (2) [back to overview]	Cumulative Incidence of NK Cell Reconstitution
NCT00553202 (2) [back to overview]	Overall Survival (OS)
NCT00555464 (2) [back to overview]	Toxicity to Medications
NCT00555464 (2) [back to overview]	Response of Hemangioma (IH) to Treatment
NCT00557193 (10) [back to overview]	Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Percent Probability for Event-free Survival (EFS) of MLL-R Infants Treated With Combination Chemotherapy With or Without Lestaurtinib at DL2
NCT00557193 (10) [back to overview]	Percent Probability of Event Free Survival (EFS) by MRD Status and Treatment Arm
NCT00557193 (10) [back to overview]	Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy
NCT00557193 (10) [back to overview]	Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2)
NCT00557193 (10) [back to overview]	Percent Probability for Event-free Survival (EFS) for Patients on Arm A
NCT00557193 (10) [back to overview]	Describe FLT3 Protein Expression as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Describe in Vitro Sensitivity as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Number of Patients Who Experienced Lestaurtinib-related Dose Limiting Toxicity (DLT)
NCT00568633 (8) [back to overview]	Relapse Rate
NCT00568633 (8) [back to overview]	Complete Donor Hematopoietic Cell Chimerism
NCT00568633 (8) [back to overview]	Disease-free Survival (DFS)
NCT00568633 (8) [back to overview]	Non-relapse Mortality
NCT00568633 (8) [back to overview]	Overall Survival (OS)
NCT00568633 (8) [back to overview]	Patients Completing the Intended Therapy in Both Arms
NCT00568633 (8) [back to overview]	Early Graft Loss
NCT00568633 (8) [back to overview]	Transplant-related Mortality
NCT00574288 (9) [back to overview]	Part 2: Progression-Free Survival
NCT00574288 (9) [back to overview]	Part 1: Time to Response
NCT00574288 (9) [back to overview]	Part 2: Overall Survival
NCT00574288 (9) [back to overview]	Part 2: Duration of Response as Assessed Using the Method of Kaplan-Meier
NCT00574288 (9) [back to overview]	Overall Response Rate
NCT00574288 (9) [back to overview]	Number of Participants With Adverse Events
NCT00574288 (9) [back to overview]	Part 2: Time to Response
NCT00574288 (9) [back to overview]	Part 2: Time to Response
NCT00574288 (9) [back to overview]	Part 2: Time to Progression (TTP)
NCT00577993 (2) [back to overview]	Number of Participants With Progression Free Survival (10 Years) by Treatment
NCT00577993 (2) [back to overview]	Number of Participants With Overall Survival (10 Years) by Treatment
NCT00578305 (16) [back to overview]	Percentage of Participants Achieving a Major Clinical Response at Week 52
NCT00578305 (16) [back to overview]	Percentage of Participants With an Improvement of at Least 20%, 50%, or 70% in the American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline at Weeks 24 and 52
NCT00578305 (16) [back to overview]	Percentage of Participants With European League Against Rheumatism (EULAR) Good, Moderate, or no Response at Weeks 24 and 52
NCT00578305 (16) [back to overview]	Percentage of Participants With Improvement in Osteitis at Weeks 24 and 52
NCT00578305 (16) [back to overview]	Change From Baseline in the Disease Activity Score 28 (DAS28) at Weeks 24 and 52
NCT00578305 (16) [back to overview]	Percentage of Participants With Improvement in Synovitis at Weeks 24 and 52
NCT00578305 (16) [back to overview]	Percentage of Participants With Low Disease Activity (Disease Activity Score 28 [DAS28] ≤ 3.2) at Weeks 24 and 52
NCT00578305 (16) [back to overview]	Percentage of Participants With no Newly Eroded Joints at Weeks 24 and 52
NCT00578305 (16) [back to overview]	Percentage of Participants With no Progression/no Worsening in Bone Erosion at Weeks 24 and 52
NCT00578305 (16) [back to overview]	Change in Magnetic Resonance Imaging (MRI) Osteitis Score From Baseline to Weeks 12, 24, and Week 52
NCT00578305 (16) [back to overview]	Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Weeks 24 and 52
NCT00578305 (16) [back to overview]	Change in Magnetic Resonance Imaging (MRI) Erosion Score From Baseline to Week 24
NCT00578305 (16) [back to overview]	Change in Magnetic Resonance Imaging (MRI) Erosion Score From Baseline to Weeks 12 and 52
NCT00578305 (16) [back to overview]	Change in Magnetic Resonance Imaging (MRI) Synovitis Score From Baseline to Weeks 12, 24, and Week 52
NCT00578305 (16) [back to overview]	Correlation of Magnetic Resonance Imaging Assessments and Clinical Outcome Measures
NCT00578305 (16) [back to overview]	Percentage of Participants in Remission Response (Disease Activity Score 28 [DAS28] < 2.6) at Weeks 24 and 52
NCT00579527 (8) [back to overview]	Immune Reconstitution Efficacy - Naive CD4 T Cells
NCT00579527 (8) [back to overview]	Immune Reconstitution Efficacy - Naive CD8 T Cells
NCT00579527 (8) [back to overview]	Immune Reconstitution Efficacy - Total CD8 T Cells
NCT00579527 (8) [back to overview]	Survival at 2 Years Post-CTTI
NCT00579527 (8) [back to overview]	Survival at 1 Year Post-CTTI
NCT00579527 (8) [back to overview]	Immune Reconstitution Efficacy - Response to Mitogens
NCT00579527 (8) [back to overview]	Immune Reconstitution Efficacy - Total CD4 T Cells
NCT00579527 (8) [back to overview]	Immune Reconstitution Efficacy - Total CD3 T Cells
NCT00595335 (8) [back to overview]	Failure Rate
NCT00595335 (8) [back to overview]	Graves' Ophthalmopathy Quality of Life Score Using the Short Form-12 (SF-12) Health Survey
NCT00595335 (8) [back to overview]	Change in Disease Severity
NCT00595335 (8) [back to overview]	Failure Rate at One Year
NCT00595335 (8) [back to overview]	Change in Lid Fissure
NCT00595335 (8) [back to overview]	Change in Clinical Activity Score (CAS)
NCT00595335 (8) [back to overview]	Change in Proptosis
NCT00595335 (8) [back to overview]	Change in Extraocular Motility
NCT00608517 (7) [back to overview]	Number of Subjects With All-cause Mortality
NCT00608517 (7) [back to overview]	Overall Survival
NCT00608517 (7) [back to overview]	Number of Participants With 100-day Non-relapse Mortality
NCT00608517 (7) [back to overview]	Number of Participants With Acute Graft-versus-host Disease (GVHD)
NCT00608517 (7) [back to overview]	Number of Participants With Chronic Graft Versus Host Disease (GVHD)
NCT00608517 (7) [back to overview]	Number of Participants With Sustained Donor Engraftment of Umbilical Cord Blood Stem Cells
NCT00608517 (7) [back to overview]	Number of Participants Who Relapsed at 1 Year
NCT00609609 (3) [back to overview]	Percentage of Participants Alive, In Remission & Without GVHD Progression Day 28 & Day 56
NCT00609609 (3) [back to overview]	Non-relapse Mortality (NRM) at 6 Months
NCT00609609 (3) [back to overview]	Day 56 Treatment Success
NCT00609739 (4) [back to overview]	Disease-free Survival
NCT00609739 (4) [back to overview]	Patients Who Relapsed
NCT00609739 (4) [back to overview]	Patients With Graft-Versus-Host-Disease
NCT00609739 (4) [back to overview]	Patients With Regimen-Related Toxicity
NCT00623766 (9) [back to overview]	Overall Survival (OS)
NCT00623766 (9) [back to overview]	Disease Control Rate by Modified World Health Organization (mWHO) Tumor Assessment Criteria
NCT00623766 (9) [back to overview]	Duration of Response (DOR) by Modified World Health Organization (mWHO) Criteria and by Immune-related Response Criteria (irRC)
NCT00623766 (9) [back to overview]	Number of Participants Surviving at 6, 12, 18, 24, and 36 Months (Overall Survival [OS] Rate)
NCT00623766 (9) [back to overview]	Number of Participants Who Died or Had a Treatment-related Adverse Event (AE), Immune-related AE, Immune-related Serious Adverse Event (SAE), Nervous System Disorder, Treatment-related Nervous System Disorder, SAE, and AE Leading to Discontinuation
NCT00623766 (9) [back to overview]	Onset of Response by Modified World Health Organization (mWHO) Criteria and Immune-related Response Criteria (irRC)
NCT00623766 (9) [back to overview]	Progression-free Survival (PFS) by Modified World Health Organization (mWHO) Criteria and by Immune-related Response Criteria (irRC)
NCT00623766 (9) [back to overview]	Best Overall Response Rate (BORR) by Modified World Health Organization (mWHO) Criteria and by Immune-relate Response Criteria (irRC)
NCT00623766 (9) [back to overview]	Disease Control Rate by Immune-related Response Criteria (irRC)
NCT00624416 (3) [back to overview]	The Number of Lipoma Increased in Volume.
NCT00624416 (3) [back to overview]	The Number of Subjects Elected to Have the Lipoma Removed.
NCT00624416 (3) [back to overview]	The Average Percent Volume Reduction in the Lipoma.
NCT00630253 (5) [back to overview]	Number of Participants With Transplant Related Deaths
NCT00630253 (5) [back to overview]	Number of Participants With Chronic Graft-Versus-Host Disease (GVHD)
NCT00630253 (5) [back to overview]	Number of Participants With Acute Graft-Versus-Host Disease (GVHD)
NCT00630253 (5) [back to overview]	Number of Participants Experiencing Overall Survival
NCT00630253 (5) [back to overview]	Number of Participants Experiencing Graft Failure
NCT00634933 (12) [back to overview]	Visual Analogue Scale for Pain (VAS-pain)
NCT00634933 (12) [back to overview]	Percentage of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28
NCT00634933 (12) [back to overview]	Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
NCT00634933 (12) [back to overview]	Health Assessment Questionnaire Disability Index (HAQ-DI)
NCT00634933 (12) [back to overview]	Percentage of Participants With an American College of Rheumatology 50% (ACR 50) Response at Week 24
NCT00634933 (12) [back to overview]	Disease Activity Score Based on 28-joints Count (DAS28)
NCT00634933 (12) [back to overview]	Number of Swollen Joints
NCT00634933 (12) [back to overview]	Number of Tender Joints
NCT00634933 (12) [back to overview]	Patient Global Assessment (PtGA) of Disease Activity
NCT00634933 (12) [back to overview]	Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
NCT00634933 (12) [back to overview]	Physician Global Assessment (PGA) of Disease Activity
NCT00634933 (12) [back to overview]	Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
NCT00671658 (1) [back to overview]	Number of Participants With a Response
NCT00682357 (4) [back to overview]	Change in Serum Cortisol
NCT00682357 (4) [back to overview]	Change in Serum Tartrate-resistant Acid Phosphatase 5b (TRACP-5b)
NCT00682357 (4) [back to overview]	Change in Testosterone
NCT00682357 (4) [back to overview]	Change in Serum Osteocalcin
NCT00689078 (10) [back to overview]	Ocular Itching at Day 7
NCT00689078 (10) [back to overview]	Ocular Redness at Day 7
NCT00689078 (10) [back to overview]	Ocular Redness at Day 6
NCT00689078 (10) [back to overview]	Ocular Redness at Day 28
NCT00689078 (10) [back to overview]	Ocular Redness at Day 27
NCT00689078 (10) [back to overview]	Ocular Redness at Baseline (Day 0)
NCT00689078 (10) [back to overview]	Ocular Itching at Day 6
NCT00689078 (10) [back to overview]	Ocular Itching at Day 28
NCT00689078 (10) [back to overview]	Ocular Itching at Day 27
NCT00689078 (10) [back to overview]	Ocular Itching at Baseline (Day 0)
NCT00699803 (1) [back to overview]	Mean Aqueous Humor Prednisolone Acetate Concentration
NCT00720109 (5) [back to overview]	Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation
NCT00720109 (5) [back to overview]	Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)
NCT00720109 (5) [back to overview]	Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy
NCT00720109 (5) [back to overview]	Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy
NCT00720109 (5) [back to overview]	Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events
NCT00732498 (4) [back to overview]	Complete Response Rate
NCT00732498 (4) [back to overview]	Median Time to Progression
NCT00732498 (4) [back to overview]	Overall Response Rate
NCT00732498 (4) [back to overview]	Progression-free Survival at 1 Year
NCT00733096 (4) [back to overview]	Oswestry Disability Score
NCT00733096 (4) [back to overview]	Numerical Rating Leg Pain Score
NCT00733096 (4) [back to overview]	Medication Reduction
NCT00733096 (4) [back to overview]	Global Perceived Effect
NCT00771875 (7) [back to overview]	Renal Allograft Survival
NCT00771875 (7) [back to overview]	Number of Patients With Allografts With C4d Focal Positive Pretreatment Biopsy
NCT00771875 (7) [back to overview]	Number of Patients With Allografts With C4d Diffuse Positive Pretreatment Biopsy
NCT00771875 (7) [back to overview]	Mean Serum Creatinine
NCT00771875 (7) [back to overview]	Incidence of Death
NCT00771875 (7) [back to overview]	Incidence of Post Transplant Lymphoproliferative Disorder (PTLD)
NCT00771875 (7) [back to overview]	Number of Patients in Each Group With Any of the Following: Rejection Reversal or Recurrent Rejection
NCT00782717 (2) [back to overview]	Percent of Patients With a Decrease of More Than 5 Letters in Best-corrected Visual Acuity (BCVA).
NCT00782717 (2) [back to overview]	Percent of Patients Who Developed Macular Edema (ME) Within 90 Days Following Cataract Surgery
NCT00787722 (6) [back to overview]	Survival
NCT00787722 (6) [back to overview]	Post HSCT Immune -Modulating Medication and Relapse
NCT00787722 (6) [back to overview]	Quality of Life (QOL) Short Form - 36 (SF-36)
NCT00787722 (6) [back to overview]	Disability Score: Expanded Disability Status Scale (EDSS)
NCT00787722 (6) [back to overview]	NMO-IgG Aquaporin- 4 Autoantibody Titer
NCT00787722 (6) [back to overview]	Number of Patients Who Require No Device Assistance for Ambulation
NCT00792948 (3) [back to overview]	Relapse-free Survival (RFS) After Allogeneic Stem Cell Transplantation
NCT00792948 (3) [back to overview]	Overall Survival (OS)
NCT00792948 (3) [back to overview]	Continuous Complete Remission (CCR) Rate
NCT00801632 (8) [back to overview]	Change in Renal Function
NCT00801632 (8) [back to overview]	Time to Platelet Recovery Following Transplant
NCT00801632 (8) [back to overview]	Percentage of Participants With Graft Survival Through 156 Weeks
NCT00801632 (8) [back to overview]	Number of Participants Successfully Withdrawn Off of Immunosuppressant Medication for 104 Weeks
NCT00801632 (8) [back to overview]	Percentage of Participants Experiencing a Clinically Significant Invasive or Resistant Opportunistic Infection
NCT00801632 (8) [back to overview]	Percentage of Participants Experiencing Acute Rejection
NCT00801632 (8) [back to overview]	Time to Neutrophil Recovery Following Transplant
NCT00801632 (8) [back to overview]	Percentage of Participants Surviving Through 156 Weeks
NCT00802529 (3) [back to overview]	Vertigo Attacks
NCT00802529 (3) [back to overview]	Change in Speech Discrimination
NCT00802529 (3) [back to overview]	Change in Hearing
NCT00806598 (1) [back to overview]	Overall Response
NCT00807586 (3) [back to overview]	Number of Participants With Clinically Significant Atrial Arrhythmias at 6 Weeks
NCT00807586 (3) [back to overview]	Repeat Intervention
NCT00807586 (3) [back to overview]	Cardiac Pain Assessment
NCT00808210 (1) [back to overview]	Percentage of Participants With Adverse Events (AEs)
NCT00854061 (1) [back to overview]	Means Aqueous Humor Prednisolone Acetate Concentration
NCT00908583 (4) [back to overview]	Number of Patients Whose Cytotoxic Panel Reactive Antibody (PRA) is Decreased by 50%
NCT00908583 (4) [back to overview]	Number of Living Donor Transplant Candidates That Are Transplanted
NCT00908583 (4) [back to overview]	Acute Rejection Rate
NCT00908583 (4) [back to overview]	Overall Safety of Bortezomib
NCT00915473 (4) [back to overview]	Mean Frequency of Days With a Migraine
NCT00915473 (4) [back to overview]	Number of Subjects With at Least 50% Reduction in the Frequency of Days With Moderate or Severe Migraine in the 4 Week Post Injection Compared to the 4 Week Pre-injection Baseline Period
NCT00915473 (4) [back to overview]	Mean Number of Hours With Moderate or Severe Migraine
NCT00915473 (4) [back to overview]	Mean Number of Days With Acute Medication Use
NCT00929695 (12) [back to overview]	Chronic Extensive GVHD
NCT00929695 (12) [back to overview]	Prednisone-associated Toxicity as Assessed by Invasive Infections (Bacterial, Fungal and Viral)
NCT00929695 (12) [back to overview]	Prednisone-associated Toxicity as Assessed by Myopathy
NCT00929695 (12) [back to overview]	Prednisone-associated Toxicity as Assessed by Hypertension
NCT00929695 (12) [back to overview]	Prednisone-associated Toxicity as Assessed by Hyperglycemia
NCT00929695 (12) [back to overview]	Overall Survival
NCT00929695 (12) [back to overview]	Non-relapse Mortality
NCT00929695 (12) [back to overview]	Mean Cumulative Prednisone Dose (mg/kg) Over 42 Days From the Start of Treatment
NCT00929695 (12) [back to overview]	Prednisone-associated Toxicity as Assessed by Quality of Life
NCT00929695 (12) [back to overview]	Progression to Grade III-IV Acute GVHD
NCT00929695 (12) [back to overview]	Recurrent or Progressive Malignancy
NCT00929695 (12) [back to overview]	Secondary Therapy for Acute GVHD Beyond Prednisone
NCT00929981 (7) [back to overview]	Change From Baseline in Participant-rated Clinical Severity Score of Lesions at First, Second, Third and Final Follow-up Visits
NCT00929981 (7) [back to overview]	Change From Baseline in Investigator-rated Total Signs and Symptoms of CD Score at First, Second, Third and Final Follow-up Visits
NCT00929981 (7) [back to overview]	Treatment Status (Success/Failure) of Contact Dermatitis (CD) at the Second Follow-up Visit
NCT00929981 (7) [back to overview]	Change From Baseline in Participant-rated Pruritus Score at First, Second, Third and Final Follow-up Visits
NCT00929981 (7) [back to overview]	Treatment Status (Success/Failure) of CD at the Final Follow-up Visit
NCT00929981 (7) [back to overview]	Treatment Status (Success/Failure) of CD at the First Follow-up Visit
NCT00929981 (7) [back to overview]	Treatment Status (Success/Failure) of CD at the Third Follow-up Visit
NCT00934843 (5) [back to overview]	Number of Participants Who Died Between 36 Hours and 30 Days Following Cardiac Surgery
NCT00934843 (5) [back to overview]	Inotropic Score
NCT00934843 (5) [back to overview]	Primary Endpoint: Number of Participants With Low Cardiac Output Syndrome (LCOS) or Death at 36 Hours From Admission to the Intensive Care Unit (ICU) After Surgery.
NCT00934843 (5) [back to overview]	Total Intake/Output of Fluid
NCT00934843 (5) [back to overview]	Urine Output
NCT00947765 (8) [back to overview]	Pain(at 6 Months): Nirschl Staging
NCT00947765 (8) [back to overview]	Pain(at 12 Weeks): Nirschl Staging
NCT00947765 (8) [back to overview]	Pain(at 1 Week): Nirschl Staging (0 to 7)
NCT00947765 (8) [back to overview]	Pain (at 1 Week): Visual Analogue Scale(0 to 10)
NCT00947765 (8) [back to overview]	Pain(at 4 Weeks): Nirschl Staging
NCT00947765 (8) [back to overview]	Pain(at 6 Months): Visual Analogue Scale
NCT00947765 (8) [back to overview]	Pain(at 12 Weeks): Visual Analogue Scale
NCT00947765 (8) [back to overview]	Pain(at 4 Weeks): Visual Analogue Scale
NCT00957801 (40) [back to overview]	Serum Estradiol Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Prostate Specific Antigen (PSA) Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Prostate Specific Antigen (PSA) Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Low-Density Lipoproteins (LDL) Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Low-Density Lipoproteins (LDL) Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Insulin Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Insulin Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Insulin Like Growth Factor 1 (IGF-1) Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	High-Density Lipoproteins (HDL) Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	High-Density Lipoproteins (HDL) Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Hematocrit Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Hematocrit Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Global Fatigue Score as Measured by Brief Fatigue Inventory (BFI) in the Pre-treatment Week
NCT00957801 (40) [back to overview]	Global Fatigue Score as Measured by Brief Fatigue Inventory (BFI) During the Treatment Week
NCT00957801 (40) [back to overview]	Dehydroepiandrosterone Sulfate (DHEA-S) Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Dehydroepiandrosterone Sulfate (DHEA-S) Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Cortisol Measured on Treatment Day 8 (Post Study) BEFORE Exercise Protocol
NCT00957801 (40) [back to overview]	Cortisol Measured on Treatment Day 8 (Post Study) AFTER Exercise Protocol
NCT00957801 (40) [back to overview]	Cortisol Measured on Treatment Day 1 (Baseline Study) BEFORE Exercise Protocol
NCT00957801 (40) [back to overview]	Cortisol Measured on Treatment Day 1 (Baseline Study) AFTER Exercise Protocol
NCT00957801 (40) [back to overview]	C-Reactive Protein (CRP) Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	C-Reactive Protein (CRP) Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Insulin Like Growth Factor 1 (IGF-1) Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Triglycerides Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Very Low-Density Lipoproteins (VLDL) Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Very Low-Density Lipoproteins (VLDL) Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Triglycerides Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Total Cholesterol Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Total Cholesterol Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Sex Hormone Binding Globulin (SHBG) Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Sex Hormone Binding Globulin (SHBG) Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Serum Total Testosterone Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Serum Total Testosterone Measured on Treatment Day 7
NCT00957801 (40) [back to overview]	Serum Total Testosterone Measured on Treatment Day 6
NCT00957801 (40) [back to overview]	Serum Total Testosterone Measured on Treatment Day 5
NCT00957801 (40) [back to overview]	Serum Total Testosterone Measured on Treatment Day 4
NCT00957801 (40) [back to overview]	Serum Total Testosterone Measured on Treatment Day 3
NCT00957801 (40) [back to overview]	Serum Total Testosterone Measured on Treatment Day 2
NCT00957801 (40) [back to overview]	Serum Total Testosterone Measured Before Treatment on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Serum Estradiol Measured on Treatment Day 8 (Post Study)
NCT00968253 (3) [back to overview]	Overall Response Rate (OR) Where OR = CR + CRp + CRi
NCT00968253 (3) [back to overview]	Participant Responses by Daily Dose Level Assignment (RAD001 5 mg, 10 mg and MTD 5 mg)
NCT00968253 (3) [back to overview]	Maximum Tolerated Dose [MTD] Determination by Number of Participants With Dose Limiting Toxicity (DLT)
NCT00987831 (2) [back to overview]	Time to Flare Comparing Patients With Moderate vs Severe Disease Activity at Baseline
NCT00987831 (2) [back to overview]	Time to Flare Comparing Patients With (at Baseline) British Isles Lupus Assessment Group Index (BILAG) >/= 17 (Severe Disease) to Those With BILAG < 17 (Moderate Disease Activity).
NCT01000610 (4) [back to overview]	Percentage Change in Disease Activity Score 28 (DAS28) From Baseline to Week 24
NCT01000610 (4) [back to overview]	Change in Bone Density (in Participants Untreated With Bisphosphonates)
NCT01000610 (4) [back to overview]	Percentage of Participants Whose DAS28 Improved by >1.2 at Week 24
NCT01000610 (4) [back to overview]	Number of Participants Reporting Adverse Events (AEs)
NCT01071083 (2) [back to overview]	Time Course to Return of Radiological Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance Imaging (MRI) Rescue Criteria.
NCT01071083 (2) [back to overview]	Time Course to Return of Radiological and/or Clinical Evidence of Multiple Sclerosis Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance Imaging (MRI) and/or Clinical Relapse Rescue Criteria.
NCT01085097 (2) [back to overview]	Percent Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 24
NCT01085097 (2) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT01086540 (19) [back to overview]	Time to the Change or Addition of New Pulmonary Arterial Hypertension (PAH) Therapeutic Medications
NCT01086540 (19) [back to overview]	Change From Baseline in Quality of Life as Measured by the Short Form Health Survey (SF-36): Physical Component Summary Score
NCT01086540 (19) [back to overview]	Percent Change From Baseline in Pulmonary Vascular Resistance Measured by Right Heart Catheterization
NCT01086540 (19) [back to overview]	Number of Infection-Related Adverse Events (AEs) Through Week 48
NCT01086540 (19) [back to overview]	Change From Baseline in Pulmonary Vascular Resistance Measured by Right Heart Catheterization at Week 24
NCT01086540 (19) [back to overview]	Change From Baseline in Distance Walked During a Six Minute Walk Test
NCT01086540 (19) [back to overview]	All-Cause Mortality: From Treatment Initiation to Week 48
NCT01086540 (19) [back to overview]	All-Cause Mortality: From Treatment Initiation to Week 104
NCT01086540 (19) [back to overview]	Change From Baseline in Quality of Life as Measured by the Short Form Health Survey (SF-36): Mental Component Summary Score
NCT01086540 (19) [back to overview]	Treatment-Related Mortality: From Treatment Initiation to Week 48
NCT01086540 (19) [back to overview]	Change From Baseline in Distance Walked During a Six Minute Walk Test at Week 24 and Week 48
NCT01086540 (19) [back to overview]	Time to Clinical Worsening
NCT01086540 (19) [back to overview]	Number of New Digital Ulcers
NCT01086540 (19) [back to overview]	Oxygen Saturation Levels at Week 24 and Week 48
NCT01086540 (19) [back to overview]	Number of Infusion-Related Toxicities
NCT01086540 (19) [back to overview]	Number of Grade 3 or Higher Adverse Events (AEs) Through Week 48
NCT01086540 (19) [back to overview]	Change in Severity of Raynaud's Phenomenon
NCT01086540 (19) [back to overview]	Change in Quality of Life as Measured by the Disability Index of the Scleroderma Health Assessment Questionnaire (HAQ-DI)
NCT01086540 (19) [back to overview]	Change in Carbon Monoxide Diffusing Capacity (DLCO)
NCT01093586 (14) [back to overview]	Recurrence or Relapse
NCT01093586 (14) [back to overview]	Transplant Related Mortality
NCT01093586 (14) [back to overview]	Transplant Related Mortality
NCT01093586 (14) [back to overview]	Toxicity Related to UCB Transplantation and Cytoreduction as Assessed by CTC v3.0
NCT01093586 (14) [back to overview]	Recurrence or Relapse
NCT01093586 (14) [back to overview]	Occurrence of Serious Infections
NCT01093586 (14) [back to overview]	Disease Free
NCT01093586 (14) [back to overview]	Overall Survival
NCT01093586 (14) [back to overview]	Disease Free
NCT01093586 (14) [back to overview]	Overall Survival
NCT01093586 (14) [back to overview]	Overall Survival
NCT01093586 (14) [back to overview]	Incidence of Chronic GVHD
NCT01093586 (14) [back to overview]	Hematologic Engraftment
NCT01093586 (14) [back to overview]	Incidence of Acute Graft-versus-host Disease (GVHD)
NCT01105650 (4) [back to overview]	Number of Participants With Progressive Disease at One Year
NCT01105650 (4) [back to overview]	Overall Survival
NCT01105650 (4) [back to overview]	Response Rate
NCT01105650 (4) [back to overview]	Time to Disease Progression
NCT01114503 (8) [back to overview]	Number of Participants With Thyroid Function Assessment, Hormone and Glucose Assay Abnormalities Meeting the Criteria for PCC
NCT01114503 (8) [back to overview]	Number of Participants With an Epstein Barr Virus (EBV) Viral Load Abnormalities Meeting the Criteria for PCC
NCT01114503 (8) [back to overview]	Number of Participants With Electrocardiogram (ECG) Abnormalities Meeting the Criteria for PCC
NCT01114503 (8) [back to overview]	Number of Participants With Laboratory Clinical Chemistry Abnormalities Meeting the Criteria for Potential Clinical Concern (PCC)
NCT01114503 (8) [back to overview]	Number of Participants With Laboratory Hematology Abnormalities Meeting the Criteria for PCC
NCT01114503 (8) [back to overview]	Number of Participants With Laboratory Urinalysis Abnormalities Meeting the Criteria for PCC
NCT01114503 (8) [back to overview]	Number of Participants With Vital Signs Abnormalities Meeting the Criteria for PCC
NCT01114503 (8) [back to overview]	Number of Participants With at Least One Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event
NCT01124045 (13) [back to overview]	Global Assessment Score of Postoperative Inflammation by Visit
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Vitritis
NCT01124045 (13) [back to overview]	Percentage of Patients With an Anterior Cell Grade of 0 (no Cells) at Day 15 ± 2 Days
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Anterior Chamber Cell Grade
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Lacrimation
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Corneal Clarity
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Hypopyon
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Wound Integrity
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Conjunctival Injection
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Ciliary/Limbal Injection
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Chemosis
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Anterior Chamber Flare Grade
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Photophobia
NCT01144143 (5) [back to overview]	Change in Joint Effusions From Day 0 to Day 56 Target Knee
NCT01144143 (5) [back to overview]	Change in Levels of Serum IL-6
NCT01144143 (5) [back to overview]	Change in Serum CRP Day 0 to Day 56
NCT01144143 (5) [back to overview]	Change in Serum SAA Levels Day 0 to Day 56
NCT01144143 (5) [back to overview]	Change in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score Target Knee
NCT01181258 (4) [back to overview]	Serious Adverse Events
NCT01181258 (4) [back to overview]	Patients With Expansion of NK Cells
NCT01181258 (4) [back to overview]	Time to Disease Progression
NCT01181258 (4) [back to overview]	Number of Patients With an Objective Response
NCT01201798 (10) [back to overview]	Proportion of Subjects With Anterior Chamber Cell Count ≤5 and Flare Grade of 0
NCT01201798 (10) [back to overview]	Proportion of Subjects With Anterior Chamber Cell Grade ≤1
NCT01201798 (10) [back to overview]	Proportion of Subjects Who Discontinued Due to Lack of Efficacy
NCT01201798 (10) [back to overview]	Proportion of Subjects With Anterior Chamber Cell Count of 0
NCT01201798 (10) [back to overview]	Change From Baseline (Day 0) in Anterior Chamber Cell Grade at Day 14
NCT01201798 (10) [back to overview]	Change From Baseline (Day 0) in Anterior Chamber Flare Grade at All Time Points
NCT01201798 (10) [back to overview]	Change From Baseline (Day 0) in Slit-Lamp Total Sign Score at All Visits
NCT01201798 (10) [back to overview]	Change From Baseline (Day 0) in Visual Analog Scale (VAS) Total Symptom Score at All Time Points
NCT01201798 (10) [back to overview]	Proportion of Subjects With Anterior Chamber Cell Grade of 0
NCT01201798 (10) [back to overview]	Change From Baseline (Day 0) in Anterior Chamber Cell Grade at All Time Points Other Than Day 14
NCT01211665 (3) [back to overview]	Number of Participants Who Survived at 6 Months Following Completion of Plasma Exchange (PLEX)
NCT01211665 (3) [back to overview]	Severity of AEs and SAEs
NCT01211665 (3) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01219933 (33) [back to overview]	Short-Form 36 (SF-36) Mental Component Score (MCS) and Physical Component Score (PCS) During the Interventional Phase
NCT01219933 (33) [back to overview]	SJC and TJC During the Interventional Phase
NCT01219933 (33) [back to overview]	Type of GC Taken at the End of the Noninterventional Phase
NCT01219933 (33) [back to overview]	VAS for Pain (VAS-Pain) During the Interventional Phase
NCT01219933 (33) [back to overview]	VAS-Physician's Global Assessment of Disease Activity (GDA) During the Interventional Phase
NCT01219933 (33) [back to overview]	Median Dose of Tocilizumab During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Median Time Interval Between V1 and V2
NCT01219933 (33) [back to overview]	Number of Participants With Changes in Tocilizumab Dose During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Number of Participants With GC Switches During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Percentage of Participants Able to Acheive LDA Assessed Using DAS28 While Receiving Oral GC on Background Tocilizumab Treatment During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Percentage of Participants Able to Discontinue GCs During the Interventional Phase by V9
NCT01219933 (33) [back to overview]	Percentage of Participants Able to Reduce Oral GCs by ≥50 Percent (%) During the Interventional Phase by V9
NCT01219933 (33) [back to overview]	Percentage of Participants Able to Start the GC Reduction Phase at V3
NCT01219933 (33) [back to overview]	Percentage of Participants Acheiving Remission Assessed Using DAS28 While Receiving Oral GC on Background TocilizumabTreatment During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Percentage of Participants in the Interventional Phase Who Achieved LDA and Discontinued Oral GC Within 20 Weeks
NCT01219933 (33) [back to overview]	Percentage of Participants With Changes in RA Treatment During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Time-Averaged GC Dose Changes During the Interventional Phase
NCT01219933 (33) [back to overview]	CDAI Score During the Interventional Phase
NCT01219933 (33) [back to overview]	Clinical Disease Activity Index (CDAI) During the Noninterventional Phase
NCT01219933 (33) [back to overview]	DAS28-CRP During the Interventional Phase
NCT01219933 (33) [back to overview]	DAS28-CRP During the Noninterventional Phase
NCT01219933 (33) [back to overview]	DAS28-ESR During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score During the Interventional Phase
NCT01219933 (33) [back to overview]	HAQ-DI During the Interventional Phase
NCT01219933 (33) [back to overview]	Health Assessment Questionnaire Disability Index (HAQ-DI) During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Median GC Dose Taken During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Number of Erosions During the NonInterventional Phase
NCT01219933 (33) [back to overview]	Percentage of Participants Positive for Anti-cyclic Citrullinated Peptide (Anti-CCP) Antibody During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Percentage of Participants Positive for Rheumatoid Factor (RF) During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Percentage of Participants With Erosions During the NonInterventional Phase
NCT01219933 (33) [back to overview]	Percentage of Participants With LDA or Remission During the Interventional Phase Assessed Using CDAI
NCT01219933 (33) [back to overview]	Percentage of Participants With LDA or Remission During the Interventional Phase Assessed Using DAS28-CRP
NCT01219933 (33) [back to overview]	SF-36 Subscale Scores During the Interventional Phase
NCT01267201 (4) [back to overview]	Maximum Observed Plasma Concentration (Cmax)
NCT01267201 (4) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
NCT01267201 (4) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax)
NCT01267201 (4) [back to overview]	Plasma Decay Half-life (t1/2)
NCT01272635 (5) [back to overview]	Drug Related Side Effects
NCT01272635 (5) [back to overview]	Urgent Care Visits, ED Visits and Hospitalizations
NCT01272635 (5) [back to overview]	Progression to Clinically Significant Lower Respiratory Tract Symptoms
NCT01272635 (5) [back to overview]	Asthma Related Symptoms Among RTI Progressing to Severe LRTI
NCT01272635 (5) [back to overview]	OCELOT: Pediatric Respiratory Assessment Measure
NCT01283009 (1) [back to overview]	60-day Mortality
NCT01319981 (3) [back to overview]	Complete Response Duration
NCT01319981 (3) [back to overview]	Overall Survival
NCT01319981 (3) [back to overview]	Number of Patients With Complete Remission at One Year
NCT01369745 (1) [back to overview]	Change From Baseline in DAS28-CRP at 12 Weeks
NCT01381874 (7) [back to overview]	Overall Survival (OS)
NCT01381874 (7) [back to overview]	Overall Response Rate (ORR)
NCT01381874 (7) [back to overview]	Change From Baseline in Serum Endocrine Biomarkers (Estradiol and Estrone) at End of Treatment
NCT01381874 (7) [back to overview]	Duration of Response
NCT01381874 (7) [back to overview]	Clinical Benefit Rate
NCT01381874 (7) [back to overview]	Change From Baseline in Serum Endocrine Biomarkers (Progesterone and Testosterone) at End of Treatment
NCT01381874 (7) [back to overview]	Progression-Free Survival (PFS)
NCT01382940 (7) [back to overview]	Percentage of Participants Experiencing Any Serious IRR (SIRR) Associated With the Second Rituximab Infusion
NCT01382940 (7) [back to overview]	Percentage of Participants Experiencing Any Infusion-related Reaction (IRR) Associated With the Second Rituximab Infusion
NCT01382940 (7) [back to overview]	Percentage of Participants Experiencing Any Common Toxicity Criteria (CTC) Grade 3 or 4 Adverse Events (AEs) Associated With the Third Rituximab Infusion
NCT01382940 (7) [back to overview]	Percentage of Participants Experiencing Any Common Toxicity Criteria (CTC) Grade 3 or 4 Adverse Events (AEs) Associated With the Second Rituximab Infusion
NCT01382940 (7) [back to overview]	Percentage of Participants Experiencing the Stopping, Slowing or Interrupting of the Third Rituximab Infusion
NCT01382940 (7) [back to overview]	Percentage of Participants Experiencing the Stopping, Slowing or Interrupting of the Second Rituximab Infusion
NCT01382940 (7) [back to overview]	Percentage of Participants Experiencing Any IRR or SIRR Associated With the Third Rituximab Infusion
NCT01390441 (7) [back to overview]	Part A: Area Under the Concentration-time Curve From Day 0 to Day 84 (AUC0-84day) After a Single Course of Treatment
NCT01390441 (7) [back to overview]	Number of Participants Who Discontinued Study Drug Due to Adverse Events
NCT01390441 (7) [back to overview]	Number of Participants Who Experienced at Least One Adverse Event
NCT01390441 (7) [back to overview]	Part A: Maximum Concentration (Cmax) After the Second Infusion of a Single Course of Treatment
NCT01390441 (7) [back to overview]	Change From Baseline in Disease Activity in 28 Joints C-Reactive Protein Score (DAS28-CRP) by Time-point
NCT01390441 (7) [back to overview]	Part A: Number of ACR20, ACR50, and ACR70 Responders at Week 24
NCT01390441 (7) [back to overview]	Part B: Number of ACR20, ACR50, and ACR70 Responders at Week 24
NCT01436305 (31) [back to overview]	Count of Participants With Estimated Glomerular Filtration Rate (GFR) < 60 mL/Min/1.73 m^2 by CKD EPI
NCT01436305 (31) [back to overview]	Count of Participants With Infections Requiring Hospitalization or Systemic Therapy Reported as Serious Adverse Events
NCT01436305 (31) [back to overview]	Number of All Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01436305 (31) [back to overview]	Total Daily Prescribed Pill Number at Days 28 and 84, and Wks 24, 36, 52, 72, 104 and 156
NCT01436305 (31) [back to overview]	Type of Treatment of Rejection
NCT01436305 (31) [back to overview]	Count of Participants With Rejection
NCT01436305 (31) [back to overview]	Fasting Lipid Profile (Total Cholesterol, Non-HDL Cholesterol, LDL, HDL, and Triglyceride) at Baseline and Wks 24, 52, 104 and 156
NCT01436305 (31) [back to overview]	Count of Participants With Fever > 39 Degrees Celsius and Blood Pressure < 90mm Hg Within 24 Hours of Onset of Transplant Procedure
NCT01436305 (31) [back to overview]	HbA1c Measured at Days 28 & 84, and Weeks 24, 36, 52, 72, 104 and 156
NCT01436305 (31) [back to overview]	Count of Participants With Use of Lipid Lowering Medications at Baseline and Wks 24, 52, 104 and 156
NCT01436305 (31) [back to overview]	Count of Participants by Severity of First Acute Cellular Rejection by Wk 52
NCT01436305 (31) [back to overview]	Mean Calculated eGFR Using MDRD 4 Variable Model
NCT01436305 (31) [back to overview]	Standardized Blood Pressure Measurement at Wk 52
NCT01436305 (31) [back to overview]	Count of Participants With Treated Diabetes Between Day 14 and Wk 52
NCT01436305 (31) [back to overview]	Count of Participants With Use of Anti-hypertensive Medications at Wk 52
NCT01436305 (31) [back to overview]	Mean Glomerular Filtration Rate (GFR) Calculated for Each Treatment Group Using the CKD-EPI Equation at Wk 52
NCT01436305 (31) [back to overview]	The Slope of eGFR by CKD-EPI Over Time Based on Serum Creatinine
NCT01436305 (31) [back to overview]	Count of Participants With Either New Onset Diabetes After Transplant (NODAT) or Impaired Fasting Glucose (IFG) at Wk 52 Based on Criteria Specified by the ADA and WHO
NCT01436305 (31) [back to overview]	Count of Participants With CKD Stage 4 or 5
NCT01436305 (31) [back to overview]	Count of Participants by Chronic Kidney Disease (CKD) Stage Post-Transplant
NCT01436305 (31) [back to overview]	Count of Participants With BKV and CMV Viremia (Local Center Monitoring) Reported as Adverse Events
NCT01436305 (31) [back to overview]	Count of Participants With EBV Infection as Reported on the Case Report Form as Adverse Events
NCT01436305 (31) [back to overview]	Count of Participants With Delayed Graft Function Post-Transplant
NCT01436305 (31) [back to overview]	Number of Events of Death or Graft Loss
NCT01436305 (31) [back to overview]	HbA1c Measured at Days 28 & 84, and Weeks 24, 36, 52, 72, 104 and 156
NCT01436305 (31) [back to overview]	Count of Participants With CAN/IFTA Grade I, II or III at Any Time Post-transplant
NCT01436305 (31) [back to overview]	Count of Participants With Biopsy Proven Acute Rejection at Any Time Post-Transplant
NCT01436305 (31) [back to overview]	Count of Participants With Antibody Mediated Rejection
NCT01436305 (31) [back to overview]	Count of Participants With Acute Cellular Rejection Grade Equal to or Greater Than IA, by the Banff 2007 Criteria
NCT01436305 (31) [back to overview]	Total Daily Prescribed Pill Number at Days 28 and 84, and Wks 24, 36, 52, 72, 104 and 156
NCT01436305 (31) [back to overview]	Count of Participants With de Novo Anti-donor HLA Antibodies at Wk 52
NCT01445821 (2) [back to overview]	Number of Participants With Treatment Failure
NCT01445821 (2) [back to overview]	Survival of Treatment
NCT01448213 (2) [back to overview]	Number of Eyes With Intraocular Pressure (IOP) Elevation
NCT01448213 (2) [back to overview]	Number of Eyes With Immunologic Graft Rejection Episodes
NCT01465334 (11) [back to overview]	3-Year Progression-Free Survival (PFS) Probability
NCT01465334 (11) [back to overview]	Induction Overall Response Rate (ORR)
NCT01465334 (11) [back to overview]	3-year Overall Survival (OS) Probability
NCT01465334 (11) [back to overview]	Overall MRD Negative Rate
NCT01465334 (11) [back to overview]	Overall Objective Response Rate (ORR)
NCT01465334 (11) [back to overview]	Transplant Rate
NCT01465334 (11) [back to overview]	Number of Participants Completing Part A Treatment
NCT01465334 (11) [back to overview]	Number of Participants With Overall CR
NCT01465334 (11) [back to overview]	Number of Participants Completing Only 2 Cycles of Part A Treatment
NCT01465334 (11) [back to overview]	Number of Participants With Treatment-Related Grades 1-3 Hyperglycemia During Part A Induction
NCT01465334 (11) [back to overview]	Number of Participants Achieving Induction Complete Response (CR)
NCT01475643 (2) [back to overview]	Anterior Chamber Cells & Flare
NCT01475643 (2) [back to overview]	Anterior Chamber Inflammation
NCT01496976 (4) [back to overview]	Rate of Progression/Relapse Free Survival (PFS)
NCT01496976 (4) [back to overview]	Number of Participants With Overall Survival (OS)
NCT01496976 (4) [back to overview]	Number of Participants With Complete Response (CR)
NCT01496976 (4) [back to overview]	Number of Participants With Partial Response (PR)
NCT01497496 (1) [back to overview]	Objective Response Rate (ORR)
NCT01534195 (4) [back to overview]	Ocular Itching Change From Baseline to Day 11
NCT01534195 (4) [back to overview]	Episcleral Redness Change From Baseline to Day 6
NCT01534195 (4) [back to overview]	Conjunctival Redness Change From Baseline to Day 11
NCT01534195 (4) [back to overview]	Ciliary Redness Change From Baseline to Day 6
NCT01559675 (1) [back to overview]	Orthostatic Hypotension
NCT01579513 (5) [back to overview]	Neurodevelopmental Outcome
NCT01579513 (5) [back to overview]	Number of Participants With a Clinically Derived Composite Morbidity-mortality Outcome
NCT01579513 (5) [back to overview]	Intensive Care Unit Stay
NCT01579513 (5) [back to overview]	Hospital Stay
NCT01579513 (5) [back to overview]	Duration of Mechanical Ventilation Post Cardiac Surgery.
NCT01621880 (2) [back to overview]	Number of Participants With a Treatment Response
NCT01621880 (2) [back to overview]	Percentage Change in Radiological Measures of Lesion Volume
NCT01652495 (3) [back to overview]	Reduction of Pain Severity Expressed as Percentage Change in VAS Score
NCT01652495 (3) [back to overview]	Functional Improvement Measured According to Percentage Change in Constant Score
NCT01652495 (3) [back to overview]	Percentage of Patients With Suppression of Hypothalamus-pituitary-adrenal Axis
NCT01680861 (7) [back to overview]	BPAR (Biopsy-proven Acute Rejection) Incidence During the First 12 Months Post-transplant
NCT01680861 (7) [back to overview]	Discontinuance of Any Study Medication (Tacrolimus, Everolimus, or EC-MPS)
NCT01680861 (7) [back to overview]	eGFR (Renal Function) at Month 3 Post-transplant
NCT01680861 (7) [back to overview]	Graft Loss (Return to Permanent Dialysis or Death)
NCT01680861 (7) [back to overview]	Incidence of Chronic Allograft Nephropathy (CAI) at 12 Months Post-transplant
NCT01680861 (7) [back to overview]	eGFR (Calculated Glomerular Filtration Rate), i.e., Renal Function, at 1 Month Post-transplant.
NCT01680861 (7) [back to overview]	eGFR (Renal Function) at 6 Months Post-transplant
NCT01724021 (14) [back to overview]	Progression-free Survival (PFS)
NCT01724021 (14) [back to overview]	Time Required for Rituximab Administration (Subcutaneous [SC] or Intravenous [IV])
NCT01724021 (14) [back to overview]	Cancer Therapy Satisfaction Questionnaire (CTSQ) Score
NCT01724021 (14) [back to overview]	Percentage of Participants With Anti-Recombinant Human Hyaluronidase (rHuPH20) Antibodies Over Time
NCT01724021 (14) [back to overview]	Percentage of Participants With Anti-Rituximab Antibodies Over Time
NCT01724021 (14) [back to overview]	Rituximab Administration Satisfaction Questionnaire (RASQ) Score
NCT01724021 (14) [back to overview]	Summary of Observed Serum Rituximab Concentration
NCT01724021 (14) [back to overview]	Complete Response (CR) Rate
NCT01724021 (14) [back to overview]	Disease-free Survival (DFS)
NCT01724021 (14) [back to overview]	Event-free Survival (EFS)
NCT01724021 (14) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (AEs)
NCT01724021 (14) [back to overview]	Overall Survival (OS)
NCT01724021 (14) [back to overview]	Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6
NCT01724021 (14) [back to overview]	Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8
NCT01730872 (3) [back to overview]	Ocular Redness Change From Baseline to Day 6
NCT01730872 (3) [back to overview]	Inflammation Change From Baseline to Day 6
NCT01730872 (3) [back to overview]	Ocular Itching Change From Baseline to Day 6
NCT01783847 (2) [back to overview]	Number of Participants With Change/Improvement Visual Acuity From the Beseline
NCT01783847 (2) [back to overview]	Number of Participants With Relative Afferent Papillary Defect (RAPD) Grade +4
NCT01790594 (30) [back to overview]	Type of Treatment(s) Participants Received for Biopsy-Proven Pancreatic Allograft Rejection During the First 52 Weeks Post-Transplant
NCT01790594 (30) [back to overview]	Count of Participants With Full Pancreatic Graft Function (Insulin Independent) at Wk 52 Post-Transplant
NCT01790594 (30) [back to overview]	Count of Participants With Evidence of Partial Pancreatic Graft Function at Week 52 Post-Transplant
NCT01790594 (30) [back to overview]	Count of Participants With Evidence of Pancreatic Loss at Week 52 Post-Transplant
NCT01790594 (30) [back to overview]	Count of Participants With eGFR < 60 mL/Min/1.73 m^2 Measured by CKD-EPI at Wk 52 Post-Transplant
NCT01790594 (30) [back to overview]	Count of Participants With Defined CKD Stage 4 or 5 at Wk 52 Post-Transplant
NCT01790594 (30) [back to overview]	Count of Participants With an Infectious Disease Serious Adverse Event(s) Requiring Hospitalization or Systemic Therapy
NCT01790594 (30) [back to overview]	Count of Participants Diagnosed With Malignancy as an Adverse Event
NCT01790594 (30) [back to overview]	Count of Participants Diagnosed With Epstein-Barr Virus (EBV) Infection as an Adverse Event
NCT01790594 (30) [back to overview]	Count of Participants With Delayed Graft Function at Wk 52 Post-Transplant
NCT01790594 (30) [back to overview]	Fasting Lipid Profile at Baseline (Pre-Transplant)
NCT01790594 (30) [back to overview]	Type of Treatment(s) Participants Received for Biopsy-Proven Renal Allograft Rejection During the First 52 Weeks Post-Transplant
NCT01790594 (30) [back to overview]	Standardized Blood Pressure Measurement From Baseline (Pre-Transplant) Through Wk 52 Post-Transplant
NCT01790594 (30) [back to overview]	Severity Grade of First Biopsy-Proven Acute Rejection (AR) During the First 52 Weeks Post-Transplant
NCT01790594 (30) [back to overview]	Lipid Profile at Wk 52 Post-Transplant
NCT01790594 (30) [back to overview]	HbA1c at Baseline (Pre-Transplant) Through Wk 52 Post-Transplant
NCT01790594 (30) [back to overview]	Fasting Lipid Profile at Wk 28 Post-Transplant
NCT01790594 (30) [back to overview]	Fasting Blood Sugar (FBS) From Baseline (Pre-Transplant) Through Wk 52 Post-Transplant
NCT01790594 (30) [back to overview]	Count of Participants With Use of Lipid Lowering Medications at Baseline, Wk 28 and Wk 52 Post-Transplant
NCT01790594 (30) [back to overview]	Count of Participants With Use of Anti-hypertensive Medication From Baseline (Pre-Transplant) Through Wk 52 Post-Transplant
NCT01790594 (30) [back to overview]	Count of Participants With the Occurrence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01790594 (30) [back to overview]	Count of Participants With Event of Death, Graft Loss, or Undetectable C-peptide
NCT01790594 (30) [back to overview]	Count of Participants With De Novo Anti-Donor Antibodies or Anti-Human Leukocyte Antigen (HLA) Antibodies During the First 52 Weeks Post-Transplant
NCT01790594 (30) [back to overview]	Count of Participants With Biopsy-Proven Humoral Rejection During the First 52 Weeks Post-Transplant
NCT01790594 (30) [back to overview]	Count of Participants With Acute Rejection (AR) of Kidney or Pancreatic Transplant During the First 52 Wks Post-Transplant
NCT01790594 (30) [back to overview]	Count of Participant Diagnosed With BK Polyoma Virus (BKV) and Cytomegalovirus (CMV) Viremia As Adverse Events
NCT01790594 (30) [back to overview]	The Slope of eGFR by CKD-EPI Over Time Based on Serum Creatinine Post-Transplant
NCT01790594 (30) [back to overview]	Mean Estimated Glomerular Filtration Rate (eGFR) Calculated for Each Treatment Group Using the CKD-EPI Equation at Wk 52 Post-Transplant
NCT01790594 (30) [back to overview]	Mean Calculated eGFR Using MDRD 4 Variable Model at Wk 52 Post-Transplant
NCT01790594 (30) [back to overview]	Count of Participants With Successful Discontinuation of Tacrolimus in Recipients Randomized to the Investigational Arm
NCT01809132 (4) [back to overview]	MELD Score at 180 Days
NCT01809132 (4) [back to overview]	180 Days Mortality
NCT01809132 (4) [back to overview]	MELD Score at 28 Days
NCT01809132 (4) [back to overview]	MELD Score at 90 Days
NCT01853072 (6) [back to overview]	Percentage of Participants With Best-corrected Visual Acuity (BCVA) Improvement of ≥ 15 Letters From Preoperative Baseline to Day 14 and Maintained Through Day 90
NCT01853072 (6) [back to overview]	Percentage of Participants With With a > 10-letter Loss in BCVA From Day 7 to Any Visit
NCT01853072 (6) [back to overview]	Percentage of Participants With BCVA Improvement of ≥ 15 Letters From Preoperative Baseline to Day 60
NCT01853072 (6) [back to overview]	Percentage of Participants With a > 5-letter Loss in BCVA From Day 7 to Any Visit [Time Frame: Day 7 up to Any Visit]
NCT01853072 (6) [back to overview]	Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0)
NCT01853072 (6) [back to overview]	Percentage of Participants With BCVA Improvement of ≥ 15 Letters From Preoperative Baseline to Day 90
NCT01853696 (2) [back to overview]	Immunologic Graft Rejection Episode
NCT01853696 (2) [back to overview]	Intraocular Pressure
NCT01856257 (29) [back to overview]	Type of Rejection Classified by Pathologist - For Cause Kidney Biopsies
NCT01856257 (29) [back to overview]	Total Daily Prescribed Pill Count
NCT01856257 (29) [back to overview]	Standardized Blood Pressure Measurement at Wk 52 Post-Transplant
NCT01856257 (29) [back to overview]	Hemoglobin A1c (HbA1c) Measurements Over Time
NCT01856257 (29) [back to overview]	Fasting Lipid Profile at Wk 52 Post-Transplant
NCT01856257 (29) [back to overview]	Fasting Lipid Profile at Wk 28 Post-Transplant
NCT01856257 (29) [back to overview]	Fasting Lipid Profile at Baseline (Pre-Transplant)
NCT01856257 (29) [back to overview]	Count of Participants With Fever > 39 Degrees Celsius and Blood Pressure < 90 mmHg Within 24 Hours of Onset of Transplant Procedure
NCT01856257 (29) [back to overview]	Count of Participants With Either New Onset Diabetes After Transplant (NODAT) or Impaired Fasting Glucose (IFG) at Week 52 Post-Transplant -Based on Criteria Specified by the ADA and WHO
NCT01856257 (29) [back to overview]	Count of Participants With Treated Diabetes Between Day 14 and Wk 52 Post-Transplant
NCT01856257 (29) [back to overview]	Count of Participants With Use of Anti-hypertensive Medication at Wk 52 Post-Transplant
NCT01856257 (29) [back to overview]	Mean Calculated eGFR Using MDRD 4 Variable Model at Wk 52 Post-Transplant
NCT01856257 (29) [back to overview]	Mean Estimated Glomerular Filtration Rate (eGFR) Calculated for Each Treatment Group Using the CKD-EPI Equation at Wk 52 Post-Transplant
NCT01856257 (29) [back to overview]	Count of Participants by Severity of First Acute Cellular Rejection by Wk 52 Post-Transplant
NCT01856257 (29) [back to overview]	Count of Participants Experiencing ≥ 1 Adverse Event (AEs) or Serious Adverse Events (SAEs) by Wk 52
NCT01856257 (29) [back to overview]	Type of Treatment for Detected Graft Rejection
NCT01856257 (29) [back to overview]	Count of Participant Deaths or Graft Loss by Wk 52 Post-Transplant
NCT01856257 (29) [back to overview]	Count of Participants With BK Polyoma Virus (BKV) and Cytomegalovirus (CMV) Viremia (Local Center Monitoring) as Adverse Events by Wk 52 Post-Transplant
NCT01856257 (29) [back to overview]	The Slope of eGFR by CKD-EPI Over Time Based on Serum Creatinine Post-Transplant
NCT01856257 (29) [back to overview]	Count of Participants With Use of Lipid Lowering Medications at Baseline and Wk 28 and Wk 52 Post-Transplant
NCT01856257 (29) [back to overview]	Count of Participants With Acute Cellular Rejection Grade ≥ IA Defined by Banff 2007 Criteria By Wk 52 Post-Transplant
NCT01856257 (29) [back to overview]	Count of Participants With Antibody Mediated Rejection by Wk 52 Post-Transplant
NCT01856257 (29) [back to overview]	Count of Participants With Biopsy Proven Acute Rejection By Wk 52 Post-Transplant
NCT01856257 (29) [back to overview]	Count of Participants With Defined CKD Stage 4 or 5 at Wk 52 Post-Transplant
NCT01856257 (29) [back to overview]	Count of Participants With Delayed Graft Function at Wk 52 Post-Transplant
NCT01856257 (29) [back to overview]	Count of Participants With eGFR < 60 mL/Min/1.73 m^2 Measured by CKD-EPI at Wk 52 Post-Transplant
NCT01856257 (29) [back to overview]	Count of Participants With Epstein-Barr Virus (EBV) Infection as Reported on the Case Report Form as Adverse Events
NCT01856257 (29) [back to overview]	Count of Participants With Graft Rejection by Wk 52 Post-Transplant
NCT01856257 (29) [back to overview]	Count of Participants With Infections Requiring Hospitalization or Systemic Therapy by Wk 52 Post-Transplant
NCT01872611 (6) [back to overview]	Percentage of Participants With With a > 10-letter Loss in BCVA From Day 7 to Any Visit
NCT01872611 (6) [back to overview]	Percentage of Participants With Best-corrected Visual Acuity (BCVA) Improvement of ≥ 15 Letters From Preoperative Baseline to Day 14 and Maintained Through Day 90
NCT01872611 (6) [back to overview]	Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0)
NCT01872611 (6) [back to overview]	Percentage of Participants With a > 5-letter Loss in BCVA From Day 7 to Any Visit
NCT01872611 (6) [back to overview]	Percentage of Participants With BCVA Improvement of ≥ 15 Letters From Preoperative Baseline to Day 90
NCT01872611 (6) [back to overview]	Percentage of Participants With BCVA Improvement of ≥ 15 Letters From Preoperative Baseline to Day 60
NCT01875237 (8) [back to overview]	To Assess Post Donor Lymphocyte Infusion (DLI) Chimerism
NCT01875237 (8) [back to overview]	To Assess the Proportion of Patients Developing Grade I-IV Acute GvHD
NCT01875237 (8) [back to overview]	To Assess the Proportions of GvHD Response Post-administration of AP1903.
NCT01875237 (8) [back to overview]	To Assess the Incidence of Acute GvHD Flare After CR/PR Requiring Additional Agent for Systemic Therapy Before Day 56 Post-administration of AP1903.
NCT01875237 (8) [back to overview]	To Assess the Incidence of GvHD Treatment Failure Post-administration of AP1903.
NCT01875237 (8) [back to overview]	Number of Participants Assessed Post Donor Lymphocyte Infusion (DLI): Disease-free Survival & Non-relapse Mortality, Chimerism and GVHD.
NCT01875237 (8) [back to overview]	To Assess the Incidence of Epstein-Barr Virus -PTLD or EBV Reactivation Requiring Therapy Post DLI.
NCT01875237 (8) [back to overview]	To Evaluate the Safety of Donor Lymphocyte Infusion Followed by Dimerizer Drug, AP1903 by Number of Participants With Adverse Events.
NCT01884571 (8) [back to overview]	Mean Rate of Change of Slow Vital Capacity (SVC) During Treatment Compared to Pre-Treatment
NCT01884571 (8) [back to overview]	Mean Rate of Change of Hand-Held Dynamometry (HHD) During Treatment Compared to Pre-Treatment
NCT01884571 (8) [back to overview]	Mean Rate of Change of ALSFRS-R Scores During Treatment Compared to Pre-Treatment
NCT01884571 (8) [back to overview]	Mean Rate of Change in Grip Strength Treatment Compared to Pre-Treatment
NCT01884571 (8) [back to overview]	Collection of Cerebrospinal Fluid for Future Analysis of Cytokine Levels
NCT01884571 (8) [back to overview]	Collection of Blood for Future Analysis of Peripheral Blood Mononuclear Cells (PBMCs)
NCT01884571 (8) [back to overview]	Mean Rate of Change of T-cell Subsets in Blood Treatment Compared to Pre-Treatment
NCT01884571 (8) [back to overview]	Number of Participants With an Average Increase in ALSFRS-R Score of One Point Per Month
NCT01950819 (22) [back to overview]	Incidence of Failure on the Composite of (Treated Biopsy Proven Acute Rejection (tBPAR), Graft Loss or Death
NCT01950819 (22) [back to overview]	Incidence of Failure on the Composite of (Treated Biopsy Proven Acute Rejection (tBPAR), Graft Loss or Death or Loss to Follow-up
NCT01950819 (22) [back to overview]	Incidence of Failure on the Composite of Treated Biopsy-proven Acute Rejection (tBPAR) or Estimated Glomerular Filtration Rate (eGFR) < 50 mL/Min/1.73m2 Among Compliant Subjects.
NCT01950819 (22) [back to overview]	Incidence of Failure on the Composite of Treated Biopsy-proven Acute Rejection (tBPAR) or Estimated Glomerular Filtration Rate (eGFR) < 50 mL/Min/1.73m2.
NCT01950819 (22) [back to overview]	Incidence of tBPAR (Excluding Grade IA Rejections) or GFR<50 mL/Min/1.73m2
NCT01950819 (22) [back to overview]	Incidence of tBPAR (Treated Biopsy-proven Acute Rejection) Excluding Grade IA Rejections
NCT01950819 (22) [back to overview]	Incidence tBPAR (Treated Biopsy-proven Acute Rejection) by Severity and Time to Event (Events)
NCT01950819 (22) [back to overview]	Incidence tBPAR (Treated Biopsy-proven Acute Rejection) by Severity and Time to Event (Participants)
NCT01950819 (22) [back to overview]	Renal Allograft Function : Mean Estimated Glomerular Filtration Rate, eGFR
NCT01950819 (22) [back to overview]	Renal Function Assessed by Creatinine Lab Values
NCT01950819 (22) [back to overview]	Renal Function by Alternative Formulae (e.g. CKD-EPI). eGFR Values Reported
NCT01950819 (22) [back to overview]	Urinary Protein and Albumin Excretion by Treatment Estimated by Urinary Protein/Creatinine and Urinary Albumin/Creatinine Ratios.
NCT01950819 (22) [back to overview]	Evolution of Renal Function, as eGFR, Over Time by Slope Analysis.
NCT01950819 (22) [back to overview]	Incidence of Adverse Events, Serious Adverse Events and Adverse Events Leading to Study Regimen Discontinuation.
NCT01950819 (22) [back to overview]	Incidence of Major Cardiovascular Events.
NCT01950819 (22) [back to overview]	Incidence of Malignancies.
NCT01950819 (22) [back to overview]	Incidence of Composite of tBPAR (Treated Biopsy-proven Acute Rejection)or eGRF<50 mL/Min/1.73m2 by Subgroup
NCT01950819 (22) [back to overview]	Incidence of Cytomegalovirus and BK Virus, New Onset Diabetes Mellitus, Chronic Kidney Disease With Associated Proteinuria and Calcineurin Inhibitor Associated Adverse Events.
NCT01950819 (22) [back to overview]	Incidence of Death, Graft Loss, tBPAR, BPAR, tAR, AR and Humoral Rejection
NCT01950819 (22) [back to overview]	Incidence of eGFR < 50 mL/Min/1.73m2
NCT01950819 (22) [back to overview]	Incidence of Failure on the Composite Endpoint of Graft Loss or Death.
NCT01950819 (22) [back to overview]	Incidence of Failure on the Composite Endpoint of tBPAR, Graft Loss, Death or eGFR < 50 mL/Min/1.73m2
NCT01977781 (7) [back to overview]	Tear Film Break-Up Time
NCT01977781 (7) [back to overview]	Schirmer Tear Test (mm)
NCT01977781 (7) [back to overview]	Ocular Surface Disease Index (OSDI) Questionnaire
NCT01977781 (7) [back to overview]	Intraocular Pressure
NCT01977781 (7) [back to overview]	Corneal Epitheliopathy (Corneal Fluorescein Staining Using the NEI Grading Scheme)
NCT01977781 (7) [back to overview]	Visual Acuity
NCT01977781 (7) [back to overview]	Ocular Burning Sensation, Ocular Discharge, Ocular Redness, Ocular Itching, Foreign Body Sensation
NCT01985126 (7) [back to overview]	Progression Free Survival
NCT01985126 (7) [back to overview]	Percentage of Participants With Overall Response
NCT01985126 (7) [back to overview]	Percentage of Participants With Clinical Benefit
NCT01985126 (7) [back to overview]	Overall Survival
NCT01985126 (7) [back to overview]	Duration of Response
NCT01985126 (7) [back to overview]	Time to Response
NCT01985126 (7) [back to overview]	Time to Disease Progression
NCT02005562 (12) [back to overview]	Graft Histology - Percentage of Participants With at Least One Borderline Lesion at Week 12 and Week 52
NCT02005562 (12) [back to overview]	Creatinine Clearance Values Estimated With the Modification of Diet in Renal Disease (MDRD) Simplified Equation
NCT02005562 (12) [back to overview]	Creatinine Clearance Values Estimated With the Cockcroft-Gault Equation (Milliliters Per Minute [mL/Min])
NCT02005562 (12) [back to overview]	Time to Occurrence of First BPAR Between Day 0 and Week 52 - Percentage of Participants With an Event
NCT02005562 (12) [back to overview]	Time to Occurrence of First BPAR Between Day 0 and Week 52
NCT02005562 (12) [back to overview]	Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR) Before Week 12 or Acute Subclinical Rejection on Protocol Biopsy at Week 12
NCT02005562 (12) [back to overview]	Time to Graft Loss
NCT02005562 (12) [back to overview]	Participant Survival
NCT02005562 (12) [back to overview]	Graft Loss - Percentage of Participants With an Event
NCT02005562 (12) [back to overview]	Serum Creatinine Values [Micromoles Per Liter (µmol/L)]
NCT02005562 (12) [back to overview]	Percentage of Participants With at Least One BPAR at Week 12 and Week 52
NCT02005562 (12) [back to overview]	Graft Histology - Percentage of Participants With at Least One Chronic Graft Nephropathy at Week 12 and Week 52
NCT02006706 (2) [back to overview]	Health Assessment Questionnaire-Disability Index (HAQ-DI)
NCT02006706 (2) [back to overview]	Change From Baseline Disease Activity Score Based on 28-Joint Count (DAS28) at Week 24
NCT02029638 (18) [back to overview]	Number of Transplanted Participants Who Developed Donor- Specific Antibody After Initiation of Immunosuppression Withdrawal
NCT02029638 (18) [back to overview]	Number of Transplanted Participants Who Developed Donor-Specific Antibody During Study Participation
NCT02029638 (18) [back to overview]	Number of Transplanted Participants Who Died
NCT02029638 (18) [back to overview]	Number of Transplanted Participants Who Remained Off Immunosuppression for at Least 52 Weeks, Including Those in Whom the 52 Week Biopsy Was Not Performed
NCT02029638 (18) [back to overview]	Number of Transplanted Participants With Acute Renal Allograft Rejection
NCT02029638 (18) [back to overview]	Number of Transplanted Participants With Chronic T Cell-Mediated or Antibody-Mediated Rejection
NCT02029638 (18) [back to overview]	Number of Transplanted Participants With Engraftment Syndrome
NCT02029638 (18) [back to overview]	Percent of Participants Who Achieved Operational Tolerance
NCT02029638 (18) [back to overview]	Number of Days From Transplant to Platelet Count Recovery
NCT02029638 (18) [back to overview]	Duration in Days of Adverse Events (AEs)- Including Infection, Wound Complications, Post-transplant Diabetes, Hemorrhagic Cystitis and Malignancy
NCT02029638 (18) [back to overview]	Duration in Days of Graft-versus-Host Disease in Transplanted Participants
NCT02029638 (18) [back to overview]	Number of Days From Neutrophil Nadir to Absolute Neutrophil Recovery
NCT02029638 (18) [back to overview]	Number of Days Post-Transplant to the First Episode of Acute Rejection Requiring Treatment
NCT02029638 (18) [back to overview]	Number of Participants Experiencing an Incidence of Graft-versus-Host Disease Post-Transplant
NCT02029638 (18) [back to overview]	Number of Participants Free From Return to Immunosuppression for the Duration of the Study
NCT02029638 (18) [back to overview]	Number of Adverse Events (AEs)- Including Infection, Wound Complications, Post-transplant Diabetes, Hemorrhagic Cystitis and Malignancy
NCT02029638 (18) [back to overview]	Number of Adverse Events (AEs) by Severity- Including Infection, Wound Complications, Post-Transplant Diabetes, Hemorrhagic Cystitis and Malignancy
NCT02029638 (18) [back to overview]	Histological Severity of Biopsies Demonstrating Acute Rejection as Defined by Banff 2007 Classification Renal Allograft Pathology
NCT02038452 (44) [back to overview]	BCTQ Functional Limitations Subscale 6 Months
NCT02038452 (44) [back to overview]	BCTQ Functional Limitations Subscale 6 Months (CC)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Weeks (SG, Did Not State a Preference of Intervention)
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity 6 Weeks (CC)
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity 6 Weeks (PP)
NCT02038452 (44) [back to overview]	NHS Cost Differences at 6 Months
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity 6 Months (PP)
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity 6 Months (CC)
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity 6 Months
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity Over 24 Months: 24 Months
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity Subscale 6 Weeks (PP)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Weeks (SG, Did Not Receive the Intervention of Their Preference)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Weeks (Per-Protocol Analysis (PP))
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Weeks (Complete Case Analysis (CC))
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity Over 24 Months: 6 Months
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity Over 24 Months: 6 Weeks
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Months (PP)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Months (CC)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Months
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Weeks (SG, Preferred Injection)
NCT02038452 (44) [back to overview]	NHS Cost Differences at 12 Months
NCT02038452 (44) [back to overview]	BCTQ Functional Limitations Subscale 6 Weeks (PP)
NCT02038452 (44) [back to overview]	BCTQ Functional Limitations Subscale 6 Weeks (CC)
NCT02038452 (44) [back to overview]	BCTQ Functional Limitations Subscale 6 Weeks
NCT02038452 (44) [back to overview]	BCTQ Functional Limitations Subscale 6 Months (PP)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Weeks (SG, Preferred Splint)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Weeks (Subgroup Analysis (SG), Intervention of Their Preference)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations Over 24 Months: 12 Months
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations Over 24 Months: 6 Months
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations Over 24 Months: 6 Weeks
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity Subscale 6 Months (PP)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity Subscale 6 Months
NCT02038452 (44) [back to overview]	NHS Cost Differences at 24 Months
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity Subscale 6 Months (CC)
NCT02038452 (44) [back to overview]	Symptom Severity and Limitations in Hand Function as Assessed by the BCTQ 6 Weeks
NCT02038452 (44) [back to overview]	Secondary: BCTQ Symptom Severity and Functional Limitations Over 24 Months: 24 Months
NCT02038452 (44) [back to overview]	QALYS at 6 Months (Cross-walk Tariff)
NCT02038452 (44) [back to overview]	QALYS at 24 Months (Cross-walk Tariff)
NCT02038452 (44) [back to overview]	QALYS at 12 Months (Cross-walk Tariff)
NCT02038452 (44) [back to overview]	NHS Cost Differences at 6 Months (CC)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity Subscale 6 Weeks
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity Subscale 6 Weeks (CC)
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity Over 24 Months: 12 Months
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity 6 Weeks
NCT02093026 (14) [back to overview]	Percentage of Participants With ACR20 Response After Third Course
NCT02093026 (14) [back to overview]	Percentage of Participants Who Discontinued Treatment Due to Insufficient Response
NCT02093026 (14) [back to overview]	Percentage of Participants With ACR50 and ACR70 Response
NCT02093026 (14) [back to overview]	Percentage of Participants With Low Disease Activity and Clinical Remission Based on DAS28-ESR
NCT02093026 (14) [back to overview]	Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at 24 Weeks Following Each Course
NCT02093026 (14) [back to overview]	Percentage of Participants With ACR20 Response After Seventh Course
NCT02093026 (14) [back to overview]	Percentage of Participants With ACR20 Response After Second Course
NCT02093026 (14) [back to overview]	Percentage of Participants With an American College of Rheumatology 20 (ACR20) Response After First Course
NCT02093026 (14) [back to overview]	Percentage of Participants With ACR20 Response After Fourth Course
NCT02093026 (14) [back to overview]	Percentage of Participants With ACR20 Response After Fifth Course
NCT02093026 (14) [back to overview]	American College of Rheumatology Index of Improvement (ACRn) Response
NCT02093026 (14) [back to overview]	Percentage of Participants With European League Against Rheumatism (EULAR) Response of 'Good' or 'Moderate'
NCT02093026 (14) [back to overview]	Percentage of Participants With ACR20 Response After Sixth Course
NCT02093026 (14) [back to overview]	Time Since Last Treatment Course
NCT02133924 (8) [back to overview]	Number of Participants With Overall Response Rate (CR + PR)
NCT02133924 (8) [back to overview]	Number of Participants With Complete Response (CR)
NCT02133924 (8) [back to overview]	Number of Participants Who Received Additional GVHD Therapies
NCT02133924 (8) [back to overview]	Number of Participants With Non-Relapse Mortality (NRM)
NCT02133924 (8) [back to overview]	Time to Discontinuation of Steroid Therapy
NCT02133924 (8) [back to overview]	Number of Serious Infections
NCT02133924 (8) [back to overview]	Number of Participants With SR GVHD
NCT02133924 (8) [back to overview]	Number of Participants With Overall Survival (OS)
NCT02137239 (28) [back to overview]	Absolute Values of Fasting Lipid Values: Mean
NCT02137239 (28) [back to overview]	Percentage of Participants With Serious Adverse Events (SAEs)
NCT02137239 (28) [back to overview]	Percentage of Participants With Adverse Events (AEs)
NCT02137239 (28) [back to overview]	Percentage of Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR) at 6 Months
NCT02137239 (28) [back to overview]	Absolute Values of Fasting Lipid Values: Median
NCT02137239 (28) [back to overview]	Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR) at 6, 12 and 24 Months
NCT02137239 (28) [back to overview]	Mean and Mean Change From Baseline in Blood Glucose
NCT02137239 (28) [back to overview]	Urine Protein Creatinine Ratio (UPr/Cr)
NCT02137239 (28) [back to overview]	Treatment Differences in Therapeutic Modalities
NCT02137239 (28) [back to overview]	Time to Event: Graft Loss and Death
NCT02137239 (28) [back to overview]	Percentage of Particpants With Laboratory Test Abnormalities (LTAs)
NCT02137239 (28) [back to overview]	Percentage of Participants With New Onset Diabetes After Transplant
NCT02137239 (28) [back to overview]	Mean and Mean Change From Baseline in Whole Blood HbA1c
NCT02137239 (28) [back to overview]	Mean Change From Month 3 in cGFR
NCT02137239 (28) [back to overview]	Mean Changes From Baseline Values for Blood Pressure
NCT02137239 (28) [back to overview]	Mean Changes From Baseline Values of Lipid Values
NCT02137239 (28) [back to overview]	Median Calculated Glomerular Filtration Rate (cGFR)
NCT02137239 (28) [back to overview]	Number of Participants Deaths Post Transplant
NCT02137239 (28) [back to overview]	Number of Participants Who Experience Graft Loss Post Transplant
NCT02137239 (28) [back to overview]	Number of Participants Who Survive With a Functioning Graft
NCT02137239 (28) [back to overview]	Percentage of Participants With BANFF Grade by Severity Grades. BANFF Type (Grade) for Acute/Active Rejection
NCT02137239 (28) [back to overview]	Percentage of Participants With De Novo Donor Specific Anti-HLA Antibodies (DSA)
NCT02137239 (28) [back to overview]	Percentage of Participants With Donor Specific Anti-HLA Antibodies (DSA)
NCT02137239 (28) [back to overview]	Percentage of Participants With Events of Special Interest (ESIs)
NCT02137239 (28) [back to overview]	Time to Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR).
NCT02137239 (28) [back to overview]	Absolute Calculated Glomerular Filtration Rate (cGFR): Mean
NCT02137239 (28) [back to overview]	Absolute Values of Blood Pressure: Mean
NCT02137239 (28) [back to overview]	Absolute Values of Blood Pressure: Median
NCT02152345 (4) [back to overview]	Percentage of Participants With Allograft Survival
NCT02152345 (4) [back to overview]	Number of Participants With Delayed Graft Function (DGF)
NCT02152345 (4) [back to overview]	Number of Participants With an Allograft Rejection Episode
NCT02152345 (4) [back to overview]	Estimated Glomerular Filtration Rate (eGFR)
NCT02166463 (3) [back to overview]	Percentages of Patients Experiencing Grade 3+ Peripheral Neuropathy Assessed by Modified Balis Scale
NCT02166463 (3) [back to overview]	Percentages of Patients With Early Response Defined as no Slow Responding Lesions (SRL) and no Progressive Disease (PD) at Any Disease Sites Determined by Positron Emission Tomography (PET) Per Deauville Criteria Through Central Review
NCT02166463 (3) [back to overview]	Event Free Survival (EFS), Where Events Include Disease Progression or Relapse, Second Malignancy, or Death
NCT02167217 (1) [back to overview]	Bayley III Gross Motor Scaled Score (Change From Baseline to 12 Month)
NCT02176031 (6) [back to overview]	GVHD-free Survival Rate
NCT02176031 (6) [back to overview]	Overall Survival (OS) Rate
NCT02176031 (6) [back to overview]	Rate of GVHD Flares
NCT02176031 (6) [back to overview]	GI aGVHD Response Rate
NCT02176031 (6) [back to overview]	Percentage Steroid Dose Was Reduced at Day 28, 56, and 100 in Comparison to Steroid Dose at First Administration of Natalizumab.
NCT02176031 (6) [back to overview]	Graft-verus-host Disease (GVHD) Response Rate
NCT02199041 (9) [back to overview]	Number of Participants With Secondary Graft Failure
NCT02199041 (9) [back to overview]	Number of Participants With Event-free Survival (EFS)
NCT02199041 (9) [back to overview]	Number of Participants by Severity With Chronic Graft Versus Host Disease (GVHD) in the First 100 Days After HCT
NCT02199041 (9) [back to overview]	Number of Participants by Severity With Acute Graft Versus Host Disease (GVHD) in the First 100 Days After HCT
NCT02199041 (9) [back to overview]	Number of Participants With Transplant-related Mortality (TRM)
NCT02199041 (9) [back to overview]	Number of Participants With Transplant-related Morbidity
NCT02199041 (9) [back to overview]	Number of Participants With Malignant Relapse
NCT02199041 (9) [back to overview]	Number of Participants With Overall Survival (OS)
NCT02199041 (9) [back to overview]	Number of Participants With Neutrophil Engraftment
NCT02242630 (2) [back to overview]	Change in Shoulder Function, as Measured by the QuickDASH ®
NCT02242630 (2) [back to overview]	Change in Subject Reported Shoulder Pain as Measured by the Visual Analogue Scale
NCT02256969 (4) [back to overview]	Corneal Fluorescein Staining (CFS)
NCT02256969 (4) [back to overview]	Ocular Surface Disease Index (OSDI)
NCT02256969 (4) [back to overview]	Tear Break Up Time (TBUT)
NCT02256969 (4) [back to overview]	Symptom Assessment in Dry Eye (SANDE)
NCT02260934 (15) [back to overview]	Percentage of Participants With a Sustained Complete Response
NCT02260934 (15) [back to overview]	Count of Participants: Frequency of Non-renal Flares by Week 24
NCT02260934 (15) [back to overview]	Count of Participants: Frequency of Non-renal Flares by Week 48
NCT02260934 (15) [back to overview]	Frequency of Specific Adverse Events of Interest By Event by Week 96
NCT02260934 (15) [back to overview]	Frequency of Specific Adverse Events of Interest By Participant, By Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants Hypocomplementemic for Complement Component C3 at Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants Hypocomplementemic for Complement Component C4 at Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With a Complete Response at Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With an Negative Anti-dsDNA Result at Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With an Overall Response at Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With At Least One Grade 3 or Higher Infectious Adverse Event By Week 24, Week 48 and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With B Cell Reconstitution at Week 24, Week 48 and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With Grade 4 Hypogammaglobulinemia by Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With Treatment Failure by Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Count of Participants: Frequency of Non-renal Flares by Week 96
NCT02282514 (3) [back to overview]	Reduction of Muscle Relaxation Anti-spasmatic Medications
NCT02282514 (3) [back to overview]	Short-form 36 Quality of Life Questionnaire (SF-36 QOL)
NCT02282514 (3) [back to overview]	Overall Survival
NCT02292082 (11) [back to overview]	Time to Meet Physical Therapy Discharge Criteria
NCT02292082 (11) [back to overview]	NRS Pain Score With Movement POD2
NCT02292082 (11) [back to overview]	Numerical Rating Scale (NRS) Pain Scores With Ambulation Postoperative Day 1
NCT02292082 (11) [back to overview]	Opioid Consumption POD2
NCT02292082 (11) [back to overview]	Opioid Consumption Postoperative Day (POD) 1
NCT02292082 (11) [back to overview]	Patient Outcome Questionnaire (painOUT) Least Pain for 0-24 Hours Postoperatively
NCT02292082 (11) [back to overview]	Patient Outcome Questionnaire (painOUT) Least Pain for 24-48 Hours Postoperatively
NCT02292082 (11) [back to overview]	Hospital Length of Stay
NCT02292082 (11) [back to overview]	Knee Society Score (KSS) at 6 Weeks Postoperatively
NCT02292082 (11) [back to overview]	Patient Outcome Questionnaire (painOUT) Most Pain for 24-48 Hours Postoperatively
NCT02292082 (11) [back to overview]	Patient Outcome Questionnaire (painOUT) Most Pain for 0-24 Hours Postoperatively
NCT02296346 (1) [back to overview]	Multiple Sclerosis Functional Composite (MSFC) Z-score and Expanded Disability Status Scale (EDSS)
NCT02392286 (6) [back to overview]	Number of Participants With Response or Remission at End of 4 Weeks
NCT02392286 (6) [back to overview]	Number of Participants With Response or Remission at End of 12 Weeks
NCT02392286 (6) [back to overview]	Number of Participants With Response or Remission at End of 1 Week
NCT02392286 (6) [back to overview]	Number of Participants With Response at End of 2 Weeks
NCT02392286 (6) [back to overview]	Number of Participants With Corticosteroid-associated Side Effects
NCT02392286 (6) [back to overview]	Number of Participants in Remission at End of 2 Weeks
NCT02406209 (1) [back to overview]	Anterior Chamber Cell Grade at Week 8
NCT02464657 (4) [back to overview]	Relapse Free Survival
NCT02464657 (4) [back to overview]	Overall Survival
NCT02464657 (4) [back to overview]	Maximum Tolerated Dose (MTD) of Nivolumab
NCT02464657 (4) [back to overview]	Event-Free Survival (EFS)
NCT02495077 (44) [back to overview]	Change in eGFR Between 6 Months and 24 Months as Measured by CKD-EPI
NCT02495077 (44) [back to overview]	Change in eGFR Between 6 Months and 24 Months as Measured by MDRD
NCT02495077 (44) [back to overview]	Change in eGFR Between Post-transplant Nadir and 24 Months as Measured by CKD-EPI
NCT02495077 (44) [back to overview]	Percent of Participants With de Novo DSA.
NCT02495077 (44) [back to overview]	Percent of Participants With Death or Graft Failure.
NCT02495077 (44) [back to overview]	Percent of Participants With Impaired Wound Healing Manifested by Wound Dehiscence, Wound Infection, or Hernia at the Site of the Transplant Incision
NCT02495077 (44) [back to overview]	Percent of Participants With Locally Treated Rejection, Defined as Treatment Administered for Rejection Based on Clinical Signs or Biopsy Findings.
NCT02495077 (44) [back to overview]	Percent of Participants With Locally Treated Rejection, Defined as Treatment Administered for Rejection Based on Clinical Signs or Biopsy Findings.
NCT02495077 (44) [back to overview]	Percent of Participants With Malignancy.
NCT02495077 (44) [back to overview]	Percent of Participants With Mycobacterial or Fungal Infections
NCT02495077 (44) [back to overview]	Percent of Participants With Only Graft Failure.
NCT02495077 (44) [back to overview]	Percent of Participants With Primary Non-Function (PNF), Defined as Dialysis-dependency for More Than 3 Months.
NCT02495077 (44) [back to overview]	The Difference Between the Mean eGFR (Modified MDRD) in the Experimental vs. Control Groups.
NCT02495077 (44) [back to overview]	The Percent of Participants Who Need Dialysis After Week 1.
NCT02495077 (44) [back to overview]	The Percent of Participants Whose Day 2 Serum CRR Was Less Than 30%.
NCT02495077 (44) [back to overview]	The Percent of Participants Whose Day 5 Serum CRR Was Less Than 70%.
NCT02495077 (44) [back to overview]	The Percent of Participants With a Serum Creatinine of More Than 3 mg/dL.
NCT02495077 (44) [back to overview]	Change From Baseline (Immediately After Surgery) in Serum Creatinine.
NCT02495077 (44) [back to overview]	eGFR Values as Measured by CKD-EPI
NCT02495077 (44) [back to overview]	eGFR Values as Measured by MDRD
NCT02495077 (44) [back to overview]	Duration of Delayed Graft Function (DGF), Defined as Time From Transplantation to the Last Required Dialysis Treatment.
NCT02495077 (44) [back to overview]	Days From Transplantation Until Event (ACR, AMR, or Hospitalization for Infection and/or Malignancy)
NCT02495077 (44) [back to overview]	Creatinine Reduction Ratio (CRR), Defined as the First Creatinine on Day 5 Divided by the First Creatinine After Surgery.
NCT02495077 (44) [back to overview]	Creatinine Reduction Ratio (CRR), Defined as the First Creatinine on Day 2 Divided by he First Creatinine After Surgery
NCT02495077 (44) [back to overview]	Change in eGFR Between Post-transplant Nadir and 24 Months as Measured by MDRD
NCT02495077 (44) [back to overview]	BANFF Grades of First AMR.
NCT02495077 (44) [back to overview]	Number of Dialysis Sessions.
NCT02495077 (44) [back to overview]	Percent of Participants That Required at Least One Dialysis Treatment.
NCT02495077 (44) [back to overview]	Percent of Participants With Any Infection Requiring Hospitalization or Resulting in Death.
NCT02495077 (44) [back to overview]	eGFR Values as Measured by MDRD
NCT02495077 (44) [back to overview]	Percent of Participants With BANFF Chronicity Scores > or Equal 2 on the 24 Month Biopsy.
NCT02495077 (44) [back to overview]	Percent of Participants With Biopsy Proven Acute Antibody Mediated Rejection (AMR)
NCT02495077 (44) [back to overview]	Percent of Participants With Biopsy Proven Acute Antibody Mediated Rejection (AMR).
NCT02495077 (44) [back to overview]	Percent of Participants With Biopsy Proven Acute Antibody Mediated Rejection AMR or Suspicious for AMR
NCT02495077 (44) [back to overview]	Percent of Participants With Biopsy Proven Acute Antibody Mediated Rejection AMR or Suspicious for AMR.
NCT02495077 (44) [back to overview]	Percent of Participants With Biopsy Proven Acute Cellular Rejection (BPAR)
NCT02495077 (44) [back to overview]	Percent of Participants With Biopsy Proven Acute Cellular Rejection (BPAR) or Borderline Rejection
NCT02495077 (44) [back to overview]	Percent of Participants With Biopsy Proven Acute Cellular Rejection (BPAR) or Borderline Rejection.
NCT02495077 (44) [back to overview]	Percent of Participants With Biopsy Proven Acute Cellular Rejection (BPAR).
NCT02495077 (44) [back to overview]	Percent of Participants With BK Viremia That Require a Change in Immunosuppression or Anti-viral Treatment as Per Standard of Care at the Site.
NCT02495077 (44) [back to overview]	Percent of Participants With CMV Viremia That Require a Change in Immunosuppression or Anti-viral Treatment as Per Standard of Care at the Site
NCT02495077 (44) [back to overview]	Change in eGFR Between 3 Months and 24 Months as Measured by CKD-EPI
NCT02495077 (44) [back to overview]	Change in eGFR Between 3 Months and 24 Months as Measured by MDRD
NCT02495077 (44) [back to overview]	eGFR Values as Measured by CKD-EPI
NCT02515045 (3) [back to overview]	Change From Baseline (Preoperative Exam) in Macular Thickness
NCT02515045 (3) [back to overview]	Change From Baseline (Preoperative Exam) in Intraocular Pressure (IOP)
NCT02515045 (3) [back to overview]	Change From Baseline (Preoperative Exam) in Pachymetry (Corneal Thickness)
NCT02539394 (19) [back to overview]	Patients' Bazaz Dysphagia Score - Liquid
NCT02539394 (19) [back to overview]	Patients' Pain Scores on the Visual Analog Scale - Right Arm Pain
NCT02539394 (19) [back to overview]	Patients' Pain Scores on the Visual Analog Scale - Neck Pain
NCT02539394 (19) [back to overview]	Patients' Pain Scores on the Visual Analog Scale - Left Arm Pain
NCT02539394 (19) [back to overview]	Patients' Neck Disability
NCT02539394 (19) [back to overview]	Patient Reported Swallowing Difficulty Over 1 Year
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Social)
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Sleep)
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Mental)
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Food Selection)
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Fear Swallow)
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Fatigue)
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Eating Duration)
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Communication)
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Burden)
NCT02539394 (19) [back to overview]	Adverse Event
NCT02539394 (19) [back to overview]	Fusion Rate
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Eating Desire)
NCT02539394 (19) [back to overview]	Patients' Bazaz Dysphagia Score - Solid
NCT02550652 (22) [back to overview]	Terminal Plasma Half-Life (t1/2) of Obinutuzumab
NCT02550652 (22) [back to overview]	Systemic Clearance of Obinutuzumab
NCT02550652 (22) [back to overview]	Percentage of Participants With First Protocol Defined Overall Response Over the Course of 52 Weeks
NCT02550652 (22) [back to overview]	Percentage of Participants With First Protocol Defined CRR Over the Course of 52 Weeks
NCT02550652 (22) [back to overview]	Percentage of Participants With Anti-Drug Antibody (ADA) to Obinutuzumab
NCT02550652 (22) [back to overview]	Percentage of Participants Who Achieve Protocol Defined Third mCRR (mCRR3) at Week 52
NCT02550652 (22) [back to overview]	Percentage of Participants With Adverse Events of Special Interest: Infusion Related Reactions, Grade 3 or Higher Infections, Drug-related Neutropenia and Drug-related Thrombocytopenia
NCT02550652 (22) [back to overview]	Percentage of Participants Who Achieve Protocol Defined Second mCRR (mCRR2) at Week 52
NCT02550652 (22) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Obinutuzumab
NCT02550652 (22) [back to overview]	Percentage of Participants Who Achieve Protocol Defined Partial Renal Response (PRR) at Week 52
NCT02550652 (22) [back to overview]	Percentage of Participants Who Achieve Protocol Defined Overall Response (OR) at Week 52
NCT02550652 (22) [back to overview]	Change From Baseline of Participant's Global Assessment of Disease Activity Visual Analog Scale (VAS) Score
NCT02550652 (22) [back to overview]	Area Under the Plasma Concentration Versus Time Curve (AUC) of Obinutuzumab
NCT02550652 (22) [back to overview]	Volume of Distribution Under Steady State (Vss) of Obinutuzumab
NCT02550652 (22) [back to overview]	Percentage of Participants Who Achieve Protocol Defined Modified CRR (mCRR1) at Week 52
NCT02550652 (22) [back to overview]	Percentage of Participants Who Achieve Protocol Defined Complete Renal Response (CRR) at Week 52
NCT02550652 (22) [back to overview]	Change From Baseline in Complement Component 3 (C3) Levels at Week 52
NCT02550652 (22) [back to overview]	Change From Baseline in C4 Levels at Week 52
NCT02550652 (22) [back to overview]	Change From Baseline in Anti-Double Stranded Deoxyribonucleic Acid (Anti-dsDNA) Antibody Levels at Week 52
NCT02550652 (22) [back to overview]	Percentage of Participants Who Achieve Protocol Defined CRR at Week 24
NCT02550652 (22) [back to overview]	Percentage of Participants With Adverse Events (AEs)
NCT02550652 (22) [back to overview]	Percent Change From Baseline in Circulating CD19-Positive B-Cell Levels
NCT02569437 (5) [back to overview]	Visual Analog Scale
NCT02569437 (5) [back to overview]	Subjective Symptom Composite Scoring
NCT02569437 (5) [back to overview]	Sino-nasal Outcome Test (SNOT 22)
NCT02569437 (5) [back to overview]	Middle Meatus Culture
NCT02569437 (5) [back to overview]	Endoscopic Nasal Polyp Score
NCT02576249 (3) [back to overview]	The Knee Osteoarthritis Outcome Score (KOOS) Pain Subscale
NCT02576249 (3) [back to overview]	Pain Scale Score
NCT02576249 (3) [back to overview]	Tegner Activity Level Scale
NCT02652390 (6) [back to overview]	11-item Disabilities of the Arm, Shoulder and Hand (DASH) Score
NCT02652390 (6) [back to overview]	Bodily Pain Score
NCT02652390 (6) [back to overview]	Number of Patients Who Have Had Carpal Tunnel Release Surgery on the Study Hand
NCT02652390 (6) [back to overview]	Satisfaction Score
NCT02652390 (6) [back to overview]	Palmar Pain Score
NCT02652390 (6) [back to overview]	Symptom Severity Score
NCT02790788 (22) [back to overview]	Left and Right Ventricular Diastolic Area (cm^2) by Echocardiography.
NCT02790788 (22) [back to overview]	Early Postresuscitation Cardiac Output (L/Min) Measured by Either Pulse Index Continuous Cardiac Output (PiCCO) or a Continuous Cardiac Output (CCO) Thermodilution Pulmonary Artery Catheter.
NCT02790788 (22) [back to overview]	Early Postresuscitation Cardiac Output (L/Min) Measured by Either Pulse Index Continuous Cardiac Output (PiCCO) or a Continuous Cardiac Output (CCO) Thermodilution Pulmonary Artery Catheter.
NCT02790788 (22) [back to overview]	Early Postresuscitation Cardiac Output (L/Min) Measured by Either Pulse Index Continuous Cardiac Output (PiCCO) or a Continuous Cardiac Output (CCO) Thermodilution Pulmonary Artery Catheter.
NCT02790788 (22) [back to overview]	Early Postresuscitation Arterial Blood Pressure (mmHg) Measured Through Institution of Invasive Intra-arterial Pressure Monitoring.
NCT02790788 (22) [back to overview]	Early Postresuscitation Arterial Blood Pressure (mmHg) Measured Through Institution of Invasive Intra-arterial Pressure Monitoring.
NCT02790788 (22) [back to overview]	Early Postresuscitation Arterial Blood Pressure (mmHg) Measured Through Institution of Invasive Intra-arterial Pressure Monitoring.
NCT02790788 (22) [back to overview]	Early Postresuscitation Arterial Blood Pressure (mmHg) Measured Through Institution of Invasive Intra-arterial Pressure Monitoring (as Feasible).
NCT02790788 (22) [back to overview]	Early Postresuscitation Arterial Blood Pressure (mmHg) Measured Through Institution of Invasive Intra-arterial Pressure Monitoring (as Feasible).
NCT02790788 (22) [back to overview]	Steroid-associated Complications.
NCT02790788 (22) [back to overview]	Left and Right Ventricular Ejection Fraction (%) by Echocardiography.
NCT02790788 (22) [back to overview]	Eccentricity Index by Echocardiography.
NCT02790788 (22) [back to overview]	Early Postresuscitation Inflammatory Response as Assessed by Serum Cytokine Levels (pg/mL).
NCT02790788 (22) [back to overview]	Core Body Temperature in Degrees Celcius.
NCT02790788 (22) [back to overview]	Cerebral Blood Flow Index by Near Infrared Spectroscopy With Indocyanine Green.
NCT02790788 (22) [back to overview]	Survival to Hospital Discharge With Favorable Functional Outcome.
NCT02790788 (22) [back to overview]	Organ Failure-free Days.
NCT02790788 (22) [back to overview]	Early Postresuscitation Central Venous Oxygen Saturation (%) Measured in Blood Samples Obtained Through a Central Venous Catheter Port.
NCT02790788 (22) [back to overview]	Early Postresuscitation Central Venous Oxygen Saturation (%) Measured in Blood Samples Obtained Through a Central Venous Catheter Port.
NCT02790788 (22) [back to overview]	Early Postresuscitation Central Venous Oxygen Saturation (%) Measured in Blood Samples Obtained Through a Central Venous Catheter Port.
NCT02790788 (22) [back to overview]	Early Postresuscitation Central Venous Oxygen Saturation (%) Measured in Blood Samples Obtained Through a Central Venous Catheter Port (as Feasible).
NCT02790788 (22) [back to overview]	Early Postresuscitation Cardiac Output (L/Min) Measured by Either Pulse Index Continuous Cardiac Output (PiCCO) or a Continuous Cardiac Output (CCO) Thermodilution Pulmonary Artery Catheter.
NCT02798523 (1) [back to overview]	Number of Participants Sampled for RNA-seq Differential Expression Analysis (Biological Replicates)
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to First Course of Azacitidine
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of Second Course of Azacitidine
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of First Course of Azacitidine
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to Second Course of Azacitidine
NCT02828358 (5) [back to overview]	Tolerability of Azacitidine in Combination With Interfant-06 Standard Chemotherapy in Evaluable Infant Patients With Newly Diagnosed ALL With KMT2A Gene Rearrangement (KMT2A-R). KMT2A Gene Rearrangement (KMT2A-R)
NCT02847494 (3) [back to overview]	Medication Preference as Assessed by Self-report
NCT02847494 (3) [back to overview]	Number of Participants With Sustained Headache Freedom
NCT02847494 (3) [back to overview]	Headache Days as Self-reported by Participants
NCT02953678 (10) [back to overview]	Failure-free Survival (FFS)
NCT02953678 (10) [back to overview]	Relapse-related Mortality Rate
NCT02953678 (10) [back to overview]	Percentage of Participants With Six-month Duration of Response (DOR)
NCT02953678 (10) [back to overview]	Overall Survival (OS)
NCT02953678 (10) [back to overview]	Percentage of Participants With Three-month DOR
NCT02953678 (10) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAES), Serious TEAEs, And Grade 3 or Higher TEAEs
NCT02953678 (10) [back to overview]	Relapse Rate
NCT02953678 (10) [back to overview]	Overall Response Rate (ORR) at Day 28
NCT02953678 (10) [back to overview]	Overall Response Rate (ORR)
NCT02953678 (10) [back to overview]	Nonrelapse Mortality (NRM)
NCT02953873 (5) [back to overview]	Dose Modifications
NCT02953873 (5) [back to overview]	Number of Days to Reach Therapeutic Trough Goal
NCT02953873 (5) [back to overview]	Dose-normalized Trough
NCT02953873 (5) [back to overview]	Total Daily Dose
NCT02953873 (5) [back to overview]	Weight-Based Dose Requirement
NCT02954198 (4) [back to overview]	Self-reported Medication Adherence From Baseline to 6 Months.
NCT02954198 (4) [back to overview]	Percent of Participants Who Experienced Kidney Transplant Graft Loss
NCT02954198 (4) [back to overview]	Percent of Participants Experiencing Acute Allograft Rejection
NCT02954198 (4) [back to overview]	Subject Specific Change on Medication Side Effect Scale
NCT02956122 (22) [back to overview]	Failure-free Survival - Percentage of Participants With an Event
NCT02956122 (22) [back to overview]	Graft-versus-host Disease (GvHD)-Free Survival - Percentage of Participants With an Event
NCT02956122 (22) [back to overview]	Percentage of Participants Achieving Overall Response (OR) At Day 28
NCT02956122 (22) [back to overview]	Number of Participants With Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs and Temporally-associated AEs
NCT02956122 (22) [back to overview]	Infection-related Mortality - Percentage of Participants With an Event
NCT02956122 (22) [back to overview]	Incidence of Chronic Graft-versus-host Disease (GvHD)
NCT02956122 (22) [back to overview]	Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments
NCT02956122 (22) [back to overview]	"Area Under the Plasma Concentration Curve From Time Zero to Time t AUC(0-t) of GLASSIA"
NCT02956122 (22) [back to overview]	Apparent Terminal Half-life (t1/2) of GLASSIA
NCT02956122 (22) [back to overview]	Apparent Volume of Distribution at Steady State (Vss) of GLASSIA
NCT02956122 (22) [back to overview]	Number of Participants With Clinically Significant Changes in Vital Signs
NCT02956122 (22) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of GLASSIA
NCT02956122 (22) [back to overview]	Number of Participants With Recurrence of Primary Malignancies
NCT02956122 (22) [back to overview]	Acute Graft-versus-host Disease (GvHD) Grading at Days 28, 56 and 180
NCT02956122 (22) [back to overview]	Transplant-related Mortality
NCT02956122 (22) [back to overview]	Overall Survival (OS) - Percentage of Participants With an Event
NCT02956122 (22) [back to overview]	Area Under the Plasma Concentration Curve (AUC0-inf) From Time Zero to Infinity
NCT02956122 (22) [back to overview]	Graft-versus-host Disease (GvHD)-Related Mortality - Percentage of Participants With an Event
NCT02956122 (22) [back to overview]	Percentage of Participants Achieving Overall Response at Day 56
NCT02956122 (22) [back to overview]	Systemic Clearance at Steady State (CLss) of GLASSIA
NCT02956122 (22) [back to overview]	All-cause Mortality - Percentage of Participants With an Event
NCT02956122 (22) [back to overview]	Percentage of Participants Achieving Gastrointestinal (GI) Response at Day 28
NCT02962284 (6) [back to overview]	Prostate Specific Antigen Levels
NCT02962284 (6) [back to overview]	Testosterone Complete Suppression
NCT02962284 (6) [back to overview]	Percentage of Subjects With Prostate Specific Antigen - 50 Response
NCT02962284 (6) [back to overview]	Number of Subjects With Adverse Events
NCT02962284 (6) [back to overview]	Testosterone Levels
NCT02962284 (6) [back to overview]	Proportion of Subjects With Disease Progression
NCT03123614 (4) [back to overview]	Best Corrected Visual Acuity at 3 Months
NCT03123614 (4) [back to overview]	Number of Eyes With Corneal Haze
NCT03123614 (4) [back to overview]	Uncorrected Visual Acuity
NCT03123614 (4) [back to overview]	Change in Intraocular Pressure (IOP) From Baseline Through Month 3
NCT03139604 (20) [back to overview]	Cmin of Itacitinib When Administered in Combination With Corticosteroids
NCT03139604 (20) [back to overview]	Duration of Response
NCT03139604 (20) [back to overview]	Failure-free Survival
NCT03139604 (20) [back to overview]	Incidence Rate of aGVHD Flares
NCT03139604 (20) [back to overview]	Incidence Rate of Secondary Graft Failure
NCT03139604 (20) [back to overview]	Malignancy Relapse-related Mortality Rate
NCT03139604 (20) [back to overview]	Number of Treatment-emergent Adverse Events With INCB39110
NCT03139604 (20) [back to overview]	Overall Response Rate Based on Center for International Blood and Marrow Transplant Research (CIBMTR) Response Index
NCT03139604 (20) [back to overview]	AUC of Itacitinib When Administered in Combination With Corticosteroids
NCT03139604 (20) [back to overview]	CL/F of Itacitinib When Administered in Combination With Corticosteroids
NCT03139604 (20) [back to overview]	Nonrelapse Mortality
NCT03139604 (20) [back to overview]	Proportion of Subjects Who Discontinue Immunosuppressive Medications
NCT03139604 (20) [back to overview]	Proportion of Subjects Who Discontinue Corticosteroids
NCT03139604 (20) [back to overview]	Objective Response Rate
NCT03139604 (20) [back to overview]	Cmax of Itacitinib When Administered in Combination With Corticosteroids
NCT03139604 (20) [back to overview]	Incidence Rate of cGVHD
NCT03139604 (20) [back to overview]	Tmax of Itacitinib When Administered in Combination With Corticosteroids
NCT03139604 (20) [back to overview]	Time to Response
NCT03139604 (20) [back to overview]	Relapse Rate of Malignant and Nonmalignant Hematologic Disease
NCT03139604 (20) [back to overview]	Overall Survival (OS)
NCT03229538 (7) [back to overview]	Number of Participants With a Post-operative Length of Stay Greater Than 90 Days
NCT03229538 (7) [back to overview]	Number of Participants With Any Other Post-operative Complications From the Start of Study Drug Administration Until Hospital Discharge.
NCT03229538 (7) [back to overview]	Number of Participants With Death or Major Complication as Defined by an Outcome in One of the 7 Highest Global Ranking Categories
NCT03229538 (7) [back to overview]	Number of Participants With Mortality, Including In-hospital Mortality or Mortality After Hospital Discharge But Within 30 Days of the Last Dose of Study Drug
NCT03229538 (7) [back to overview]	Number of Participants With Occurrence of Any One or More of the Following STS-CHSD-defined Major Post-operative Infectious Complications: Postprocedural Infective Endocarditis, Pneumonia, Sepsis, Deep Wound Infection, Mediastinitis.
NCT03229538 (7) [back to overview]	Number of Participants With Post-operative Low Cardiac Output Syndrome
NCT03229538 (7) [back to overview]	Number of Participants With Prolonged Mechanical Ventilation (Greater Than 7 Days)
NCT03232749 (3) [back to overview]	ASES Scores at Each Time Point
NCT03232749 (3) [back to overview]	SST (Simple Shoulder Test) Scores at Each Time Point
NCT03232749 (3) [back to overview]	Visual Analog Scale Scores at Each Time Point.
NCT03320434 (4) [back to overview]	Conjunctival Redness at 7, 15, and 20 Minutes Post CAC on Day 15
NCT03320434 (4) [back to overview]	Conjunctival Redness at 7, 15, and 20 Minutes Post CAC on Day 1
NCT03320434 (4) [back to overview]	Ocular Itching at 5, 7, and 10 Minutes Post CAC on Day 15
NCT03320434 (4) [back to overview]	Ocular Itching at 5, 7, and 10 Minutes Post CAC on Day 1
NCT03368664 (3) [back to overview]	Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Months 4 and 8
NCT03368664 (3) [back to overview]	Brain Magnetic Resonance Imaging (MRI) Assessment: Number of Participants With New or Enlarged T2 Lesions Per MRI Scan
NCT03368664 (3) [back to overview]	Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New or Enlarged T2 Lesions Per MRI Scan
NCT03387046 (16) [back to overview]	Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 12 and 24
NCT03387046 (16) [back to overview]	Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24
NCT03387046 (16) [back to overview]	25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
NCT03387046 (16) [back to overview]	Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 8
NCT03387046 (16) [back to overview]	Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
NCT03387046 (16) [back to overview]	Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24
NCT03387046 (16) [back to overview]	Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
NCT03387046 (16) [back to overview]	Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
NCT03387046 (16) [back to overview]	Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS)
NCT03387046 (16) [back to overview]	Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS)
NCT03387046 (16) [back to overview]	Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24
NCT03387046 (16) [back to overview]	Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24
NCT03387046 (16) [back to overview]	9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
NCT03387046 (16) [back to overview]	9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
NCT03387046 (16) [back to overview]	25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
NCT03387046 (16) [back to overview]	Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
NCT03388008 (1) [back to overview]	Donor-specific HLA Antibodies, Re-transplantation, or Death
NCT03403517 (5) [back to overview]	PACU Stay
NCT03403517 (5) [back to overview]	Total Complication Rate
NCT03403517 (5) [back to overview]	Mortality
NCT03403517 (5) [back to overview]	Complications, Post-anesthesia Care Unit (PACU)
NCT03403517 (5) [back to overview]	Hospital Stay
NCT03578276 (3) [back to overview]	Change From Baseline (Preoperative Exam) in Macular Thickness
NCT03578276 (3) [back to overview]	Change From Baseline (Preoperative Exam) in Pachymetry (Corneal Thickness)
NCT03578276 (3) [back to overview]	Change From Baseline (Preoperative Exam) in Intraocular Pressure (IOP)
NCT03593902 (2) [back to overview]	Survival of Treatment
NCT03593902 (2) [back to overview]	Change in Skin Score by mRSS
NCT03640949 (3) [back to overview]	Number of Participants With a Favorable Neurological Outcome at 30 Days
NCT03640949 (3) [back to overview]	Number of Participants That Survived 30 Days
NCT03640949 (3) [back to overview]	Number of Participants With Return of Spontaneous Circulation
NCT03704584 (3) [back to overview]	Visual Analog Pain Scale (VAS-pain) Daily Until Post-injection Day 7
NCT03704584 (3) [back to overview]	Number of Patients With Subsequent Reinjection and Surgical Operation
NCT03704584 (3) [back to overview]	10 Point Likert Scale of Pain Scores Before the Injection and After the Injection and During Follow up in the Corticosteroid Plus Lidocaine Group as Compared to the Corticosteroid Alone Group
NCT03721965 (1) [back to overview]	Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT03797872 (1) [back to overview]	Number of Participants Who Are Eligible, Consent, and Complete the 48 Weeks Study
NCT03817853 (8) [back to overview]	Percentage of IRRs Regardless of Grade by Cycle
NCT03817853 (8) [back to overview]	Percentage of Grade >=3 Infusion-Related Reactions (IRRs) During Cycle 2 in Patients Who Had Previously Received Obinutuzumab at the Standard Infusion Rate During Cycle 1 Without Experiencing a Grade 3 or 4 IRR
NCT03817853 (8) [back to overview]	Duration of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle
NCT03817853 (8) [back to overview]	Objective Response Rate (ORR) at the End of Induction (EOI) Therapy
NCT03817853 (8) [back to overview]	Duration (In Minutes) of Obinutuzumab Administration by Cycle
NCT03817853 (8) [back to overview]	Time to IRR From Infusion to Onset of the IRR During Cycle 2
NCT03817853 (8) [back to overview]	Percentage of Participants With Adverse Events (AEs)
NCT03817853 (8) [back to overview]	Type of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle
NCT03818737 (6) [back to overview]	Change in EuroQuality of Life (EQ-5D-3L) Index Score
NCT03818737 (6) [back to overview]	Patient-Reported Outcomes Measurement Information System (PROMIS-29) Score
NCT03818737 (6) [back to overview]	Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Pain Subscale Score
NCT03818737 (6) [back to overview]	Overall MRI Grade of Osteoarthritis
NCT03818737 (6) [back to overview]	Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Total Score
NCT03818737 (6) [back to overview]	Change in Visual Analog Pain Scale (VAS-pain) Score
NCT03852537 (14) [back to overview]	Cardiovascular Dysfunction
NCT03852537 (14) [back to overview]	ICU Admission
NCT03852537 (14) [back to overview]	Mortality
NCT03852537 (14) [back to overview]	Organ Failure
NCT03852537 (14) [back to overview]	Timely Initiation of Corticosteroids and Implementation of Biomarker-titrated Corticosteroid Dosing
NCT03852537 (14) [back to overview]	Need for Invasive Mechanical Ventilation
NCT03852537 (14) [back to overview]	Occurrence of Delirium
NCT03852537 (14) [back to overview]	Oxygen-free Days
NCT03852537 (14) [back to overview]	Occurrence of Secondary Infection
NCT03852537 (14) [back to overview]	Occurrence of Hyperglycemia
NCT03852537 (14) [back to overview]	New Onset Cardiac Arrhythmias
NCT03852537 (14) [back to overview]	Need for Noninvasive Mechanical Ventilation
NCT03852537 (14) [back to overview]	Need for High Flow Nasal Cannula Oxygen
NCT03852537 (14) [back to overview]	Myocardial Injury
NCT03994731 (6) [back to overview]	Percentage of sUA (sUA < 6 mg/dL) Responders During Month 12
NCT03994731 (6) [back to overview]	Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6
NCT03994731 (6) [back to overview]	Percentage of Participants With Complete Resolution of ≥ 1 Tophi at Week 52
NCT03994731 (6) [back to overview]	Mean Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52
NCT03994731 (6) [back to overview]	Mean Change From Baseline in HAQ Health Score at Week 52
NCT03994731 (6) [back to overview]	Mean Change From Baseline HAQ Pain Score at Week 52
NCT04046549 (7) [back to overview]	Percentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR) of Grade 1A or Higher, Graft Loss or Death at Week 24
NCT04046549 (7) [back to overview]	Percentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR), Graft Loss, Death or Loss to Follow-up (LTFU)
NCT04046549 (7) [back to overview]	Percentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR) of Grade 1A or Higher, Graft Loss or Death at Weeks 12 and 48
NCT04046549 (7) [back to overview]	Percentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR)
NCT04046549 (7) [back to overview]	Percentage of Participants With Treated Acute Rejections
NCT04046549 (7) [back to overview]	Percentage of Participants With Biopsy Proven Acute Rejection (BPAR)
NCT04046549 (7) [back to overview]	Percentage of Participants With Antibody-Mediated Rejection
NCT04184999 (1) [back to overview]	Evaluation of Intraoperative Use of Dexycu on Tear Film Osmolarity at 3 Weeks Postoperatively
NCT04233164 (1) [back to overview]	Number of SLE Patients That Were Sampled for RNA-seq Differential Expression Analysis (Biological Replicates)
NCT04294459 (23) [back to overview]	Duration for Achieving Target cPRA
NCT04294459 (23) [back to overview]	Duration of Response (DOR)
NCT04294459 (23) [back to overview]	Number of Kidney Transplant Offers
NCT04294459 (23) [back to overview]	Number of Participants Achieving Target cPRA
NCT04294459 (23) [back to overview]	Number of Participants With Graft Survival at 6 Months Post-Transplant
NCT04294459 (23) [back to overview]	Pharmacokinetics (PK) Parameters: Concentration Observed at the End of First Intravenous Infusion (Ceoi) of Isatuximab
NCT04294459 (23) [back to overview]	PK Parameters: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 168 Hours Over the Dosing Interval (AUC0-168 Hours) After First Infusion of Isatuximab
NCT04294459 (23) [back to overview]	PK Parameters: Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Isatuximab
NCT04294459 (23) [back to overview]	PK Parameters: Maximum Concentration Observed (Cmax) After the First Infusion of Isatuximab
NCT04294459 (23) [back to overview]	PK Parameters: Time of Clast (Tlast) After First Infusion of Isatuximab
NCT04294459 (23) [back to overview]	PK Parameters: Time Taken to Reach Cmax (Tmax) After the First Infusion of Isatuximab
NCT04294459 (23) [back to overview]	PK Parameters: Trough Plasma Concentrations (Ctrough) of Isatuximab
NCT04294459 (23) [back to overview]	Time to First Transplant Offer
NCT04294459 (23) [back to overview]	Time to Transplant
NCT04294459 (23) [back to overview]	Number of Participants With Abnormal Electrolytes Parameters
NCT04294459 (23) [back to overview]	Number of Participants With Abnormal Metabolism Parameters
NCT04294459 (23) [back to overview]	Number of Participants With Anti-drug Antibodies (ADA) Against Isatuximab
NCT04294459 (23) [back to overview]	Number of Participants With Anti-Human Leukocyte Antigen (HLA)-Antibody Reduction
NCT04294459 (23) [back to overview]	Number of Participants With Hematological Abnormalities
NCT04294459 (23) [back to overview]	Number of Participants With Liver Function Abnormalities
NCT04294459 (23) [back to overview]	Number of Participants With Renal Function Abnormalities
NCT04294459 (23) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)
NCT04294459 (23) [back to overview]	Percentage of Participants With Response
NCT04323592 (6) [back to overview]	Admission to Intensive Care Unit (ICU)
NCT04323592 (6) [back to overview]	Change in C-reactive Protein (CRP)
NCT04323592 (6) [back to overview]	Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28
NCT04323592 (6) [back to overview]	Endotracheal Intubation (Invasive Mechanical Ventilation)
NCT04323592 (6) [back to overview]	In-hospital Death Within 28 Days
NCT04323592 (6) [back to overview]	Number of Days Free From Mechanical Ventilation
NCT04380857 (5) [back to overview]	Patient Preference Between Groups
NCT04380857 (5) [back to overview]	Mean Change in Pain
NCT04380857 (5) [back to overview]	Loss of Lines in Uncorrected Visual Acuity
NCT04380857 (5) [back to overview]	Post op Pain Management Per Eye
NCT04380857 (5) [back to overview]	Number of Lines Lost From Best Corrected Visual Acuity
NCT04900220 (2) [back to overview]	Intensity of Pain
NCT04900220 (2) [back to overview]	Incidence of Pain
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Post Treatment Pain Scores
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Post Treatment Pain Scores (6 Weeks)
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Pre Treatment Pain Scores Using Knee Society Scores
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee 6 Weeks After Treatment
NCT05113901 (18) [back to overview]	Number of Participants With Complications Following Treatment
NCT05113901 (18) [back to overview]	Adverse Events or Outcomes Outside of Manipulations Under Anesthesia
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee 6 Weeks After Treatment
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee 6 Weeks After Treatment
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee 6 Wks After Treatment
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee After Surgery and Treatment
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee After Surgery and Treatment
NCT05113901 (18) [back to overview]	Range of Motion in Degrees at Pre and Post Treatment
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee Before Treatment
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee Prior to Treatment
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee Prior to Treatment
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Post Treatment Pain Scores
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures:(Immediate) Post Treatment Pain Scores
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee Before Treatment
NCT05438277 (1) [back to overview]	Incidence of a Flare Reaction

Progression-free Survival

time to disease progression or death due to any cause (NCT00003270)
Timeframe: 1 year

Intervention	% of participants (Number)
Arm 1	50

Intervention	participants (Number)
	Hematocrit-high (n=210, 203)	Hematocrit-low (n=210, 203)	Hemoglobin-high (n=210, 204)	Hemoglobin-low (n=210, 204)	Platelets-high (n=210, 203)	Platelets-low (n=210, 203)	RBC-high (n=209, 203)	RBC-low (n=209, 203)	Basophils-high (n=199, 195)	Eosinophils-high (n=199, 195)	Lymphocytes-high (n=199, 198)	Lymphocytes-low (n=199, 198)	Monocytes-high (n=199, 198)	Monocytes-low (n=199, 198)	Neutrophils-low (n= 199, 198)	WBC-high (n=207, 201)	WBC-low (n=207, 201)
Daclizumab	0	116	0	107	2	30	1	116	4	0	2	157	5	14	33	61	43
Placebo	0	117	0	112	1	22	2	106	4	0	2	157	6	20	33	57	29

Intervention	mg/dL (Median)
	Total cholesterol, change at 3 months (n=119,119)	Total cholesterol, change at 6 months (n=126,130)	LDL, Change at 3 months (n=92,89)	LDL, Change at 6 months (n=91,99)	HDL, change at 3 months (n=97, 101)	HDL, change at 6 months (n=102,112)	Triglycerides,change at 3 months (n=104,108)	Triglycerides,change at 6 months (n=109,117)	LDL/HDL ratio,change at 3 months (n=91,89)	LDL/HDL ratio,change at 6 months (n=91, 99)
Daclizumab	0.65	0.28	0.25	0.03	0.34	0.23	0.26	0.20	-0.44	-0.50
Placebo	0.91	0.61	0.34	0.21	0.31	0.20	0.46	0.44	-0.12	-0.14

Intervention	days (Median)
	Within 6 months (n= 77, 104)	Within 12 months (n=97, 116)
Daclizumab	61	96
Placebo	21	26

Intervention	participants (Number)
	Within 6 months, 0 episode	Within 6 months, 1 episode	Within 6 months, 2 episodes	Within 6 months, 3 episodes	Within 6 months, 4 episodes	Within 12 months, 0 episode	Within 12 months, 1 episode	Within 12 months, 2 episodes	Within 12 months, 3 episodes	Within 12 months, 4 episodes
Daclizumab	139	63	12	2	0	119	68	23	3	3
Placebo	114	82	19	2	1	102	90	19	5	2

Intervention	participants (Number)
	Within 6 months	Within 12 months	Within 3 years
Daclizumab	16	21	NA
Placebo	10	12	NA

Intervention	participants (Number)
	Any AEs	Any SAE's	Any AEs leading to premature discontinuation
Daclizumab	214	108	14
Placebo	207	102	11

Intervention	participants (Number)
	Participants with malignancies	Participants with opportunistic infections
Daclizumab	11	71
Placebo	11	80

Intervention	participants (Number)
	SGPT-high (n=200, 200)	ALP-high (n=201, 200)	SGOT-high (n=201, 200)	GGT-high (n=180, 175)	LDH-high (n=194, 191)	Total bilirubin-high (n=201, 200)	BUN-high (n= 210, 200)	Creatinine-high (n=211, 203)	Albumin-low (n=198,197)	Total protein-high (n=195,196)	Total protein-low(n=195,196)	Cholesterol-high (n=174, 174)	Triglycerides-high (n=164, 164)	Carbondioxide-high (n=206, 197)	Carbondioxide-low (n=206, 197)	Chloride-high (n=211, 203)	Chloride-low (n=211, 203)	Potassium-high (n=211, 204)	Potassium-low (n=211, 204)	Sodium-high (n=211, 203)	Sodium-low (n=211, 203)	Calcium-low (n=207, 201)	Glucose fasting-high (n=210, 203)	Glucose fasting-low (n=210, 203)	Phosphate-high (n=199, 194)	Phosphate-low (n=199,194)	Uric acid high (n=191, 188)
Daclizumab	48	15	22	90	53	28	93	66	47	5	85	3	35	27	12	1	42	7	4	2	8	39	28	3	54	32	23
Placebo	45	7	25	74	54	20	95	64	50	0	79	4	30	21	5	3	36	7	2	1	11	44	27	3	48	26	20

Intervention	participants (Number)
	Within 6 months, Grade 0	Within 6 months, Grade IA	Within 6 months, Grade IB	Within 6 months, Grade II	Within 6 months, Grade IIIA	Within 6 months, Grade IIIB	Within 6 months, Grade IV	Within 12 months, Grade 0	Within 12 months, Grade IA	Within 12 months, Grade IB	Within 12 months, Grade II	Within 12 months, Grade IIIA	Within 12 months, Grade IIIB	Within 12 months, Grade IV
Daclizumab	9	64	26	55	48	8	1	7	56	22	51	63	11	1
Placebo	5	51	28	38	74	15	1	4	39	21	47	85	15	1

Intervention	mg (Mean)
	MMF dose, 6 months PT (n=193, 201)	MMF dose,12 months PT (n=188, 194)	IV Cyclosporine dose, 6 months PT (n=2, 1)	IV Cyclosporine dose, 12 months PT (n=4, 2)	PO/NG Cyclosporine dose, 6 months PT (n=184, 182)	PO/NG Cyclosporine dose, 12 months PT (n=170, 170)	Cumulative corticosteroids,6 months PT(n=203, 206)	Cumulative corticosteroids,12 months PT(n=195,200)
Daclizumab	2522.2	2394.1	86.11	93.5	321.9	294.7	848.1	1199.6
Placebo	2450	2380.1	38.1	46.7	331.1	305.7	955.4	1288.9

Intervention	percentage of samples analyzed (Number)
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)	22
Group C (Chemotherapy, Monoclonal Antibody Therapy)	70

Intervention	participants (Number)
	Incidence of grade ≥ 3 stomatitis	No incidence of grade ≥ 3 stomatitis
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)	4	41
Group C (Chemotherapy, Monoclonal Antibody Therapy)	6	34

Intervention	participants (Number)
	Toxic death	No toxic death
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)	0	45
Group C (Chemotherapy, Monoclonal Antibody Therapy)	2	38

Intervention	cells/mL^3 (Mean)
	Day 0	1 month	3 months	6 months	1 year	2 years
Autologous HSCT in SLE	0.34	138.68	318.47	334.91	736.67	674.69

Intervention	EU (Mean)
	Day -7	Day 0	1 month	3 months	6 months	1 year	18 months	2 years	3 years
Autologous HSCT in SLE	66.9	64.8	61.5	58.5	51.3	57.2	60.6	50.6	26.3

Intervention	adverse events (Number)
Alemtuzumab (Withdrawn From Sirolimus)	2
Alemtuzumab (Not Withdrawn From Sirolimus)	8

Intervention	mg/dL (Mean)
Alemtuzumab (Withdrawn From Sirolimus)	-4.2
Alemtuzumab (Not Withdrawn From Sirolimus)	-5.4

Intervention	participants (Number)
	# Participants with at least one SAE	Blood and Lymphatic System Disorders	Cardiac Disorders	Eye Disorders	Gastrointestinal Disorders	General Disorders and Administration Site	Immune System Disorders	Infections and Infestations	Injury, Poisoning, and Procedural Complications	Investigations	Metabolism and Nutrition Disorders	Musculoskeletal and Connective Tissue Disorders	Neoplasms Benign, Malignant, and Unspecified	Nervous System Disorders	Pregnancy, Puerperium, and Perinatal Conditions	Psychiatric Disorders	Renal and Urinary Disorders	Respiratory, Thoracic, and Mediastinal Disorders	Vascular Disorders
Control Group	37	5	2	1	1	3	2	12	0	0	2	3	2	0	0	1	3	8	7
Rituximab	42	4	2	1	4	5	2	12	2	2	2	2	1	1	1	1	4	8	1

Intervention	Days (Number)
	25% Quartile (95%CI)	50% Quartile (95%CI)	75% Quartile (95%CI)
Control Group	29	43	112
Rituximab	30	57	119

Intervention	participants (Number)
	Death	Grade 2 or Higher Leukopenia	Grade 2 or Higher Thrombocytopenia	Grade 3 or Higher Infections	Hemorrhagic Cystitis (Grade 2 or Lower)	Malignancy	Venous Thromboembolic Event	Hospitalization Resulting from the Disease	Cerebrovascular Accident (CVA)	Infusion Reactions Leading to Infusion Disc.
Control Group	2	23	1	16	1	2	8	7	1	0
Rituximab	2	7	4	18	2	5	6	16	1	1

methylprednisolone

Description

Cross-References

Synonyms (204)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (6)

Drug Classes (3)

Pathways (1)

Protein Targets (40)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (140)

Molecular Functions (64)

Ceullar Components (47)

Bioassays (214)

Research

Studies (18,767)

Study Types

Clinical Trials (952)

Trial Overview

Trial Outcomes

Progression-free Survival

Number of Participants With Marked Laboratory Abnormalities: Hematology Parameters

Median Change From Baseline for Lipid Profile (Total Cholesterol, Low Density Lipoproteins, High Density Lipoproteins, and Triglycerides)

Median Time to First Acute Rejection Episode Within the First 6 Months and 12 Months PT

Number of Acute Rejection Episodes Per Participant Within the First 6 Months and 12 Months PT

Number of Participant Who Died Within 6 Months 12 Months and 3 Years PT

Number of Participants Using Monomurab Cluster of Differentiation 3, Orthoclone Polyclonal Antithymocyte Globulin or Antilymphocyte Globulin in the First 6 Months and 12 Months PT

Number of Participants With Any Adverse Events and Any Serious Adverse Event, and Adverse Events Leading to Premature Withdrawal

Number of Participants With Malignancies and Opportunistic Infections

Number of Participants With Marked Laboratory Abnormalities: Biochemistry Parameters

Number of Participants With Worst ISHLT Biopsy Grade Within First 6 Months and 12 Months PT

Median Change From Baseline for LDL/HDL Ratio

Mean Maintenance Doses of Mycophenolate Mofetil, Cyclosporine, and Cumulative Dose of Corticosteroids at 6 and 12 Months PT

Number of Participants Who Developed Acute Rejection Episode Within the 12 Months PT

Number of Participants Who Developed Acute Rejection Episode Within 6 Months Post-Transplant

PFS

OS

Acute GvHD

Day 100 TRM

Minimal Residual Disease

Response Rate

Grade ≥ 3 Stomatitis

Toxic Death

Event-free Survival

Cluster of Differentiation 8 (CD8) + Cells

Extractable Nuclear Antigen (ENA)

Natural Killer Cells

Platelet Count

Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)

White Blood Cells

Cluster of Differentiation 4 (CD4) + Cells

Number of Participants With Adverse Events

Absolute Lymphocyte Count

Absolute Neutrophil Count

Anti-Double Stranded Deoxyribonucleic Acid (DNA) Antibody

Anti-Nuclear Antibody

Anti-Smith-Ribonuclear Protein Antibody

Cluster of Differentiation 19 (CD19) + Cells

Cluster of Differentiation 3 (CD3) + Cells

Relapse-free Complete Clinical Response

Number of Alemtuzumab Associated Adverse Events, Stratified by Sirolimus Withdrawal Status

Number of Deaths Stratified by Sirolimus Withdrawal Status

Number of Acute Rejections in All Enrolled Participants

Number of Participants Requiring Anti-lymphocyte Therapy for an Acute Rejection, Stratified by Sirolimus Withdrawal Status

Number of Participants Who Experienced Graft Loss Stratified by Sirolimus Withdrawal Status

Number of Severe Acute Rejections Stratified by Sirolimus Withdrawal Status

Number of Side Effects of Conventional Immunosuppression, Stratified by Withdrawal Status

Number of Acute Rejections Between Initiation of Sirolimus Withdrawal and End of Study

Time From Transplantation to Acute Rejection in Participants for Whom Acute Rejection Occurred During the 1 Year Post-transplant Period

Change in Renal Function as Measured by Serum Creatinine, Stratified by Withdrawal Status

Time From Transplantation to Acute Rejection in Participants for Whom Sirolimus Withdrawal Was Not Initiated

Number of Sirolimus Associated Adverse Events, Stratified by Sirolimus Withdrawal Status

Number of Tacrolimus Associated Adverse Events, Stratified by Sirolimus Withdrawal Status

Intervention	Participants (Number)
	Albumin, serum-low (hypoalbuminemia)	Allergic reaction/hypersensitivity	Anorexia	Ataxia (incoordination)	Auditory/Ear-Other (Specify)	Blood/Bone Marrow-Other (Specify)	Colitis, infectious (e.g., Clostridium difficile)	Creatinine	Diarrhea	Dysphagia (difficulty swallowing)	Dyspnea (shortness of breath)	Fatigue (asthenia, lethargy, malaise)	Febrile neutropenia	Gastrointestinal-Other (Specify)	Glucose, serum-high (hyperglycemia)	Glucose, serum-low (hypoglycemia)	Hemoglobin	Hemorrhage, CNS	Hypotension	Incontinence, anal	Inf (clin/microbio) w/Gr 3-4 neuts - Blood	Inf (clin/microbio) w/Gr 3-4 neuts - Colon	Inf w/normal ANC or Gr 1-2 neutrophils - Bladder	Inf w/normal ANC or Gr 1-2 neutrophils - Lung	Leukocytes (total WBC)	Lymphopenia	Magnesium, serum-low (hypomagnesemia)	Nausea	Neurology-Other (Specify)	Neuropathy: motor	Neuropathy: sensory	Neutrophils/granulocytes (ANC/AGC)	Pain - Abdomen NOS	Platelets	Potassium, serum-low (hypokalemia)	Renal failure	Sodium, serum-low (hyponatremia)	Thrombotic microangiopathy	Tinnitus	Tumor lysis syndrome	Uric acid, serum-high (hyperuricemia)
PEGS	1	1	2	1	1	1	2	2	2	1	1	2	4	1	4	1	9	1	2	1	1	1	1	1	8	7	2	1	1	1	2	16	1	8	1	2	2	1	1	1	1

Intervention	participants (Number)
	Complete Response	Unconfirmed Complete Response	Partial Response	No Response
PEGS	6	2	5	20

Intervention	ng/mL (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Adult	674.46	503.71	-183.96
Tacrolimus - Adult	766.58	590.30	-227.58

Intervention	Rejection Episodes (Number)
	Total Acute Rejection Episodes	Acute Rejection Episodes with ISHLT Grade ≥3A	Acute Rejection Episodes w/ Hemodynamic Compromise
Cyclosporine - Adult	8	7	2
Tacrolimus - Adult	8	3	6

Intervention	Patients (Number)
	Week 26	Week 52
Cyclosporine - Adult	16	29
Tacrolimus - Adult	22	33

Intervention	Patients (Number)
	Week 26	Week 52
Cyclosporine - Pediatric	3	1
Tacrolimus - Pediatric	2	1

Intervention	Patients (Number)
	Treatment Failures	Crossover for Treatment Failures
Cyclosporine - Adult	11	8
Tacrolimus - Adult	6	2

Intervention	Densitometry / Densitometry of GAPDH (Mean)
	p-ERK ½ - Week 2	p-ERK ½ - Week 52	p-ERK ½ - Change from Week 2	p-JNK - Week 2	p-JNK - Week 52	p-JNK - Change from Week 2	p-p38 MAPK - Week 2	p-p38 MAPK - Week 52	p-p38 MAPK - Change from Week 2
Cyclosporine - Adult	0.90	0.79	-0.05	1.23	1.46	0.22	0.54	0.77	0.23
Tacrolimus - Adult	0.70	0.87	0.05	1.10	1.33	0.03	0.48	0.63	0.14

Intervention	Participants (Number)
	Mortality within 100 days, all causes	Nonrelapse mortality within 1 year	Relapse + mortality within 1 year
Prophylactic Rituximab	0	1	2

Intervention	Percentage of participants by disease (Number)
Prophylactic Rituximab (CLL Patients)	73
Prophylactic Rituximab (MCL Patients)	69